CLINICAL STUDY PROTOCOL  
 
 
Study ID: [REMOVED] 
 Study Title:  A Phase 3, Multicenter, Randomized, Open -label, Active -controlled Study  to 
Assess the Efficacy and Safety of Maribavir Treatment Compared to  Investigator-
assigned Treatment in Transplant Recipients with  Cytomegalovirus (CMV) 
Infections that are Refractory or Resistant to  Treatment with Ganciclovir, 
Valganciclovir, Foscarnet, or Cidofovir  
 
 Study Number:   SHP6 20-303 
 
 
Protocol Version  and Date :   
Amendment 6:  07 Dec 2018  
PROTOCOL: SHP620 -303
TITLE: A Phase 3, Multicenter, Randomized, Open- label, Active -controlled Study 
to Assess the Efficacy  and Safety  of Maribavir Treatment Compared to 
Investigator -assigned Treatment in Transplant Recipients with 
Cytomegalovirus (CMV) I nfections that are Refractory  or Resistant to 
Treatment with Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir.
DRUG: SHP620
IND: IND 051001
EUDRACT NO.: 2015-004725-13
SPONSOR: Shire ViroPharma , Incorporated
300 Shire Way , Lexington, MA 02421 USA
PRINCIPAL/
COORDINATING
INVESTIGATOR:Multicenter
PROTOCOL 
HISTORY:Amendment 6: 07December 2018
Amendment 6.1: 07December 2018
Amendment 5.1: 20 August 2018 (German y, Singapore, Switzerland)
Amendment 5: 11 July  2018
Amendment 4: 26 March 2018
Amendment 3.1: 10 October 2017 (German y and Singapore)
Amendment 3: 01 March 2017
Amendment 2.1 : 18 May  2017 (Germany )
Amendment 2 (Version 3.0): 01 December 2016 
Amendment 1 (Version 2.0): 08 July  2016 
Original Protocol (Version 1.0): 25 April 2016
This document contains confidential and proprietary information of Shire and is disclosed pursuant to confidentiality 
andnondisclosure obligations. This information should be used solely for the purposes for which it was provided 
and should not be copied, shared w ith, or disclosed to any third party without the express written consent of Shire.
For non-commercial use only
PROTOCO L SIGNATURE PAGE 
Sponsor's (Shi•·e Vil·oPbarma, Incorporated) 
I Signat ure: 
, MD 
Investigator 's Aclmowledgement Date: 
T have read this protoco l for Shir e ViroPharma , Incorporated Study SHP620-303. 
Title: A Phase 3, Multi center, Ra ndomi zed, Open- label, Active-controlled Study to Assess the 
Efficacy and Safety ofMa ribavir Treatment Com pared to Investigator-assigned Tr eatmen t in 
Trans plant Recipients with Cytomega lovirus (CMV) Infections that are Refractory or Resistant 
to Treatment with Ganciclovir, Val ganciclovir, Foscarnet, or Cidofovir. 
I have fully discussed the object ive(s) of this study and the contents of this proto col with the 
sponsor's re presentative. 
I understa nd that the information in this protocol is confidential and should not be disclosed, 
other than to those direct ly involved in the execution or the scientific/ethical review of the study, 
without written authorization from the sponsor. lt is, however, perm issible to provide the 
information contain ed herein to a s ubject in order to o btain their consent to participate. 
I agree to conduct this study according to this protoco l and to co mply with its requirements, 
subject to ethical and safety considerations and guidelines, and to conduct the stu dy in 
accordance with International Confe1·ence on Ha rmonisation guidelines on Good Clinical 
Practice and with the applicable regulatory requirements. 
1 under stand that failure to comp ly wi th the re quirements of the protocol may lead to the 
termination of my participation as an investigator for this study. 
I undel'sta nd that the spo nsor may decide to suspe nd or prematurely terminate the study at any 
time for whatever reason; su ch a decision will be communicated to me in writing. Conversely, 
should T decide to withdraw from exec ution of the study I will communic ate my intention 
immediately in writing to the sponsor. 
Investigator N ame and Address: 
(please hand print or type) 
Signature: --------------------------------Date: 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 2 
 
07 Dec 2018
For non-commercial use only
Shire Page 3
SHP620 -303 Protocol Am endment 6
Maribavir 07Dec 2018
SUMMAR Y OF CHANGES F ROM PREVIOUS VERSION
Amendment 6 to protocol SHP620 -303 incorporates the following major changes:
Specified that an y subject not tested for HIV within 3 months prior to s creening must be 
tested during s creening by  a local laboratory  and must have a negative HIV test result 
available before r andomization.
Removed Hematopoetic Cell Transplant Comorbidity  Index from asses sments, and 
deleted corresponding appendix describing the tool. Specified Karnofsk y Performance 
Status and L ansky scale s as the only  assessment tools for evaluation of comorbidity  
status.
Reduced minimum washout period prior to the first dose of study  treatment for 
letermovir from 14 days to 3 days.
For subjects failing to attain viral clearance, added Visit 18/Week 20 (previously  only 
Visit 16/Week 16) CMV DNA assessment result above the pre -defined cut off to 
necessitate CMV genot yping.  
Identified specific dated SmPCs as reference safety  information for investigator -assigned 
treatments
Removed requirement of duplicate SAE and pregnancy  reporting to PPD/CRO and 
Medical Monitors, removed corresponding erroneous contacts, updated name of Shire 
Global Drug Safet y Department , and removed individual names of medical contacts at 
PPD.
Clarified that a product quality  complaint from any  site should be directed to a single 
central e
-mail address.
Noteworth y changes to the protocol are captured in the table below. Other minor editorial 
revisions (including changes for consistency  and clarity ) are not described in this table.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 3 
 
07 Dec 2018
For non-commercial use only
Shire Page 4
SHP620 -303 Protocol Am endment 6
Maribavir 07Dec 2018
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
6Amendment Date
07 Dec 2018Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
Modified SAE and pregnancy reporting procedure and limited contact 
information to only Shire Global Drug Safety; removed 
specific contact information and names of CRO 
medical monitors, and updated name of Shire Global 
Drug Safety Department .Emergency Contact Information ; 
Section 8.2.2 ; 
Section 8.2.4
Clarified th at a product quality complaint from any site should be 
directed to a single central e- mail address.Product Quality Complaints
Specified need for negative HIV test result within prior 3 months before 
randomization after exclusion criterion 8 to better 
ensure HIV negativity for all randomized subjects ..Synopsis , Section 3.1, Study 
Schedule Table 1, 
footnote i.; 
Section 4.2; 
Section 7.1.1 , 
Section 7.2.3.5 ;
Section 7.2.5 ; 
Table 5
Reduced minimum washout period prior to the first dose of study 
treatment for letermovir from 14 days to 3 days to 
facilitate enrollment .Synopsis , Section 4.2
Removed Hem atopoetic Cell Transplant Com orbidity Index from S tudy 
Schedules , Procedures, and appendices as 
inappropriate assessment for the study. Specified 
Karnofsky Performance Status and Lansky scales as 
the only assessment tools for evaluation of comorbidity 
status.Table 1, Table 2 , Section 7.1.2, 
Section 7.1.3 ,
Section 7.2.2.7 ,
Appendix 5
Specified Summary of Product Characteristics versions to be used as 
reference safety information for investigator -prescribed 
medications to promote consistent reporting of 
treatment -related eventsSection 8.2.1
For subjects failing to attain viral clearance, added Visit 18/Week 20 
(previously only Visit 16/Week 16) CMV DNA 
assessment result above the pre- defined cut off to 
necessitate CMV genotyping.  Section 7.1.3
See Appendix 1 for protocol history .
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 4 
 
07 Dec 2018
For non-commercial use only
Shire Page 5
SHP620 -303 Protocol Am endment 6
Maribavir 07Dec 2018
EMERGENCY  CONT ACT IN FORMA TION
In the event of a serious adverse event (SAE), the investigator must fax or e -mail the “Shire 
Clinical Study  Adverse Event Form for Serious Adverse Events (SAEs) and Non -serious AEs as 
Required b y Protocol” within 24 hours to the Shire Global Drug Safet y Department. The fax 
number and e -mail address are provided on the form (sent under separate cover). 
Fax:  
e-mail: 
For protocol -or safety- related issues during normal business hours 8:00am -5:00pm (local 
time per regio n), the investigator must contact the PPD medical monitor: 
Hotline numbers (24 hours a day /7 day s a week):
North America: 
Europe, Middle East, Africa (EMEA)/Asia- Pacific (APAC): 
Fax numbers :
North America:  and 
EMEA/APAC: 
E-mail:
North America: RTP Safety  Mailbox (SM) -
EMEA ASIA Safet y Central Mailbox (SM) -
For protocol -or safety-related issues outside of normal business hours, the Investigator 
must contact:
Hotline numbers (24 hours a day  /7 day s a week): North America - ; EMEA 
/APAC -   
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 5 
 
07 Dec 2018
For non-commercial use only
Shire Page 6
SHP620 -303 Protocol Am endment 6
Maribavir 07Dec 2018
PRODUCT QUALITY  COMP LAINTS
Investigators are required to report investigational product quality  complaints to Shire within 
24hours. This includes any  instances wherein the quality  or performance of a Shire product 
(marketed or investigational) does not meet expectations (eg, inadequate or faulty  closure, 
product contamination) or that the product did not m eet the specifications defined in the 
application for the product (eg, wrong product such that the label and contents are different 
products). For instructions on reporting AEs related to product complaints, see Section 8.
Please report the Product Quality Complaint to: 
Telephone number (provided for reference if needed):
300 Shire Way, Lexington, MA 02421 USA
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 6 
 
07 Dec 2018
For non-commercial use only
Shire Page 7
SHP620 -303 Protocol Am endment 6
Maribavir 07Dec 2018
TABLE OF  CONTENTS
PROTOCOL  SIGNATURE P AGE .................................................................................................2
SUMMARY OF CHANGES F ROM PREVI OUS VERSI ON........................................................3
EMERGENCY CONTACT I NFORMATION ................................................................................5
PRODUCT QUALITY COMP LAINTS ..........................................................................................6
TABLE OF CONTENTS .................................................................................................................7
LIST OF TABLES .........................................................................................................................12
LIST OF FIGURES .......................................................................................................................12
LIST OF APPENDICES ................................................................................................................12
ABBREVIAT IONS .......................................................................................................................13
DEFIN ITIO NS...............................................................................................................................15
STUDY SYNOPSI S ......................................................................................................................17
STUDY SCHEDULES ................................................................
..................................................34
1.BACKGROUND INFORMATI ON.......................................................................................42
1.1 Indication and Current Treatment Options...............................................................
42
1.2 Product Background and Clinical I nformation ........................................................43
1.2.1 Pharmacokinetics, metabolism, and drug- drug interactions ..................................43
1.2.2 Efficacy ..................................................................................................................45
1.2.3 Safet y ................................
.....................................................................................47
2.STUDY OBJECTIVES AND PURPOSE ..............................................................................49
2.1 Rationale for the Stud y
.............................................................................................49
2.2 Rationale for the Stud y Design ................................................................................49
2.3 Rationale for Dose Selection ....................................................................................51
2.4 Study  Objectives ................................
......................................................................52
2.4.1 Primary  Objective ..................................................................................................52
2.4.2 Key Secondary  Objective ................................
......................................................52
2.4.3 Secondary  Objectives .............................................................................................52
2.4.4 Exploratory  Objectives ..........................................................................................53
3.STUDY DESIGN ................................ ................................ ................................ ................... 54
3.1 Study  Design and Flow Chart ................................ ................................ .................. 54
3.2 Duration and Study  Completion Definition .............................................................61
3.3 Sites and Regions .....................................................................................................61
4.STUDY POPUL ATION.........................................................................................................62
4.1 Inclusion Criteria
................................ ................................ ................................ ......62
4.2 Exclusion Criteria................................ ................................ ................................ .....63
4.3 Restrictions ................................ ................................ ................................ ............... 65
4.4 Reproductive Potential ................................ ................................ ............................. 65
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 7 
 
07 Dec 2018
For non-commercial use only
Shire Page 8
SHP620 -303 Protocol Am endment 6
Maribavir 07Dec 2018
4.4.1 Female Contraception ............................................................................................65
4.4.2 Male Contraception................................................................................................66
4.5 Discontinuation and/or Withdrawal of Subjects ......................................................66
4.5.1 Reasons for Discontinuation and/or Withdrawal ...................................................68
4.5.2 Subjects ‘L ost to Follow -up’ Prior to Last Scheduled Visit ..................................68
5.PRIOR AND CONCOMITAN T MEDICATIONS, THERAPI ES, AND 
PROCEDURES ..................................................................................................................69
5.1 Prior Medications, Therapies, and Procedures .........................................................69
5.2 Concomitant Medications, Treatments and Procedures ...........................................70
5.2.1 Permitted Treatment during the Stud y Drug Treatment ........................................70
5.2.2 Prohibited Treatment .............................................................................................71
5.2.3 Treatments Taken D uring the Follow -up Phase ....................................................73
6.IDENTITY OF STUDY TR EATMENTS ..............................................................................74
6.1 Blinding the Treatment Assignment ................................
........................................74
6.2 Administration of I nvestigational Product(s) ...........................................................74
6.2.1 Interactive Response Technology  for Investigational Product Management ........74
6.2.2 Allocation of Subjects to Treatment ......................................................................74
6.2.3 Dosing ................................
....................................................................................75
6.3 Labeling, Packaging, Storage, and Handling ...........................................................77
6.3.1 Labeling .................................................................................................................77
6.3.2 Packaging ...............................................................................................................78
6.3.3 Storage ...................................................................................................................78
6.4 Drug Accountability .................................................................................................79
6.5 Subject Compliance ..................................................................................................80
7. STUDY PROCEDURES........................................................................................................81
7.1 Study  Schedule .........................................................................................................81
7.1.1 Screening Period ....................................................................................................81
7.1.2 Study  Drug Administration Period ........................................................................82
7.1.3 Follow -up Phase .....................................................................................................84
7.1.4 Maribavir Rescue Arm ................................
...........................................................85
7.1.5 Additional Care of Subjects after the Study ..........................................................85
7.2 Study  Evaluations and Procedures ...........................................................................85
7.2.1 Demographic and Other Baseline Characteristics ................................ ................. 85
7.2.2 Efficacy ................................ ................................ ................................ .................. 86
7.2.2.1 CMV DNA Quantitation (CMV I nfection) ............................................86
7.2.2.2 CMV Genoty ping and Phenoty ping .......................................................86
7.2.2.3 Tissue I nvasive CMV Disease and CMV S yndrome Assessments ........86
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 8 
 
07 Dec 2018
For non-commercial use only
Shire Page 9
SHP620 -303 Protocol Am endment 6
Maribavir 07Dec 2018
7.2.2.5 Graft Status .............................................................................................88
7.2.2.6 Graft -versus- host-disease (GVHD) Assessments ..................................88
7.2.2.7 Comorbidity  Status .................................................................................89
7.2.2.8 Subject Survival .....................................................................................89
7.2.3 Safet y .....................................................................................................................89
7.2.3.1 Medical History ......................................................................................89
7.2.3.2 Physical Examination (Including Weight) .............................................90
7.2.3.3 Vital Signs ................................
..............................................................90
7.2.3.4 Electrocardiogram ................................
..................................................91
7.2.3.5 Clinical L aboratory  Evaluations .............................................................91
7.2.3.6 Adverse Event Collection................................
.......................................93
7.2.4 Others .....................................................................................................................93
7.2.4.1 Clinical Pharmacology  Assessments ......................................................93
7.2.5 Volume of Blood to be Drawn from Each Subjec t Per Visit .................................96
8.ADVERSE AND SERIOUS ADVERSE EVENTS ASSES SMENT ....................................99
8.1 Definition of Adverse Events, Period of Observation, Recording of Adverse 
Events .......................................................................................................................99
8.1.1 Severity  Categorization ................................
..........................................................99
8.1.2 Relationship Categorization .................................................................................100
8.1.3 Outcome Categorization ......................................................................................100
8.1.4 Adverse Events of Special Interest ......................................................................101
8.1.5 Disease Under Study ............................................................................................102
8.1.6 Clinical L aboratory  and Other Safet y Evaluations ..............................................104
8.1.7 Pregnancy .............................................................................................................104
8.1.8 Abuse, Misuse, Overdose, and Medication Error ................................................105
8.2 Serious Adverse Event Procedures ........................................................................105
8.2.1 Reference Safet y Information ..............................................................................105
8.2.2 Reporting Procedures ................................
...........................................................106
8.2.3 Serious Adverse Event Definition .......................................................................106
8.2.4 Serious Adverse Event Collection Time Frame...................................................107
8.2.5 Serious Adverse Event Onset and Resolution Dates ................................ ........... 107
8.2.6 Fatal Outcome ................................ ................................ ................................ ......107
8.2.7 Regulatory  Agency , Institutional Review Board, Ethics Committee, and Site 
Reporting ................................ ................................ ................................ .............. 108
9.DATA MANAGEMENT AND STATISTICAL METHODS................................ ............. 109
9.1 Data Collection ................................ ................................ ................................ .......109
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 9 
 
07 Dec 2018
For non-commercial use only
Shire Page 10
SHP620 -303 Protocol Am endment 6
Maribavir 07Dec 2018
9.2 Clinical Data Management .....................................................................................109
9.3 Statistical Analysis Process ....................................................................................109
9.4 Data Monitoring Committee ..................................................................................110
9.5 Endpoint Adjudication Committee .........................................................................110
9.6 Sample Size Calculation and Power Considerations..............................................110
9.7 Study  Anal ysis Population .....................................................................................111
9.8 Efficacy  Anal yses...................................................................................................111
9.8.1 Primary  Efficacy  Endpoint ................................
..................................................112
9.8.2 Key Secondary  Efficacy  Endpoint .......................................................................114
9.8.3 Multiplicity  Adjustment .......................................................................................116
9.8.4 Subgroup Analy ses................................
..............................................................117
9.8.5 Secondary  Efficacy  Endpoints .............................................................................117
9.8.6 Exploratory  Efficacy  Endpoints ...........................................................................119
9.9 Safet y Anal yses......................................................................................................120
9.10 Other Anal yses.......................................................................................................122
9.10.3 Pharmacokinetic Anal yses...................................................................................122
10.SPONSOR’S AND I NVEST IGATOR’S RESPONSIBILIT IES.........................................124
10.1 Sponsor’s Responsibilities ................................
.....................................................124
10.1.1 Good Clinical Practice Compliance .....................................................................124
10.1.2 Indemnity /Liability  and Insurance .......................................................................124
10.1.3 Public Posting of Study  Information ....................................................................124
10.1.4 Submission of Summary  of Clinical Study  Report to Competent Authorities 
of Member States Concerned and Ethics Committees.........................................125
10.1.5 Study  Suspension, Termination, and Completion
................................................125
10.2 Investigator’s R esponsibilities ...............................................................................125
10.2.1 Good Clinical Practice Compliance .....................................................................125
10.2.2 Protocol Adherence and Investigator Agreement ................................ ................ 126
10.2.3 Documentation and Retention of Records ...........................................................126
10.2.3.1 Case Report Forms ...............................................................................126
10.2.3.2 Recording, Access, and Retention of Source Data and Study  
Documents ............................................................................................126
10.2.3.3 Audit/I nspection ...................................................................................127
10.2.3.4 Financial Disclosure ................................
.............................................127
10.2.4 Compliance to all Local, State, and National Controlled- substance 
Biohazard and Infectious Disease Regulations and Legislation ..........................127
10.3 Ethical Considerations ............................................................................................128
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 10 
 
07 Dec 2018
For non-commercial use only
Shire Page 11
SHP620 -303 Protocol Am endment 6
Maribavir 07Dec 2018
10.3.1 Informed Consent .................................................................................................128
10.3.2 Institutional Review Board or Ethics Committee ................................................128
10.4 Privacy  and Confidentiality ....................................................................................129
10.5 Study  Results/Publication Policy ...........................................................................129
11.REFERENCES .....................................................................................................................131
12.APPENDI CES ......................................................................................................................136
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 11 
 
07 Dec 2018
For non-commercial use only
Shire Page 12
SHP620 -303 Protocol Am endment 6
Maribavir 07Dec 2018
LIST  OF TABLES
Table 1: Schedule of Assessment 1: Screening Phase and Study  Treatment 
Phase ..............................................................................................................34
Table 2: Schedule of Assessment 2: Follow- up Phase ................................................39
Table 3: Prior Medication s, Therapies, and Procedures ..............................................69
Table 4: Maribavir Dosing Regimen ...........................................................................76
Table 5: Volume of Blood Drawn Per Study  Visit ......................................................97
Table 6: Criteria for reporting CMV infection as an AE or as an SAE .....................103
Table 7: Assessments of Virological Responders at Study  Week 8 ..........................113
Table 8: Assessments of Responders for Key  Secondary  Endpoint ..........................116
LIST  OF FIGURES
Figure 1: Study  Design Flow Chart ..............................................................................56
LIST  OF APPENDICES
Appendix 1
Protocol History...........................................................................................137
Appendix 2 Child -Pugh Classification of Chronic L iver Disease ..................................167
Appendix 3 Definitions of Tissue Invasive CMV Disease AND CMV SYndrome .......168
Appendix 4 CMV Gen etic Mutations Associated with Resistance to anti- CMV 
Drugs ...........................................................................................................171
Appendix 5 Karnofsk y Performance Status Scale ..........................................................177
Appendix 6 Lansky  Performance Status Scale ...............................................................179
Appendix 7 Scales and Assessments ...............................................................................181
Appendix 8 Acute Graft -versus
-host Disease: Clinical Staging and Grading ................182
Appendix 9 Recommendations for Chronic GVHD Diagnosis and Grading
.................184
Appendix 10 Diagnostic Criteria for Chronic GVHD ......................................................189
Appendix 11 Modification of Diet in Renal Disease (MDRD) and Schwartz 
Formulae ......................................................................................................19 5
Appendix 12 Bacterial and Fungal Infections Assessment ................................ ............... 196
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 12 
 
07 Dec 2018
For non-commercial use only
Shire Page 13
SHP620 -303 Protocol Am endment 6
Maribavir 07Dec 2018
ABBREVIA TIONS
AAG alpha -1-1acid -glycoprotein
AE adverse event
AESI adverse events of special interest
ALP alkaline phosphatase
ALT alanine aminotransferase
ANC absolute neutrophil count
AST aspartate aminotransferase
ATP adenosine triphosphate
AUC area under the plasma concentration versus time curve
-HCG beta-human chorionic gonadotropin
BAL bronchoalveolar lavage
BID twice dail y
Cmax maximum observed plasma concentration 
Cmin minimum observed plasma concentration
CMV cytomegalovirus
CNS central nervous s ystem
CoD Certificates of Destruction 
CRA clinical research associate
CRF case report form
CRO contract research organization
CTCAE Common Terminology  Criteria for Adverse Events 
DMC data monitoring committee
EAC Endpoint Adjudication Committee
EC ethics committee
ECG/EKG electrocardiogram
EIND emergency  investigational new drug
EU European Union
FDA Food and Drug Administration
GCP Good Clinical Practice
GI gastrointestinal
GVHD graft -versus- host disease
HBV hepatitis B virus
HCV hepatitis C virus
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 13 
 
07 Dec 2018
For non-commercial use only
Shire Page 14
SHP620 -303 Protocol Am endment 6
Maribavir 07Dec 2018
HIPAA Health Insurance Portability  and Accountability  Act
HIV human immunodeficiency  virus
HLA human leukocy te antigen
HSA human serum albumin
HSCT hematopoietic stem cell transplant
HSV herpes simplex virus
IAT investigator -assigned anti -CMV treatment
ICH International Conference on Harmonisation
IRB Institutional Review Board
IRT interactive response technology
IVIg intravenous immunoglobulin
KPS Karnofsk y Performance Status 
LLOQ lower limit of quantification
OTC over-the-counter
PCR polymerase chain reaction
P-gp P-glycoprotein
PK pharmacokinetic(s)
PO per os (oral)
qPCR quantitative poly merase chain reaction
QTc corrected QT interval
SAE serious adverse event
SAP statistical analy sis plan
SOT solid organ transplant
TEAE treatment -emergent adverse event
TID 3 times daily
ULN upper limit of normal
US United States
VZV varicella zoster virus
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 14 
 
07 Dec 2018
For non-commercial use only
Shire Page 15
SHP620 -303 Protocol Am endment 6
Maribavir 07Dec 2018
DEFINITIONS
Term Definition
Confirmed viremia 
clearanceDefined as plasma cy tomegalovirus (CMV) DNA concentration 
below the lower limit of quantification (<LLOQ; ie, <137 
IU/mL]), when assessed by  COBAS ®AmpliPrep/COBAS ®
TaqMan ®CMV Test at a central specialt y laboratory, in 2 
consecutive post -baseline samples, separated b y at least 5 day s.
Recurrence of CMV 
viremiaDefined as plasma CMV DNA concentration ≥LLOQ when 
assessed b y COBAS® AmpliPrep/COBAS® Ta qMan® CMV 
Test in 2 consecutive plasma samples at least 5 days apart, after 
achieving confirmed viremia clearance.
Rebound of CMV viremiaDefined as increase in viral DNA load for >1 log10 above nadir 
without prior clearance of viremia. 
Recurrence of s ymptomatic 
CMV infectionDefined as the presence of signs or s ymptoms of the tissue 
invasive CMV disease or CMV sy ndrome (same or new 
symptomatology ) confirmed as per Ljungman et al. 2017, after the 
period of resolution of symptomatic CMV infection in subjects 
symptomatic at baseline.
RefractoryDocumented failure to achieve >1 log10 (common logarithm to 
base 10) decrease in CMV DNA level in whole blood or plasma 
after a 14 day  or longer treatment period with IV ganciclovir/oral 
valganciclovir, IV foscarnet, or IV cidofovir. This definition 
applies to the current CMV infection and the most recently  
administered anti -CMV agent.
ResistantDocumented failure to achieve >1 log 10(common logarithm to 
base 10) decrease in CMV DNA level in whole blood or plasma 
after a 14 day  or longer treatment period with IV ganciclovir/oral 
valganciclovir, IV foscarnet, or IV cidofovir. This definition 
applies to the current CMV infection and the most recently  
administered anti -CMV agent.
AND
Documentation of 1 or more CMV genetic mutations associated
with resistance to ganciclovir/valganciclovir, foscarnet, and/or 
cidofovir.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 15 
 
07 Dec 2018
For non-commercial use only
Shire Page 16
SHP620 -303 Protocol Am endment 6
Maribavir 07Dec 2018
Term Definition
Symptomatic subjects Eligible enrol led subjects who have tissue -invasive CMV disease 
or CMV sy ndrome (SOT subjects only ) at baseline, as determined 
by the investigator.
Asymptomatic subjects Eligible enrolled subjects who do not have tissue- invasive CMV 
disease or CMV s yndrome (SOT subjects only ) at baseline, as 
determined by the investigator.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 16 
 
07 Dec 2018
For non-commercial use only
Shire Page 17
SHP620 -303 Protocol Am endment 6
Maribavir 07Dec 2018
STUDY  SYNOPSIS
Protocol num ber: SHP620 -303 Drug: Maribavir
Title of the study: A phase 3, multicenter, randomized, open -label, active -controlled study to assess the efficacy 
and safety of maribavir treatment compared to investigator -assigned treatment in transplant recipients with 
cytomegalovirus (CMV) infections that are refractory or resistant to treatment with ganciclovir, valganciclovir, 
foscarnet, or cidofovir.
Number of subjects (total and for each treatm ent arm): Approximately 413 subjects will be screened to 
randomize approximately 351 subjects in a 2:1 ratio (234 [maribavir treatment]: 117 
[investigator -assigned anti -CMV treatment (IAT)]) 
Investigator(s): Amulticenter study to be conducted at approximately 140 sites worldwide. 
Site(s) and Region(s): Approximately 140 sites in North America, Europe, and Asia Pacific.
Study period (planned): 2016 -2019 Clinical phase: 3
Prim ary Objective:
To compare the efficacy of maribavir to investigator -assigned anti -CMV therapy on CMV viremia clearance at the 
end of Study Week 8, in transplant recipients who are refractory or resistant to prior anti -CMV treatment.
Key Secondary Objective:
To compare the efficacy of the 2 study treatment arms on CMV viremia clearance and symptomatic CMV infection 
(tissue invasive disease and CMV syndrome) improvement or resolution at the end of Study Week 
8, and maintenance of this treatment effect through S tudy Week 16 (8 w eeks of post -
treatment/follow -up phase).
Secondary Objectives :
To compare the efficacy of maribavir to investigator -assigned anti-CMV therapy on CMV viremia clearance 
after completion of 8 weeks of study treatment in transplant recipients who are refractory or resistant to prior 
anti-CMV treatment.
To compare the efficacy of the 2 study treatment arms on CMV viremia clearance and symptomatic CMV 
infection (tissue invasive disease and CMV syndrome) improvement or resolution after completion of 8 weeks 
of study treatment and maintenance of this treatment effect through Study Weeks 12 (4 w eeks post -treatment 
period), 16 (8 w eeks post -treatment/follow -up phase), and 20 (12 w eeks post -treatment).
To assess the 2 study treatment arms for maintenan ce of CMV viremia clearance, and resolution or 
improvement of tissue invasive CMV disease, achieved at the end of Study Week 8, through weeks 12 (4 w eeks 
of post treatment period), and 20 (12 w eeks post treatment).
To evaluate the incidence of recurrence of CMV viremia in the 2 study treatment arms during the first 8 weeks 
of the study, during the 12 weeks of the follow -up study phase, and any time during the study.
To evaluate the incidence of recurrence of CMV virem ia in the 2 study treatment arms when patients are on 
treatment and off treatment.
To assess the profile of mutations in the CMV genes conferring resistance to maribavir.
To evaluate the all -cause mortality.
To assess the safety and tolerability of maribavir.
To assess the efficacy, maintenance of the treatment effect, and the safety of maribavir administered as the 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 17 
 
07 Dec 2018
For non-commercial use only
Shire Page 18
SHP620 -303 Protocol Am endment 6
Maribavir 07Dec 2018
rescue treatment.
To characterize the pharmacokinetics of maribavir.
Exploratory Objectives:
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 18 
 
07 Dec 2018
For non-commercial use only
Shire Page 19
SHP620 -303 Protocol Am endment 6
Maribavir 07Dec 2018
Rationale:
The population of hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) recipients whose 
CMV infections are refractory to available antiviral treatment (ie, ganciclovir, valganciclovir, 
foscarnet, or cidofovir) is an area of high unmet medical need. Some patients refractory to anti -
CMV treatment are found to harbor virus with mutations conferring resistance to a particular d rug.
Maribavir is a potent member of a new class of drugs, the benzimidazole ribosides, which bind to viral 
serine/threonine kinase (UL97) that plays a role in nuclear viral egress, viral replication, or 
regulation of host cell cycle. Favorable results fro m a Phase 2 study support the safety, 
tolerability, and anti -viral activity of maribavir as a potential option for the treatment of CMV 
infections that are refractory to treatment with ganciclovir, valganciclovir, foscarnet, or cidofovir ,
including CMV inf ections with confirmed resistance to anti -CMV agents, in HSCT and SOT 
recipients. Consequently, Study SHP620 -303 has been designed to further assess the efficacy of 
maribavir 400 mg twice daily (BID) treatment compared to investigator- assigned anti -CMV 
treatm ent in HSCT and SOT recipients with refractory CMV infections, including confirmed 
resistance to prior anti -CMV treatment.
The study will enroll pediatric subjects ≥12 to <18 years of age. Inclusion of adolescent patients in the study is 
based on the population PK modeling that showed that the same systemic exposures are reached in 
individuals ≥35 kg dosed with 400 mg BID of maribavir. Maribavir metabolism and excretion are 
not expected to differ in adolescents and adults, as the primary metabolism is th rough liver 
enzymes CYP3A4, CYP 2C19 and CYP 1A2 that reach adult levels in children of 1 -2 years of age 
(Lu et al. 2014). It is not expected that the bioavailability and systemic exposure to maribavir in 
adolescent subjects of 12 -18 years of age is differ ent from adults at the same oral dose.
Study treatm ent
Investigational product, dose, and m ode of administration:
Maribavir
The sponsor w ill provide maribavir 200 mg strength tablets, which will be administered orally (PO) at 400 mg twice 
daily (BID).
Investigator- assigned anti -CMV drugs:
Ganciclovir
Valganciclovir
Foscarnet
Cidofovir
Investigators will choose and administer/prescribe the anti -CMV agent best suited to treat the respective subject’s 
CMV infection based on their clinical judgment. The an ti-CMV agents of choice include the 
following commercially available drugs: ganciclovir, valganciclovir, foscarnet, or cidofovir. In 
clinical practice, these agents are utilized for treatment of CMV infection/disease and endorsed by 
published guidelines ( Kotton et al. 2013; Tomblyn et al., 2009 ), and by local institutional 
guidelines. The dose of these agents will be determined by the Investigator. 
Methodology:
This is a multicenter, randomized, open -label, active -controlled study to assess the efficacy and safety of maribavir 
treatment compared to investigator -assigned anti -CMV treatment in HSCT and SOT recipients with CMV infections 
that are refractory to treatment w ith ganciclovir, valganciclovir, foscarnet, or cidofovir ,including CMV infections 
with confirmed resistance to 1or more anti -CMV agents . The study will assess the efficacy of maribavir by 
measuring the plasma CMV DNA clearance. To be eligible for the study, subjects must have a documented CMV 
infection in whole blood or plasma, with a screen ing value of ≥2730 IU/mL in whole blood or ≥910 IU/mL in 
plasma in 2 consecutive assessments, separated by at least 1 day, as determined by local or central specialty 
laboratory quantitative polymerase chain reaction (qPCR) or comparable quantitative CMV D NA results. Results 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 19 
 
07 Dec 2018
For non-commercial use only
Shire Page 20
SHP620 -303 Protocol Am endment 6
Maribavir 07Dec 2018
should be available before the subject is randomized to verify subject eligibility for the study. Both samples should 
be taken within 14 days prior to randomization with the second sample obtained within 5 days before randomization 
and will be used for the stratification level for the randomization. The same laboratory must be used for these 
assessments. The CMV infection must be refractory to 1 or more of the anti -CMV agents (ganciclovir, 
valganciclovir, foscarnet, or cidofovir) and the subjects must meet the remaining specified eligibility criteria.
“Refractory ” will be defined as: 
Documented failure to achieve >1 log 10(common logarithm to base 10) decrease in CMV DNA level in whole 
blood or plasma after a 14 day or longer treatment period with IV ganciclovir/oral valganciclovir, IV foscarnet, or 
IV cidofovir. This definition applies to the current CMV infection and the most recently administered ant i-CMV 
agent. 
“Resistant ” will be defined as: 
Documented failure to achieve >1 log 10(common logarithm to base 10) decrease in CMV DNA level in whole 
blood or plasma after a 14 day or longer treatment period with IV ganciclovir/oral valganciclovir, IV fos carnet, or 
IV cidofovir . This definition applies to the current CMV infection and the most recently administered anti -CMV 
agent.
AND
Documentation of 1 or more CMV genetic mutations associated w ith resistance to ganciclovir/valganciclovir, 
foscarnet, and/ or cidofovir.
Results from the same laboratory and the same sample type (whole blood or plasma) are to be used to determine the 
refractoriness. Note: Failure to respond to these agent(s) due to intolerance will not be considered ‘refractoriness’.
The docum entation of the resistance during screening will be based on the local specialty laboratory genotyping 
assay results. Plasma samples obtained at baseline for CMV DNA genotyping will be used for the final 
determination of mutations in the UL97, UL27, and UL 54 genes known to confer resistance to anti -CMV agent; this 
assessment will be based on the results from the central specialty laboratory and utilized for analysis. Subject 
enrollment will be monitored to achieve an approximate target of 60% of subjects wh o have a CMV infection with 
documented resistance to any of the anti -CMV agents (ganciclovir, valganciclovir, foscarnet, or cidofovir) according 
to the central specialty results from samples taken at baseline.
The subjects randomized to maribavir treatment arm will discontinue the therapy they were currently on at the time 
of enrollment. For subjects randomized to the investigator assigned treatment arm, the investigator w ill determine at 
the time of randomization/treatment initiation whether the subject w ill change the therapy they were currently on at 
the time of enrollment, or w ill remain on the same therapy (single or dual anti -CMV agent therapy) after 
randomization (per Inclusion Criterion 5). If the treatment was continued or started as 2 anti -CMV agen ts, 
withdrawal of 1 agent, while continuing the second one will be possible. Addition of or switch to another anti -CMV 
agent will be declared as a failure for the purpose of study analysis. After randomization changes to the investigator 
treatment of choice could include, change in dosing, dosing regimen, but will not include an addition of or switch to 
another anti -CMV agent. Note that changes between IV ganciclovir and oral valganciclovir are allow ed. 
Com bination therapy with cidofovir and foscarnet is pr ohibited.
All eligible subjects will be stratified by transplant type (HSCT or SOT) and screening whole blood or plasma CMV 
DNA concentration (high viral load w ith CMV DNA ≥273000 IU/mL in whole blood or ≥91000 IU/mL in 
plasma, intermediate viral load ≥27300 IU/mL and <273000 IU/mL in whole blood or ≥9100 IU/mL and <91000 
IU/mL in plasma, and low  viral load <27300 IU/mL and ≥2730 IU/mL in whole blood or CMV DNA <9100 
IU/mL and ≥910 IU/mL in plasma as determined by the most recent local or central special ty laboratory qPCR 
results available at the time of randomization) as 2 stratification factors and then randomized in a 2:1 allocation ratio 
to receive maribavir 400 mg B ID or investigator -assigned anti -CMV treatment for 8 w eeks.
A cohort of subjects will have tissue -invasive CMV disease or CMV syndrome at baseline, as determined by the 
investigator (also referred as “ symptomatic subjects ”). Therefore, this study will also assess improvement or 
resolution of tissue -invasive CMV disease and CMV syndrome at t he end of the 8 -week study treatment phase and 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 20 
 
07 Dec 2018
For non-commercial use only
Shire Page 21
SHP620 -303 Protocol Am endment 6
Maribavir 07Dec 2018
during the follow -up phase for subjects with symptomatic infection present at baseline. “ Asymptomatic subjects ” 
will be defined as: Eligible enrolled subjects w ho do not have tissue- invasive CMV disease or CMV syndrome at 
baseline, as diagnosed by the investigator.
The investigator w ill perform the initial diagnosis of tissue invasive CMV disease or CMV syndrome (absence or 
presence) for the symptomatic subjects at baseline and new occurrence of tissue invasive CMV disease or CMV 
syndrome for the asymptomatic subjects at baseline through the study, and w ill continue with the assessment of the 
status (ie, no change, improvement, w orsening, or resolution) at subsequent visits through the study. All 
investigator -assessed cases of tissue invasive CMV disease and CMV syndrome will be review ed and adjudicated by 
an independent Endpoint Adjudication Committee (EAC) both for the confirmation of the diagnosis of baseline and 
new symptomatic CMV infection and for the outco me (ie, no change, improvement, w orsening, or resolution).
An independent data monitoring committee (DMC) will be established to act in an expert, advisory capacity for 
periodic assessment of the data to monitor participant safety and to ensure the validi ty and scientific merit of the 
trial.
As shown in the study schematic in the Study Design Flow Chart (below ), the study will have 3 phases: (1) Up to a 
2-week screening phase; (2) 8 -week study treatment phase; and (3) 12 -week follow -up phase. Subjects will be 
required to visit the site up to 19 times for up to a 22 -week period. Subjects entering the maribavir rescue arm may 
participate in the study for a longer duration, depending on the time of the transition from the investigator -assigned 
study treatment to maribavir, with a maximal time of 29 w eeks.
Screening Phase
Approximately 413 subjects will be screened during an approximately 2 -week screening phase to establish 
eligibility for study participation. Historical laboratory results for tests specified in the Schedule of Assessment 1 
may be used during screening for the assessment of the eligibility, including local CMV DNA quantification test 
results. If local laboratory results are not available, the central laboratory assessments may be conducted. All clinical 
laboratory results required for eligibility verification must be available prior to randomization.
Study Treatment Phase
Approximately 351 eligible subjects with refractory or resistant CMV infection will be stratified and then 
randomized at Visit 2/Day 0 to receive either maribavir or investigator -assigned anti -CMV treatment (IAT) 
(collectively, study -assigned treatment) fo r 8 w eeks.
The screening and Visit 2/Week 0/Day 0 visits can occur on the same day in the case when historical local 
laboratory results are available for determination of eligibility.
All Visit 2/Day 0 procedures and screening laboratory results needed to confirm eligibility must be completed and 
documented prior to randomization and study treatment administration. The whole blood/plasma samples for CMV 
DNA quantification, hematology, and chemistry testing must be taken for all patients at Visit 2/Week 0/Da y 0. The 
test results of these assays will not be available prior to the start of treatment. Initiation of study treatment (ie, first 
dose) w ill only occur after completion of all required Visit 2/Day 0 procedures, confirmation of eligibility, and 
completion of randomization. This w ill be done under the supervision of investigator site personnel.
Subjects Randomized to Maribavir Treatment
Depending on the time of the first maribavir dose on Visit 2/Day 0, a second dose should be administered on 
Visit 2/Day 0 provided that doses can be separated by a minimum of 8 hours; otherwise, only 1 dose w ill be 
administered on Visit 2/Day 0. Maribavir w ill then be administered (preferably) every 12 hours (q12h). When q12h 
dosing is not feasible, the doses should be sepa rated by a minimum of 8 hours. Since 200 mg strength maribavir 
tablets will be utilized, subjects will be required to take 2 tablets of maribavir q12h as shown below .
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 21 
 
07 Dec 2018
For non-commercial use only
Shire Page 22
SHP620 -303 Protocol Am endment 6
Maribavir 07Dec 2018
Maribavir Dosing Regim en
Regim en AM PM
400mg BID 200mg × 2 tablets 200mg × 2 tablets
Subjects will take the maribavir 400 mg BID dose for the 8 weeks of the study treatment phase.
Subjects Randomized to Investigator -Assigned Anti -CMV Therapy
Investigator -assigned anti -CMV treatment strategies for the 8 w eeks of the study treatment phase must only utilize 
up to 2 available anti -CMV agents from the following: ganciclovir, valganciclovir, foscarnet, or cidofovir (foscarnet 
and cidofovir in combination is prohibited).
After randomizatio n,changes to the investigator treatment of choice could include, change in dosing, change in 
dosing regimen, but will not include a switch to or an addition of another anti -CMV agent (sw itching between 
valganciclovir and ganciclovir is allow ed). The ratio nale for dose adjustment will be documented. Investigational 
anti-CMV agents are not permitted.
Subjects will follow  the investigator’s prescribed anti -CMV treatment. Subjects will remain on their investigator -
assigned anti -CMV therapy for the 8 w eeks of t he study treatment phase. Subjects may stop treatment at the 
discretion of the investigator, for lack of confirmed viremia clearance and/or intolerance to the assigned treatment. 
Subjects may be assessed for rescue arm eligibility at the investigator’s dis cretion. Intolerance to assigned treatment 
without clear evidence of virologic and/or clinical failure will not qualify a patient for the rescue arm. Viremia 
clearance should be based on the results from the same laboratory used for randomization. Subjects may be assessed 
for entry into a rescue arm, starting at Visit 5/Week 3 (after a minimum 3 weeks of treatment), for treatment with 
maribavir 400 mg BID for 8 weeks. Subjects must meet 1 of the following criteria to be eligible to enter the 
maribavir rescu e arm :
1.Subject has increased whole blood or plasma CMV viremia levels of ≥1 log 10from baseline as measured 
by the local or central specialty laboratory qPCR assay (results from the same laboratory will be 
compared). Local specialty laboratory results must be documented.
2.Subjects with tissue invasive CMV disease must meet both criteria after being on treatment for at least 
3weeks:
Subject whole blood or plasma CMV DNA has decreased <1 log 10from baseline as measured by the 
local or specialty laboratory qPCR assay (results from the same laboratory will be compared). Local 
specialty laboratory results must be documented.
Symptomatic subject’s presenting tissue invasive CMV disease did not impr ove, or w orsened as 
assessed by the investigator OR subject w ho was asymptomatic at baseline developed tissue invasive 
CMV disease.
3.No CMV viremia clearance was achieved (results from the same laboratory will be assessed) necessitating 
continued anti -CMV t reatment AND the subject has demonstrated intolerance to the investigator -assigned 
anti-CMV treatment as evidenced by 1 of the conditions:
Acute increase in serum creatinine, at least 50% increase from the baseline value, attributed to 
treatment (cidofovir , foscarnet) toxicity
Development of hemorrhagic cystitis when on treatment with cidofovir or foscarnet
Development of neutropenia (absolute neutrophil count [ANC <500/mm3[0.5 x 109/L]) when on 
treatment with ganciclovir or valganciclovir
The transition into the rescue arm will be allowed after the study medical monitor has review ed the investigator’s 
request and has approved the subject’s eligibility for the rescue arm. Blood sample taken for CMV DNA test at the 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 22 
 
07 Dec 2018
For non-commercial use only
Shire Page 23
SHP620 -303 Protocol Am endment 6
Maribavir 07Dec 2018
first visit of the maribavi r rescue treatment period w ill be used as the ‘baseline’ assessment for the purpose of the 
analyses of the response to maribavir rescue treatment (including resistance analyses). Subjects who are unable to 
continue taking investigator -assigned anti -CMV tre atment due to the lack of anti -viral activity and/or intolerance to 
the assigned treatment and who do not meet the eligibility criteria to enter the maribavir rescue arm will be treated 
as deemed appropriate by the investigator.
The investigator may also choose to interrupt therapy for a maximum of 7 consecutive days, or up to 2 study 
treatment interruptions for a total of up to 7 days. This will not result in permanent study treatment 
discontinuation. If study drug is interrupted for any reason and subsequ ently resumed, the end of 
the study drug administration period would remain fixed at a maximum of 8weeks after the date 
of the start of treatment.
All subjects will undergo study -specific evaluations weekly during the study treatment phase. All subjects who 
complete the study treatment phase through Visit 10/Week 8 w ill enter the 12 -week follow -up 
phase.
Subjects who prematurely discontinue study treatment in the investigator assigned treatment arm, and are not 
transferred to the maribavir r escue arm, will complete the end of treatment procedures described 
for Visit 10/Study Week 8 in the Schedule of Assessment 1. T hese subjects will continue on a 
modified schedule of assessments through the remaining weekly visits scheduled for the study 
treatm ent phase and the regular schedule of assessments through the 12 -week follow -up phase. 
The end of treatment sample for immunosuppressant drug concentration level will be collected at 
the next visit scheduled 1 w eek after the treatment discontinuation. S ubjects who discontinue 
maribavir treatment early will not be asked to complete the follow ing procedures after the end of 
treatment visit for subsequent visits in the treatment phase: the use of the diary for study treatment 
compliance, dispense or use of any study treatment, and PK sample collection. After completing 
the 8 -week duration specified for the study treatment phase, subjects will enter the 12 -week 
follow -up phase. During the period after the study treatment discontinuation, and until the end of 
the study, subjects might be administered an anti -CMV treatment for lack of efficacy, recurrence 
of CMV viremia, or for w orsening or new onset of CMV disease as deemed necessary by the 
investigator. Subjects who withdraw  from  the study during the follow -upphase will perform the 
end of study evaluations and procedures for Visit 18/Week 20 (Follow -up Week 12) as soon as 
possible.
Subjects who withdraw  consent during the study treatment phase will be asked to undergo all end of treatment 
evaluations and proce dures listed for Visit 10/Week 8. Subjects who withdraw  from  the study 
during the follow -up phase will undergo all end of study evaluations and procedures listed for 
Visit 18/Week 20 (Follow -up Week 12) as soon as possible and whenever possible, prior to 
initiation of any nonstudy anti -CMV treatment (as deemed by the investigator) for lack of 
efficacy, recurrence of CMV viremia, or for w orsening or new  onset of CMV disease ; no further 
follow -up will be performed.
Subjects who are transferred to maribavir re scue arm will complete the end of treatment evaluations listed for 
Visit 10/Week 8 prior to being transferred. They will be treated w ith maribavir for 8 w eeks and 
will follow the procedures in the manner similar to that followed by subjects in the maribavi r 
treatment arm, as indicated in the Schedule of Assessment 1 (visits denoted with letter R). After 
the completion of 8 weeks of maribavir rescue treatment, subjects will enter the 12 -week follow -
up phase and will follow the procedures indicated in the Sch edule of Assessment 2.
Follow -up Phase
Study -specific evaluations including central specialty laboratory CMV testing and safety assessments will occur 
weekly for the first 4 weeks, then every 2 weeks for the final 8 w eeks of the 12 -week follow -up 
phase. Refer to Schedule of Assessment 2 for a complete list of the evaluations.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 23 
 
07 Dec 2018
For non-commercial use only
Shire Page 24
SHP620 -303 Protocol Am endment 6
Maribavir 07Dec 2018
Study Design Flow Chart
*Visit 2A/A- R is only required for subjects taking tacrolimus, cyclosporine, everolimus, or sirolimus at Visit 
2/2R.
BID=tw ice daily; BL=baseline; R=rescue; Rand=randomized; wks=weeks
Note: Eligibility to enter maribavir rescue arm will be assessed starting at Visit 5/Week 3 up to Visit 9/Week 7
Notable Study Evaluations during Study Treatment Phase and Follow -up Phase
CMV DNA Quantitation 
Blood samples will be assessed at a central specialty laboratory for the quantitation of CMV DNA in plasma using 
the COBAS®AmpliPrep/COBAS®TaqMan®CMV Test. Central Specialty laboratory plasma 
CMV DNA results will be reported to the investigator site as availa ble. Additional CMV DNA 
testing at local specialty laboratories may be performed at more frequent intervals or use 
additional assay methods at the discretion of the investigator .
Confirmed CMV viremia clearance will be defined as plasma CMV DNA concentrati on below  the lower limit of 
quantification (<LLOQ; ie, <137 IU/mL]), when assessed by COBAS®Amp liPrep/COBAS®
TaqMan®CMV Test at a central specialty laboratory ,in 2 consecutive post -baseline samples, 
separated by at least 5 days.
Recurrence or the recurrence of CMV viremia will be defined as plasma CMV DNA concentration ≥LLOQ when 
assessed by COBAS®AmpliPrep/COBAS®TaqMan®CMV Test in 2 consecutive plasma samples 
at least 5 days apart, after achieving confirmed viremia clearance. Every attempt should be made 
to collect the 2 consecutive plasma samples and monitor results to confirm r ecurrence.
CMV genotyping and phenotyping
Visit 2/Day 0 plasma samples will be used for CMV DNA genotyping to identify mutations in the viral UL97 and 
UL54 genes known to confer resistance to commercially available anti -CMV agents. In addition, viral UL27 gene 
will be tested. During the study, CMV genotyping will be conducted when the CMV DNA viral load is above a 
predefined cut off level (validated for this assay) in cases of failure to clear viremia during treatment, cases of 
recurrence of viremia on and off treatment and cases of viremia reboun d if >1 log 10above nadir while on treatment 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 24 
 
07 Dec 2018
For non-commercial use only
Shire Page 25
SHP620 -303 Protocol Am endment 6
Maribavir 07Dec 2018
(rebound is defined as increase in viral DNA load for >1 log 10above nadir w ithout prior clearance of viremia ). The 
entire UL97, UL27, and UL54 CMV genes will be sequenced in every sample that meets the criteria for genotyping, 
including the baseline samples. Additionally, virus susceptibility testing will be performed on selected de novo 
CMV variant sequences of the relevant gene of maribavir treated subjects by recombinant resistance phenotyping. 
Details of the analysis will be specified in the resistance analysis plan.
Symptomatic CMV Infection Assessment
Tissue -invasive CMV disease will be defined as described by Ljungman et al. (2002 and 2017). The gold standard 
for diagnosing CMV tissue invasive disease is the identification of CMV inclusions in the infected cells of the 
tissues OR identification of CMV in biopsy tissue samples. How ever, in some cases both diagnostic methods are 
required w hen tissue samples have a high chance of being contaminated by body fl uids that shed virus 
(bronchoalveolar lavage [BAL], urine or stool). In some subjects, when it is not possible to obtain a tissue biopsy, a 
culture of CMV from body fluids or CMV DNA quantitation (for selected cases) may be used to confirm diagnosis, 
with a lower level of confidence in diagnosis. CMV syndrome (in SOT subjects only) will also be defined as 
described by Ljungman et al. (2017), and requires at least 2 of 6 signs and symptoms to be present (see Appendix 3 
for full description of criteria).
All subjects will be monitored for the occurrence of CMV tissue invasive disease and CMV syndrome throughout 
the study. For symptomatic subjects who present with tissue invasive CMV disease and CMV 
syndrome at baseline, the investigator w ill document the initi al diagnosis of CMV tissue invasive 
disease and CMV syndrome at Visit 2/Day 0 (ie, absence or presence at baseline) and all serial 
assessments of infection status (ie, no change, improvement, worsening, or resolution) at all 
subsequent visits in the study. Case charts documenting the symptomatic infection diagnosis 
(present at baseline or new symptomatic infection) and follow -up infection status at study visits 
will be provided for adjudication to an independent Endpoint Adjudication Committee. The roles, 
responsibilities, and rules governing operation of the independent Endpoint Adjudication 
Committee will be fully documented in an Endpoint Adjudication Committee charter.
The recurrence of symptomatic CMV infection will be defined as the presence of signs o r symptoms of the tissue 
invasive CMV disease or CMV syndrome (same or new  symptomatology) confirmed as per Ljungman et al. (2017) 
after the period of resolution of symptomatic CMV infection in subjects symptomatic at baseline.
In subjects asymptomatic at baseline, the occurrence of new CMV tissue invasive disease or CMV syndrome after 
start of study treatment will be initially assessed by the investigator followed by adjudication by 
the EAC.
Inclusion and exclusion criteria:
Inclusion Criteria:
1.The subject must be able to provide w ritten, personally signed, and dated informed consent to participate in the 
study before completing any study -related procedures. As applicable, a parent/both parents or legally authorized 
representative (LAR) must provide signatu re of informed consent and there must be documentation of assent by 
the subject before completing any study -related procedures.
2.The subject must be a recipient of hematopoietic stem cell or solid organ transplant.
3.The subject must have a documented CMV infection in whole blood or plasma, with a screening value of 
≥2730 IU/mL in whole blood or ≥910 IU/mL in plasma in 2 consecutive assessments, separated by at least 1 
day, as determined by local or central specialty laboratory quantitative polymerase chain reaction (qPCR) or 
comparable quantitative CMV DNA results. Both samples should be taken within 14 days prior to 
randomization with second sample obtained within 5 days prior to randomization. The same laboratory an d 
same sample type (whole blood or plasma) must be used for these assessments.
4.The subject must have a current CMV infection that is refractory to the most recently administered of the four 
anti-CMV treatment agent(s). Refractory is defined as documented f ailure to achieve >1 log 10(common 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 25 
 
07 Dec 2018
For non-commercial use only
Shire Page 26
SHP620 -303 Protocol Am endment 6
Maribavir 07Dec 2018
logarithm to base 10) decrease in CMV DNA level in whole blood or plasma after a 14 day or longer treatment 
period w ith IV ganciclovir/oral valganciclovir, IV foscarnet, or IV cidofovir. 
Subjects who have documentation of 1 or more CMV genetic mutations associated with resistance to 
ganciclovir/valganciclovir, foscarnet, and/or cidofovir must also meet the definition of refractory CMV 
infection.
5.The investigator must be willing to treat the subject w ith at least 1 of the available anti -CMV drugs 
(ganciclovir, valganciclovir, foscarnet, or cidofovir). Note: Combination therapy with foscarnet and cidofovir is 
not permitted in the IAT arm due to the potential for serious nephrotoxicity.
6.The subject must be ≥12 y ears of age at the time of consent.
7.The subject must weigh ≥35 kg.
8.The subject must have all of the following results as part of screening laboratory assessments (results from 
either the central laboratory or a local laboratory can be used for qualification):
a.Absolute neutrophil count (ANC) ≥1000/mm3[1.0 x 109/L]
b.Platelet count ≥25000/mm3[25 x 109/L]
c.Hem oglobin ≥8g/dL
d.Estimated glomerular filtration rate (eGFR) >30 mL/min/1.73m2 as assessed by Modification of Diet in 
Renal Disease (MDRD) formula for subjects ≥18 years of age or Schwartz formula for subjects 
<18 years of age (see Appendix 12 for the formulae).
9.The subject must have a negative serum β -human chorionic gonadotropin (β -HCG) pregnancy test at screening, 
if a female of child bearing potential. Addit ional urine pregnancy tests may be done per institutional 
requirements; however they are not sufficient for eligibility determination. Sexually active females of child 
bearing potential must agree to comply with any applicable contraceptive requirements of the protocol. If male, 
must agree to use an acceptable method of birth control, as defined in the protocol, during the study treatment 
administration period and for 90 days afterward if treated with maribavir, ganciclovir, valganciclovir, or 
cidofovir and for 180 days afterw ard if treated with foscarnet.
10.The subject must be able to swallow  tablets, or receive tablets crushed and/or dispersed in water via a 
nasogastric or orogastric tube.
11.The subject must be willing and have an understanding and ability to fully comply with study procedures and 
restrictions defined in the protocol.
12.The subject must be willing to provide necessary samples (eg, biopsy) for the diagnosis of tissue invasive CMV 
disease at baseline as determined by the investigator.
13.The subject must have a life expectancy of ≥8 weeks.
Exclusion Criteria:
Subjects must not:
1.Have a current CMV infection that is considered refractory or resistant due to inadequate adherence to prior 
anti-CMV treatment, to the best knowledge of the investigator.
2.Require ganciclovir, valganciclovir, foscarnet, or cidofovir administration for conditions other than CMV when 
study treatment is initiated (example: herpes simplex virus (HSV) coinfection requiring use of any of these 
agents after the random ization) or w ould need a coadministration with maribavir for CMV infection. NOTE: A 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 26 
 
07 Dec 2018
For non-commercial use only
Shire Page 27
SHP620 -303 Protocol Am endment 6
Maribavir 07Dec 2018
subject who is not continuing with the same anti -viral drug(s) (ganciclovir, valganciclovir, or foscarnet) for the 
study treatment (if randomized to the investigator assign ed anti -CMV treatment arm), must discontinue their 
use before the first dose of study drug. If subject is currently being treated with cidofovir and is assigned 
another anti -CMV therapy by the investigator, the subject must discontinue its use at least 14 days prior to 
randomization at Visit 2/Day 0 and the first dose of study treatment.
3.Be receiving leflunomide, letermovir, or artesunate when study treatment is initiated. NOTE: subjects receiving 
leflunomide must discontinue the use at least 14 days prior to randomization at Visit 2/Day 0 and the first dose 
of study treatment. Subjects receiving letermovir must discontinue at least 3 days prior to the first dose of study 
treatment. Subjects receiving artesunate must discontinue the use prior to the first do se of study treatment.
4.Have severe vomiting, diarrhea, or other severe gastrointestinal illness within 24 hours prior to the first dose of 
study treatment that would preclude administration of oral/enteral medication.
5.Have known hypersensitivity to the act ive substance or to an excipient for a study treatment.
6.Have tissue invasive CMV disease with central nervous system involvement, including the retina (eg CMV 
retinitis).
7.Have serum aspartate aminotransferase (AST) >5 times upper limit of normal (ULN) at s creening, or serum 
alanine aminotransferase (ALT) >5 times ULN at screening, or total bilirubin ≥3.0 x ULN at screening (except 
for documented Gilbert’s syndrome), by local or central lab. Note: Subjects with biopsy confirmed CMV 
hepatitis will not be excl uded from study participation despite AST or ALT >5 times ULN at screening.
8.Have known positive results for human immunodeficiency virus (HIV). Subjects must have a confirmed 
negative HIV test result within 3 months of study entry or, if unavailable, be  t ested by a local laboratory during 
the screening period.
9.Require mechanical ventilation or vasopressors for hemodynamic support at the time of enrollment.
10.Be female and pregnant or breast feeding.
11.Have previously received maribavir.
12.Have received any investigational agent with known anti -CMV activity within 30 days before initiation of study 
treatment or CMV vaccine at any time. 
13.Have received any unapproved agent or device within 30 days before initiation of study treatment.
14.Have active malignancy with the exception of nonmelanoma skin cancer. Subjects who have had a HSCT and 
who experience relapse or progression of the malignancy, as per investigator’s opinion are not to be enrolled.
15.Be undergoing treatment for acute or chronic hepatitis C.
16.Have any clinically significant medical or surgical condition that in the investigator’s opinion could interfere 
with the interpretation of study results, contraindicate the administration of the assigned study treatment, or 
compromise the safety or well -being of t he subject.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 27 
 
07 Dec 2018
For non-commercial use only
Shire Page 28
SHP620 -303 Protocol Am endment 6
Maribavir 07Dec 2018
Maximum duration of subject involvem ent in the study:
Planned duration of screening phase: Up to 2 w eeks
Planned duration of study treatment phase: 8 w eeks
Planned duration of follow -up phase: 12 w eeks
Planned duration of maribavir rescue arm including follow -up (as applicable): Up to 29 w eeks 
Endpoints and statistical analysis:
Subject Population Sets:
The enrolled set w ill consist of all subjects who have signed an informed consent and have begun som e study  
procedures.
The randomized set will consist of all subjects in the enrolled set who have been randomized to the study. 
Subjects will be analyzed in the treatment group to which they are randomized.
The safety set will consist of all subjects who have taken any dose of study treatment. Subjects will be analyzed 
according to the treatment actually received.
The per- protocol (PP) set w ill consist of all subjects in the randomized set who do not have predefined major 
protocol deviations that may affe ct the primary efficacy assessment .
The pharmacokinetic set will consist of all subjects in the safety set who had plasma samples drawn and tested 
for maribavir concentrations.
-The adolescent pharmacokinetic set will consist of all subjects ≥12 to <18 year s of age in the safety set 
who had plasma samples drawn and tested for maribavir concentrations.
The randomized set and the PP set w ill be used for efficacy analyses, with the randomized set as the primary 
analysis set and the PP set as the supportive one. 
Sample Size Justification:
In Study SHP620 -202, the proportion of subjects with undetectable pl asma CMV DNA was 70%, 63%, and 68% for 
the 400 mg, 800 mg, and 1200 mg BID dose groups, respectively, within 6 weeks. The proportion of subjects with 
undetectable plasma CMV DNA was 70%, 65%, and 75% for the 400 mg, 800 mg, and 1200 mg BID dose groups, 
respectively, within 12 weeks. Therefore, it is assumed that at least 60% of maribavir treated subjects w ill have 
achieved undetectable plasma CMV DNA at Visit 9/Week 7 and Visit 10/Week 8 when calculating the sample size.
A proportion of approximately 40% is considered as a reasonable estimate of the proportion of subjects w ith 
confirmed undetectable plasma CMV DNA at Visit 9/Week 7 and Visit 10/Week 8 in the investigator assigned 
treatment group when calculating the sample size. It is believed that the treat ment difference of 20% higher in 
maribavir group compared to control group is larger than a clinically meaningful difference.
For the proposed trial, to demonstrate statistical superiority in the reduction of CMV DNA, it is assumed that the 
proportion of subjects with confirmed unquantifiable plasma CMV DNA at Visit 9/Week 7 and Visit 10/Week 8 in 
the maribavir and control groups is 60% and 40%, respectively, a total of 315 subjects is required in the ratio of 2:1 
(210 subjects in maribavir group and 105 su bjects in the control group) to provide 90% power in hypothesis testing 
at an alpha level of 0.05 (2 -sided test). The sample size is estimated based on a 2 -group continuity corrected 
Chi-square test of equal proportions by using nQuery Advisor 7.0. Considering 10% drop -outs, 351 subjects 
(234 subjects in maribavir group and 117 subjects in the control group) w ill be enrolled and randomized.
Prim ary Efficacy Endpoint:
The primary efficacy endpoint (a binary response) for the study is confirmed clearance of plasma CMV DNA (CMV 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 28 
 
07 Dec 2018
For non-commercial use only
Shire Page 29
SHP620 -303 Protocol Am endment 6
Maribavir 07Dec 2018
viremia clearance) at the end of Study Week 8.
For clearance of CMV viremia to be declared at the end of Study Week 8 during the treatm ent period, the subject 
must have received exclusively study -assigned treatments.
Confirmed CMV virem ia clearance at the end of Study Week 8 (Visit10) is defined as plasma CMV DNA 
concentrations <LLOQ (ie, <137 IU/mL), when assessed by COBAS®AmpliPrep/COBAS®
TaqMan®CMV Test at a central specialty laboratory , in 2 consecutive postbaseline samples 
separat ed by at least 5 days, regardless of whether either study -assigned treatment was 
discontinued before the end of the stipulated 8 w eeks of therapy (see examples table below).
Assessments of Virological Responders at Study Week 8
Scenari CMV DNA Weeks on Study
Response Rationale
Week 6 Week 7 Week 8 Week 9*
1 + / - - - +/-/NA Yes2 consecutive “ -” at Week 7 and 
Week 8
2 + / - - + +/-/NA NoNot 2 consecutive “ -” at Week 7 
and Week 8
3 + / - + - +/-/NA NoNot 2 consecutive “ -” at Week 7 
and Week 8
4 + / - - NA - Yes2 consecutive “ -” as shown by 
available data and 
both “- ” at week 
7 and w eek 9 for 
missing week 8, 
otherwise 
nonresponder
5 - NA - +/-/NA Yes2 consecutive “ -” as shown by 
available data and 
both “- ” at week 
6 and w eek 8 for 
missing Week 7, 
otherwise 
nonresponder
6 - NA NA - Yes2 consecutive “ -” as shown by 
available data at 
week 6 and week 
9 and both “ -”, 
otherwise 
nonresponder
NA = not available for evaluation of study drug effect ; reason could be starting alternative anti -CMV treatment, 
withdrawal from study, etc.
*Week 9 data to be used only if Week 8 data is unavailable or missing.
Note: Scenarios in the table above are provided as examples and may not be all -inclusive of all possibilities.
Only CMV DNA data evaluable for assessment of effect of study drug will be included (ie, prior to the start 
of alternative anti -CMV treatment if any).
“-” = CMV DNA concentration <LLOQ (<137 IU/mL)
“+” = CMV DNA concentration ≥LLOQ (ie, quantifiable)
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 29 
 
07 Dec 2018
For non-commercial use only
Shire Page 30
SHP620 -303 Protocol Am endment 6
Maribavir 07Dec 2018
Confirmed clearance of plasma CMV DNA (CMV viremia clearance) =2 consecutive post baseline 
assessments of CMV DNA target <LLOQ, separated by at least 5 days.
Statistical Methodology for Prim ary Efficacy Endpoint:
The difference in proportion of subjects w ith confirmed CMV viremia clearance, at the end of Study Week 8, 
betw een treatment groups (maribavir and investigator’s choice of anti -CMV treatment) will be obtained using 
Cochran -Mantel -Haenszel (CMH) w eighted average across all strata, and assessed using CMH test with transplant 
type and baseline plasma CMV DNA concentration as 2 stratification factors. The baseline plasma CMV DNA 
levels will be the last central laboratory assessment before the first dose of study treatment. If the p -value from the 
CMH test is ≤0.05 and the proportion of response from maribavir is higher, it will be concluded that maribavir is 
more efficacious compared to the control group.
Subjects in the investigator -assigned treatment arm who are unable to continue taking investigator -assigned 
anti-CMV treatment due to the lack of anti -viral activity and/or intolerance to the assigned treatment (as evaluated 
starting at Visit 5/Week 3) may be evaluated for entry into a maribavir rescue arm. Subjects who take rescue 
medication will be considered as failures for primary efficacy analyses. The data collected post -maribavir rescue 
initiation, will be included in separate secondary analyses for efficacy and exploratory analysis for PK. Summary of 
all safety analyses will be provided separately for the maribavir rescue arm. The same is applicable for patients who 
might be discontinued from maribavir treatment due to intolerance. Subjects who discontinue due to intolerance and 
without viremia clearance at Study Week 8 will be considered failures in both treatment arms.
Key Secondary Endpoint:
The key secondary endpoint of this study is:
Achievement of CMV viremia clearance and resolution or improvement of symptomatic CMV infection 
(tissue invasive CMV disease or CMV syndrome (in SOT subjects only) for subjects symptomatic at
baseline or achievement of clearance of viremia and no symptoms of tissue invasive CMV disease or CMV 
syndrome for subjects asymptomatic at baseline at the end of Study Week 8, followed by maintenance of 
this treatment effect for an additional 8 w eeks off -treatment (ie, Follow -up Week 16) .
For treatment effect of clearance of CMV viremia and CMV infection symptom control (resolution or improvement 
of tissue invasive disease or CMV syndrome for symptomatic subjects at baseline, or no new symptoms for subjec ts 
asymptomatic at baseline) to be declared at the end of Study Week 8, and maintenance of such effect through Week 
16, the subject must have received exclusively a study -assigned treatment.
The investigator w ill perform the initial diagnosis of tissue -invasive CMV disease or CMV syndrome (absence or 
presence) for the symptomatic subjects at baseline and new occurrence of tissue invasive CMV 
disease or CMV syndrome for the asymptomatic subjects at baseline through the study, and w ill 
continue with the as sessment of the infection status (ie, no change, improvement, worsening, or 
resolution) at subsequent visits through the study. All investigator- assessed cases of tissue 
invasive CMV disease and CMV syndrome will be reviewed and adjudicated by an independent 
EAC both for the confirmation of the diagnosis of baseline and new symptomatic CMV infection 
and for the outcome (ie, no change, improvement, worsening, or resolution ).
Endpoint Adjudication Committee adjudicated tissue invasive CMV disease and CMV synd rome will be used for 
the efficacy analyses.
Statistical Methodology for Key Secondary Endpoint:
The key secondary endpoint will be analyzed using the same approach as the primary endpoint.
Multiplicity adjustm ent: 
The hypothesis testing of the primary and key secondary endpoint will be adjusted for multiple comparisons using a 
fixed sequence testing procedure to control the family -wise Type 1 error rate at α=5% level. The testing will be done 
in the order of primary efficacy endpoint, and the key second ary endpoint. First, the primary endpoint analysis 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 30 
 
07 Dec 2018
For non-commercial use only
Shire Page 31
SHP620 -303 Protocol Am endment 6
Maribavir 07Dec 2018
(CMV viremia clearance at Week 8) w ill be assessed at α=0.05. If and only after this is statistically significant, the 
key secondary endpoint of response based on maintaining CMV viremia clearance and reso lution or 
improvement/no ne w development in symptoms at the end weeks of study through Follow -up Week 16 will be 
assessed at α=0.05. If this is statistically significant, it will be concluded that effect of maribavir is more sustainable 
compared to the con trol group at Follow -up Week 16 (ie, 8 weeks off treatment).
Subgroup Analyses:
Analyses for the primary and key secondary endpoints will be conducted for the following subgroups (inclusive, but 
not limited to):
Subjects symptomatic at baseline
SOT/HSCT r ecipients 
CMV DNA concentration levels (high, medium, low)
Resistant (yes/no)
Adolescents ≥12 to <18 years of age (exploratory analysis: may be conducted if sample size is adequate)
The secondary efficacy endpoints of this study are as follows:
The achievement of the confirmed CMV viremia clearance after 8 w eeks of receiving study -assigned treatment.
The achievement of the confirmed CMV viremia clearance and CMV infection symptom control after receiving 
8 weeks of study -assigned treatment, followed b y maintenance of this treatment effect through study weeks 12 
(4 weeks post -treatment period), 16 (8 w eeks post treatment/follow -up phase), and 20 (12 weeks post 
treatment).
The maintenance of the CMV viremia clearance, and CMV infection symptom control, a t the end of Study 
Week 8, through Weeks 12, and 20, regardless of whether either study -assigned treatment w as discontinued 
before the end of the stipulated 8 w eeks of therapy.
The recurrence of CMV viremia during the first 8 weeks of the study, in the fol low-up period of 12 w eeks, and 
at any time during the 20 weeks of the study, regardless of whether either study -assigned treatment was 
discontinued before the end of the stipulated 8 w eeks of therapy. 
The recurrence of CMV viremia during study -assigned tr eatment and in the follow -up after the subject is 
discontinued from study -assigned treatment.
The maribavir CMV resistance profile.
All causes mortality by the end of the study (Visit 18/Week 20 [Follow -up Week 12]).
The secondary efficacy endpoints assessed for the m aribavir rescue treatm ent arm are as follows: 
The clearance of plasma CMV DNA at the end of 8 w eeks after starting maribavir rescue treatment.
Achievement of viremia clearance at the end of 8 w eeks after starting maribavir rescue treatment and resolution 
or improvement of tissue invasive CMV disease or CMV syndrome for subjects who are symptomatic at the 
start of maribavir treatment or subjects who are asymptomatic at the start of maribavir treatment remai n 
symptom free, followed by maintenance of the treatment effect for an additional 8 w eeks when off maribavir 
rescue treatment (as evidenced by sustained clearance of viremia and improvement or resolution of tissue 
invasive CMV disease or CMV syndrome and no new tissue invasive CMV disease or CMV syndrome 
development betw een end of treatment and up to Week 16).
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 31 
 
07 Dec 2018
For non-commercial use only
Shire Page 32
SHP620 -303 Protocol Am endment 6
Maribavir 07Dec 2018
The exploratory efficacy endpoints are as follows :
Pharm acokinetic endpoints for m aribavir treatm ent and maribavir rescue treatm ent are as follows:
Secondary endpoint :
For all subjects who received maribavir treatment:
Maribavir C min(predose maribavir concentration).
For adolescent subjects who provided intensive PK samples at Visit 3/Week 1:
AUC (0-tau): area under the concentration time curve over the 12 -hour dosing interval at steady state
Cmax: maximum concentration
Tmax: time when maximum concentration is observed
CL/F: apparent oral clearance
Vz/F: apparent volume of distribution
Exploratory endpoints :
Safety endpoints and analysis:
The safety analyses will include evaluation and procedures to meet the secondary objective of assessing the safety 
and tolerability of maribavir.
Safety evaluation will be made during the periods as illustrated in the Study Design Flow  Chart, ie, screening phase, 
treatment phase, and follow -up phase.
Two observation periods a re defined for the purpose of analyses:
The on -treatment observation period starts at the time of study treatment initiation through 7 days after the last 
dose of study treatment or through 21 days if cidofovir is used. For subjects who transfer from the s tudy 
treatment to either maribavir rescue or to a nonstudy CMV treatment, the on treatment observation period starts 
at the time of the study treatment initiation through 7 days after the last dose of study treatment (or through 21 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 32 
 
07 Dec 2018
For non-commercial use only
Shire Page 33
SHP620 -303 Protocol Am endment 6
Maribavir 07Dec 2018
days if cidofovir is use d), or until the maribavir rescue treatment initiation or until the nonstudy CMV treatment 
initiation, whichever is earlier. This w ill serve as the primary analysis of safety.
The overall -study observation period minus the period on rescue arm starts at th e time of study treatment start 
through the end of the study. For subjects who receive maribavir rescue therapy, the overall -study observation 
period minus the period on rescue arm starts at the time of study treatment start  through the time before 
receiv ing maribavir rescue therapy.
Similar observation periods are defined for the safety analysis of the maribavir rescue arm. The events that occur 
from the time of ICF signature to first dose will be collected but will not be evaluated in the safety analyses . They 
will be listed as pretreatment adverse events. 
An AE (classified by preferred term) that has a start date on or after the first dose of study treatment or that has a 
start date before the date of first dose of study treatment, but increases in seve rity after the first dose of study 
treatment will be considered a treatment -emergent AE (TEAE). 
Safety endpoints will be summarized descriptively for the on treatment period, and overall -study period, as 
appropriate. Baseline assessments will be the last assessment before the first dose of study treatment. The safety set 
will be used to analyze the safety data. Summary of all safety analyses will be provided separately for the maribavir 
rescue arm.
The safety endpoints include the following:
TEAEs and treatm ent-emergent serious adverse events (SAEs), overall study AEs and overall study SAEs 
Clinical laboratory evaluations
Safety assessment will also include vital sign measurements, physical examination, and ECG.
The number of events, incidence, and percent ageof TEAEs and overall -study AEs will be displayed for each 
treatment group by system organ class (SOC) and by Preferred Terms using the Medical Dictionary for Regulatory 
Activities (MedDRA®). Summaries in terms of severity and relationship to study medication will also be provided. 
Treatment -emergent SAEs will be summarized separately in a similar fashion. Summaries of AEs causing 
discontinuation of study medication, withdraw als, AEs leading to death, SAEs, and adverse events of special interest 
(AESI) will be provided. 
Adverse events of special interest, eg, tissue invasive CMV disease, dysgeusia, events of nausea, vomiting, and 
diarrhea, neutropenia, increased immunosuppressant drug concentration levels, graft rejection, opportunistic 
infections, and GVHD will be analyz ed according to primary System Organ Classes (SOCs) and Preferred Term s 
(PTs). Additional grading of events of special interest will be applicable. Summary tables with SOCs andPTs will 
be generated presenting the number and percentage of subjects by AE, severity, seriousness, and relationship to 
study medication. 
Usage of concomitant medications will be summarized descriptively for each of the treatment groups and the 
maribavir rescue treatment group for the on treatment period and overall -study period. T reatment of hemopoietic 
grow th factors, blood and blood transfusion products will be summarized separately.
Change from baseline in vital signs and clinical laboratory tests will be summarized for each treatment group with 
descriptive statistics at each as sessment visit. Summary and shift tables will be produced for selected laboratory 
parameters based on National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE v4.0)
Abnorm al physical examination findings will be listed.
Summar y of electrocardiogram (ECG) findings will be provided by treatment groups. 
An independent data monitoring committee (DMC) will be established to assess the data for safety and to ensure the 
validity and scientific merit of the trial. Detailed plans for t he DMC’s purpose and responsibilities will be described 
in the DMC charter and the statistical analysis plan.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 33 
 
07 Dec 2018
For non-commercial use only
Shire Page 34
SHP620 -303 Protocol Am endment 6
Maribavir 07
STUDY  SCHEDULES
Table 1: Schedule of Assessment 1: Screening Phase and Study Treatment Phase
PhaseScreening 
PhaseStudy Treat ment Phaseu
Study Visit / Rescue Arm Visit 1/NA 2/2R 2A/ 
2ARw3/3R 4/4R 5/5R 6/6R 7/7R 8/8R 9/9R 10/10R   (End 
of Treat ment)
Study Weeka/Rescue Arm Week -2 to 0 0/0R 0.5/ 
0.5R1/1R 2/2R 3/3R 4/4R 5/5R 6/6R 7/7R 8/8R
Study Day /Rescue Arm  Day -14 to 0 0c/0R 4/4R 7/7R 14/14R 21/21R 28/28R 35/35R 42/42R 49/49R 56/56R
Informed consentbX
Inclusion/exclusion criteriacX X
Randomization X
Physical examination 
(including weight)d X X X
Height X
Weight X X X
Vital signs X X X X X X
Medical history X Xe
Prior medications, therapies, 
and proceduresX Xv
12-lead ECGfX X
Hem atology/ChemistrygX X X X X X X
UrinalysisgX X X X X
Pregnancy testg, hX X X X
HIV statusiX
HBV and HCV testsjXj,v
CMV DNA testkX X X X X X X X X X
Symptomatic CMV infection 
assessmentlX X X X X X X X X
X X
Immunosuppressant drug 
concentration levelsXnXnXnX
PK samplesoXoXoX
Rescue Arm EligibilitypXpX X X X
Interactive Response X X X X X X X X X X
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 34 
 
07 Dec 2018
For non-commercial use only
Shire Page 35
SHP620 -303 Protocol Am endment 6
Maribavir 07
Table 1: Schedule of Assessment 1: Screening Phase and Study Treatment Phase
PhaseScreening 
PhaseStudy Treat ment Phaseu
Study Visit / Rescue Arm Visit 1/NA 2/2R 2A/ 
2ARw3/3R 4/4R 5/5R 6/6R 7/7R 8/8R 9/9R 10/10R   (End 
of Treat ment)
Study Weeka/Rescue Arm Week -2 to 0 0/0R 0.5/ 
0.5R1/1R 2/2R 3/3R 4/4R 5/5R 6/6R 7/7R 8/8R
Study Day /Rescue Arm  Day -14 to 0 0c/0R 4/4R 7/7R 14/14R 21/21R 28/28R 35/35R 42/42R 49/49R 56/56R
Technologyq
Study treatment dispensedrX X X X X X X X
Study diarysX X X X X X X X X X
Invasive bacterial, viral and 
fungal infection/transplant 
relevant infections assessmentX X X X X X X X X
Transplant status X X X X X X X X X
GVHD assessment (for HSCT 
subjects only)X X X X X X X X X
Liver function assessment by 
Child- Pugh classificationXv
Com orbidity status evaluation X X X
X X X
X X X X X
X X X X X X X X X
Concomitant medications, 
therapies, and procedurest X X X X X X X X X X
AE/SAE monitoring X X X X X X X X X X
AE=adverse event; CMV=cytomegalovirus; ECG=electrocardiogram; ;GVHD=graft -versus -host disease HBV= hepatitis B 
virus; HCV= hepatitis C virus; HIV=human immunodeficiency virus; HSCT= hematopoietic stem cell transplant; hx=history; IRT=in teractive response technology 
PK=pharmacokinetic; R= rescue; SAE=serious ad verse event;
Note: Subjects in the investigator-assigned anti -CMV treatment arm who discontinue study treatment phase to enter the maribavir rescue arm will follow the study procedures in
the Schedule of Assessment 1 for the study treatment phase, beginning with Study Week 0 (visits denoted as “R”), and will exit after 8 weeks of maribavir 400 mg BID treatment 
to enter the follow -up phase. For subjects entering the maribavir rescue arm on the day of their end -of-treatment visit, dup licate procedures do not need to be repeated.
aPermissible assessment windows: Study Visit 2A/2AR (Day 4) ± 1 day; Study Visit 3/3R (Day 7) +2 days; Study Weeks 2 -4 ± 2 days; Study Weeks 5-8 ± 3 days.
bInformed consent must be obtained before any study -specific procedures are performed. All screening procedures will be completed within 14 days prior to initiation of 
study treatment, with the exception of: 1) screening clinical laboratory tests (hematology, chemistry, pregnancy), which must be performed wi thin 7 days prior to initiation of study 
treatment; either central or local laboratory results for hematology/chemistry/pregnancy testing can be used for qualification, and 2) documentation of CMV infection in whole 
blood or plasma, with a screening value of ≥2730 IU/mL in whole blood or ≥910 IU/mL in plasma 2 assessments, separated by at least 1 day, as determined by local or central 
specialty laboratory quantitative polymerase chain reaction (qPCR) or comparable quantitative CMV DNA results. Results shoul d be available before the subject is randomized to 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 35 
 
07 Dec 2018
For non-commercial use only
Shire Page 36
SHP620 -303 Protocol Am endment 6
Maribavir 07
Table 1: Schedule of Assessment 1: Screening Phase and Study Treatment Phase
PhaseScreening 
PhaseStudy Treat ment Phaseu
Study Visit / Rescue Arm Visit 1/NA 2/2R 2A/ 
2ARw3/3R 4/4R 5/5R 6/6R 7/7R 8/8R 9/9R 10/10R   (End 
of Treat ment)
Study Weeka/Rescue Arm Week -2 to 0 0/0R 0.5/ 
0.5R1/1R 2/2R 3/3R 4/4R 5/5R 6/6R 7/7R 8/8R
Study Day /Rescue Arm  Day -14 to 0 0c/0R 4/4R 7/7R 14/14R 21/21R 28/28R 35/35R 42/42R 49/49R 56/56R
verify subject eligibility for the study. Both samples should be taken within 14 days of randomization with second sample obtained within 5 days before randomization. Same 
laboratory should be used for the se assessments. 
cScreening and Visit 2/Day 0 visits can occur on the same day in the case when historical laboratory values are available for determination of the eligibility. All Visit 
2/Day 0 procedures and screening laboratory results needed to confirm eligibility must be completed and documented prior to randomization and initiation of study treatment 
administration. The test results for the samples taken at Visit 2, from central laboratory or central specialty laboratory, w ill not be available to be used for the screening. Initiation 
of study treatment (ie, first dose) will only occur after completion of all required Visit 2/Day 0 procedures, confirmation o f eligibility, and completion of randomization. This will 
be done under the supervision of investigator site personnel. For subjects randomized to receive maribavir or investigator -assigned therapy, therapy must be initiated within 24 
hours of randomization.
dSymptom -oriented physical examinations other than protocol-specified examinations will be performed when clinically indicated. 
eUpdated medical history on Visit 2/Day 0 (Section 5.1).
fElectrocardiograms other than protocol -specified ECGs will be performed when clinically indicated.
gClinical laboratory test will be performed at a central laboratory for all specified time points during the study including baseline. Central or local laboratory results for 
hematology/chemistry/serum pregnancy testing can be used for eligibility and their results must be available prior to randomi zation. L ocal laboratory -human chorionic 
gonadotropin test results can be used for the assessment of pregnancy on Day 0/Week 0. Local laboratory will be used for Visit 2A/2AR (Day 4) potassium and magnesium levels, 
and Day 4 after starting tacrolimus, cyclosporine, everolimus, or sirolimus if the subject is not taking at V2/2R.
hFemale subjects of child -bearing potential will have serum pregnancy testing performed at a central or local laboratory . Urine test results are not sufficient for eligibility 
determinatio n.   
iHIV status will be used for the evaluation of this criterion. Subjects must have a confirmed negative result within 3 months of study entry or have testing done locally 
during the screening period. The test result must be available prior to random ization..
jHepatitis B and HCV historical results available within 3 months prior to study treatment initiation will be accepted. If his torical values are not available then the test will 
be repeated at Visit 2/Day 0. The results of test do not have to be available prior to start of dosing.
kBlood samples taken at all study visits (processed to obtain plasma), for all CMV DNA tests (quantitation, genotyping), will be tested in the central specialty laboratory. 
Only during screening period, local special ty laboratory results for CMV DNA quantitation could be used for eligibility assessment; in this case CMV DNA results from ce ntral 
laboratory are not required. At all other visits, CMV DNA test will be conducted at a central specialty laboratory. The scree ning results, regardless whether from the local or 
central specialty laboratory, will be utilized for stratification for randomization. 
lSubjects with tissue invasive CMV disease or CMV syndrome (SOT subjects only) present at Visit 2/Day 0 (baseline) will have s erial assessments at all subsequent visits 
for infection status (no change, improvement, worsening, or resolution of disease/syndro me and associated symptoms) until resolution. All subjects will be assessed at each visit 
for new tissue invasive disease or CMV syndrome, and any new tissue invasive disease or CMV syndrome will have serial assessm ents at all subsequent visits for infection status 
(no change, improvement, worsening, or resolution of disease/syndrome and associated symptoms) until resolution. 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 36 
 
07 Dec 2018
For non-commercial use only
Shire Page 37
SHP620 -303 Protocol Am endment 6
Maribavir 07
Table 1: Schedule of Assessment 1: Screening Phase and Study Treatment Phase
PhaseScreening 
PhaseStudy Treat ment Phaseu
Study Visit / Rescue Arm Visit 1/NA 2/2R 2A/ 
2ARw3/3R 4/4R 5/5R 6/6R 7/7R 8/8R 9/9R 10/10R   (End 
of Treat ment)
Study Weeka/Rescue Arm Week -2 to 0 0/0R 0.5/ 
0.5R1/1R 2/2R 3/3R 4/4R 5/5R 6/6R 7/7R 8/8R
Study Day /Rescue Arm  Day -14 to 0 0c/0R 4/4R 7/7R 14/14R 21/21R 28/28R 35/35R 42/42R 49/49R 56/56R
nIf the subject is receiving immunosuppressant drugs (cyclosporine, tacrolimus, sirolimus, or everolimus), as mentioned in Section 7.2.3.5 , on Study Day 0, then a blood 
sample to measure immunosuppressant drug concentration level will be obtained on Visit 2/2R (Day 0) prior to study treatment, Visit 2A/2AR [Day 4 (±1 day)], Visit 3/3R [Day 7 
(+2 day)], and on Visit 10/10R (Week 8) If the subject is not receiving immunosuppressant drugs at Day 0, but starts any time after Day 0 while still receiving study treatme nt, 
then a blood sample to measure immunosuppressant drug concentration will be obtained 4 days after the first dose of immunosup pressant drug and at the next scheduled study 
visit. Additional monitoring of immunosuppressant drug levels may be performed at the discretion of the investigator. Tests will be performed at a local laboratory. For more 
details refer to Section 7.2.3.5 .
oPharmacokinetic samples should be obtained and analyzed for only those subjects who are randomized to maribavir treatment arm . For subjects ≥18 years of age 
randomized to maribavir, a pre -morning dose PK sample should be obtained at all 3 PK visits and a 2 -4 hour post -morning dose sample will be collected only at Visit 3/Week 1 
and Visit 10/Week 8. There will be no post dose PK sa mple collected for Visit 6/Week 4. Pharmacokinetic sample collection for adolescent subjects ≥12 to <18 years of age, 
randomized to maribavir, will be as follows: intensive PK sampling at Visit 3/Week 1 (pre -morning dose and 1, 2, 3, 4, 6, 8 [all ±5 min], and 12 hours [±15 min] post morning 
dose); at Visit 6/Week 4 (one premorning dose PK sample); at Visit 10/Week 8 (one premorning dose and one between 2 -4 hour post morning dose PK samples). Additional PK 
samples will be collected from any subjects with bio psy proven graft -versus -host disease (GVHD) of gastrointestinal (GI) with diarrhea (>300 ml/day) or biopsy proven GVHD of 
GI with nausea and vomiting or documented acute GVHD of liver (Stage II), total bilirubin >3 mg/dL or biopsy -
proven) with diarrhea (>5 00 ml/day) or biopsy proven acute 
GVHD of the skin with diarrhea (>500 mL/day) per Boeckh et al., 1998 . Refer to Section 7.2.4.1 for more details.
pThe eligibility of subjects who must discontinu e the investigator assigned anti-CMV treatment for lack of anti-viral activity and/or intolerance, will be assessed at Visit 
5/Week 3 up to Visit 9/Week 7 for entry into an rescue arm of treatment with maribavir 400 mg BID for up to 8 weeks.
qExcept at screening, baseline, and end of treatment, IRT will be used for maribavir dispensing. Subjects who are eligible for the rescue arm will be assigned maribavir by 
the IRT system. The IRT system will be used for stratification and randomization of eligible subj ects at baseline. The IRT will be used to manage maribavir.
rAll dispensed investigational product will be documented on the CRFs and/or other investigational product record. Investigato r assigned anti -CMV medication 
(ganciclovir, valganciclovir, foscarnet, or cidofovir) will also be documented on the CRFs and/or other study treatment accountability records, and may include add itional 
information as required per applicable regulations. The disposition of unused supply of dispensed investigational product a nd investigator assigned anti -CMV medication that has 
been prescribed to the subject will be documented in the accountability log. 
sThe study diary will be dispensed at baseline and will be collected at the last follow -up visit.  
. Note that the diary will only be utilized for study treatments that are given orally. The IV administration wil l be tracked 
in the source documents and CRF. 
tIncludes recording of medications and transfusions (packed red blood cells, platelets, fresh frozen plasma). Changes in immun osuppression regimens will also be 
recorded.
uSubjects who prematurely discontinu e study treatment will complete the end of treatment procedures described for Visit 10/Study Week 8; these subjects will continue a 
modified schedule of assessments through the remaining weekly visits scheduled for the study treatment phase and the regular schedule of assessments through the 12 -week 
follow -up phase or if meeting criteria to enter maribavir rescue arm will start 8 -week maribavir 400 mg BID treatment. The end of treatment (Visit 10/Study Week 8) sample for 
immunosuppressant drug concentration level will be collected at the next visit scheduled 1 week after the treatment discontinuation. For subjects entering the Res cue Arm, 
 the Visit 2R/Week 0R does not need to be 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 37 
 
07 Dec 2018
For non-commercial use only
Shire Page 38
SHP620 -303 Protocol Am endment 6
Maribavir 07
Table 1: Schedule of Assessment 1: Screening Phase and Study Treatment Phase
PhaseScreening 
PhaseStudy Treat ment Phaseu
Study Visit / Rescue Arm Visit 1/NA 2/2R 2A/ 
2ARw3/3R 4/4R 5/5R 6/6R 7/7R 8/8R 9/9R 10/10R   (End 
of Treat ment)
Study Weeka/Rescue Arm Week -2 to 0 0/0R 0.5/ 
0.5R1/1R 2/2R 3/3R 4/4R 5/5R 6/6R 7/7R 8/8R
Study Day /Rescue Arm  Day -14 to 0 0c/0R 4/4R 7/7R 14/14R 21/21R 28/28R 35/35R 42/42R 49/49R 56/56R
collected. Subjects who discontinue study treatment early will not be asked to complete the following procedures after the en d of treatment visit for subsequent visits in the 
treatment phase: the use of the diary for study treatment compliance, dispense or use of any study treatment, and PK sample collection. After completing t he 8-week study 
treatment phase, subjects will enter the 12 -week follow -up phase. 
vNot required at V2R.
wV2A/A -R is only require d for subjects taking tacrolimus, cyclosporine, everolimus, or sirolimus at Visit 2/2R.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 38 
 
07 Dec 2018
For non-commercial use only
Shire Page 39
SHP620 -303 Protocol Am endment 6
Maribavir 07
Table 2: Schedule of Assessment 2: Follow -up Phase
Phase Follow -up Phasek,l
Visit11/11R 12/12R 13/13R 14/14R 15/15R 16/16R 17/17R18/18R (End of 
Study)
Study Week (Follow -up 
Week)a 9(1) /9R(1R)10(2)/10R
(2R)11(3)/11R(3R)12(4)/12R
(4R)14(6)/15R
(6R)16(8)/16R
(8R)18(10)/18R (10R) 20(12)/20R(12R)
Study Day (Follow -up 
Day)63(7)/63R
(7R)70(14)/70R
(14R)77(21)/77R
(21R)84(28)/84R
(28R)98(42)/98R(42R) 112(56)/112R(56R) 126(70)/126R(70R)140(84)/140R
(84R)
Physical examination 
(including weight)X
Vital signs X
12-Lead ECGbX
Hem atology/ChemistrycX X X X
UrinalysiscX
Immunosuppressant drug 
concentration leveld X
Invasive bacterial, viral 
and fungal Infection(s) 
assessment X X X X X X X X
CMV DNA testeX X X X X X X X
Symptomatic CMV 
infection assessmentf X X X X X X X X
Transplant status X X X X X X X X
GVHD assessment (for 
HSCT subjects only)X X X X X X X X
Com orbidity status 
evaluation X X X
Study diarygX X X
X X X
X X X
 X X X X X X X X
 X
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 39 
 
07 Dec 2018
For non-commercial use only
Shire Page 40
SHP620 -303 Protocol Am endment 6
Maribavir 07
Table 2: Schedule of Assessment 2: Follow -up Phase
Phase Follow -up Phasek,l
Visit11/11R 12/12R 13/13R 14/14R 15/15R 16/16R 17/17R18/18R (End of 
Study)
Study Week (Follow -up 
Week)a 9(1) /9R(1R)10(2)/10R
(2R)11(3)/11R(3R)12(4)/12R
(4R)14(6)/15R
(6R)16(8)/16R
(8R)18(10)/18R (10R) 20(12)/20R(12R)
Study Day (Follow -up 
Day)63(7)/63R
(7R)70(14)/70R
(14R)77(21)/77R
(21R)84(28)/84R
(28R)98(42)/98R(42R) 112(56)/112R(56R) 126(70)/126R(70R)140(84)/140R
(84R)
 
AE monitoringiX X X X X X X X
SAE monitoringiX X X X X X X X
Concomitant medications, 
therapies, and proceduresj X X X X X X X X
Note: Subjects in the investigator-assigned anti -CMV treatment arm who discontinue the study treatment phase to enter the maribavir rescue arm will exit after 8 weeks of 
maribavir 400 mg BID treatment to enter the follow-up phase (visits denoted as “R”).
AE=adverse event; CMV=cytomegalovirus; ECG=electrocardiogram; GVHD=graft-versus -host disease; HBV= hepatitis B virus; HCV= hepatitis C virus; HIV=human 
immunodeficiency virus; HSCT=hematopoietic stem cell transplant; IRT=interactive response system; R= resc ue; SAE=serious adverse event; SF -36= Short Form -36
aPermissible assessment windows: Study Weeks 9 -12 (Follow -up Weeks 1 -4) ± 2 days; Study Weeks 14 -20 (Follow -up Weeks 6 -12) ± 3 days.
bElectrocardiograms other than protocol -specified ECGs will be performed when clinically indicated.
cClinical laboratory testing performed at a central laboratory for all specified time points during the follow-up phase.
dRefer to Section 7.2.3.5 for mor e details.
eBlood samples taken at all study visits (processed to obtain plasma), for all CMV DNA tests (quantitation, genotyping) during the follow-up phase will be tested in the central 
specialty laboratory . 
fSubjects with tissue invasive CMV disease or CMV syndrome (SOT subjects only) present at Visit 2/Day 0 (baseline) will have serial assessments at all subsequent visits for 
infection status (no change, improvement, worsening, or resolution of disease/syndr ome and associated symptoms) until resolution. All subjects will be assessed at each visit for 
new tissue invasive disease or CMV syndrome, and any new tissue invasive disease or CMV syndrome will have serial assessments at all subsequent visits for infect ion status (no 
change, improvement, worsening, or resolution of disease/syndrome and associated symptoms) until resolution . 
gThe study diary will be used for tracking completion of the during the follow -up phase. The study diary will be collected at the last follow -up visit.
iAdverse events and SAEs will be monitored and recorded through Visit 18/Week 20/Follow -up Week 12 (end of study ) according to Section 7.2.3.6 .
jAll medications, therapies, and procedures used to treat AEs will be recorded through Visit 18/Week 20 (Follow -up Week 12(end of study ). 
kSubjects who withdraw from the study during the follow -up phase will perform the Visit 18/Week 20 (Follow -up Week 12) end of study procedures.
lIf the subject is unable to or unwilling to travel to the site for the follow -up visits, these visits may be performed remotely (ie, at the subject’s home) by a qualified sponsor or site 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 40 
 
07 Dec 2018
For non-commercial use only
Shire Page 41
SHP620 -303 Protocol Am endment 6
Maribavir 07
Table 2: Schedule of Assessment 2: Follow -up Phase
Phase Follow -up Phasek,l
Visit11/11R 12/12R 13/13R 14/14R 15/15R 16/16R 17/17R18/18R (End of 
Study)
Study Week (Follow -up 
Week)a 9(1) /9R(1R)10(2)/10R
(2R)11(3)/11R(3R)12(4)/12R
(4R)14(6)/15R
(6R)16(8)/16R
(8R)18(10)/18R (10R) 20(12)/20R(12R)
Study Day (Follow -up 
Day)63(7)/63R
(7R)70(14)/70R
(14R)77(21)/77R
(21R)84(28)/84R
(28R)98(42)/98R(42R) 112(56)/112R(56R) 126(70)/126R(70R)140(84)/140R
(84R)
desig nee, and only if permitted according to local regulations. Blood sample for DNA quantitation and clinical laboratory assessme nts will be collected. Adverse events and SAE 
collection may be completed by telephone follow -up call on the day of the scheduled v isit.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 41 
 
07 Dec 2018
For non-commercial use only
Shire Page 42
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
1. BACKGROUND INFORMATI ON
1.1 Indication and Current Treatment Options 
Cytomegalovirus (CMV) is a beta herpesvirus that commonly  infects humans; serologic 
evidence of prior infection can be found in 40- 100% of various adult populations ( de la Hoz et 
al., 2002). However, serious disease occurs almost exclusively  in individuals with compromised 
immune sy stems. Cy tomegalovirus remains a significant problem for patients undergoing 
various ty pes of transplants that are associated with the use of potent immunosuppressive 
chemotherap y, including hematopoietic stem cell transplants (HSCT) and solid organ transplants 
(SOT) (de la Hoz et al., 2002; Razonable and Emery , 2004 ).
In addition to the direct effects that manifest as CMV organ disease or s ymptomatic infection, 
CMV also is known to have several potential indirect effects. These indirect effects include an 
increased incidence of opportunistic infections, an association between CMV and 
graft -versus- host disease (GVHD) predominatel y in HSCT patients, and associations between 
CMV and graft rejection or other a llograft pathology  in SOT patients, and reduced patient 
survival ( Rubin, 1989 ; Hodson et al., 2005; Ljungman et al., 2006 ). Such organ-specific 
associations with CMV include bronchiolitis obliterans in lung recipients, vanishing bile duct 
syndrome in liver recipients, accelerated transplant vasculopathy  in heart recipients and 
transplant glomerulopathy , transplant renal artery  stenosis o r increased risk of transplant 
rejection ( Razonable and Emery , 2004; Legendre and Pascual, 2008 ; Richardson et al., 1981 ; 
Pouria et al., 1998 ; Farrugia and Schwab, 1992 ). These effects are believed to be mediated by  the 
virus ’s ability  to modulate the immune sy stem, either directly  or secondary  to the host antiviral 
response through regulation of cy tokine, chemokine, and/or growth factor production. 
Cytomegalovirus prevention strategies (prophy laxis or preemptive therapy ) for various high -risk 
transplant subjects exist, however, CMV infection or disease can still occur within the earl y 
(initial ~3 months) or later post- transplantation time periods ( Boeckh et al., 2003 ; Legendre and 
Pascual, 2008 ). Cytomegalovirus viremia is considered one of the most important predictors of 
development of CMV disease ( Emery  et al., 2000; Humar et al., 1999). In kidney transplant 
recipients, the highest incidence of s ymptomatic CMV infection (s yndrome) or disease occurs in 
CMV-seronegative recipients who receive a kidney  from a CMV -seropositive donor (D+/R -) 
(Paya et al., 1989; Kanj et al., 1996 ;Singh et al., 2004; Winston et al., 1995 ). 
Although the currentl y available s ystemic anti
-CMV agents, intravenous (IV) or oral ganciclovir, 
oral valganciclovir (a prodrug of ganciclovir with improved bioavailability ), IV foscarnet, and IV 
cidofovir are generall y effective, their use is limited by  their respective toxicities; bone marrow 
suppression caused b y ganciclovir/valganciclovir and renal impairment caused by foscarnet or 
cidofovir ( Boeckh et al., 2003 ;Ljungman et al., 2001 ; Reusser et al., 2002; Salzberger et al., 
1997). These toxicities are of particular concern in transplant patients, in whom the bone marrow 
has been ablated or significantly  suppressed (HSCT patients), who receive ongoing 
immunosuppressants to prevent organ rejection (SOT patients) or GVHD (in HSCT patients), or 
who may  require the use of other therapies that are potentially  toxic to the kidney s or other 
organs (SOT and HSCT patients). 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 42 
 
07 Dec 2018
For non-commercial use only
Shire Page 43
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Development of anti -viral resistance to currentl y available anti -CMV agents is also an ongoing 
clinical problem in so lid organ and stem cell transplantation leading to graft loss and even 
mortality  for some transplant patients. As described by  Limay e et al., 2000, ganciclovir 
resistance developed in 7% D+/R- kidney , liver, and pancreas recipients who were prophy laxed 
with 3 months of oral ganciclovir. Ganciclovir -resistant disease accounted for 20% of CMV 
disease, occurred late (a median of 10 months after transplantation), was as sociated with higher 
intensity  of immunosuppression, and was considered a clinicall y serious concern ( Avery , 2007 ). 
There are no approved therapies for the treatment of CMV infection or CMV disease in 
transplant recipients, and no approved treatment for CMV infection or disease that is resistant or 
refractory  to currentl y available therapies in an y population. Maribavir is currentl y under 
development for the treatment of CMV infection or disease, including those resistant or 
refractory  to ganciclovir, valganciclovir, foscarnet, or cidofovir, in transplant recipients.
1.2 Product Background and Clinical Information
Maribavir is a potent and selective, orally  bioavailable antiviral drug with a novel mechanism of 
action against CMV ( Chulay  et al., 1999) and a favorable nonclinical and clinical safet y profile. 
It is a potent member of a new class of drugs, the be nzimidazole ribosides ( Williams et al., 
2003). In side -by-side in vitro assay s it is 3 -to 20 -fold more potent than ganciclovir and 
cidofovir, and at least 100-fold more potent than foscarnet ( Biron et al., 2002 ;Drew et al., 2006 ). 
Unlike currently available anti -CMV agents that inhibit CMV deoxy ribonucleic acid (DNA) 
polymerase, maribavir inhibits the CMV UL 97 serine/threonine kinase b y competitively  
inhibiting the binding of adenosine triphosphate (ATP) to the kinase ATP -binding site ( Biron et 
al., 2002 ;Williams et al., 2003 ; Krosky  et al., 2003 ;Wolf et al., 2001; Kern et al., 2004
); the 
dominant phenoty pic inhibitory  effect of maribavir is on viral DNA assembly  and egress of viral 
capsids from the nucleus of infected cells ( Biron et al., 2002 ). Except for ganciclovir, maribavir 
does not antagonize the effects of other anti -viral (anti- CMV) agents. Since ganciclovir is 
dependent on its initial phosphory lation by  the viral UL97 kinase, maribavir may  antagonize its 
clinical efficacy . Maribavir is active in vitro against strains of CMV that are resistant to 
ganciclovir, foscarnet, or cidofovir.
1.2.1 Pharmacokinetics, metabolism, and drug -drug interactions
Results from the Phase 1 studies demonstrated that followin g oral administration, maribavir was 
rapidly  and well absorbed with mean peak plasma concentrations generally achieved between 1 
and 3 hours post dose. After administration of single and multiple doses (both twice daily  [BID] 
and 3 times daily  [TID] regime ns) over 28 days, total maribavir plasma concentrations increased 
with increasing dose proportionally up to 900 mg. At dose levels 
≥900 mg BID, there was no 
apparent increase in maximum observed plasma concentration (Cmax) levels, and above this level, 
theincrease in area under the plasma concentration versus time curve (AUC) may  be less than 
dose proportional. Maribavir demonstrates time -independent pharmacokinetics (PK). 
Pharmacokinetic data obtained in Phase 2 studies were similar to the data observed i n healthy  
volunteers.
Administration of maribavir in conjunction with food resulted in a 28% decrease in C maxwithout 
a significant effect on AUC when compared to administration under fasting conditions. 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 43 
 
07 Dec 2018
For non-commercial use only
Shire Page 44
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Bioavailabilit y of a 100 mg tablet was unaffected by crushing the tablet or changes in gastric pH. 
Maribavir was bound to plasma proteins, namel y human serum albumin (HSA), lipoproteins, and 
alpha -1-1acid -glycoprotein (AAG). The fraction of unbound maribavir was estimated at 
approximately  1.5% in healthy  su
bjects and 0.96% in transplant patients. The apparent plasma 
elimination half -life for unchanged maribavir was approximately  5-7 hours. Maribavir is 
metabolized primarily in the liver through CYP3A4 pathway  with the formation of the primary  
metabolite, VP44469. Renal clearance is a minor route of elimination of maribavir.
A mass balance study  in healthy  male and female subjects following administration of a single 
400mg oral dose of [14C] maribavir resulted in fecal recovery of radiolabel that averaged abo ut 
14% and recovery  of radiolabel in the urine that averaged about 61%. In plasma, the 
predominant drug -related species was unchanged maribavir, representing approximately  65% of 
total radioactivity  and VP 44469 represented approximately  9% of urine and fe ces. The apparent 
plasma elimination half- lives for total radioactivity  and unchanged maribavir were 
approximately  66 and 7 hours, respectively .
In vitro studies indicated that CYP 3A4 (a hepatic metabolizing enzy me) is the primary  enzyme 
involved in the f ormation of VP 44469 from maribavir; CYP 2C19 and CYP 1A2 may  also be 
involved in VP 44469 formation. Based on an in vitro study , UGT1A1, UGT1A3, UGT2B7, and 
possibly  UGT1A9 were involved in the glucuronidation of maribavir however intrinsic clearance 
was too low to be quantified. These data suggests the contribution of glucuronidation to the 
overall clearance of maribavir is considered to be low and the potential for maribavir as the 
victim of drug interactions when coadministered with UGT inhibitors/induc ers is expected to be 
low. I n vitro studies also demonstrated that maribavir is not an inhibitor of CYP3A4, CYP2A6, 
CYP2B6, CYP2C8, CYP2D6, or CYP2E1. I t is potentially  a weak inhibitor of CYP 1A2, 2C9, 
and 2C19. VP 44469 is not an inhibitor of CYP enzy mes. Maribavir is a substrate as well as an 
inhibitor of P -glycoprotein with an I C50 of 33.7 µM (P -gp: a transporter protein). Maribavir is a 
weak inhibitor for UGT1A1, UGT1A3, UGT1A9, and UGT2B7 enzy mes with I C50 values at 
32.2µM, 184µM, 123µM, and 153 µM, respectively . Maribavir has no inhibitory  effect on 
UGT1A4 and UGT1A6 at up to 500 µM.
Clinical studies conducted to evaluate the potential of drug-drug interactions demonstrated the 
following:
Concomitant administration of maribavir (400 mg BID) with tacro limus, a substrate of 
CYP 3A4 and P -gp, resulted in increased tacrolimus C maxand AUC by  38% and 51%, 
respectivel y.
Maribavir did not have a clinically  significant effect on the activity  of CYP 1A2, CYP 
3A, CYP 2C9, or CYP 2D6; however, it inhibited CYP2C1 9 activity  (based on plasma 
omeprazole/5 -OH omeprazole ratio). A follow -up clinical study  indicated maribavir had 
no effect on the PK of voriconazole (a CYP2C19 substrate). Maribavir did not affect 
digoxin (a sensitive P -gp probe) AUC, however, it increase d Cmax by  24.8%.
Concurrent administration of rifampin, an inducer of CYP 3A4 and P -
gp, and maribavir 
significantl y reduced plasma concentrations of maribavir, resulting in a 61% reduction in 
AUC, reduced half -life, and significantl y increased clearance, most likely  due to 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 44 
 
07 Dec 2018
For non-commercial use only
Shire Page 45
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
induction of hepatic and intestinal CYP 3A4, and possible enhancement of P -gp 
transport.
Concomitant administration of antacid had no effect on maribavir exposure.
Concomitant administration of ketoconazole increased maribavir AUC and C maxby 46% 
and 10%, respectivel y.
The effect of renal impairment on maribavir pharmacokinetic was evaluated in a single dose 
(400 mg) stud y with 12 subjects with normal renal function (creatinine clearance 
>80mL/minute), 10 subjects with mild/moderate rena l impairment (creatinine clearance 
30-80 mL/minute), and 9 subjects with severe renal impairment (creatinine clearance 
<30mL/minute). Mean pharmacokinetic parameter estimates based on total or unbound plasma 
drug concentrations for subjects with normal re nal function, mild/moderate renal impairment, 
and severe renal impairment were similar. Based on the results from this study , renal impairment 
does not affect the PK of maribavir; dose adjustment for subjects with mild to severe renal 
impairment is not needed. There is no experience with the use of maribavir in subjects receiving 
peritoneal dial ysis or hemodialy sis. Due to the high plasma protein binding of maribavir, dial ysis 
is unlikely  to reduce plasma concentrations of maribavir significantly .
The effec t of hepatic impairment on the pharmacokinetic of maribavir was evaluated in a single -
dose study  (200 mg) with 10 subjects with normal hepatic function and 10 subjects with 
moderate hepatic impairment based on a Child- Pugh Class B classification. Moderate hepatic 
impairment results in a modest increase in total plasma maribavir C maxand AUC values (and 
modestly  reduced clearance values) when compared to subjects with normal hepatic function. 
However, C maxand AUC values based on unbound plasma concentration s of maribavir were 
comparable among these groups.
In Stud y 1263 -200 (a Phase 2 study  of maribavir for CMV prophy laxis), based on total drug 
concentrations in plasma, stead y-state AUC values in HSCT recipients were 19 -66% higher than 
AUC values in health y subjects. This difference can be explained based on the differences in 
plasma protein binding in healthy  subjects and transplant patients. I n Study 1263 -202 (SHP620 -
202), a Phase 2 stud y of maribavir for CMV treatment, the PK parameters (AUC and C max) at 
400mg BID dose were comparable to that in the healthy  subjects.
1.2.2 Efficacy
Once the safet y and tolerability  of maribavir was established across a wide range of doses (up to 
2400 mg/day  for 28 days) in 15 Phase 1 studies, the clinical development plan focused on 
maribavir as an anti-CMV agent for the prevention of CMV disease in transplant patients. 
Results from the Phase 3 trials for CMV prevention, where maribavir was administered at 
100mg BID for up to 12 weeks in HSCT recipients and up to 14 weeks in live r transplant 
recipients, failed to reduce the incidence of endpoint adjudication committee confirmed CMV 
disease within 6 months following HSCT when compared with placebo (Study 1263- 300), and 
failed to show noninferiority  to ganciclovir with respect to th e incidence of endpoint adjudication 
committee confirmed CMV disease within 6 months following liver transplantation (Study  
1263- 301).
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 45 
 
07 Dec 2018
For non-commercial use only
Shire Page 46
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Maribavir was used for treatment of CMV infections in 6 transplant recipients (5 SOT, 1 HSCT) 
under individual emergency  investigational new drug (EIND) applications in the United States 
(US) ( Avery  et al., 2010 ). All patients had previously  been treated with multip le other anti -CMV 
drugs, and 4 out of 6 had known genotypic CMV resistance to 1 or more of those CMV drugs. 
For all 6 patients, oral maribavir treatment was initiated at a dose of 400 mg BID. In 2 patients, 
the dose was increased to 800 mg BID. The duration of treatment was individualized for each 
patient based on response. Maribavir appeared to be safe and well -tolerated, as it was 
administered for prolonged periods of time (4 out of 6 patients were dosed >6 months). Three 
patients reported 7 serious adverse events (SAEs), all of which were considered to be unrelated 
to maribavir.
Within 6 weeks of starting maribavir treatment, all subjects had a >1 log decrease in blood CMV 
DNA, and 4 of the 6 patients had no detectable CMV. Cy tomegalovirus viremia persist ed in 
2patients despite dosing >6 months; 1 of these patients had unusually  low exposure to maribavir 
based on trough blood levels. The other patient in whom CMV viremia persisted had a very  high 
baseline CMV DNA level. The genot ypic analysis for this patient revealed the presence of UL97 
maribavir -resistance mutations T409M and H411Y ( Strasfeld et al., 2010 ). 
Subsequently , in Europe, more than 200 patients received maribavir through a named patient 
program (NPP), a nd in France, through the authorized therapeutic -use procedure. Data from only  
a small subset of the French NPP were reported. These data were consistent with the US EI ND 
experience. Additional details regarding these patients are available in the maribavi r 
investigator’s brochure.
The data obtained from the small number of patients in EI ND and NPP, suggested that maribavir 
was associated with a reduction in CMV DNA in the blood in the majority  of subjects, and could 
be a useful component for the treatment of CMV infections that are resistant or refractory  to 
currentl y available anti -CMV therapies. As a result, two Phase 2 studies were conducted to 
assess the safety , tolerability , and anti -CMV activity  of maribavir for treatment of CMV 
infections: Study  SHP6 20-202 in transplant recipients with CMV infections or disease that are 
resistant or refractory  to treatment with anti -CMV agents conducted in the US and Study  
1263- 203 (SHP620 -203) in transplant recipients with wild -type CMV infections who do not have 
CMV organ disease (as ymptomatic) conducted in Europe. In both these studies subjects received 
1 of 3 dose strengths: 400, 800, or 1200 mg BID, and both studies demonstrated favorable 
anti-CMV activity  for besides showing that was well -tolerated with no safety concerns at all 
doses evaluated.
The primary  efficacy  endpoint for Study  SHP620-202 was confirmed undetectable plasma CMV 
DNA within the 6 weeks after starting study drug treatment, defined as 2 consecutive 
postbaseline, on treatment undetectable result ( <200 copies/mL) separated by at least 5 days. 
Overall, 67% of subjects achieved confirmed undetectable plasma CMV DNA within 6 weeks. 
Among maribavir groups, there was no strong evidence of dose strength differentiation in the 
proportion of subjects achiev ing the endpoint. Among subjects with 
≥1 investigator -reported 
CMV genetic mutation associated with resistance to ganciclovir/valganciclovir or foscarnet at 
baseline, 43/71 (61%) achieved confirmed undetectable plasma CMV DNA within 6 weeks after 
starting treatment with maribavir.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 46 
 
07 Dec 2018
For non-commercial use only
Shire Page 47
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Secondary  efficacy  endpoints for Study  SHP620-202 included CMV recurrence, defined as 
achievement of undetectable plasma CMV DNA in at least 2 consecutive samples separated by  at 
least 5 day s at an y time after Day 1, followed b y detectable plasma CMV DNA in at least 2 
consecutive samples separated b y at least 5 day s. Overall, 30/86 (35%) maribavir subjects had a 
CMV recurrence at an y time during the study (Note: Percentage is based on the number of 
subjects achieving undetectable CMV DNA). Twenty -four of the 30 subjects had a CMV 
recurrence while on study  drug. Thirteen of these 24 subjects developed UL97 mutations 
previously  described to confer resistance to maribavir that were not present prior to study  drug 
dosing. The remaining 6 maribavir subjects had a CMV recurrence after the end of treatment 
with study  drug. 
The primary  efficacy  endpoint for Study  SHP620-203 was confirmed undetectable plasma CMV 
DNA within 3 and 6 weeks after starting stud y drug treatment, defined as 2 conse cutive 
postbaseline, on treatment undetectable results (<200 copies/mL) separated by  at least 5 days. 
The proportion of subjects with undetectable plasma CMV DNA within 3 and 6 weeks after 
starting stud y drug treatment was numerically higher in the maribav irgroup than the 
valganciclovir group. Among the 3 maribavir dose strength groups, there was no difference in 
the proportion of subjects achieving the endpoint. I n the subgroup of subjects whose transplant 
type was HSCT, a numerically  higher percentage of subjects in the overall maribavir group 
(75%) than the valganciclovir group (48%) achieved confirmed undetectable plasma CMV DNA 
within 6 weeks. Although the percentage of subjects with high baseline plasma CMV DNA ( ≥
10000 copies/mL) was similar between t he overall maribavir and valganciclovir groups (34% vs. 
33%), a numericall y higher percentage of maribavir subjects (77%) achieved confirmed 
undetectable plasma CMV DNA within 6 weeks compared with valganciclovir (65%). 
Secondary  efficacy  endpoints for St udy SHP620-203 included CMV recurrence; this was 
assessed within 6 weeks after starting stud y drug treatment and within the study  participation 
period. Overall, 22/98 (22%) maribavir subjects and 5/28 (18%) valganciclovir subjects 
experienced a CMV recurre nce within the study  participation period (Note: Percentages are 
based on the number of subjects achieving undetectable CMV DNA). Four of the 22 maribavir 
subjects recurred while on study  drug (2 subjects each in the 400 mg BID and 800 mg BID 
groups). All 4 of these subjects developed UL97 mutations previously  described to confer 
resistance to maribavir that were not present prior to study  drug dosing. The remaining 18 
maribavir subjects and all 5 valganciclovir subjects experienced a CMV recurrence after t he end 
of study  drug treatment.
Phase 3 registration trials are underway  based on the results from these Phase 2 studies for CMV 
treatment.
1.2.3 Safety
Maribavir has been administered across a broad range of oral doses from 50 -2400 mg/day . 
Clinical safet y exper ience has been obtained from 15 Phase 1 studies in adult healthy  volunteers, 
special populations (subjects with renal and hepatic impairment, and stable renal transplant 
recipients), and HIV -infected subjects. A definitive QT study  demonstrated no clinical ly 
significant repolarization effect of maribavir administered orall y at single doses of 100 mg and 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 47 
 
07 Dec 2018
For non-commercial use only
Shire Page 48
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
1200 mg in health y subjects. I n addition, no other significant electrocardiographic effects of 
maribavir were found.
Maribavir had a favorable safet y and tolerabilit y profile in both the Phase 2 and Phase 3 trials for 
CMV prophy laxis. Adverse events (AEs) were most commonly  associated with gastrointestinal 
(GI) disorders (eg, diarrhea, d ysgeusia, nausea, and vomiting). These events were generally  of 
mild or m oderate intensity. There were no signals of clinicall y significant effects of maribavir on 
vital signs, ECG parameters, or laboratory  findings in the studies conducted for CMV 
prophy laxis.
In both Phase 2 studies for treatment of CMV infection (Studies SHP 620-202 and SHP620 -203), 
subjects received maribavir at 1 of 3 dose strengths: 400, 800, or 1200 mg BID, and b oth studies 
demonstrated that maribavir was well- tolerated with no safet y concerns at all doses evaluated. In 
Study  SHP620- 202, treatment -emergent AEs (TEAEs) that occurred were events already  
observed in previous studies (ie, d ysgeusia, GI events, elevated immunosuppressant drug levels, 
and rash) and there were no additional safet y concerns raised from this study. In Stud y 
SHP620 -203, TEAEs that oc curred at a higher frequency  in maribavir subjects compared with 
valganciclovir were events alread y observed in previous studies with maribavir (ie, d ysgeusia, GI 
events, and elevated immunosuppressant drug levels). Analy ses of clinical laboratory , vital s igns, 
and ECG data did not identify  any clinicall y meaningful differences across the maribavir 
treatment groups.
Based on the Phase 2 CMV treatment and Phase 3 CMV prophy laxis studies, the adverse drug 
reactions (ADRs) associated with maribavir use are: ab dominal pain, abdominal pain upper, 
decreased appetite, diarrhea, dizziness, dy sgeusia, fatigue, headache, immunosuppressant drug 
level increased, nausea, and vomiting.
To date, maribavir has shown an overall favorable safet y profile in placebo -controlled studies, 
open -label studies, and in studies that compared maribavir with other CMV therapies 
(ganciclovir, valganciclovir) for proph ylaxis and for CMV treatment in HSCT and SOT patients. 
Treatment effect on viral load reduction (confirmed undetectable plas ma CMV DNA: 67% of 
subjects within 6 weeks in Study  SHP620- 202; 60.5% of subjects in 3 weeks and 77.3% of 
subjects in 6 weeks in Study  SHP620- 203) seen in Phase 2 treatment studies coupled with 
acceptable safet y and tolerability establish the positive bene fit-risk profile and warrant further 
investigation of maribavir in the treatment of refractory  CMV infections in transplant recipients.
Refer to the latest version of the maribavir investigator’s brochure for the most detailed and most 
current information regarding the drug metabolism, pharmacokinetics, efficacy  and safety  of 
maribavir.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 48 
 
07 Dec 2018
For non-commercial use only
Shire Page 49
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
2. STUDY OBJECTIVES AND PURPOSE
2.1 Rationale for the Study
The population of transplant recipients whose CMV infections are resistant or refractory  to 
treatment with ganciclovir, valganciclovir, foscarnet, or cidofovir, including the pediatric 
population, is a significant unmet medical need. There are limited treatment options for these 
patients and no anti- viral drugs specifically  approved for this purpose. Strategies to treat res istant 
or refractory  CMV infections include minimizing immunosuppression when possible; increasing 
the dose of, combining, or switching among the available anti- viral drugs (ie, 
ganciclovir/valganciclovir, foscarnet, cidofovir); and the use of adjunctive t reatments as 
intravenous immunoglobulin (I VIg), cy tomegalovirus immune globulin (CMV Ig), adoptive 
infusions of CMV -specific T- cells, altering the immune suppressive regimen to mTOR inhibitors 
(sirolimus and everolimus), use of medications such as leflunomide, and artesunate ( Kotton et 
al., 2013 ;Nishihori et al., 2015 ). No robust data are available on the effectiveness of these 
strategies reinforcing the need for an effective anti -CMV agent.
Results from the Phase 2 study  SHP620- 202 support the safet y, tolerability , and anti- viral 
activity  of maribavir for the treatment of resistant or refractory  CMV infections in transplant 
recipients. Study  SHP620 -202 was a multicenter, randomized, dose -ranging, parallel- group study  
of maribavir for the treatment of CMV infections that we re resistant or refractory  to treatment 
with ganciclovir, valganciclovir, or foscarnet in HSCT and SOT recipients. Study  subjects were 
randomized in a 1:1:1 allocation ratio to receive oral maribavir at 1 of 3 dose strengths (400 mg 
BID, 800 mg BID, or 120 0mg BID) for up to 24 weeks. While there was no strong evidence of 
differentiation among the 3 maribavir dose strengths, all maribavir doses were similarl y effective 
at clearing CMV viremia based on the proportion of subjects with confirmed undetectable 
plasma CMV DNA within 6 weeks after starting study  drug treatment. Maribavir was also 
generally  well- tolerated across the dose range studied; commonly  reported adverse events, such 
as dy sgeusia and gastrointestinal events (eg, nausea, vomiting, diarrhea), w ere consistent with 
the known maribavir safety  profile.
This Phase 3 study  is designed to further assess and demonstrate the efficacy  and safet y of 
maribavir, dosed at 400 mg BID, compared to investigator -assigned anti -CMV treatment (IAT) 
of choice for the treatment of CMV infections that are resistant or refractory  to treatment with 
ganciclovir, valganciclovir, foscarnet, or cidofovir in HSCT and SOT recipients.
2.2 Rationale for the Study Design
This study  will assess the efficacy  and safet y of maribavir for the treatment of refractory  CMV 
infections, including those with documented resistance to treatment with ganciclovir, 
valganciclovir, foscarnet, or cidofovir, on the basis of clearance of CMV viremia. Improvement 
or resolution of tissue invasive CMV diseas e and CMV sy ndrome will also be assessed as 
applicable. Based on published literature, ganciclovir- resistant disease accounted for 20% of 
CMV disease, occurred late (a median of 10 months after transplantation), was associated with 
higher intensity  of immu nosuppression, and is a clinically  serious concern ( Avery , 2007 ). As 
there are limited treatment alternatives and no anti- CMV agents specifically approved to treat 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 49 
 
07 Dec 2018
For non-commercial use only
Shire Page 50
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
resistant or refractory  CMV infections, treatment with mar ibavir may  address the unmet medical 
need for this population. 
Investigator assigned anti -CMV treatment with 1 or 2 of the 4 anti-CMV drugs (ganciclovir, 
valganciclovir, foscarnet, or cidofovir) with additional strategies when deemed necessary  by 
investig ator (eg, change in the dose of the anti- CMV drug, reduction of immunosuppressant, 
addition of IVIG or CMV Ig) is the active control group for this study . The subject on single or 
dual therap y with anti –CMV agents at the time of enrollment, may  either chan ge therap y at the 
time of randomization/treatment initiation or remain on the same therap y as the investigator 
assigned anti -CMV treatment, if randomized to this study  arm. If the treatment was continued or 
started as 2 anti -CMV agents, withdrawal of 1 age nt, while continuing the second one will be 
possible.
While there are no approved therapies for the treatment of CMV infections, and those that are 
resistant or refractory  to currentl y available anti -CMV agents, published CMV treatment 
guidelines include r ecommendations for the treatment of such infections ( Kotton et al., 2013 ).
In HSCT recipients, when CMV replication is detected above the predefined threshold during the 
monitoring of CMV infection, the pre -emptive treatment is generall y given for a minimum of 2 
weeks with further extension until CMV becomes undetectable. There is a difference in practice 
regarding the minimum duration of therap y. Valganciclovir (previously ganciclovir) is often used 
for pre -emptive therapy , although foscarnet can be used as well ( Busca et al., 2007 ; Reusser et 
al.,2002). However, foscarnet is associated with nephrotoxicity, and requires intravenous 
hydration and frequent electrol yte monitoring ( Reusser et al., 2002); cidofovir is used much less 
due to substantial side ef fects including nephrotoxicity  and m yelosuppression ( Tombly n et al., 
2009). Ganciclovir or valganciclovir use is associated with bone marrow toxicities that 
specificall y in the HSCT recipients are a considerable clinical issue. Although these agents are 
used widel y the y are not approved for the C MV treatment indication. Furthermore, the use of a 
comparator arm in the context of a pivotal Phase 3 trial will provide for a more rigorous 
interpretation of virologic response to maribavir.
Study  subjects will be randomized to receive either maribavir or investigator -assigned anti -CMV 
treatment for 8 weeks during the stud y treatment phase. In the SHP620 -202 study  (HSCT and 
SOT recipients with resistant or refractory  CMV infections), the majorit y of maribavir subjects 
achieved confirmed undetectable plasma CMV DNA levels by  Week 6 of study  drug treatment, 
while CMV recurrence occurred at rates not unexpected for a population with such an 
overwhelmingl y severe illness and concurrent lack of host immune responsiveness. A fixed 
duration, 8- week treatment regim en, in this Phase 3 study  will account for a longer duration of 
treatment need in patients of certain transplant t ypes (ie, lung transplant) consistent with clinical 
practice as well as secondary  proph ylaxis of recurrence after achieving undetectable plasm a 
CMV DNA levels; furthermore, in the context of a clinical trial, the 8 -week treatment duration 
will allow to standardize the duration for measuring the primary  efficacy  endpoint.
While the currentl y available anti -CMV agents ganciclovir, valganciclovir, foscarnet, and 
cidofovir may  be considered in clinical practice to treat refractory
 or resistant CMV infections, 
their use is limited by  their respective toxicities, most notably  bone marrow suppression caused 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 50 
 
07 Dec 2018
For non-commercial use only
Shire Page 51
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
by ganciclovir/valganciclovir and nephrotoxici ty caused b y foscarnet or cidofovir. Such 
toxicities can also worsen existing bone marrow suppression associated with transplant related 
maintenance with immunosuppressive therapy . Recognizing such safet y limitations as well 
situations where no treatment effect is observed, subjects randomized to investigator -assigned 
anti-CMV treatment will be afforded the opportunity  to enter into a maribavir rescue arm (for 
8 weeks of treatment) based on objective criteria relative to a lack of anti- CMV activity  (impact 
on viremia) after a certain duration of therapy , with or without intolerance to their assigned 
treatment.
The clearance of CMV viremia (plasma CMV DNA clearance) is considered a surrogate marker 
that may  correlate to direct clinical benefit for the treatme nt of CMV infection or disease. While 
no registration trials for the treatment of established CMV infection in transplant patients have 
been conducted the VI CTOR study  (Asberg et al., 2007) of IV ganciclovir versus oral 
valganciclovir for the treatment of CMV disease in SOT recipients demonstrated that clearance 
of CMV viremia was highly  correlated wit h resolution of CMV disease. This correlation was 
further evidenced with the subsequent analy sis of VI CTOR study  plasma samples using the 
COBAS®AmpliPrep/COBAS®TaqMan®CMV Test, a test calibrated to the World Health 
Organization I nternational Standard fo r Human CMV for Nucleic Acid Amplification 
Techniques. These recent findings, together with the maribavir Phase 2 study  results, support a 
primary  efficacy  endpoint weighted on the CMV viremia clearance to demonstrate the efficacy  
of maribavir for the trea tment of resistant or refractory  CMV infections. Clinicians consider 
CMV viremia clearance when evaluating the success of therap y hence the CMV plasma/blood 
monitoring protocols are employ ed in patients with high risk of CMV infection or reactivation of 
latent CMV infection, and information of the viral load guide the decision for the pre -emptive 
treatment in the absence of the sy mptomatic disease.
Primary  endpoint based on CMV viremia clearance will be assessed at the end of Study  Week 8 
as on treatment cl earance is the most relevant assessment to determine anti- viral treatment effect. 
Assessment of treatment effect durabilit y will be measured as key secondary  and secondary  
endpoints. Although important from the clinical stand point, recurrence of CMV DNA a fter 
treatment is more influenced b y other factors such as host immune status, other comorbidities, 
immunosuppressive treatments for prevention of transplant rejection than by  the effectiveness of 
the anti -CMV drug treatment. I n addition, CMV viremia clear ance and clinical benefit of 
maribavir on tissue invasive CMV disease or CMV sy ndrome improvement or resolution after 
8weeks of treatment and maintenance of this treatment effect through the study  will be 
evaluated in subjects with tissue invasive CMV dis ease. As there are currently  no approved 
therapies for the treatment of CMV infections in the pediatric transplant recipient population, this 
study  will initiate the assessment of maribavir use in the pediatric population by  enrolling 
adolescent subjects ≥12 to <18 y ears of age.
2.3 Rationale for Dose Selection
Results from the Phase 2 studies SHP620 -202 (HSCT and SOT recipients with resistant or 
refractory  CMV infections) and SHP620 -203 (HSCT and SOT recipients with asy mptomatic 
CMV infection) demonstrated comparable efficacy  across the 400 mg BID, 800 mg BID, a nd 
1200 mg BID maribavir dose groups in the clearance of CMV viremia within up to 6 weeks after 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 51 
 
07 Dec 2018
For non-commercial use only
Shire Page 52
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
starting stud y drug treatment. I n study  SHP620- 202, however, a numerically  higher CMV 
viremia clearance rate and lower CMV recurrence rate were observed for the 400mg BID group 
compared to the 800 mg and 1200 mg BID groups. I n both Phase 2 studies, the most common 
treatment -emergent adverse events (TEAEs) included dy sgeusia, events of nausea, vomiting, and 
diarrhea, and elevated immunosuppressant drug concentrat ion levels. There was a 
dose-dependence for d ysgeusia and elevated immunosuppressant drug concentration levels. 
These findings (comparable efficacy  and better safet y profile with the 400 mg dose) support the 
further evaluation of 400 mg BID maribavir for t he treatment of CMV.
Investigators will determine the anti- CMV therapy  best suited to treat the respective subject’s 
CMV infection. Anti -CMV therapeutic strategies for this Phase 3 study  will be limited to 
commerciall y available anti -viral (anti -CMV) agent s, including ganciclovir, valganciclovir, 
foscarnet, and cidofovir that are utilized for treatment of patients in clinical practice. Subjects 
will be then randoml y assigned (2:1) to either maribavir or investigator choice of treatment.
Currently  available maribavir pharmacokinetics, PK modeling and extrapolation of sy stemic 
exposure from adults, and safet y and tolerability data in adults support the administration of the 
400mg BID dose in adolescents who weigh ≥35 kg and are able to swallow tablets. The 
expression of CYP3A4 and CYP 2C19, which are primary  enzy mes for maribavir metabolism in 
the liver, occurs during the first weeks of life ( Lu and Rosenbaum, 2014 ). The expression of 
CYP1A2, which is also involved with maribavir metabolism, the last enzy me to develop, is 
present b y 13 months of life. By 1 to 2 y ears of age, all the isoenzy me activities are similar to 
those of adults. Therefore, the bioavailability  and sy stemic exposure of maribavir in adolescent 
subjects is not expected to be different from adults at the same oral dose.
2.4 Study Objectives
2.4.1 Primary Objective
The primary  objective of this study  is to compare the efficacy  of maribavir to 
investigator -assigned anti -CMV therap y in CMV viremia clearance at the end of Study Week 8, 
in transplant recipients who are refractory  or resistant to prior a nti-CMV treatment. 
2.4.2 Key Secondary Objective
The key  secondary  objective of this study  is to compare the efficacy  of the 2 study  treatment 
arms on CMV viremia clearance and tissue- invasive CMV disease and CMV sy ndrome 
improvement or resolution at the end of Study  Week 8, and maintenance of this treatment effect 
through Stud y Week 16 (8 weeks of post -treatment/follow -up phase).
2.4.3 Secondary Objectives 
The secondary  objectives of this study  are:
To compare the efficacy  of maribavir to investigator -assigned anti -CMV therapy  on CMV 
viremia clearance after completion of 8 weeks of study  treatment in transplant recipients who 
are refractory  or resistant to prior anti -CMV treatment.
To compare the efficacy  of the 2 study  treatment arms on CMV viremia clearance and 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 52 
 
07 Dec 2018
For non-commercial use only
Shire Page 53
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
tissue-invasive CMV disease and CMV sy ndrome improvement or resolution after 
completion of 8 weeks of study  treatment and maintenance of this treatment effect through 
Study  Weeks 12, (4 weeks post -treatment period), 16 (8 weeks post -treatment/follow -up 
phase) , and 20 (12 weeks post -treatment). 
To assess the 2 study  treatment arms for maintenance of CMV viremia clearance, and 
resolution or improvement of tissue invasive CMV disease and CMV s yndrome, achieved at 
the end of Study Week 8, through weeks 12 (4 week s of post treatment period), and 20 (12 
weeks post treatment).
To evaluate the incidence of recurrence of CMV viremia in the 2 study  treatment arms during 
the first 8 weeks of the study , during the 12 weeks of the follow -up study  phase, and at any  
time dur ing the stud y.
To evaluate the incidence of recurrence of CMV viremia in the 2 study  treatment arms, when 
subjects are on treatment and off treatment.
To assess the profile of mutations in the CMV genes conferring resistance to maribavir.
To evaluate the a ll-cause mortality .
To assess the safet y and tolerability of maribavir.
To assess the efficacy , maintenance of the treatment effect, and the safet y of maribavir 
administered as the rescue treatment.
To characterize the pharmacokinetics of maribavir.
2.4.4 Exploratory Objectives
The exploratory  objectives of this study  are:
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 53 
 
07 Dec 2018
For non-commercial use only
Shire Page 54
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
3. STUDY DESIGN
3.1 Study Design and Flow Chart
This is a multicenter, randomized, open- label, active -controlled stud y to assess the efficacy and 
safet y of maribavir treatment compared to investigator -assigned anti -CMV treatment in HSCT 
and SOT recipients with CMV infections that are refractory  to treatment with ganciclovir, 
valganciclovir, foscarnet, or cidofovir, including CMV infections with confirmed resistance to 1 
or more anti -CMV agents. The study  will assess the efficacy  of maribavir by  measuring the 
plasma CMV DNA clearance. To be eligible for the study , subjects must have a documented 
CMV infection in whole blood or plasma, with a screening value of ≥2730 IU/mL  in whole 
blood or 
≥910 IU/mL  in plasma in 2 consecutive assessments, separated by at least 1 day , as 
determined b y local or central specialt y laboratory quantitative poly merase chain reaction 
(qPCR) or comparable quantitative CMV DNA test. Results should be available before the 
subject is randomized to verify  subject eligibility  for the study . Both samples should be taken 
within 14 day s prior to randomization with the second sample obtained within 5 day s before 
randomization and will be used for the stratification level in the randomization. Results from the 
same laboratory  and same sample t ype ( whole blood or plasma) must be used for these 
assessments. The current CMV infection must be refractory  to 1 or more of the available 
anti-CMV agents (ganciclovir, valganciclovir, foscarnet, or cidofovir) and the subject must meet 
the remaining specified e ligibility  criteria. 
“Refractory ” will be defined as:
Documented failure to achieve >1 log 10(common logarithm to base 10) decrease in CMV 
DNA level in whole blood or plasma after a 14 day  or longer treatment period with I V 
ganciclovir/oral valganciclovir , IV foscarnet, or IV cidofovir. This definition applies to the 
current CMV infection and the most recentl y administered anti -CMV agent. 
“Resistant ” will be defined as:
Documented failure to achieve >1 log 10(common logarithm to base 10) decrease in CMV 
DNA level in whole blood or plasma after a 14 day  or longer treatment period with I V 
ganciclovir/oral valganciclovir, IV foscarnet, or IV cidofovir. This definition applies to the 
current CMV infection and the most recentl y administered anti -CMV agent.
AND
Documentation of 1 or more CMV genetic mutations associated with resistance to 
ganciclovir/valganciclovir, foscarnet, and/or cidofovir. 
Results from the same laboratory  and the same sample ty pe (whole blood or plasma) are to be 
used to determine the refra ctoriness. Note: Failure to respond to these agent(s) due to intolerance 
will not be considered ‘refractoriness’.
The documentation of the resistance during screening will be based on the local specialt y 
laboratory  genot yping assay results. Plasma samples obtained at baseline for CMV DNA 
genot yping will be used for the final determination of mutations in the UL 97, UL 27, and UL54 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 54 
 
07 Dec 2018
For non-commercial use only
Shire Page 55
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
genes known to confer resistance to anti- CMV agents; these assessments will be based on the 
results from the central specialt y lab oratory  and utilized for analy sis. Subject enrollment will be 
monitored to achieve an approximate target of 60% of subjects who have a CMV infection with 
documented resistance to any of the anti -CMV agents (ganciclovir, valganciclovir, foscarnet, or 
cidofovir) according to the central specialt y results from samples taken at baseline.
The subjects randomized to maribavir treatment arm will discontinue the therapy  they  were 
currentl y on at the time of enrollment. For subjects randomized to the investigator as signed 
treatment arm, the investigator will determine at the time of randomization/treatment initiation 
whether the subject will change the therap y they  were currently  on at the time of enrollment, or 
will remain on the same therap y (single or dual anti- CMV agent therap y) after randomization 
(per Inclusion Criterion 5). If the treatment was continued or started as 2 anti -CMV agents, 
withdrawal of 1 agent, while continuing the second one will be possible. Addition of or switch to 
another anti -CMV agent will be declared as a failure for the purpose of study  anal ysis. After 
randomization changes to the investigator treatment of choice could include, change in dosing, 
dosing regimen, but will not include an addition of or switch to another anti -CMV agent. Note 
that changes between IV ganciclovir and oral valganciclovir are allowed. Combination therap y 
with cidofovir and foscarnet is prohibited.
All eligible subjects will be stratified b y transplant type (HSCT or SOT) and screening whole 
blood or plasma CMV DNA c oncentration (high viral load with CMV DNA ≥273000 IU/mL  in 
whole blood or ≥91000 IU/mL in plasma, intermediate viral load ≥27300 and <273000 IU/mL 
in whole blood or ≥9100 and <91000 IU/mL in plasma, and low viral load <27300 and ≥2730 
IU/mL in whole blood or CMV DNA <9100 and ≥910 IU/mL  in plasma as determined b y the 
most recent local or central specialt y laboratory  qPCR results available at the time of 
randomization) as 2 stratification factors and then randomized in a 2:1 allocation ratio to receive 
maribavir 400 mg BID or investigator -assigned anti -CMV treatment for 8 weeks.
A cohort of subjects will have tissue-invasive CMV disease or CMV s yndrome at baseline, as 
initially  determined by  the investigator (also referred as “ symptomatic subjects”). Therefore, this 
study  will also assess improvement or resolution of tissue -
invasive CMV disease and CMV 
syndrome at the end of the 8 -week study  treatment phase and during the follow -up phase for 
subjects with sy mptomatic CMV infection present at baseline. “Asymptomatic subjects ” will be 
defined as: Eligible enrolled subjects who do not have tissue -invasive CMV disease or CMV 
syndrome at baseline, as diagnosed by  the investigator.
The investigator will perform the initial diagnosis of tissue invasive CMV dis ease or CMV 
syndrome (absence or presence) for the s ymptomatic subjects at baseline and new occurrence of 
tissue invasive CMV disease or CMV s yndrome for the as ymptomatic subjects at baseline 
through the stud y, and will continue with the assessment of the status (ie, no change, 
improvement, worsening, or resolution) at subsequent visits through the study . All investigator -
assessed cases of tissue invasive CMV disease and CMV sy ndrome will be reviewed and 
adjudicated b y an independent Endpoint Adjudication C ommittee (EAC) both for the 
confirmation of the diagnosis of baseline and new sy mptomatic CMV infection and for the 
outcome (ie, no change, improvement, worsening, or resolution).
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 55 
 
07 Dec 2018
For non-commercial use only
Shire Page 56
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
An independent data monitoring committee (DMC) will be established to act in an expert, 
advisory  capacit y for periodic assessment of the data to monitor participant safet y and to ensure 
the validity  and scientific merit of the trial.
As shown in the study  schematic in Figure 1, the study  will have 3 phases: (1) Up to a 2- week 
screening phase; (2) 8 -week study  treatment phase; and (3) 12- week follow -up phase. Subjects 
will be required to visit the site up to 19 times for up to a 22 -week period. Subjects entering the 
maribavir rescue arm may  participate in the study  for a longer dura tion, depending on the time of 
the transition from the investigator -assigned study treatment to maribavir, with a maximal time 
of 29 weeks.
Figure 1:Study Design Flow Chart
*Visit 2A/A -R is only required for subjects taking tacrolimus, cyclosporine, everolimus, or sirolimus at Visit 2/2R.
BID=twice daily; BL=baseline; R=rescue; Rand=randomized; wks=weeks
Note: Eligibility to enter maribavir rescue arm will be assessed starting at Visit 5/week 3 up to Visit 9/Week 7
Screening Phase
As presented in Schedule of Assessment 1, Table 1, 413 subjects will be screened for 
approximately  2 weeks to establish eligibility  for study  participation. All screening procedures 
will be completed within 14 day s prior to initiation of study  treatm ent, with the exception of the 
following:
1.Screening clinical laboratory  tests (hematology, chemistry , and pregnancy ) must be 
performed within 7 day s prior to initiation of study  treatment.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 56 
 
07 Dec 2018
For non-commercial use only
Shire Page 57
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
2. Subjects must have a documented CMV infection in whole blood or plasma with a screening 
value of ≥2730 IU/mL in whole blood or ≥910 IU/mL  in plasma or in 2 consecutive 
assessments, separated by  at least 1 day , as determined by  local or central specialt y 
laboratory  quantitati ve poly merase chain reaction (PCR) or comparable quantitative CMV 
DNA results. The first sample must be available within 14 days prior to study  enrollment (ie, 
start of study treatment) at Visit 2/Day 0. The second sample must be available within 5 day s 
prior to the study  enrollment. CMV DNA quantification may  be performed by  the local or 
central specialt y laboratory. Alread y available results from the local laboratory  (historical 
results) will be acceptable for screening, if taken within the time frames in dicated and if from 
the same laboratory  and same sample t ype (whole blood or plasma) .
3.Historical results for human immunodeficiency  virus (HIV) tests performed within 3 months 
prior to the study  treatment initiation will be acceptable for screening. If no HIV test result 
within 3 months is available, the subject must have testing done locall y during the screening 
period and have negative results available prior to randomization. 
4.The investigator must identify  the remaining treatment options available for t he subject and 
must be willing to treat the subject with at least 1 of the available anti -CMV drugs.
All clinical laboratory  results required for eligibility  verification (screening) must be available 
prior to randomization.
Study Treatment Phase
Approxima tely 351 eligible subjects with refractory  or resistant CMV infection will be stratified 
and then randomized in a 2:1 ratio at Visit 2/Day 0 to receive either maribavir or 
investigator -assigned anti -CMV treatment (collectively , the study  treatment; 234 sub jects 
[maribavir]: 117 subjects [investigator -assigned anti -CMV treatment]) for 8 weeks.
The screening and Visit 2/Week 0/Day  0 visits can occur on the same day  if the historical 
laboratory  results including CMV DNA quantification results, needed for evalu ation of eligibility  
are available or results can be obtained the same day . All Visit 2/Day  0 procedures and screening 
laboratory  results needed to confirm eligibility , including blood collection for CMV DNA 
quantification, hematology  and chemistry  analy sis in the central laboratory, must be completed 
and documented prior to randomization and study  treatment administration. Central laboratory  
results of CMV DNA quantification and genot yping, hematology  and chemistry  from samples 
taken at Visit 2/Day  0 will not be available for use for screening the patients. I nitiation of study  
treatment (ie, first dose) will only occur after completion of all required Visit 2/Day  0 
procedures, confirmation of eligibility , and completion of randomization. This will be done 
under the supervision of investigator site personnel.
All subjects will perform study -specific evaluations weekl y during the 8
-week study  treatment 
phase. Refer to Schedule of Assessment 1 ( Table 1) for a complete list of the evaluations 
performed in the st udy treatment phase. 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 57 
 
07 Dec 2018
For non-commercial use only
Shire Page 58
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Subjects Randomized to Maribavir Treatment
Depending on the time of the first maribavir dose on Visit 2/Week 0/Day  0, a second dose should 
be administered on Visit 2/Day  0 provided that doses can be separated by a minimum of 8 hours; 
otherwise, onl y 1 dose should be administered on Visit 2/Day  0. Maribavir will then be 
administered (preferabl y) every  12 hours (q12h). When q12h dosing is not feasible, the doses 
should be separated b y a minimum of 8 hours. Since 200 mg strength maribavir tablets will be 
utilized, subjects will be required to take 2 tablets of maribavir q12h as shown in Table 4. 
Subjects will take the maribavir 400 mg BID dose for the 8 weeks of the study  treatment phase.
Subjects Randomized to Investigator -Assigned Anti -CMV Therap y
Investigator -assigned anti -CMV treatment strategies for the 8 weeks of the study  treatment phase 
must only  utilize up to 2 available anti- CMV agents from the following: ganciclovir, 
valganciclovir, foscarnet, or cidofovir. Combination therap y ofcidofovir and foscarnet is 
prohibited due to the risk of nephrotoxicity .
If investigator’s decision is to change the pre- study  anti-CMV agent(s), the investigator can 
select up to 2 new anti -CMV drugs (ganciclovir, valganciclovir, foscarnet, cidofovir) as the study  
treatment .
Investigator may  also decide to keep the subject on the same anti- CMV drug(s), which was/were 
used for treatment of subject prior to randomization / treatment initiation.
If the treatment was continued or started as 2 anti -CMV agents, withdrawal of one agent, while 
continuing the second one will be possible. After randomization changes to the investigator 
treatment of choice could include, change in dosing, change in dosing regimen, but will not 
include an addition of or switch to anoth er anti -CMV agent (other than changing between IV 
ganciclovir and oral valganciclovir).
Dose adjustment is allowed as deemed appropriate by the investigator. The rationale for dose 
adjustment will be documented; change to another anti -CMV agent during the study  treatment 
period is not allowed. Investigational anti-CMV agents are not permitted. Additional treatment 
strategies can complement the use of a single anti -CMV agent, for example, reducing or 
modify ing the immunosuppressant drug use or use of IVIg or CMV Ig.
Subjects will follow the investigator’s prescribed anti- CMV treatment. Subjects will remain on 
their investigator- assigned anti -CMV therap y for the 8 weeks of the stud y treatment phase. 
Subjects may  stop treatment at the discretion of the investig ator, for lack of confirmed viremia 
clearance and/or intolerance to the assigned treatment. Subjects may  be assessed for rescue arm 
eligibility  at the investigator’s discretion. Intolerance to assigned treatment without clear 
evidence of virologic and/or c linical failure will not qualify  a patient for the rescue arm. Viremia 
clearance should be based on the results from the same laboratory  used for randomization. 
Subjects may  be assessed for entry  into a rescue arm, starting at Visit 5/Week 3 (after a 
minimum 3 weeks of treatment), for treatment with maribavir 400 mg BID for 8 weeks. Subjects 
must meet 1 of the following criteria to be eligible to enter the maribavir rescue arm:
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 58 
 
07 Dec 2018
For non-commercial use only
Shire Page 59
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
1. Subject has increased whole blood or plasma CMV viremia levels of ≥1 log 10from 
baseline as measured b y the local or central specialty  laboratory  qPCR assay (results 
from the same laboratory will be compared). Local specialty  laboratory  results must be 
documented.
2. Subjects with tissue invasive CMV disease must meet both criteria after being on
treatment for at least 3 weeks:
Subject whole blood or plasma CMV DNA has decreased <1 log10 from baseline as 
measured b y the local or specialt y laboratory  qPCR assay  (results from the same 
laboratory  will be compared). Local specialty  labo ratory  results must be documented.
Symptomatic subject’s presenting tissue invasive CMV disease did not improve, or 
worsened as assessed b y the investigator OR subject who was as ymptomatic at 
baseline developed tissue invasive CMV disease.
3. No CMV viremia c learance was achieved (results from the same laboratory will be 
assessed) necessitating continued anti- CMV treatment AND the subject has demonstrated 
intolerance to the investigator -assigned anti-CMV treatment as evidenced by 1 of the 
conditions:
Acute inc rease in serum creatinine, at least 50% increase from the baseline value, 
attributed to treatment (cidofovir, foscarnet) toxicity .
Development of hemorrhagic cy stitis when on treatment with cidofovir or foscarnet.
Development of neutropenia (absolute neutr ophil count ANC <500/mm3[0.5 x 
109/L]) when on treatment with ganciclovir or valganciclovir.
Assessments based on local laboratory  results must be documented.
The transition into the rescue arm will be allowed after the stud y medical monitor has reviewed 
the investigator’s request and has approved the subject’s eligibility  for the rescue arm. Blood 
sample taken for CMV DNA test at the first visit of the maribavir rescue treatment period will be 
used as the ‘baseline’ assessment for the purpose of the anal yses of the response to maribavir 
rescue treatment (including resistance anal yses). Subjects who are unable to continue taking 
investigator -assigned anti -CMV treatment due to the lack of anti- viral activity  and/or intolerance 
to the assigned treatment and d o not meet the eligibility  criteria to enter the maribavir rescue arm 
will be treated as deemed appropriate b y the investigator.
The investigator may  also choose to interrupt therapy  for a maximum of 7 consecutive day s, or 
up to 2 study  treatment interrupt ions for a total of up to 7 days. This will not result in permanent 
study  treatment discontinuation. If study  drug is interrupted for any  reason and subsequentl y 
resumed, the end of the study  drug administration period would remain fixed at a maximum of 
8 weeks after the date of the start of treatment.
All subjects will undergo study -specific evaluations weekl y during the study treatment phase. 
Refer to Schedule of Assessment 1 ( Table 1) for a complete list of the evaluations performed in 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 59 
 
07 Dec 2018
For non-commercial use only
Shire Page 60
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
the study  treatmen t phase. All subjects who complete the study  treatment phase through Visit 
10/Week 8 will enter the 12 -week follow -up phase. 
Subjects who prematurely discontinue stud y treatment and if in the investigator assigned 
anti-CMV treatment arm and not transferre d to the maribavir rescue arm, will complete the end 
of treatment procedures described for Visit 10/Study Week 8 in the Schedule of Assessment 1; 
these subjects will continue a modified schedule of assessments through the remaining weekl y 
visits scheduled for the study  treatment phase and the regular schedule of assessments through 
the 12- week follow -up phase. The modified schedule of assessments through the remaining visits 
of study  treatment phase will not include the use of the diary  for study  treatment compliance, 
dispense or use of an y study treatment, and PK sample collection. The end of treatment sample 
for immunosuppressant drug concentration level will be collected at the next visit scheduled 1 
week after the treatment discontinuation. After completing the 8 -week duration specified for the 
study  treatment phase, subjects will enter the 12- week follow -up phase. 
Subjects who withdraw consent during the study treatment phase will be asked to undergo all 
end of treatment evaluations and procedures liste d for Visit 10/Week 8; no further follow -up will 
be performed. 
Further details regarding discontinuation of subjects are provided in Section 4.5.1. 
Subjects who are transferred to maribavir rescue arm will be treated with maribavir for 8 weeks 
and will follow the procedures similar to subjects in the maribavir treatment arm, as indicated in 
the Schedule of Assessment 1 ( Table 1
; visits denoted with letter R). After the completion of 
8 weeks of maribavir rescue treatment, subjects will enter the 12-week f ollow -up phase and will 
follow the procedures indicated in the Schedule of Assessment 2 ( Table 2 ).
Follow -up Phase
Study -specific evaluations including central specialty  laboratory  CMV test and safet y 
assessments will occur weekl y for the first 4 weeks, th en every  2 weeks for the final 8 weeks of 
the 12- week follow -up phase. Refer to Schedule of Assessment 2 (Table 2 ) for a complete list of 
evaluations. Subjects who withdraw from the study  during the follow -up phase will undergo the 
end of study  evaluations and procedures for Visit 18/Week 20 (Follow -up Week 12) as soon as 
possible, and whenever possible, prior to initiation of an y nonstudy anti -CMV treatment (as 
deemed b y the investigator); no further follow- up will be performed.
If the subject is unable to travel to the site for the follow -up visits, these visits may  be on 
exceptional basis performed remotel y (ie, at subjects’ home) b y a qualified sponsor or site 
designee, and onl y if permitted according to local regulations. Clinical laboratory  assessments
will be collected and all other follow -up assessments will be completed. Adverse events and 
SAE collection may  be completed by  telephone follow -up call on the day  of the scheduled visit. 
It is recommended that the end of stud y visit be completed at the si te if the subject is able to 
travel.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 60 
 
07 Dec 2018
For non-commercial use only
Shire Page 61
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
3.2 Duration and Study Completion Definition
The subject’s maximum duration of participation is expected to be approximately  22 weeks 
(screening: up to 2 weeks; open- label phase: 8 weeks; follow -up phase: 12 weeks). Follow-up 
visits will occur weekly for the first 4 weeks (Weeks 9 -12), followed b y visits every  2 weeks for 
the last 8 weeks (Weeks 12 -20) of this 12- week follow -up phase.
For subjects in the maribavir rescue arm the maximal duration of study  will be 29 weeks, 
depending on the time of the transfer into the rescue arm. 
The study  will be completed in approximately  25 months. The study  completion date is defined 
as the date the final subject, across all sites, completes their final protocol- defined assessment. 
This includes the follow -up visit or contact, whichever is later. The stud y completion date is used 
to ascertain timing for study  results posting and reporting.
3.3 Sites and Regions
This is a multicenter study. Approximately  140 sites in North America, Europe, and Asia Pacific 
will participate.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 61 
 
07 Dec 2018
For non-commercial use only
Shire Page 62
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
4. STUDY POPULATION
Approximately  351 subjects, including adolescents ≥12 to <18 y ears of age, who are transplant 
recipients (HSCT or SOT) with a current CMV infection that is refractory or resistant to 
treatment with commercially  available anti- CMV agents (ie, ganciclovir, valganciclovir, 
foscarnet, or cidofovir) will be enrolled. Each subject must participate in the informed consent 
process and provide written informed consent/assent before any  procedures specified in the 
protocol are performed.
4.1 Inclusion Criteria 
The subject will not be considered eligible for the study  without meeting all of the criteria below.
1.The subject must be able to provide written, personally  signed, and dated informed consent to 
participate in the study  before completing any  study -related procedures. As applicable, a 
parent/both parents or legall y authorized representative (LAR) must provide signature of 
informed consent and there must be documentation of assent by  the subject before 
completi ng an y stud y-related procedures.
2. The subject must be a recipient of hematopoietic stem cell or solid organ transplant.
3. The subject must have a documented CMV infection in whole blood or plasma, with a 
screening value of ≥2730 IU/mL  in whole blood or ≥910 I U/mL in plasma in 2 consecutive 
assessments, separated by  at least 1 day , as determined by  local or central specialt y 
laboratory  quantitative poly merase chain reaction (qPCR) or comparable quantitative CMV 
DNA results. Both samples should be taken within 1 4 day s prior to randomization with 
second sample obtained within 5 day s prior to randomization. The same laboratory  and same 
sample ty pe (whole blood or plasma) must be used for these assessments.
4. The subject must have a current CMV infection that is refra ctory  to the most recentl y 
administered of the four anti -CMV treatment agents. Refractory  is defined as documented 
failure to achieve >1 log 10(common logarithm to base 10) decrease in CMV DNA level in 
whole blood or plasma after a 14 day  or longer treatme nt period with IV ganciclovir/oral 
valganciclovir, IV foscarnet, or IV cidofovir. 
Subjects with documentation of 1 or more CMV genetic mutations associated with 
resistance to ganciclovir/valganciclovir, foscarnet, and/or cidofovir must also meet the 
defin ition of refractory  CMV infection.
5. The investigator must be willing to treat the subject with at least 1 of the available anti- CMV 
drugs (ganciclovir, valganciclovir, foscarnet, or cidofovir). Note: Combination therapy  with 
foscarnet and cidofovir is not p ermitted in the IAT arm due to the potential for serious 
nephrotoxicity . 
6.The subject must be ≥12 y ears of age at the time of consent.
7.The subject must weigh ≥35 kg.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 62 
 
07 Dec 2018
For non-commercial use only
Shire Page 63
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
8.The subject must have all of the following results as part of screening laboratory  assessm ents 
(results from either the central laboratory  or a local laboratory  can be used for qualification):
a.Absolute neutrophil count (ANC) ≥1000/mm3[1.0 x 109/L]
b. Platelet count ≥25000/mm3[25 x 109/L]
c.Hemoglobin ≥8g/dL
d.Estimated glomerular filtration rate (eGFR) >30 mL/min/1.73m2 as assessed by 
Modification of Diet in Renal Disease (MDRD) formula for subjects ≥18 years of 
age or Schwartz formula for subjects <18 years of age (see Appendix 11 for the 
formulae)
9.The subject must have a negative serum β -human chorionic gonadotropin (β -HCG) 
pregnancy  test at screening, if a female of child bearing potential. Additional urine pregnancy  
tests may  be done per institutional requirements. Sexually  active females of child bearing 
potential must agree to comply  with an y applicable contraceptive requirements of the 
protocol. If male, must agree to use an acceptable method of birth control, as defined in the 
protocol, during the study treatment administration period and for 90 day s afterward if 
treated with maribavir, ganciclovir, valganciclovir, or cidofovir and for 180 day s afterward if 
treated with foscarnet.
10. The subject must be able to swallow tablets, or receive tablets crushed and/or dispersed in 
water via a nasogastric or orogastric tube.
11.The subject must be willing and have an understanding and ability  to full y comply  with study  
procedures and restrictions defined in the protocol.
12.The subject must be willing to provide necessary
 samples (eg, biops y) for the diagnosis of 
tissue invasive CMV disease at baseline as determined by  the investigator.
13.The subject must have a life expectancy  of ≥8 weeks.
4.2
Exclusion Criteria
Subjects are excluded from the study  if an y of the following exclusion criteria are met. 
Subjects must not:
1.Have a current CMV infection that is considered refractory  or resistant due to inadequate 
adherence to prior anti-CMV treatment, to the best knowledge of the investigator
2.
Require ganciclovir, valganciclovir, foscarnet, or cidofovir administration for conditions 
other than CMV when study treatment is initiated (example: herpes simplex virus (HSV) 
coinfection requiring use of an y of these agents after the randomization) or would need a 
coadministration with maribavir for CMV infection. NOTE: A subject who is not continuing 
with the same an ti-viral drug(s) (ganciclovir, valganciclovir, or foscarnet) for the study  
treatment (if randomized to the investigator assigned anti -CMV treatment arm), must 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 63 
 
07 Dec 2018
For non-commercial use only
Shire Page 64
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
discontinue their use before the first dose of study drug. If subject is currently  being treated 
with cidofovir and is assigned another anti- CMV therap y by the investigator, the subject 
must discontinue its use at least 14 day s prior to randomization at Visit 2/Day  0 and the first 
dose of study  treatment.
3. Be receiving leflunomide, letermovir, or artes unate when study  treatment is initiated. NOTE: 
Subjects receiving leflunomide must discontinue the use at least 14 day s prior to 
randomization at Visit 2/Day  0 and the first dose of study  treatment. Subjects receiving 
letermovir must discontinue use at lea st 3 day s prior to the first dose of study  treatment. 
Subjects receiving artesunate must discontinue the use prior to the first dose of study  
treatment.
4.Have severe vomiting, diarrhea, or other severe gastrointestinal illness within 24 hours prior 
to the f irst dose of study  treatment that would preclude administration of oral/enteral 
medication.
5.Have known h ypersensitivity  to the active substance or to an excipient for a study treatment.
6.Have tissue invasive CMV disease with central nervous sy stem involveme nt, including the 
retina (eg CMV retinitis).
7. Have serum aspartate aminotransferase (AST) >5 times upper limit of normal (ULN) at 
screening, or serum alanine aminotransferase (ALT) >5 times ULN at screening, or total 
bilirubin ≥3.0 x UL N at screening (excep t for documented Gilbert’s s yndrome), b y local or 
central lab. Note: Subjects with biopsy  confirmed CMV hepatitis will not be excluded from 
study  participation despite AST or ALT >5 times ULN at screening.
8.Have known positive results for human immunodefici ency  virus (HIV). Subjects must have a 
confirmed negative HIV test result within 3 months of study  entry  or, if unavailable, be 
tested by  a local laboratory  during the screening period.
9.Require mechanical ventilation or vasopressors for hemody namic support at the time of 
enrollment.
10. Be female and pregnant or breast feeding.
11.Have previously  received maribavir.
12.Have received an y investigational agent with known anti -CMV activity  within 30 day s 
before initiation of stud y treatment or investigational CMV vaccine at an y time.
13.Have received an y unapproved agent or device within 30 day s before initiation of study  
treatment.
14.Have active malignancy  with the exception of nonmelanoma skin cancer. Subjects who have 
had a HSCT and who experience relapse or progres sion of the malignancy , as per 
investigator’s opinion are not to be enrolled.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 64 
 
07 Dec 2018
For non-commercial use only
Shire Page 65
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
15.Be undergoing treatment for acute or chronic hepatitis C.
16.Have any clinicall y significant medical or surgical condition that in the investigator’s opinion 
could interfere with th e interpretation of study  results, contraindicate the administration of 
the assigned study  treatment, or compromise the safet y or well -being of the subject.
4.3 Restrictions 
There will be no special restrictions for subjects participating in this study . Subje cts are to 
maintain their normal diets, medications (except those listed in Section 5.2.2), and activities of 
daily  life as determined by  the investigator.
4.4 Reproductive Potential
4.4.1 Female Contraception
There is no clinical experience with maribavir in pregnant subjects. The investigator assigned 
treatments (ganciclovir, valganciclovir, or cidofovir) have no clinical experience in pregnant 
subjects and based on the reproductive toxicity  observed in animal studies should be considered 
a potential teratogen and carcinogen in humans ( Valcy te Prescribing Information). The 
reproduct ive toxicity  studies with foscarnet (Foscavir) in animals were conducted using 
exposures that are inadequate to define the potential of teratogenicity  at levels to which women 
will be exposed (Foscavir Prescribing Information ). All female subjects of child -bearing potential 
will be tested and should have negative serum -human chorionic gonadotropin pregnancy test 
results prior to randomization. They  must agree to abstain from sexual activity  that could result 
in pregnancy  or agree to use an acceptable method of contraception. Females of child- bearing 
potential must be advised to use acceptable contraceptives throughout the study  period and for 
90 day s after the last dose of study  treatment . If hormonal contraceptives are used they  should be 
administered ac cording to the package insert and in conjunction with another acceptable method 
of contraception. Females of child- bearing potential who are not currently  sexually  active must 
agree to use acceptable contraception, as defined below, if they  become sexually active during 
the period of the stud y and 90 days following the last dose of study treatment. Sexually  active 
females of child -bearing potential should be using an acceptable form of highl y effective method 
of contraception, as defined below. 
Methods of contraception that can achieve a failure rate of less than 1% per y ear when used 
consistently  and correctly  are considered highly effective birth control methods for females of 
child-bearing potential are presented below: 
 Combined (estrogen and progestoge n containing) hormonal contraception associated with 
inhibition of ovulation (oral, intravaginal, transdermal) or progestogen -only hormonal 
contraception associated with inhibition of ovulation (oral, injectable, implantable [low 
user dependency ]) stabiliz ed for at least 30 day s prior to the screening visit (Visit 1), plus 
condoms. Note: Since hormonal contraception may  be susceptible to interaction with the 
study  treatment(s) in the study , which may  reduce the efficacy  of the contraception 
method, this met hod must be supplemented with a barrier method (preferably  male 
condom). 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 65 
 
07 Dec 2018
For non-commercial use only
Shire Page 66
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
 Intrauterine devices (IUD, all ty pes) or intrauterine hormone releasing s ystems (IUS) plus 
condoms. Note: contraception methods that in the context of the clinical trial facilitation
group (CTFG) guidance are considered to have lower user dependency .
 Bilateral tubal occlusion.
 Vasectomized male partner is a highly  effective birth control method provided that partner 
is the sole sexual partner of the female trial participant who is of child bearing potential 
and that the vasectomized partner has received medical assessment of the surgical success.
 Sexual abstinence defined as refraining from heterosexual intercourse during the entire 
period of risk associated with the study treatments. Note: the reliability  of sexual 
abstinence needs to be evaluated in relation to the duration of the clinical trial and the 
preferred and usual lifesty le of the subject.
Female subjects 12 years of age and older, who are amenorrheic for reasons other than 
menopause (12 consecutive months of spontaneous amenorrhea in patients with previous normal 
menstruation), including subjects who did not yet have the menarche, would be allowed to 
participate provided they agree to abstinence or an acceptable form of contr aception, as defined 
above.
Female subjects who are postmenopausal (12 consecutive months of spontaneous amenorrhea) or 
surgically  sterile (having undergone 1 of the following surgical acts: hy sterectomy , bilateral 
tubal ligation, bilateral oophorectom y orbilateral salpingectomy )and are at least 6 weeks 
poststerilization do not need a pregnancy  test performed prior to randomization and do not have 
to agree to the use of acceptable methods of contraception.
4.4.2 Male Contraception
Male subjects will be required to use a condom in conjunction with a highly effective method of 
birth control for their female partners of child- bearing age (described in Section 4.4.1). Both 
male participants and their female partners must use this form of birth control from the time prior 
to first dosing until 90 days after the last dose of study  treatment (ie, maribavir, ganciclovir, 
valganciclovir, or cidofovir) or 180 day s after the last dose, if treated with foscarnet. For male 
subjects, sexual inter course with pregnant partners should also be avoided during the course of 
the study  unless condoms are used from the time prior to the first dose until 90 day s after the last 
dose of study  treatment (ie, maribavir, ganciclovir, valganciclovir, or cidofovir ) or 180 day s after 
the last dose, if treated with foscarnet. Male subjects must not donate sperm until 90 day s after 
the last dose of study treatment (ie, maribavir, ganciclovir, valganciclovir, or cidofovir) or 
180 day s after the last dose, if treated w ith foscarnet .
4.5 Discontinuation and/or Withdrawal of Subjects
A subject may  withdraw (eg, withdraw consent) from the study  at an y time for an y reason 
without prejudice to their future medical care b y the phy sician or at the institution. The 
investigator or the sponsor may  withdraw the subject at an y time (eg, in the interest of the 
subject’s safety ). The investigator is encouraged to discuss withdrawal of a subject from study  
treatment with the sponsor’s medical monitor when possible. Subjects who withdraw c onsent 
during the stud y treatment phase will be asked to undergo all end of treatment evaluations and 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 66 
 
07 Dec 2018
For non-commercial use only
Shire Page 67
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
procedures listed for Visit 10/Week 8, if they  agree; subjects who withdraw from the study  
during the follow- up phase will undergo all end of study  evalua tions and procedures listed for 
Visit 18/Week 20 (Follow -up Week 12) as soon as possible and whenever possible, if they  agree, 
prior to initiation of any  nonstudy  anti-CMV treatment (as deemed by  the investigator); no 
further follow -up will be performed. 
Subjects who prematurely discontinue study treatment and if in the investigator -assigned 
treatment and not transferred to the maribavir rescue arm, will complete the end of treatment 
procedures described for Visit 10/Study Week 8 in the Schedule of Assessm ent 1 ( Table 1); 
these subjects will continue a modified schedule of assessments through the remaining weekl y 
visits scheduled for the study  treatment phase and the regular schedule of assessments through 
the 12- week follow -up phase. The modified schedule will exclude the use of the diary  for study  
treatment compliance, dispense or use of an y study treatment, and PK sample collection. The end 
of treatment sample for immunosuppressant drug concentration level will be collected at the next 
visit scheduled 1 week after the treatment discontinuation. During the period after the stud y 
treatment discontinuation and until the end of the study , subjects might be administered an 
anti-CMV treatment for lack of efficacy , recurrence of CMV viremia, or for worsening or n ew 
onset of CMV disease as deemed necessary  by the investigator. 
Subjects in the investigator -assigned anti -CMV treatment who cannot continue the treatment 
they have been randomized to and meet the criteria (see Section 3.1) to be transferred to 
maribavir rescue arm will complete the end of treatment evaluations listed for Visit 10/Week 8 
prior to being transferred. Overlapping study  procedures for Visit 2R/Week 0R do not need to be 
repeated when the end -of-treatment visit is performed on the same day  as rescue arm entry . They  
will be treated with maribavir for 8 weeks and will follow the procedures in the manner similar 
to that followed by  subjects in the maribavir treatment arm, as indicated in the Schedule of 
Assessment 1 ( Table 1) (visits denoted with l etter R). After the completion of 8 weeks of 
maribavir rescue treatment, subjects will enter the 12 -week follow -up phase and will follow the 
procedures indicated in the Schedule of Assessment 2 ( Table 2).
Subjects who withdraw consent during the stud y trea tment phase will be asked to undergo all 
end of treatment evaluations and procedures listed for Visit 10/Week 8 as soon as possible, if 
they agree, prior to initiation of any  nonstudy  anti- CMV treatment for lack of efficacy , 
recurrence of CMV viremia, or for worsening or new onset of CMV disease (as deemed b y the 
investigator). Subjects who withdraw consent during the follow- up phase will be asked to 
undergo all end of stud y evaluations and procedures listed for Visit 18/Week 20 as soon as 
possible, if they agree, prior to initiation of any  nonstudy  anti-CMV treatment (as deemed by  the 
investigator). No further follow -up will be performed.
The reason for treatment discontinuation, study  termination, date of stopping study  treatment 
(maribavir or investigator- assigned anti -CMV treatment), and the total amount of study  treatment 
taken will be recorded in the electronic diary , case report form (CRF), and source documents as 
appropriate.
Subjects who discontinue will not be replaced.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 67 
 
07 Dec 2018
For non-commercial use only
Shire Page 68
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
4.5.1 Reasons for Discontinuation a nd/or Withdrawal
The reason for stud y treatment discontinuation (maribavir or investigator- assigned anti -CMV 
treatment) and/or withdrawal from the stud y must be determined b y the investigator and 
recorded in the subject’s medical record and in the CRF. If a subject discontinues treatment or is 
withdrawn from the study for more than 1 reason, each reason should be documented in the 
source document and the most clinically  relevant reason should be entered in the CRF.
Reasons for discontinuation include but ar e not limited to:
Withdrawal of consent (by subject or b y a parent or both parents/legal guardian for pediatric 
subjects)
Adverse event (must specify  on the CRF)
CMV central nervous system (CNS) infection
-Maribavir does not cross the blood -brain barrier. If a subject in the study  develops CMV 
CNS infection (eg, meningo -encephalitis), then the subject will discontinue study  
treatment in order to be treated for this condition.
Protocol deviation (eg, lack of compliance, use of experimental drug) 
Pregnancy
Sponsor decision (must specify  on the CRF)
Death
Lost to follow -up
Lack of efficacy
Other (must specify  on the CRF)
The end of stud y treatment and the end of stud y date for each subject (ie, the date of completion 
of the study  or premature withdrawal from the study ) will be recorded in the CRF.
4.5.2 Subjects ‘Lost to Follow -up’ Prior to Last Scheduled Visit
A minimum of 3 documented attempts must be made to contact an y subject lost to follow -up at 
any time point prior to the last scheduled contact (office visit or telephone contact). At least 1 of 
these documented attempts must include a written communication sent to the subject’s last 
known address via courier or mail (with an acknowledgement of receipt request) asking that they  
return to the site for final safe ty evaluations and return any  unused investigational product.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 68 
 
07 Dec 2018
For non-commercial use only
Shire Page 69
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
5. PRIOR AND CONCOMITAN T MEDICATIONS, THERA PIES, AND 
PROCEDURES
5.1 Prior Medications, Therapies, and Procedures
Prior treatment information must be recorded on the appropriate CRF page, and will include the 
following presented in Table 3 .
Table 3: Prior Medications, Therapies, and Procedures
Time Period
(Prior to Visit 2/Day 0)Category Prior Medications, Therapies, and Procedures
Medications/procedures 
administered/performed 
for transplant related 
reason from their start 
or date of transplant 
(whichever is first )to 
the first dose of study 
treatment on 
Visit 2/Day 0Induction 
Therapy for 
Transplant*Including but not limited to: 
Pre-transplant irradiation
Chemotherapy agents
Lymphocyte depleting and nondepleting therapies, 
including monoclonal, polyclonal, and 
anti-thymocyte globulin preparations
Anti-CMV 
Prophylaxis 
and Treatment*Including, but not limited to:
Ganciclovir
Valganciclovir
Foscarnet
Cidofovir
CMV immune globulin (CCMV -GIV, Cytogam®)
Leflunomide
IVIG
Artesunate
CMV specific T -cell transfer (considered investigational)
Letermovir
All medications within 
3 months prior to the 
first dose of study 
treatment on Visit 
2/Week 0/ Day 0Transplant 
maintenance, 
rejection 
treatment, and 
other 
adjuvant/related 
therapyIncluding, but not limited to:
Systemic steroids
Cyclosporine, tacrolimus, sirolimus, everolimus, 
mycophenol ate
GVHD prophylaxis and treatment
Antirejection medications including T -cell depleting 
therapies
Photopheresis
Hematopoietic 
Growth 
Factors
Blood or Blood 
Product 
Transfusions
Other
Anti-Infective 
AgentsProphylaxis and/or treatment of viral, bacterial and 
fungal infections
Within 30 days or 5 
half-lives (whichever is 
longer)All Other All other prescription medications
All other over -the-counter medications (OTC)
All herbal supplements**
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 69 
 
07 Dec 2018
For non-commercial use only
Shire Page 70
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Table 3: Prior Medications, Therapies, and Procedures
Time Period
(Prior to Visit 2/Day 0)Category Prior Medications, Therapies, and Procedures
Any therapeutic or 
diagnostic intervention 
performed within 30 
days prior to the first 
dose of study treatment 
on Visit 2/Week 0/Day 
0Including, but not limited to:
Biopsies (along with the results obtained)
Dialysis
X-rays, CT scans, MRI, ultrasound imaging (along with 
significant findings)
CMV=cytomegalovirus; GVHD=graft -versus -host -disease; HSV=herpes simplex virus; IVIg=intravenous immunoglobulin; 
VZV=varicella zoster virus; OTC=over -the-counter medications
*Subjects for whom transplant was performed >3 months from the time of screening li mited (no dose data) information for 
induction therapy will be collected. Similarly for anti -CMV treatment data older than >3 month prior to screening will be 
recorded in more limited manner (dose prescribed, major interruptions, overall treatment duration ).
**If half -life is unknown, report use within 30 days prior to study. 
5.2 Concomitant Medications, Treatments and Procedures 
Concomitant treatment refers to all treatment (including medications) taken between the dates of 
the first dose of stud y treatment and the end of the follow -up phase, inclusive. A concomitant 
procedure is an y therapeutic and diagnostic intervention (eg, surgery /biopsy ) or diagnostic 
assessment (bacterial cultures, imaging such as X -ray, CT scans) performed between the dates of 
the fi rst dose of the stud y treatment and the end of the follow -up phase, inclusive.
5.2.1 Permitted Treatment during the Study Drug Treatment
All concomitant treatment information must be recorded on the appropriate CRF page. 
Additional treatment strategies may  compl ement the use of the study  specified anti -CMV agents, 
eg, reducing or modify ing the immunosuppressant drug use, or use of hemopoietic growth 
factors as needed for neutropenia.
Of note, changes in the net state of immunosuppression can influence response to treatment of 
CMV infection, so the reason for the change in immunosuppression with the date of change must 
be provided on the CRF. Note that the sample for the assessment of immunosuppressant agent 
concentration is included in the schedule of assessments as maribavir was found to impact the 
metabolism of some immunosuppressive agents. Any  changes in immunosuppression regimens 
due to the concomitant administration with maribavir or other reasons must be recorded in the 
CRF.
Maribavir is specificall y intended to treat human CMV infections. Maribavir is not active in vitro 
against most non CMV herpesvirus infections, including herpes simplex virus (HSV ty pe 1 and 
type 2) and VZV. At baseline, investigators will assess subjects to determine whether 
prophy laxis for these viruses is appropriate according to institutional guidelines or standard 
practices. If considered appropriate, permitted medications to use for this purpose include 
systemic acy clovir, valacy clovir, or famciclovir. Choice of medication, dose, and duration of 
such therap y is at the discretion of the investigator based on a given subject’s clinical condition 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 70 
 
07 Dec 2018
For non-commercial use only
Shire Page 71
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
(eg, net state of immunosuppression, risk factors, and other medications). These medications 
(acyclovir, valacy clovir, or famciclovir) also can be used to treat an y HSV or VZV infection that 
may occur during the study . Antifungal and antibacterial prophylactic medications will be 
allowed. Although potent inhibitors of CYP 3A4 (such as ketoconazole) could increase blood 
levels of maribavir, they  are likel y to be associated with minimal increased risk given the safet y 
profile of maribavir demonstrated at up to 1200mg BID in Phase 2 studies. 
The following concomitant medications should be taken with caution: 
Maribavir has the potential to inhibit C YP2C19 and P -gp and therefore, may increase the 
concentration of drugs that are substrates of CYP2C19 and P -gp. For drugs with narrow 
therapeutic window, the increase in drug concentration may  lead to toxicity . A drug interaction 
study  showed that maribavir (400 mg BID) increased blood concentrations of tacrolimus (a 
substrate of CYP3A and P- gp) with C maxand AUC increased b y 38% and 51%, respectivel y. 
Therefore monitoring tacrolimus (and other narrow therapeutic index immunosuppressants) 
blood concentration and tacrolimus -associated adverse events, and the appropriate dose 
adjustment of tacrolimus is reco mmended when maribavir and tacrolimus are used 
concomitantly . Conversely , after a period of coadministration, discontinuation of maribavir
could lead to reduced blood levels of tacrolimus and potentially  reduced therapeutic effect. 
Similarly , for drugs that are substrates of CYP2C19 or P -gp and have narrow therapeutic 
window, careful monitoring is recommended both after initiation of maribavir (when substrate 
levels may  increase) and after discontinuation of maribavir (when substrate levels may  decrease).
Although maribavir does not affect the activit y of CYP3A enzy me nor other CYP enzy mes other 
than CYP2C19 (including CYP1A2, CYP2B6, CYP 2C9 , CYP2C8, CYP2D6, and CYP2E1 ), 
additional caution is needed when a patient receives other concomitant medications that affect 
cytochrome P450. For patients who receive concomitant medications that are inhibitors/inducers 
of CYP3A while on maribavir treatment, additional monitoring of immunosuppressant blood 
concentrations and immunosuppressant- associated adverse events ma y be needed within a few 
days after the start of concomitant medications or maribavir.
5.2.2 Prohibited Treatment 
Concomitant use of the following medications/treatments is prohibited for all subjects during the 
study : 
Any unapproved agent or device.
Any inves tigational anti -CMV agent, including receipt of CMV vaccine at any  time prior 
to study .
Infusion of T -cells specific for CMV or regulatory T -cells (Tregs) for the control of 
transplant tolerance, which is an experimental treatment.
Maribavir 
Concomitant use of an y of the following medications is prohibited while the subject is receiving 
maribavir :
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 71 
 
07 Dec 2018
For non-commercial use only
Shire Page 72
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Strong CYP 3A inducers: avasimibe, carbamazepine, phen ytoin, rifampin, rifabutin, 
St. John’s wort ( Hypericum perforatum)
Herbal medications known to have potential toxicities or drug interactions, eg, 
Ginkgo biloba or Piper methysticum (kava)
Any of the following s ystemic anti- CMV therapies (except unintentional 
administration for no longer than 1 day ):
-Ganciclovir
-Valgancic lovir
-Foscarnet
-Cidofovir
-Leflunomide
-Artesunate
-Letermovir
Except for ganciclovir/valganciclovir, maribavir does not antagonize the effects of other 
anti-viral (anti -CMV) agents. Maribavir inhibits the CMV UL97 serine/threonine kinase by  
competitively  inhibiting the binding of adenosine triphosphate (ATP) to the kinase ATP -binding 
site. Since ganciclovir/valganciclovir is dependent on its initial phosphory lation by  the viral 
UL97 kinase, maribavir may  antagonize its clinical efficacy . Therefore, concomitan t treatment 
with maribavir and ganciclovir/valganciclovir is not allowed.
Potent inducers of CYP 3A4 and/or P -gp (such as rifampin, rifabutin, or phenobarbital) could 
reduce blood levels of maribavir , potentiall y reducing its antiviral activity . Use of alternate 
agents with less enzy me induction potential should be considered during administration of 
maribavir .
In vivo drug interaction studies with Valcy te have not been performed. Since valganciclovir is 
extensively  and rapidly metabolized to ganciclovir; drug interactions associated with ganciclovir 
will be expected for valganciclovir (Valcy te SmPC).
Maribavir does not cross the blood -brain barrier. If a subject in the maribavir treatment arm 
develops CMV central nervous s ystem (CNS) infection (eg, meningo -encephalitis) then the 
subject will discontinue maribavir treatment in order to be treated for this condition. Subjects 
who develop new CMV retinitis while in the maribavir treatment arm may  continue on therap y if 
the investigator does not intend to add another s ystemic or intraocular anti -CMV agent to treat 
the retinitis.
Administration of any  of the prohibited treatments (except coadministration of foscarnet or 
cidofovir for indications other than C MV infection) will require discontinuation of maribavir 
(including the subjects in the maribavir rescue arm).
Investigator -assigned anti -CMV treatment strategies for the 8 weeks of the study  treatment phase 
must only  utilize available 1 or 2 anti -CMV agent from the following: ganciclovir, 
valganciclovir, foscarnet, or cidofovir. Dual agent therapy  is allowed onl y if 1) the subject is on 
dual therap y prior to enrollment and this is continued as IAT during the treatment period or 2) if 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 72 
 
07 Dec 2018
For non-commercial use only
Shire Page 73
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
dual therap y is initiat ed at the time of randomization. Addition of a second agent after 
randomization is not allowed. If on dual therap y, withdrawal of one of the two agents during the 
treatment phase is allowed. Dose adjustment for safet y or efficacy will be allowed as deemed 
appropriate b y the investigator. The rationale for dose adjustment will be documented; change to 
another anti -CMV agent during the study  treatment period is not allowed (except for change 
from valganciclovir to ganciclovir, or vice versa).
Investigational anti-CMV agents are not permitted. Additional treatment strategies can 
complement the use of a single anti -CMV agent, for example, reducing or modify ing the use of 
immunosuppressant drug or use of IVIg or CMV Ig. 
Concomitant use of an y of the following me dications is prohibited while the subject is receiving 
investigator-assigned anti- CMV treatment (except unintentional administration for no longer 
than one day ):
Leflunomide
Artesunate
Letermovir
Investigator should refer to the Prescribing Information for ganciclovir, valganciclovir, foscarnet, 
and cidofovir for details on contraindication and precaution to ensure the appropriate use and 
monitoring of these drugs and concurrent medications. Addition of any  of these treatments to the 
single investigator -assigned anti -CMV treatment strategy  is not allowed during study  treatment.
5.2.3 Treatments Taken During the Follow- up Phase
All permitted (Section 5.2.1) and prohibited medications (Section 5.2.2) specified for the study  
treatment phase are applicable to the follow -up phase; however, in case of no viremia clearance, 
presence of tissue invasive CMV disease, a CMV recurrence, appropriate medications required 
for CMV treatment may  be administered in the follow -up phase as deemed necessary  by the 
investigator. The secondary  proph ylaxis for subjects with viral clearance is not recommended in 
the follow-up phase. All medications will be recorded on the CRF.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 73 
 
07 Dec 2018
For non-commercial use only
Shire Page 74
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
6. IDENTITY OF STUDY TR EATMENTS
The investigational product is maribavir ( SHP620) , which will be provided by  the s ponsor in 
200mg strength tablet form. Additional information is provided in the current maribavir 
investigator's brochure.
Investigator -assigned anti -CMV treatment will not be considered an investigational product in 
the context of this study . Study  investigators will choose and prescribe an anti -CMV drug of 
their choice from the available products utilized for treatment of CM V infection/disease in 
clinical practice, as endorsed in published guidance documents, institutional guidelines, and 
other published literature (Kotton et al., 2013 ;Tombly n et al., 2009) . The investigator -assigned 
anti-CMV treatment arm may  utilize 1 or 2 (onl y if the subject’s current dual therap y at 
enrollment is continued after randomization or started at randomization) of the following 4 
anti-CMV agents: (change from ganciclovir to valganciclovir or vice versa will be allowed):
Ganciclovir
Valganciclovir
Foscarnet
Cidofovir
Combination therapy  of cidof ovir with foscarnet is prohibited.
Dose and dose regimen of the investigator- assigned anti -CMV treatment will be at the discretion 
of the investigator following clinical practice. Adjustment of the dose (increase or decrease) 
could be done for either effic acy or safet y, as deemed appropriate b y the investigator. Reason for 
dose adjustment will be recorded.
6.1 Blinding the Treatment Assignment
This is an open -label study . The investigator(s) and the subjects will be unblinded to the 
treatment assignment.
6.2 Admini stration of Investigational Product(s)
6.2.1 Interactive Response Technology for Investigational Product Management
An IRT (interactive response technology ) will be employ ed in this study  to manage the tracking 
and confirmation of shipment, supply , inventory , ordering, expiration, randomization, 
site-assignments of the investigational product, and accountabilit y. The IRT provider will 
provide a user manual and training to each site, with detailed instruction on the use of the IRT.
6.2.2 Allocation of Subjects to Trea tment 
This is a randomized, open -label, active -controlled study . Subject numbers are assigned to all 
subjects as they  consent to take part in the study. Within each site (numbered uniquely  within a 
protocol), the subject number is assigned to subjects acc ording to the sequence of presentation 
for study  participation.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 74 
 
07 Dec 2018
For non-commercial use only
Shire Page 75
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
All eligible subjects will first be stratified based on 2 factors:
1.By transplant t ype (HSCT or SOT)
2.By the most recent screening whole blood or plasma CMV DNA concentration 
categorized in to 3 CMV DNA concentration level groups based on local or central 
specialt y laboratory  qPCR results:
High viral load with CMV DNA ≥273,000 IU/mL in whole blood or ≥
91,000 IU/mL in plasma , or
Intermediate viral load with CMV DNA ≥27,300 and < 273,000 IU/mL in whole 
blood or ≥9,100 and <91,000 IU/mL  in plasma , or
Low viral load with CMV DNA <27,300 and ≥2,730 IU/mL  in whole blood or 
<9100 and ≥910 IU/mL in plasma
Following stratification, subjects will be randomized in a 2:1 allocation ratio to receive 
open -label maribavir 400 mg BID or investigator- assigned anti -
CMV treatment for 8 weeks. The 
actual treatment given to individual subjects is determined by  a randomization schedule 
automatically  assigned by  the interactive response technology  (IRT). The randomization number 
represents a unique number corresponding to study treatment allocated to the subject, once 
eligibility  has been determined. Once a randomization number/unique identifier has been 
assigned, that number must not be used again if, for example, a subject is withdrawn from the 
study . If a randomization number/unique identifier is allocated incorrectl y, the clinical research 
associate (CRA)/stud y monitor must be notified as soon as the error is discovered.
Investigational product packag ing identification numbers, separate from randomization 
numbers/unique identifiers, may  also be assigned to subjects for specific treatment assignment as 
dictated b y the stud y. In these cases, the same investigational product packing identification 
number may  not be assigned to more than 1 subject.
6.2.3 Dosing
Initiation of stud y treatment, ie, the first dose administration, will occur at Visit 2/Week 0 on 
Day 0 after completion of all required assessments for that visit. The first dose should be 
administered un der supervision of investigator site personnel, and be initiated as soon as possible 
after randomization. I n cases where IV anti -
CMV agents cannot be ordered, prepared, and 
administered immediately  after randomization, the first dose of drug must be given within 24 
hours of randomization.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 75 
 
07 Dec 2018
For non-commercial use only
Shire Page 76
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Subjects Randomized to Maribavir Treatment
Depending on the time of the first maribavir dose on Visit 2/Day  0, a second dose should be 
administered on Visit 2/Day  0 provided that doses can be separated b y a minimum of 8 ho urs; 
otherwise, onl y 1 dose should be administered on Visit 2/Day  0. Maribavir will then be 
administered (preferabl y) every  12 hours (q12h). When q12h dosing is not feasible, the doses 
should be separated b y a minimum of 8 hours. Since 200 mg strength mari bavir tablets will be 
utilized, subjects will be required to take 2 tablets of maribavir q12h as shown in Table 4.
Maribavir may  be administered with or without food. Maribavir tablets may  be administered 
crushed and/or dispersed in water via orogastric or nasogastric tube for a short period of time 
during the stud y treatment phase to avoid interruption or discontinuat ion of treatment. Consult 
the maribavir pharmacy  manual for additional information. 
Table 4: Maribavir Dosing Regimen
Regim en AM PM
400 mg BID 200 mg ×2 tablets 200 mg × 2 tablets
Duration of Dosing: Subjects will take the maribavir 400 mg BID dose for the 8 weeks of the 
study  treatment phase. 
The investigator may  also choose to interrupt therapy  for a maximum of 7 consecutive day s, or 
up to 2 study  treatment interruptions for a to tal of up to 7 days. This will not result in permanent 
study  treatment discontinuation. If study  drug is interrupted for any  reason and subsequentl y 
resumed, the end of the study  drug administration period would remain fixed at a maximum of 
8weeks after t he date of the start of treatment. Subjects can be on the investigational studies of 
approved products, such as different proph ylactic regimens for GVHD or other anti- infective 
agents. However, the use of investigational treatment is prohibited.
Subjects Randomized to Investigator -Assigned anti -CMV Treatment
Investigator -assigned anti -CMV treatment strategies for the 8 weeks of the study  treatment phase 
must only  utilize 1 or 2 of the available anti- CMV agent from the following: ganciclovir, 
valganciclovir , foscarnet, or cidofovir. The subject receiving 1 or 2 anti –CMV agents at the time 
of enrollment, may  either change therapy  at the time of randomization/treatment initiation or 
remain on the same therapy  as the investigator assigned anti -CMV agent, if ran domized to this 
study  treatment arm. After randomization, changes to the investigator treatment of choice could 
include, change in dosing, change in dosing regimen, but will not include an addition of or 
switch to another anti -CMV agent (switching between valganciclovir and ganciclovir is 
allowed). If the treatment was continued or was started (post -randomization) as 2 anti -CMV 
agents, withdrawal of one agent while continuing with the second one will be possible. 
Combination therapy of cidofovir with foscar net is prohibited.
Dose adjustment is allowed as deemed appropriate by the investigator. The rationale for dose 
adjustment will be documented; change of treatment to another anti -CMV agent or addition of 
another anti -CMV agent during the study  treatment wi ll be declared as treatment failure. 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 76 
 
07 Dec 2018
For non-commercial use only
Shire Page 77
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Subjects will follow the investigator’s prescribed dosing regimen for their investigator’s choice 
of anti -CMV treatment. 
Investigational anti -CMV agents are not permitted. Subjects will remain on their assigned 
treatm ent for the 8 weeks of the study  treatment phase. Subjects may  be assessed, based on the 
eligibility  criteria specified in Section 3.1, for entry into a rescue arm for treatment with 
maribavir 400 mg BID for up to 8 weeks. 
The investigator may  also choose to interrupt therapy  for a maximum of 7 consecutive day s, or 
up to 2 study  treatment interruptions for a total of up to 7 days. This will not result in permanent 
study  treatment discontinuation. If study  drug is interrupted for any  reason and subsequentl y
resumed, the end of the study  drug administration period would remain fixed at a maximum of 
8 weeks after the date of the start of treatment.
Subjects who would require the treatment with 1 of the 4 available anti -CMV drugs in the 
dosages comparable or hi gher than used in the study  for longer than 1 day , for indications other 
than CMV treatment (eg, foscarnet for other viral infections), would continue with assigned 
study  treatment for 8 weeks per protocol. Concomitant treatment of ganciclovir/valganciclov ir 
with maribavir is not allowed (see Section 5.2.2). 
Additional treatment strategies can complement the use of maribavir treatment and the stud y 
specified anti -CMV agents, for example, reducing or modify ing the immunosuppressant drug use 
if possible or u se of IVIg or CMV Ig.
6.3 Labeling, Packaging, Storage, and Handling
6.3.1 Labeling
Labels containing stud y information and pack identification are applied to the maribavir 
container. Study drug kits and individual bottles will be affixed with a label containing 
minimally  the protocol number, study  drug kit number, dosage form, storage conditions, the 
statements 'For clinical trial use only ', and/or 'CAUTION: New Drug -Limited by  Federal (US) 
Law to Investigational Use', and other information that may  be required by the local laws.
Maribavir will be supplied as blue, film- coated, oval shaped convex tablets intended for oral 
administration. The tablet cores are composed of common compendial ingredients 
(Microcrystalline Cellulose, NF; Sodium Starch Gly colate, NF; and Magnesium Stearate, NF). 
The core tablet contains 200 mg maribavir and is coated with a blue standard Opadry II 
pharmaceutical coating.
Investigator -assigned anti -CMV treatment (ganciclovir, valganciclovir, foscarnet or cidofovir) 
will be prescribed b y the investigator and either administered at the hospital or other facility  used 
to administer IV products as per local site standard practice, or will be prescribed b y the 
investigator and ty picall y purchased b y the study  subject at the commercial pharmacy . This study  
protocol does not modify the treatment that the subject normall y would have received regardless 
of his/her participation in the study . For feasibility reasons and because there is no modification 
to the treatment plan that the investigator would otherwise follow, if the patient was not enrolled 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 77 
 
07 Dec 2018
For non-commercial use only
Shire Page 78
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
in the study , labeling of the investigator treatment of choice is not planned, unless required b y 
country -specific regulations. The investigator assigned anti -CMV treatment will be chosen and 
prescribed b y the investigator and t ypicall y purchased b y the stud y subject at the commercial or 
hospital pharmacy , or will be administered at the hospital (in case of drugs that require IV 
administration, per local guidelines).
6.3.2 Packaging
The investigational product, maribavir, is packaged in 40 -count white 60cc square HDPE bottles 
with child -resistant cap and foil induction seal.
Changes to sponsor- supplied packaging prior to dosing may  not occur without full agreement in 
advance b y the sponsor.
6.3.3 Storage
The investigator has overall responsibility  for ensuring that investigational product is stored in a 
secure, limited -access location. Maribavir tablets will be stored at room temperature (15 -30°C or 
59-86°F). Limited responsibility  may  be delegated to the pharmacy  or memb er of the stud y team, 
but this delegation must be documented. Investigational products are distributed by the pharmacy 
or nominated member of the study  team. The pharmacist/nominated team member will enter the 
unique subject identifier on the investigation al product bottle/carton labels as they  are 
distributed.
Investigational product must be stored in accordance with labeled storage conditions. 
Temperature monitoring is required at the storage location to ensure that the investigational 
product is maintain ed within an established temperature range. The investigator is responsible 
for ensuring that the temperature is monitored throughout the duration of the study  and that 
records are maintained; the temperature should be monitored continuously  by using eithe r an 
in-house sy stem, a mechanical recording device such as a calibrated chart recorder, or by  manual 
means, such that both minimum and maximum thermometric values over a specific time period 
can be recorded and retrieved as required. Such a device (ie, certified min/max thermometer) 
would require manual resetting upon each recording. The sponsor must be notified immediately  
upon discovery  of any  excursion from the established range. Temperature excursions will require 
site investigation as to cause and rem ediation. The sponsor will determine the ultimate impact of 
excursions on the investigational product and will provide supportive documentation as 
necessary . Under no circumstances should the product be dispensed to subjects until the impact 
has been deter mined and the product is deemed appropriate for use by  the sponsor.
The sponsor should be notified immediately  if there are an y changes to the storage area of the 
investigational product that could affect the integrity  of the product(s), eg, fumigation of a 
storage room.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 78 
 
07 Dec 2018
For non-commercial use only
Shire Page 79
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
6.4 Drug Accountability
Investigators will be provided with sufficient amounts of the investigational product (maribavir) 
to carry  out this protocol for the agreed number of subjects. The investigator or designee will 
acknowledge receipt of the investigational product, documenting shipment content and 
condition. Accurate records of all investigational product dispensed, used, returned, and/or 
destroy ed must be maintained as detailed further in this section. An interactive response 
technology  (IRT) will be used to manage subject randomization and the investigational product.
The investigator has overall responsibility  for administering/dispensing investigational 
product. Where permissible, tasks may  be delegated to a qualified designee (eg, a pharmacist) 
who is adequatel y trained in the protocol and who works under the direct supervision of the 
investigator. This delegation must be documented in the applicable study  delegation of authorit y 
form.
The investigator or his/her designee (as document ed by  the investigator in the applicable study  
delegation of authorit y form) will dispense the investigational product (maribavir) only to 
subjects included in this study  following the procedures set out in the study  protocol. Each 
subject will be given (if assigned to maribavir) or prescribed (if assigned to the 
investigator -assigned anti -CMV treatment) onl y the study  treatment carry ing his/her treatment 
assignment. The principal investigator must maintain accurate records of investigational products 
recei ved, including dates of receipt, expiry , dispensing, and lot numbers. All dispensed or 
prescribed medication will be documented on the CRFs and/or other investigational product 
record. The investigator is responsible for assuring the retrieval of all inves tigational product 
supplies from subjects. Investigator -assigned anti -CMV medication (ganciclovir, valganciclovir, 
foscarnet, or cidofovir) will also be documented on the CRFs and/or other study  treatment 
accountabilit y records, and may include additional information as required per applicable 
regulations. Compliance will be collected in the subject's e- diary . The disposition of the unused 
supply  of the dispensed investigational product and the prescribed investigator -assigned 
anti-CMV medication will be documented in the accountability  log.
No investigational product stock or returned inventory  from a Shire -sponsored study  may  be 
removed from the site where originall y shipped without prior knowledge and consent b y the 
sponsor. If such transfer is authorized by the sponsor, all applicable local, state, and national 
laws must be adhered to for the transfer.
The sponsor or its representatives must be permitted access to review the supplies storage and 
distribution procedures and records.
With the written agreement of the sponsor, at the end of the study , or as instructed by  the 
sponsor, all unused investigational product stock, subject-returned investigational product, and 
empty /used investigational product packaging will be returned to a sponsor specified 
desig nation. Should local, state or national laws prohibit the return of unused stock, subject 
returned investigational product, or empt y/used investigational product packaging to the sponsor 
designated locations, it may  be destroy ed at the site or local facili ty once the sponsor has 
reviewed and approved the site's SOP. In this case, Certificates of Destruction (CoD) identify ing 
what was destro yed, when and how, must be obtained with copies provided to the sponsor. 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 79 
 
07 Dec 2018
For non-commercial use only
Shire Page 80
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Destruction of investigational products must b e in accordance with local, state, and national 
laws.
Based on entries in the site drug accountability forms, it must be possible to reconcile 
investigational products delivered with those used and returned. All investigational products 
must be accounted f or and all discrepancies investigated and documented to the sponsor’s 
satisfaction.
6.5 Subject Compliance
For drug administration at the site, hospital staff or study personnel will administer all doses of 
study  drug. Missed/incorrect doses will be recorded i n the subject’s electronic diary  (e-diary ) and 
CRF, as appropriate.
Investigator assigned anti -CMV treatments will be chosen and prescribed by  the investigator, 
and will be either administered at the hospital or other facilities used to administer I V products, 
as per local site standard practice, or will be prescribed by  the investigator and ty picall y 
purchased b y the study  subject at the commercial or hospital pharmacy. For drug administration 
as outpatients, a study  diary  for tracking adherence to study  drug dosing and an adequate suppl y 
of study  drug will be dispensed for home use. Subjects must be instructed to bring their unused 
study  drug, empt y/used study  treatment packaging, and the study  diary  to every  visit. Drug 
accountabilit y must be assessed at the container/packaging level for unused study  drug that is 
contained within the original tamper- evident sealed container (eg, bottles, tray s, vials) or at the 
individual count level for opened containers/packaging. Unused investigational product will not 
be redispensed. The pharmacist/nominated person will record details on the drug accountability  
form. Instructions will be provided in the pharmacy  manual.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 80 
 
07 Dec 2018
For non-commercial use only
Shire Page 81
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
7. STUDY PROCEDURES
7.1 Study Schedule
See Table 1for study  procedures for the study  treatment phase and Ta ble 2 for study  procedures 
for the follow -up phase. 
7.1.1 Screening Period 
Screening Visit (Visit 1/ Day -14 to Day 0/Week -2 to Week 0) 
As specified in Table 1, the screening procedures will include:
Informed consent
Inclusion/Exclusion criteria (see Section
s4.1and 4.2)
Height and bod y weight (Section 7.2.3.2)
Vital signs (Section 7.2.3.3 )
Medical history , including transplant history  and CMV history
Prior medication, including an y prior anti -CMV medication used to treat the current CMV 
infection, therapies, and procedures (Section 5.1)
HIV status: Historical results for human immunodeficiency  virus (HIV) tests performed 
within 3 months prior to the study  treatment initiation will be acceptable for screening. If no 
HIV test result within 3 months is available, the subject must have testing done locall y during 
the screening period and have the results available prior to randomization (Exclusion 
Criterion 8)
Hematology /Chemistry  (Section 7.2.3.5)
Serum pregnancy  test for all females of child bearing p otential (Inclusion Criterion 9; see 
Section 7.2.3.5). Additional urine pregnancy  tests may  be done per institutional requirements. 
Urine pregnancy test results are not sufficient for eligibility  determination.
Interactive response technology  (IRT [ IV/WRS] ; Section 6.2.1)
CMV DNA test (quantitation): 
Documentation of CMV infection in whole blood or plasma 
(with a screening value of ≥910 IU/mL, 
in 2 consecutive samples separated by  at least 1 day  
as determined b y local or central specialt y laboratory qPCR or comparable quantitative CMV 
DNA results with the first sample available within 14 daysprior to randomization at 
Visit 2/Week 0/Day 0. The second sample must be taken within 5 day s prior to 
randomization. Results from the same laboratory  are to be used to assess subject eligibility  
criteria. The laboratory  used for DNA quantification could be either local specialt y 
laboratory  or central specialty  laboratory .
Available local specialt y laboratory  genot yping results from the plasma samples obtained within 
thescreening period will be collected.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 81 
 
07 Dec 2018
For non-commercial use only
Shire Page 82
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Informed consent must be obtained before an y study specific procedures are performed. All 
screening procedures will be completed within 14 day s prior to randomization, with the 
exception of following:
At screening, eith er central or local laboratory  results for CMV DNA quantification 
hematology /chemistry /pregnancy  testing can be used for qualification.
A screen failure is a subject who has given informed consent and failed to meet the inclusion 
and/or met at least 1 of the exclusion criteria and has not been randomized or administered study  
treatment. Screen failures due to low platelet count, hemoglobin, and low neutrophil counts or 
liver and renal parameters can be rescreened once within the 14 day  screening period at t he 
investigator’s discretion when other inclusion criteria are fulfilled. Other screen failures may  be 
rescreened in the future (with new informed consent and screening period) if their clinical course 
results in a change that deems them eligible for the t rial.
The screening visit (Visit 1) and Visit 2/Week 0/Day  0 visits can occur on the same day .
7.1.2 Study Drug Administration Period
Visit 2/Week 0 (Baseline; Day 0) to Visit 10/Week 8 (End of Treatment)
Permissible assessment windows during the 8 -week study  treatment phase are: Study  Visit 2A 
(Day  4) ± 1 day ; Study  Visit 3 (Day  7) +2 day s; Study  Weeks 2 to 4 ± 2 day s; Study  Weeks 5 to 
8 ± 3 day s.
As specified in Table 1thefollowing assessments will be performed during the study  treatment 
phase:
Randomization on Visit 2/Week 0 (Day 0; baseline)
Physical examination (including weight) at Visit 2/Week 0, Visit 6/Week 4, and 
Visit 10/Week 8 (Section 7.2.3.2)
Review of medical history and prior medication at Visit 2/Week 0 (Section 5.1)
Weight at Visit 4/Week 2 and Visit 8/Week 6 (Section 7.2.3.2)
Vital signs at Visit 2/Week 0, Visit 4/Week 2, Visit 6/Week 4, Visit 8/Week 6, and 
Visit 10/Week 8 (Section 7.2.3.3)
12-lead electrocardiogram (ECG) at Visit 2/Week 0, Visit 10/Week 8 (Section 7.2.3.4)
Hematology /Chemistry at Visit 2/Week 0, Visit 4/Week 2, Visit 6/Week 4, Visit 8/Week 6, 
and Visit 10/Week 8; Potassium and magnesium at Visit 2A (Section 7.2.3.5)
Urinal ysis at Visit 2/Week 0, Visit 4/Week 2, Visit 6/Week 4, Visit 8/Week 6, and 
Visit 10/Week 8 (Section 7.2.3.5)
Pregnancy  test at Visit 2/Week 0, Visit 6/Week 4, Visit 10/Week 8 (Section 7.2.3.5 )
HBV and HCV test at Visit 2/Week 0
CMV DNA test: Cy tomegalovirus quantification in the plasma samples taken at each visit of 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 82 
 
07 Dec 2018
For non-commercial use only
Shire Page 83
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
study  treatment phase will be conducted at c entral specialt y laboratory . Cytomegalovirus 
genot yping to assess for mutations in the UL 97, UL 27, and UL54 genes will be conducted 
only on the following samples: at baseline; from subjects with failure to attain CMV viremia 
clearance AND viral load above the predefined cut off (presented in the CMV resistance 
plan) taken at Study  Weeks 4 and 8; and collected during recurrence or rebound of viremia at 
any time during the study treatment. 
Tissue invasive CMV disease and CMV syndrome assessment (see Appendix 3) at all visits 
through the stud y treatment phase.
  
Immunosuppressant drug concentration levels measured at Visit 2/Week 0, Visit 2A/Day  4, 
Visit 3/Week 1, and Visit 10/Week 8 (see Section 7.2.3.5). If maribavir is discontinued earl y 
during the treatment phase, Immunosuppressant drug concentration should also be measured 
one week after discontinu ation.
Pharmacokinetic sample collection for adult subjects ≥18 y ears of age, randomized to 
maribavir will be as follows: at Visit 3/Day 7/Week 1 (premorning maribavir dose and 
between 2 -4 hour postmorning maribavir dose); at Visit 6/Week 4 (only  one premorning 
maribavir dose); and at Visit 10/Week 8 (one premorning dose and one between 2 -4 hour 
postmorning maribavir dose). Pharmacokinetic sample collection for adolescent subjects ≥
12 to <18 y ears of age, randomized to maribavir, will be as follows: intensi ve PK sampling at 
Visit 3/Week 1 (pre -morning dose and 1, 2, 3, 4, 6, 8 [all ±5 min], and 12 hours [±15 min] 
post morning dose); at Visit 6/Week 4 (one premorning dose PK sample); at Visit 10/Week 8 
(one premorning dose and one between 2 -4 hour post mornin
g dose PK samples).
Maribavir rescue arm eligibility  assessed at Visit 5/Week 3 up to Visit 9/Week 7 
(Section 7.1.2).
IRT at all visits through the study  treatment phase, except Visit 10/Week 8. 
Study  drug dispensed at every  visit except Visit 10/Week 8; study  drug administration 
through 8 weeks of stud y treatment phase (Study Week 0 through Stud y Week 7).
Study  diary  dispensed at baseline and collected at the last follow -up visit; will be used for 
tracking compliance throughout the stud y treatment phase a nd for tracking completion of 
 
. Note: The diary  will only  be utilized for study  
treatments that are given orally . The IV administration will be tracked in the source 
documents and CRF.
Invasive bacterial, viral and fungal infections/transplant relevant infection assessed at 
baseline, Visit 2/Week 0, and at all visits throughout the study  treatment phase.
Transplant status at baseline, Visit 2/Week 0, and at all visits throughout the study  treatment 
phase.
Hepatic function grading according to the Child
-Pugh classification (see Appendix 2 and
Section 7.2.3.1) at Visit 2/Week 0.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 83 
 
07 Dec 2018
For non-commercial use only
Shire Page 84
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
GVHD assessment (for HSCT subjects only ) at all visits through t he study treatment phase.
Comorbidity  status evaluation: Karnofsky  Performance Status (KPS) scale for subjects ≥
16years of age and Lansky  performance status scale for subjects ≥12 to <16 years of age; at 
baseline, Visit 2/Week 0, Visit 6/Week 4, and Visit 10/Week 8.
 
Concomitant medications, therapies, and procedures through the stud y treatment phase.
AE/SAE monitoring throughout the stud y treatment phase.
7.1.3 Follow -up Phase 
Visit 11/Week 9/Follow -up Week 1 to Visit 18/Week 20/Follow -up Week 12 (End of St udy)
The follow -up period for this protocol is 84 day s or 12 weeks (post -treatment Visits 11-18). The 
permissible assessment windows for the visits are: Study  Weeks 9- 12 (Follow -up Weeks 1- 4) ± 2 
days; Study  Weeks 14- 20 (Follow -up Weeks 6- 12) ± 3 day s. 
Asspecified in Table 2 study  evaluations include:
Physical examination (including weight) at Visit18/Week 20
Vital signs at Visit18/Week 20
12-Lead ECG at Visit 18/Week 20
Hematology /Chemistry  at Visit 12/Week 10, Visit 14/Week 12, Visit 16/Week 16, 
Visit 18/Week 20
Urinal ysis at Visit 18/Week 20
Immunosuppressant drug concentration level at Visit 11/Week 9, if treatment continued until 
Week 8 (drug concentration level to be measured 1 week after the end of the study  treatment)
Invasive bacterial, viral and fungal infection assessment at all visits during the follow-
up 
phase; Visit 11/Week 9, Visit 12/Week 10, Visit 13/Week 11, Visit 14/Week 12, 
Visit 15/Week 14, Visit 16/Week 16, Visit 17/Week 18, and Visit 18/Week 20
CMV DNA test: Cy tomegalovirus DNA quantification in the plasma samples taken at each 
visit of study  follow -up phase (Visit 11/Week 9, Visit 12/Week 10, Visit 13/Week 11, Visit 
14/Week 12, Visit 15/Week 14, Visit 16/Week 16, Visit 17/Week 18, and Visit 18/Week 20) 
will be conducted at c entral specialt y laboratory . Cytomegalovirus genot yping will be 
conducted onl y on the samples: from subjects who fail to attain CMV viremia clearance 
AND have viral load above the predefined cut off (presented in the CMV resistance plan), 
taken at Visit 16 /Week 16 and Visit 18/Week 20; from cases of recurrence of viremia at an y 
visit in the follow -up phase.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 84 
 
07 Dec 2018
For non-commercial use only
Shire Page 85
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Tissue invasive CMV disease and CMV sy ndrome assessment (see Appendix 3 ) at all visits 
through the stud y follow up phase
Transplant status at all visit s throughout the follow -up phase
GVHD assessment (for HSCT subjects only ) at all visits through the follow -up phase
Comorbidity  status evaluation: KPS scale for subjects ≥16years of age and Lansk y 
performance status scale for ≥12 to <16years of age; at Visit 14/Week 12, 
Visit 16/Week 16, and Visit 18/Week 20

AE/SAE monitoring through the follow -up phase according to Section 7.2.3.6
Concomitant medications and procedures collected throughout the follow -up phase
All SAEs not resolved at the time of end of stud y visit (Visit 18/Week 12 or Follow -up Week 12) 
will be followed to closure or stabilization (see Section 8.1). If a subject is withdrawn from the 
study , all Follow -up Week 12/end of study  procedures must be performed as soon as possible 
after discontinuat ion. 
7.1.4 Maribavir Rescue Arm
All procedures presented in Table 1(Schedule of Assessment 1), beginning at Visit 2/Week 0, 
will be performed for the subjects who discontinue the investigator -assigned anti -CMV 
treatment, meet the eligibility  criteria to enter the rescue arm where maribavir 400 mg BID will 
be administered for a duration of 8 weeks, and complete the end
-of-treatment evaluations listed 
for Visit 10/Week 8 prior to being transferred to the maribavir rescue arm . Subjects will enter the 
12-week follow-up phase after completing 8 weeks of maribavir treatment in the rescue arm.
7.1.5
Additional Care of Subjects after the Study
No after care is planned for this study .
7.2 Study Evaluations and Procedures
All study  evaluations and procedures are specified in Schedu le of Assessment 1, Table 1, and 
Schedule of Assessment 2, Table 2.
7.2.1 Demographic and Other Baseline Characteristics
Age and/or year of birth, sex, race, and ethnicity  will be recorded for all subjects.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 85 
 
07 Dec 2018
For non-commercial use only
Shire Page 86
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
7.2.2 Efficacy
7.2.2.1 CMV DNA Quantitation (CMV Infection)
Blood samples collected will be assessed at a central specialty laboratory  for the quantification of 
CMV DNA in plasma using the COBAS®AmpliPrep/COBAS®TaqMan®CMV Test. Central 
specialt y laboratory plasma CMV DNA results will be reported to the investigator si te as 
available. Additional CMV DNA tests at local specialty  laboratories may  be performed and 
collected at more frequent intervals or use additional assay  methods at the discretion of the 
investigator utilizing local specialty  laboratory . These results wi ll also be collected when 
available.
Confirmed CMV viremia clearance will be defined as plasma CMV DNA concentration below 
the lower limit of quantification (<LLOQ; ie, <137 IU/mL) when assessed by  COBAS®
AmpliPrep/COBAS®TaqMan®CMV Test at a central spec ialty laboratory, in 2 consecutive 
postbaseline samples, separated b y at least 5 day s.
Recurrence or the recurrence of CMV viremia will be defined as plasma CMV DNA 
concentration ≥LLOQ when assessed b y COBAS®AmpliPrep/COBAS®TaqMan®CMV Test 
in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia 
clearance. Every  attempt should be made by  study  investigators to collect the 2 consecutive 
plasma samples and monitor results to confirm recurrence prior to initiating alternative available 
therap y.
7.2.2.2 CMV Genotyping and Phenotyping
Plasma samples collected at Visit 2/Week 0 for protocol- specified CMV DNA testing at the 
central specialt y laboratory will be genot yped for the final determination of mutations in th e viral 
UL97 and UL54 genes known to confer resistance to commercially  available anti -CMV agents. 
In addition, viral UL27 gene will be tested. During the stud y, CMV genot yping will be 
conducted at prespecified time points when the CMV DNA viral load is above a predefined cut 
off level (validated for this ty pe of anal ysis) in cases of failure to clear CMV viremia, in cases of 
recurrence of viremia on and off treatment, and in cases of viremia rebound if >1 log 10above 
nadir while on treatment ( Rebound is defined as increase in viral DNA load for >1 log 10above 
nadir without prior clearance of viremia ) at any  time during the study . The entire UL97, UL27, 
and UL54 CMV genes will be sequenced in every  sample that meets the criteria for genot yping, 
including t he baseline samples . Additionally , virus susceptibility  testing will be performed on 
selected de novo CMV sequence variants of maribavir treated subjects b y recombinant resistance 
phenoty ping. Details of the anal ysis will be specified in the resistance ana lysis plan . The list of 
CMV mutations conferring resistance to ganciclovir, valganciclovir, foscarnet, or cidofovir is 
presented in Appendix 4 .
7.2.2.3 Tissue Invasive CMV Disease and CMV Syndrome Assessments 
Tissue -invasive CMV disea se will be defined as described b y Ljungman et al., 2002 and 
Ljungman et al., 2017 (see Appendix 3 ). The gold standard for diagnosing CMV tissue invasive 
disease is the identification of CMV inclusions in the infected cells of the tissues OR 
identification of CMV in biopsy  tissue samples. However, in some cases both diagnostic 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 86 
 
07 Dec 2018
For non-commercial use only
Shire Page 87
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
methods are required, for example when tissue samples have a high chance of being 
contaminated b y bod y fluids that shed virus (bronchoalveolar lavage [BAL], urine or stool). I n 
some subjects, when it is not possible to obtain a tissue biopsy , a culture of body  fluids or DNA 
quantification (for selected cases) may  be used to confirm diagnosis, with a lower level of 
confidence. In cases of CMV retinitis, the retinal images taken b y the ophthalmologist may  be 
used as the evidence supporting the diagnosis. CMV sy ndrome (in SOT subjects only ) will also 
be defined as described by  Ljungman et al., 2017 , and requires at least 2 of 6 signs and 
symptoms to be present (see Appendix 3 for full description of criteria).
All subjects will be monitored for the occurrence of tissue invasive CMV disease and CMV 
syndrome throughout the study . For symptomatic subjects who present with tissue invasive CMV 
disease or CMV s yndrome at baseline, the investigator will document the in itial diagnosis of 
CMV disease at Visit 2/Day  0 (ie, absence or presence at baseline) and all serial assessments of 
infection status (ie, no change, improvement, worsening, or resolution) at all subsequent visits in 
the study . In subjects as ymptomatic at b aseline, the occurrence of new tissue invasive CMV 
disease or CMV s yndrome after start of stud y treatment will be initially  assessed by  the 
investigator at the study  visit when the diagnosis is made, and serial assessments of infection 
status (ie, no chang e, improvement, worsening, or resolution) at all subsequent visits in the 
study . Case charts documenting the infection diagnosis (baseline or new symptomatic infection) 
and follow -up status at study  visits will be provided for adjudication to an independen t Endpoint 
Adjudication Committee. The definitions and requirements for the diagnosis of different CMV 
diseases and CMV s yndrome will be the basis for the data collection charts that are required to 
support the diagnosis of the each tissue invasive CMV dis ease t ype or CMV syndrome. Sites are 
encouraged to take tissue biopsies to support the diagnosis of the disease as per Ljungman et al., 
2002 and Ljungman et al., 2017. The roles, responsibilities, and rules governing operation of the 
independent Endpoint Adjudication Committee will be fully  documented in an Endpoint 
Adjudication Committee charter.
During the medical monitoring, additional cases not identified by  the investigator with 
symptomatology similar to tissue invasive disease (eg, GVHD with GI s ymptoms, transplanted 
organ rejection) may be identified as requiring adjudication by  the EAC for confirmation or 
exclusion of the tissue invasive CMV disease.
The recurrence of the symptomatic CMV inf ection will be defined as the presence of signs or 
symptoms of the tissue invasive CMV disease or CMV sy ndrome (same or new 
symptomatology ) confirmed as per Ljungman et al., 2002 and Ljungman et al., 2017 after the 
period of resolution of symptomatic CMV infection in subjects sy mptomatic at baseline.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 87 
 
07 Dec 2018
For non-commercial use only
Shire Page 88
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
CMV antigen (pp65) producing l ymphokines, interferon gamma (IFN , tumor necrosis factor 
alpha (TNF or interleukin -2 (IL -2) will be assessed using flow cy tometry .
7.2.2.5 Graft Status 
History  of the current transplant and its status at screening and baseli ne will be collected for all 
transplant ty pes, including dates of transplant, graft complications, and use of antirejection 
therapies for proph ylaxis or treatment of graft rejection.
Assessment of the transplant throughout the stud y will include the status of the graft function, the 
presence of the episode(s) of acute rejection, or development of other relevant complications (eg, 
new onset diabetes). The outcome of graft failure is a clinical determination that the graft 
irreversibly  and irrevocably  ceases functioning (eg, in case of renal transplant, with the subject 
returning to permanent dialy sis if dial ysis-dependent prior to transplant or return to insulin 
dependency  in the case of pancreas transplant) as determined by the investigator.
Detailed informa tion will be collected in separate CRF forms for SOT (by  organ) or HSCT, as 
specified in the stud y manual.
7.2.2.6 Graft -versus- host-disease (GVHD) Assessments
GVHD is a well -recognized complication of transplantation, much more frequently  in HSCT 
transplants. GVH D occurs when the donor cells (the “graft”) recognize the patient being 
transplanted (the “host”) as being foreign, ie, when donor T ly mphocy tes respond to mismatched 
protein antigens expressed in host T -cells. I t presents in an acute and chronic form.
Themost influential protein mismatches are human leukocy te antigens (HLAs) and the incidence 
of acute GVHD is directly related to the degree of mismatch between HLA proteins expressed by  
the HCT donor and recipient ( Loiseau et al., 2007 ). Even in patients that receive HLA -matched 
(HLA- A/B/C/DRB1) grafts, however, GVHD arises in approximately  40% of patients due to 
differences in minor hi stocompatibility  antigens, and requires sy stemic therapy . Acute GVHD 
that ty picall y occurs in first 100 days after transplant includes: ery thema, maculopapular rash, 
nausea, vomiting, anorexia, profuse diarrhea, ileus or cholestatic liver disease.
Chronic GVHD t ypicall y occurs later (>100 days after transplant) and is manifested on skin, 
appendages, mouth, ey es, lungs, genitalia, esophagus and connective tissues. Chronic GVHD 
diagnosis is supported b y histologic evidence of GVHD from an y affected site. The diagnosis 
might be difficult as negative histological findings do not exclude the existence of chronic 
GVHD, and similarit y to other conditions that often occur in HSCT patients (such as 
mycophenolate mofetil (MMF) toxicity  or the presence of GI tissue inv asive CMV disease.
Investigators are expected to consider recommendations for diagnosis provided in guidance in 
Appendix 9 and Appendix 10 (Jagasia et al., 2015 ; Shulman et al., 2015). Detailed information 
on GVHD and its grading, a t baseline and during the study  will be collected in separate CRF 
forms.
Assessment of absence or presence of acute GVHD will be done at baseline, and if present, 
grading will be performed according to published guidelines provided in Appendix 8 (Harris et 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 88 
 
07 Dec 2018
For non-commercial use only
Shire Page 89
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
al., 2016 ); acute or chronic GVHD present at baseline will also be followed throughout the study  
treatment phase, at every study  visit, utilizing the same diagnosis until resolu tion (during the 
duration of the stud y) as indicated in Table 1and Table 2. New onset of acute or chronic GVHD 
will be reported as the event of special interest.
7.2.2.7 Comorbidity Status
Transplant patients often have multiple other comorbidities, resulting fro m their 
immunosuppressed status (co-infections, graft versus host disease, transplant malfunctioning due 
to rejection), toxicities from therapies for maintenance of the transplant or reactivation of the 
baseline disease for which they  had been transplanted (malignancy  for example), and other 
concomitant diseases resulting in very diverse population that might be enrolled into the study . 
The comorbidity  assessment will be conducted to allow for the comparison of the population 
enrolled into 2 treatment arms and to account for the subjects’ health status when assessing 
overall and individual subject response.
Comorbidity  assessment as evaluated by  the Karnofsky  Performance Sstatus or Lansky  
performance s tatus scale will be performed at time points indicated in Table 1and Table 2. 
Given the possible difference in confounding comorbidities in the HSCT and SOT recipients, 
assessment of comorbidity  at baseline and over time in the study  will be performed. The 
difference between treatment arms in terms of baseline comorbidities might be controlled for in 
the anal yses if determined to be substantial.
Comorbidity  assessment for both HSCT and SOT recipients will utilize KPS scale for subjects 
≥16 y ears of age ( Peus et al., 2013; Schag et al., 1984) and Lansk y performance status scale for 
≥
12 to <16 years of age ( Lansk y et al., 1987).
Karnofsk y Performance Status is a valuable tool for measurement of and comparison between 
the functional statuses of individual patients. I t is increasingl y utilized as the prognostic factor in 
renal transplant patients (prior to transplantation).
Refer to 
Appendix 5 and Appendix 6 , respectivel y, for the KPS and Lansk y performance status 
scale forms.
7.2.2.8 Subject Survival 
Subject survival (y es/no) will be determined at all visits during the study . The date and cause of 
death will be recorded in the CRF, and will be reported as a serious adverse event according to 
Section 8.2.
7.2.3 Safety 
7.2.3.1 Medical History
A medical history  will be taken during the screening period and updated on 
Visit 2/Day 0/Week 0 as specified in Table 1. All medical history  findings that have been 
present/active within the 2 years prior to enrollment at Visit 2/Day  0 will be recorded reg ardless 
of clinical relevance or presence at stud y start. Medical history finding that have not been 
present/active within the 2 years prior to enrollment will be recorded if deemed clinically  
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 89 
 
07 Dec 2018
For non-commercial use only
Shire Page 90
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
relevant b y the investigator to the conduct of the study. Medic al history  related to the transplant 
(including the disease/diseases leading to transplant) and CMV infection will be recorded 
without a time limit. The medical history  should include any  history  of allergic reactions to 
drugs. Refer to Section 5.1for pri or medication history .
Specific information regarding the subject’s transplant history  that will be collected, including 
but not limited to, are: the number of past transplants prior to the current transplant; the ty pe of 
transplant and details for each, s uch as cell source and ty pe for HSCT or organ for SOT; the 
human leukocy te antigen (HLA) matching level; the date and the history  of the current transplant 
including complications; transplant related infections; induction and maintenance therapy  
received f or transplant; history  of relevant viral serology ; history  of anti -viral prophy laxis; and 
status of the transplant at baseline.
Specific information regarding the subject’s CMV infection will be collected in separate CRFs. 
The collected information will in clude, but will not be limited to: CMV serology of donor and 
recipient; CMV infection episodes with viral loads and/or treatment; CMV resistance 
information (sequencing data); proph ylactic treatment, if utilized. More details will be specified 
in the study manual.
Subjects will be classified into 1 of the following categories with respect to hepatic function, 
based on baseline clinical and laboratory  assessments (see Appendix 2 ). This information will 
primarily  be utilized in th e interpretation of the PK data for which the samples will be collected 
at the specified visits in the study :
No chronic liver disease
Chronic liver disease -Child -Pugh Class A
Chronic liver disease -Child -Pugh Class B
Chronic liver disease -Child -Pugh Class C
7.2.3.2 Physical Examination (Including Weight)
Abnormalities identified at the screening visit (Visit 1) will be documented in the subject’s 
source documents and on the medical history  CRF. Changes after the screening visit (Visit 1) 
will be captured as A Es on the AE CRF page, as deemed clinically  relevant by  the investigator.
The investigator or designee will perform ph ysical examinations at time points specified in 
Table 1and Table 2 . Physical examinations will be performed in accordance with standard 
practices at the investigational site. Body  weight and height will be measured at time points 
specified in the schedule of assessments.
7.2.3.3 Vital Signs
Vital signs (bod y temperature, arterial blood pressure, and pulse) will be collected in a standard 
manner at the time points specified in Table 1and Table 2. An y clinically significant deviations 
from baseline (Visit 2/Day 0/Week 0) vital signs which are deemed clinically  significant in the 
opinion of the investigator are to be recorded as an AE.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 90 
 
07 Dec 2018
For non-commercial use only
Shire Page 91
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
7.2.3.4 Electrocardiogr am 
A 12 -lead ECG will be performed at Visit 2/Day 0, Visit 10/Week 8 (end of treatment visit), 
Visit 18/Week 20 (end of study  visit), and at an y additional time during the study , if clinicall y 
indicated. Each ECG will include heart rate, RR Duration, PR duration, QT duration, QRS 
duration. The corrected QT interval (QTc) will be calculated using the Fridericia’s formula. The 
investigator will be responsible for providing the interpretation for all ECGs in terms of clinical 
significance to the subject.
7.2.3.5 Clinical Laboratory Evaluations
Laboratory  Assessments
Clinical laboratory  tests (hematology , chemistry , urinaly sis, HBV, HCV, pregnancy ) will be 
performed b y a central laboratory at the time points specified in Table 1and Table 2. During 
screening, clinical laboratory  tests will be performed by  the central laboratory , however local 
laboratory  results if available might be utilized for the assessment of the eligibility . If no result of 
HIV testing within 3 months prior to screening is available, an HIV tes t will be performed at a 
local laboratory  during the screening period for eligibility  assessment. If local laboratory  results 
are used for the assessment of the eligibility , the reference ranges must be provided. This also 
applies to CMV DNA quantitation r esults. At baseline (Visit 2/Week 0) blood samples will be 
taken for CMV DNA quantitation and genot yping, hematology  and chemistry  and tested in the 
central specialt y laboratory. All clinical laboratory assay s will be performed according to the 
central laboratory ’s standard procedures. Reference ranges will be supplied by  the central 
laboratory  and will be used to assess the clinical laboratory  data for clinical significance and out-
of-range pathological changes. The investigator should assess out -of-range clinical laboratory  
values for clinical significance, indicating if the value(s) is/are not clinically  significant or 
clinically significant. Clinically  significant finding should be reported as an AE unless signs of 
alread y reported conditions exist. Abnormal clinical laboratory  values that are unexpected or not 
explained by  the subject’s clinical condition may , at the discretion of the investigator or sponsor, 
be repeated as soon as possible until confirmed, explained, or resolved.
The following clinical laboratory  assessments will be performed: 
Chemistry
Serum sodium, potassium, chloride, bicarbonate/carbon dioxide, glucose, blood urea nitrogen, 
creatinine, calcium, phosphorus, magnesium, uric acid, total protein, albumin, creatine 
phosphokinase, total bilirubin, direct bilirubin, ALT, AST, gamma -glutam yltransferase 
(GGT), alkaline phosphatase (ALP), cholesterol (total and HDL/LDL ratio), trigl ycerides, and 
immunoglobulins. The samples for chemistry  are preferred to be taken under fasting 
conditions, although this is not mandatory . The information whether samples were taken 
under fasting conditions will be collected.
Potassium and magnesium levels will be performed at a local laboratory  at Visit 2A/2AR 
(Day  4
 ±1 day) if on tacrolimus, cyclosporine, everol imus or sirolimus at Visit 2/2R, and at 
four days ±1 day after initiation of tacrolimus, cyclosporine, everolimus, or sirolimus (if the 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 91 
 
07 Dec 2018
For non-commercial use only
Shire Page 92
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
subject is not taking the agent at baseline).
Hematology
White blood cell (WBC) and differential counts (with absolute neutrophil count [ANC]), 
hemoglobin, hematocrit, red blood cell (RBC) count, reticulocy tes, and platelet count.
International normalized ratio (INR) and prothrombin time at baseline only .
Urinalysis
pH, specific gravit y, protein, glucose, ketones, hemoglobin, leukocy te esterase, 
protein/creatinine ratio and microscopic evaluation (RBC, WBC, cry stals, casts, bacteria).
Virology
Hepatitis (hepatitis B Surface Antigen and/or viral DNA, hepatitis C antibody  and/or viral 
RNA). Historical results within 3 months of randomization are acceptable. If historical 
results are unavailable, blood will be drawn at Visit 2/Week 0 for hepatitis B surface 
antigen and hepatitis C antibody  testing at the central lab. Central lab results do not need 
to be available prior to randomization.
Human immunodeficiency virus (HIV) test. Historical results within 3 months prior to the 
study  treatment initiation will be acceptable for screening. If no result of HIV testing 
within the prior 3 months is available, the subject must have testing done locally during 
the screening period, and must have the results available prior to randomization.
Local Laboratory  Test to Monitor I mmunosuppressant Drug Concentration Levels
For subjects who are receiving tacrolimus, cy closporine, sirolimus, or everolimus, testing of the 
blood concentration levels of these drugs will be performed at each site’s local laboratory , using 
each site’s standard assay  and standard therapeutic drug monitoring practice (eg, time of sample 
collection relative to dosing). The testing will be performed at the time points outlined below, 
provided the subject is still receiving tacrolimus, cyclosporine, or everolimus on these study  
days.
If the subject is receiving tacrolimus, cy closporine, sirolimus or everolimus on Study  Visit 
2/Day 0/Week 0, obtain a tacrolimus, cy closporine, sirolimus or everolimus blood level:
On Visit 2/Day 0/Week 0 prior to initiation of study  treatment
At the Visit 2A/Day  4 (± 1 day ) study  visit
At the Visit 3/Day 7 (+2 day)/Week 1 study  visit
At Visit 10/Week 8 (± 2 day ) or on end of treatment visit (if earlier than Week 8)
At the Week 1 post -treatment follow -up visit (ie, 1 week [± 2 days] after discontinuation 
of study  treatment)
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 92 
 
07 Dec 2018
For non-commercial use only
Shire Page 93
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
If the subject is not receiving tacrolimus, cy closporine, sirol imus or everolimus on Study  Day 0, 
but starts any  of these drugs after Day 0 while still receiving study  treatment, obtain a tacrolimus, 
cyclosporine, sirolimus or everolimus blood level:
Four day s (± 1 day ) after the first dose of tacrolimus, cy closporine , sirolimus, or 
everolimus
At the next scheduled study  visit after first starting the tacrolimus, cy closporine, 
sirolimus or everolimus, while still receiving study treatment
At Visit 10/Week 8 (± 2 day) or on end of treatment visit (if earlier than Week 8 )
At the Week 1 post -treatment follow -up visit (ie, 1 week [± 2 days] after 
discontinuation of study  treatment
For the subjects transferred to the maribavir rescue arm, obtain a tacrolimus, cy closporine, 
sirolimus or everolimus blood level prior to initiation of maribavir, at Visit 2AR/Day 4R (± 1 
day) at Visit 3R/Week 1R, at Visit 10R/Week 8R or at the end of rescue treatment, and at 
Week 1 post -treatment follow -up visit after the end of the rescue treatment.
Pregnancy  Test
A serum β -HCG pregnancy  test wi ll be performed on all females of child -bearing potential at the 
screening visit (Visit 1), baseline (Visit 2/Week 0), Visit 6/Week 4, and at the end of stud y 
treatment visit (Visit 10/Week 8), or if pregnancy is suspected, or on withdrawal of the subject 
from the study . A pregnancy  test performed within 7 day sprior to randomization will not be 
repeated at baseline (if central laboratory  is utilized). Local or central laboratory  anal ysis 
performed on samples taken between Day  -7 and Day  -14 will be repeate d on Day 0 before 
randomization. Local laboratory  test results can be used for the assessment of pregnancy  on 
Day 0/Week 0.
7.2.3.6 Adverse Event Collection
At each stud y visit, subjects will be questioned in a general way to ascertain if AEs have 
occurred since t he previous visit (eg, “Have you had an y health problems since your last visit?”). 
All AEs will be recorded from the time informed consent is signed through 30 day s after the last 
dose of investigational product. Following the 30- day capture period for all AEs, only  those AEs 
deemed related to investigational product or other protocol -mandated procedures and all SAEs 
(regardless of causalit y assessment) will be collected through the end of the study (Visit 
18/Week 20 [Follow -up Week 12]). Refer to Section 8for detailed AE reporting requirements.
7.2.4 Others 
7.2.4.1 Clinical Pharmacology Assessments 
For subjects ≥18 y ears of age, randomized to maribavir, 1 or 2 PK samples will be collected on 
each of the study  days specified in Table 1. The premorning dose PK sample will be obtained at 
all 3 PK visits. The postmorning dose PK samples at Visit 3/Week 1 and at Visit 10/Week 8 will 
be obtained an y time between 2- 4 hours after the morning dose. Any  episode of vomiting 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 93 
 
07 Dec 2018
For non-commercial use only
Shire Page 94
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
occurring within 2 to 4 hours after the morning dose an d before the postmorning dose PK sample 
collection must be documented. Subjects will record the date and time of the previous maribavir 
dose taken before a PK visit in their electronic diary . The instructions will be provided in the 
study  manual.
Subjects ≥18 years Sparse PK Schedule
Week 1, Day 7 (±1d) Week 4, Day 28 (±2d) Week 8, Day 56 (±2d)
Study Treatment Period
Pre-morning dose
2-4 hours post morning doseOne pre -morning dose Pre-morning dose 
2-4 hours post morning dose
For subjects ≥12 to <18 years of age, an intensive PK sampling will be performed at 
Visit 3/Week 1. Subjects will be asked to complete the 12 hour post morning dose PK sample 
prior to taking their evening dose of maribavir. Sparse PK sampling similar to adults ( ≥18 
years) will be performed at Week 4 and Week 8.
Subjects ≥12 to < 18, Including Intensive PK (Week 1) Schedule
Week 1, Day 7 (±1d) (Intensive PK) Week 4, Day 28 (±2d) Week 8, Day 56 (±2d)
Study Treatment Period
Premorning dose, 1, 2, 3, 4, 6, 8 (all ±5 
min), and 12 hours (±15 min) post 
morning doseOne premorning dose Premorning dose and
2-4 hours post morning 
dose
The following will be recorded in the CRF:
Date and time of the last dose of maribavir before the predose PK sample was taken
Date and time that the predose PK sample was taken
Date and time of the last dose of maribavir before the postdose PK sample was taken
Date and time that the 2 -4 hour postdose PK sample was taken
Date and time of vomiting within 2 -4 hours after the morning dose and before the 
postmorning dose PK sample collection
If a subject has maribavir dose interrupted for 2 consecutive day s prior to the morning maribavir 
dose on a PK visit, no PK sample will be collected. If a subject has completed the premorning 
dose PK sample collection, but has missed the morning dose of maribavir on the day  of the PK 
visit, then no postdose PK sample will be collected.
Unscheduled PK sample collection
For purposes of special PK sampling, gastrointestinal (GI) GVHD is defined as any  of the 
following ( Boeckh et al., 1998 ):
Biopsy -proven GVHD of the GI tract plus diarrhea (>300 mL/day )
Biopsy  proven GVHD of the GI tract and nausea
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 94 
 
07 Dec 2018
For non-commercial use only
Shire Page 95
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Documented acute GVHD of the liver (stage II, total bilirubin >3 mg/dL or 
biopsy -proven) plus diarrhea (>500 mL /day) with no other explanation or
Biopsy -proven acute GVHD of the skin plus diarrhea (>500 mL /day) with no 
other explanation
If a subject on maribavir treatment is diagnosed with GI  GVHD during the study  treatment phase 
and therap y with study  drug remained permissible, study  drug will be continued and blood 
samples for the determination of maribavir plasma concentrations will be collected. This 
unscheduled PK sampling will occur at the next visit after the first occurrence of a GI GVHD 
diagnosis, and will follow the schedule of sampling and recording of information as described in 
Table 1(Schedule of Assessment 1).
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 95 
 
07 Dec 2018
For non-commercial use only
Shire Page 96
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
7.2.5 Volume of Blood to be Drawn from Each Subject Per Visit
The volume of blood drawn from each subject per visit is shown in Table 5. 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 96 
 
07 Dec 2018
For non-commercial use only
Shire Page 97
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Table 5: Volume of Blood Drawn Per Study Visit
Study Visit / Rescue Arm Visit Blood Volum e per Visit (mL)
Visit 1/NA Rescue Arm Visit (Screening) 33a
Visit 2/2R 48
Visit 2A/2A-R 11
Visit 3/3R 26
Visit 4/4R 23
Visit 5/5R 15
Visit 6/6R 29
Visit 7/7R 35
Visit 8/8R 23
Visit 9/9R 15
Visit 10/10R (End of Treatment) 60
Visit 11/11R 20
Visit 12/12R 23
Visit 13/13R 15
Visit 14/14R 23
Visit 15/15R 15
Visit 16/16R 23
Visit 17/17R 15
Visit 18/18R (End of Study) 43
Additional PK PK Blood Volum e per Visit (mL)
See Section 7.2.4.1 4
aIncludes an additional 4 mL sample for local HIV testing to be drawn from subjects lacking result of an HIV test within 3 
months prior to Screening.
Note: Refer to Schedule of Assessments 1 ( Table 1) and 2 (Table 2 )
PK=pharmacokinetics
During this stud y,it is expected that approximately  491 mL of blood will be drawn from each 
subject, regardless of sex. I n addition, subjects between the ages of 12 and 18 y ears will have up 
to 24 mL  of blood drawn for intensive PK visits.
Note: The amount of blood to be drawn for each assessment at an y visit is an estimate. The 
amount of blood to be drawn may  vary  according to the instructions provided by  the 
manufacturer or laboratory  for an individual assessment. When more than 1 blood assessment is 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 97 
 
07 Dec 2018
For non-commercial use only
Shire Page 98
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
to be done at the tim e point/period, if they  require the same t ype of tube, the assessments may be 
combined.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 98 
 
07 Dec 2018
For non-commercial use only
Shire Page 99
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
8. ADVERSE AND SERIOUS ADVERSE EVENTS ASSES SMENT
8.1 Definition of Adverse Events, Period of Observation, Recording of Adverse Events
An AE is an y untoward medical occurrence in a clinical investigation subject administered a 
pharmaceutical product and that does not necessarily  have a causal relationship with this 
treatment. An AE can therefore be an y unfavorable and unintended sign (including an abnormal 
laboratory  finding), s ymptom, or disease temporally  associated with the use of a medicinal 
(investigational/investigator assigned anti -CMV treatment) product, whether or not related to the 
medicinal (investigational/investigator assigned anti -CMV treatment) product (Internation al 
Conference on Harmonisation [I CH] Guidance E2A 1995). 
All AEs will be recorded from the time the informed consent is signed through 30 day s after the 
last dose of investigational product. This includes events occurring during the screening phase of 
thestudy , regardless of whether or not study  treatment is administered. Following the 30 -day 
capture period for all AEs, only  those AEs deemed related to investigational product or other 
protocol -mandated procedures and all SAEs (regardless of causality  asse ssment) will be 
collected until the defined follow -up period stated in Section 7.1.3. Where possible, a diagnosis 
rather than a list of sy mptoms should be recorded. If a diagnosis has not been made, then each 
symptom should be listed individually . All AEs should be captured on the appropriate AE pages 
in the CRF and in source documents. In addition to untoward AEs, unexpected benefits outside 
the investigational product indication should also be captured on the AE CRF.
All SAEs must be followed to closure ( the subject’s health has returned to his/her baseline status 
or all variables have returned to normal), regardless of whether the subject is still participating in 
the study . Closure indicates that an outcome is reached, stabilization achieved (the investi gator 
does not expect an y further improvement or worsening of the event), or the event is otherwise 
explained. When appropriate, medical tests and examinations are performed so that resolution of 
event(s) can be documented.
8.1.1 Severity Categorization
The severity  of AEs must be recorded during the course of the event including the start and stop 
dates. The highest level of severit y will be recorded for an event. Worsening of pretreatment 
events, after initiation of study  treatment, must be recorded as new AEs (for example, if a subject 
experiences mild intermittent dy spepsia prior to dosing of investigational product, but the 
dyspepsia becomes severe and more frequent after first dose of investigational product has been 
administered, a new AE of severe d yspepsia [with the appropriate date of onset] is recorded on 
the appropriate CRF).
The medical assessment of severit y is determined by  using the following definitions:
Mild: A type of AE that is usually  transient and may  require only  minimal treatment or 
therapeutic intervention. The event does not generally  interfere with usual 
activities of daily  living.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 99 
 
07 Dec 2018
For non-commercial use only
Shire Page 100
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Moderate: A type of AE that is usually  alleviated with specific therapeutic intervention. The 
event interferes with usual activities of dail y living, causin g discomfort but poses 
no significant or permanent risk of harm to the research subject.
Severe: A type of AE that interrupts usual activities of daily  living, or significantl y affects 
clinical status, or may  require intensive therapeutic intervention.
Besides the above mentioned standard categories of severit y grading for tissue invasive CMV 
disease and a few selected events of special interest (see Section 8.1.4), the severit y (intensity) of 
AEs will also be assessed according to the National Cancer In stitute Common Terminology  
Criteria for Adverse Events (CTCAE) Version 4.03. 
8.1.2 Relationship Categorization
A phy sician/investigator must make the assessment of relationship to study  treatment for each 
AE. The investigator should decide whether, in his or he r medical judgment, there is a reasonable 
possibility  that the event may  have been caused by the study  treatment. If there is no valid reason 
for suggesting a relationship, then the AE should be classified as “not related”. Otherwise, if 
there is an y valid reason, even if undetermined or untested, for suspecting a possible cause -and-
effect relationship between the study  treatment and the occurrence of the AE, then the AE should 
be considered “related”. The causality  assessment must be documented in the sour ce document.
The following additional guidance may  be helpful:
Term Relationship Definition
RelatedThe temporal relationship between the event and the administration of the study 
treatment is compelling and/or follows a known or suspected 
response patter n to that product, and the event cannot be 
explained by the subject’s medical condition, other therapies, or 
accident.
Not RelatedThe event can be readily explained by other factors such as the subject’s 
underlying medical condition, concomitant therapy, or accident 
and no plausible temporal or biologic relationship exists between 
the study treatment and the event.
8.1.3 Outcome Categorization
The outcome of AEs must be recorded during the course of the study  on the CRF. Outcomes are 
as follows:
Fatal
Not Recovered/Not Resolved
Recovered/Resolved
Recovered/Resolved with Sequelae 
Recovering/Resolving
Unknown
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 100 
 
07 Dec 2018
For non-commercial use only
Shire Page 101
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
8.1.4 Adverse Events of Special Interest 
In addition, the following adverse events of special interest will be closel y monitored and 
reported throughout the study  regardless of seriousness or of relationship to study  treatment. 
Medical assessment of severity will be determined using standard grading category  (mild, 
moderate, and severe), and by  using other specific severit y grading for each AESI as mentioned 
below:
Adverse Events of Special Interest (severity grading based on CTCAE Version 4.03)
1.Tissue invasive CMV disease and CMV sy ndrome. I t is expected that certain number of 
subjects will also have tissue invasive CMV disease or CMV sy ndrome at baseline and its 
clinical course will be monitored throughout the study ; the effect of the study  treatment 
on this event will be assessed. At each visit the investigator will provide the evaluation of 
the tissue invasive CMV disease or CMV syndrome until resolution, which will be 
collected on the CRF. The investigator will have the final discretion in det ermining 
whether or not the CMV DNA test results and other clinical data represent a new tissue 
invasive CMV disease or CMV sy ndrome for a given subject. When these events are 
entered into the CRF, they should be recorded using the terminology  shown in Appendix 
3(eg, 'CMV pneumonitis', 'CMV colitis', etc.). For details on how the disease under stud y 
will be reported see Section 8.1.5.
2.Taste disturbance (d ysgeusia): If a subject reports an AE of taste disturbance, the 
investigat or will record the subject’s description of the taste disturbance (when available) 
as part of the event verbatim in the CRF.
4. Events of nausea, vomiting, and diarrhea will be recorded. Additional information for 
each case of diarrhea will be collected, i ncluding the information whether condition such 
as GVHD, GI -CMV or enteric infection confirmed by culture/PCR or other method is 
present.
5.Neutropenia.
Adverse Events of Special Interest (grading based on standard severity categorization to 
mild, moderat e, and severe) 
1. Immunosuppressant drug concentration level increased: Immunosuppressant drug levels 
will be monitored as specified Section 7.2.3.5. High to toxic levels will be recorded as 
AEs.
2. Graft rejection (acute, chronic, or failure): Transplant statu s will be captured at every  
visit as shown in the Schedule of Assessments ( Table 1and Table 2 ), and graft rejections 
will be captured.
3. Invasive fungal (aspergillus, candida, Pneumocystis jiroveci , etc.) o r bacterial infections 
(Staphylococcus aureus, Streptococcus pneumonia , enterococcus, pseudomonas, etc.). 
Baseline conditions will be captured as part of medical history , while new events will be 
captured as AEs. The additional information such as diagnostic method used for the 
pathogen and the source of t he sample used for the diagnosis will be collected. 
Additionally  the presence of viral infections frequently occurring in transplant population 
will also be collected.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 101 
 
07 Dec 2018
For non-commercial use only
Shire Page 102
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
4.Graft -versus- host-disease (HSCT subjects): GVHD will be diagnosed based on the 
investiga tor’s judgment (see Section 7.2.2.6). Severity  of Acute GVHD (Grading I -IV) 
will be assessed using grading scale provided in Appendix 8 as in published guidelines 
(Harris et al., 2016 )and for chronic GVHD using severit y grading into mild, moderate 
and severe according to the scoring provided in Appendix 9 ,as in the published 
guidelines ( Jagasia et al., 2015). Harris et al ( 2016 ) provides the confidence levels of the 
diagnosis (see Confidence Level Criteria Table in Appendix 9). For the purpose of this 
study  the disease considered ‘confirmed’ or ‘probable’ should be reported as GVHD. 
Acute or chronic GVHD present at baseline will also be followed utilizing the same 
diagnosis and severit y assessments at every stud y visit until resolution (during the 
duration of t he stud y). The baseline presence of the acute or chronic GVHD will be 
reported on the Transplant History  page.
8.1.5 Disease Under Study
Subjects will be enrolled in study  after fulfilling the criteria for CMV viremia ( ≥910 IU/mL) 
and their viral load will be monitored throughout the study . Viremia clearance, persistence, or 
recurrence will be reported as the part of efficacy  assessment based on central laboratory  result.
It is expected that certain number of subjects will also have tissue invasive CMV disease or
CMV sy ndrome (SOT subjects only ) at baseline and its clinical course will be monitored 
throughout the stud y and will be reported as part of the secondary efficacy assessment.
Since new tissue invasive CMV disease or CMV sy ndrome constitutes a medicall y important 
event, independent of hospitalization or prolongation of hospitalization required for this event, it 
will qualify  to be reported as an SAE.
In the event of worsening of tissue invasive CMV disease or CMV s yndrome present at baseline, 
an SAE reporti ng will be determined based on that event fulfilling the seriousness criteria 
(definition in Section 8.2.3).
The investigator has the final discretion in determining whether or not CMV test results and 
other clinical data represent a new CMV event for a gi ven subject.
If a CMV event crosses into different categories over time, the category  of greatest severit y 
should be recorded.
If a subject is initially  diagnosed with an as ymptomatic CMV infection, but this event evolves 
into CMV organ disease (eg, coliti s), the event would be recorded as CMV colitis and reported 
as SAE.
The terminology  used for reporting should be:
Asymptomatic CMV infection
CMV sy ndrome (applicable only  in SOT subjects)
Tissue invasive CMV disease, specify  organ for example CMV 
pneumonitis, CMV 
colitis
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 102 
 
07 Dec 2018
For non-commercial use only
Shire Page 103
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Table 6 presents the criteria for reporting CMV infection as an AE or as an SAE during its 
clinical course during the study .
Table 6: Criteria for reporting CMV infection as an AE or as an SAE
Course during the study 
(based on the 
investigator’s 
assessment)Reportable as AE Reportable as SAE
Tissue invasive CMV 
disease at baseline No change No No
Improving No No
Worsening, but does not 
meet criteria for SAE as 
determined by the 
investigatorYes No
Worsening and meeting 
criteria for SAE (see 
definition in Section 8.2.3 ) No Yes 
New onset of tissue 
invasive CMV disease No Yes 
Improving No No
Worsening No Yes but same event with 
upgraded severity
CMV syndrom e at 
baseline Improving No No
Worsening but does not 
meet criteria for SAEYes No
Worsening and meeting 
criteria for SAE (see 
definition Section 8.2.3 )No Yes
Worsening to 
tissue -invasive CMV 
disease No Yes 
Asymptomatic CMV 
infection at baseline Improving No No 
Worsening CMV viremia 
(or CMV viremia 
recurrence or rebound 
after clearance) Determined by the 
investigator based on the 
assessment of clinical 
significance; either local 
or central laboratory 
results to be used at 
investigator’s discretion.Yes, if fulfi lling 
seriousness criteria.
If the only reason for 
hospital admission or 
prolongation of 
hospitalization is the need 
for IV treatment in the 
hospital setting, then this 
will not qualify as an SAE 
Worsening to tissue 
invasive CMV disease No Yes 
Worsening to CMV 
syndrome No Yes
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 103 
 
07 Dec 2018
For non-commercial use only
Shire Page 104
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Table 6: Criteria for reporting CMV infection as an AE or as an SAE
Course during the study 
(based on the 
investigator’s 
assessment)Reportable as AE Reportable as SAE
CMV=cytomegalovirus; AE=adverse event; SAE=serious adverse event
8.1.6 Clinical Laboratory and Other Safety Evaluations
A change in the value of a clinical laboratory , vital sign, or ECG assessment can represent an AE 
if the change is clinically relevant or if, during study, a shift of a parameter is observed from a 
normal value to an abnormal value, or a further worsening of an alread y abnormal value. When 
evaluating such changes, the extent of deviation from the reference r ange, the duration until 
return to the reference range, either while continuing treatment or after the end of treatment with 
the investigational product, and the range of variation of the respective parameter within its 
reference range, must be taken into consideration.
If, at the end of the stud y treatment phase or at the end of the follow -up phase, there are 
abnormal clinical laboratory , vital sign, or ECG values which were not present at baseline, 
further investigations should be performed until the values return to within the reference range or 
until a plausible explanation (eg, concomitant disease) is found for the abnormal values.
The investigator should decide, based on the above criteria and the clinical condition of a 
subject, whether a change in a clinical laboratory , vital sign, or ECG parameter is clinicall y 
significant and therefore represents an AE.
8.1.7 Pregnancy
All pregnancies are to be reported from the time informed consent is signed until the defined 
follow -up period stated in Section 7.1.3.
Any report of pregnancy  for any  female study  participant or the partner of a male study  
participant must be reported within 24 hours to the Shire Global Drug Safety  Department using 
the Shire investigational and marketed products pregnancy  report form. The p regnant female 
study  participant must be withdrawn from the study .
Every  effort should be made to gather information regarding the pregnancy  outcome and 
condition of the infant. It is the responsibility of the investigator to obtain this information within
30 calendar day s after the initial notification and approximately  30 calendar day s and 1 year 
postpartum. An ethics committee (EC) and Institutional Review Board (IRB) approved informed 
consent form must be signed by  a pregnant partner of a study  particip ant prior to obtaining 
pregnancy  outcome information from the nonstudy  participant.
Pregnancy  complications such as spontaneous abortion/miscarriage or congenital abnormalit y 
are considered SAEs and must be reported using the Shire clinical study  serious a dverse event 
and nonserious AEs required by  the protocol form. Note: An elective abortion is not considered 
an SAE.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 104 
 
07 Dec 2018
For non-commercial use only
Shire Page 105
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
In addition to the above, if the investigator determines that the pregnancy  meets serious criteria, 
it must be reported as an SAE using the Shire clinical study  serious adverse event and nonserious 
AEs required b y the protocol form as well as the Shire investigational and marketed products 
pregnancy  report form. The test date of the first positive serum/urine -HCG test or ultrasound 
result wi ll determine the pregnancy  onset date.
8.1.8 Abuse, Misuse, Overdose, and Medication Error
Abuse, misuse, overdose, or medication error (as defined below) must be reported to the sponsor 
according to the SAE reporting procedure whether or not they  result in an A E/SAE as described 
in Section 8.2. Note: The 24 -hour reporting requirement for SAEs does not apply  to reports of 
abuse, misuse, overdose, or medication errors unless these result in an SAE.
The categories below are not mutually  exclusive; the event can mee t more than 1 category .
 Abuse –Persistent or sporadic intentional intake of study  treatment when used for a 
nonmedical purpose (eg, to alter one’s state of consciousness or get high) in a manner that 
may be detrimental to the individual and/or society.
 Misu se–Intentional use of study  treatment other than as directed or indicated at any  dose 
(Note: this includes a situation where the investigational product is not used as directed at 
the dose prescribed b y the protocol).
 Overdose –Intentional or unintentional intake of a dose of maribavir exceeding a total dail y 
dose of 400 mg BID , or a prespecified dose of the investigator- assigned anti -CMV 
treatment. The highest dose of maribavir studied in Phase 2 treatment studies (SHP620 -202 
and SHP620- 203) was 1200 mg BID . There was no significant difference in safet y across 
all 3 doses (400 mg BID, 800 mg BID, and 1200 mg BID) studied.
 Medication Error –An error made in prescribing, dispensing, administration, and/or use of 
the study  treatment. For studies, medication erro rs are reportable to the sponsor only  as 
defined below.
Cases of subjects missing doses of the study  treatment are not considered reportable as 
medication errors. Medication errors should be reported for all products under investigation. The 
administration and/or use of an expired investigational product or an investigator -assigned 
anti-CMV treatment should be considered as a reportable medication error.
8.2 Serious Adverse Event Procedures
8.2.1 Reference Safety Information
The reference safet y information to assess the expectedness of an AE for this study  is as follows:
The maribavir investigator's brochure which the sponsor has provided under separate 
cover to all investigators
The respective summary  of product characteristics (SmPC) for each 
investigator -assigned anti -CMV treatment (valganciclovir [Valcy te®, 
11March 2015], ganciclovir [Cy mevene®, 27October 2016], and foscarnet 
[Foscavir®, 28February  2014]) or country -specific product package insert for 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 105 
 
07 Dec 2018
For non-commercial use only
Shire Page 106
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
cidofovir (eg, Tillomed Laboratories, Ltd ;12 September 2017 [UK], 
23February 2017 [EU] ) 
8.2.2 Reporting Procedures
-All initial and follow -up SAE reports must be reported b y the investigator to the Shire Global 
Drug Safet y  Department within 24 hours of the first awareness of the event. Note: The 24 -hour 
reporting requirement for SAEs does not apply  to reports of abuse, misuse, overdose, or 
medication errors (see Section 8.1.8) unless they  result in an SAE.
The investigator must complete, sign, and date the Shire clinical study  serious adverse event and 
nonserious AEs required by  the protocol form and verify  the accuracy  of the information 
recorded on the form with the corresponding source documents (Note: Source documents are not 
to be sent unless requested) and fax or e-mail the form to the Shire Global Drug Safet y  
Department. .
In the event of an SAE, the investigator must fax or e-mail the Shire clinical trial serious adverse 
event form within 24 hours to the Shire Global Drug Safet y Department . Applicable fax numbers 
and an e -mail address can be found on the form (sent under separate cover) and are provided 
below:
Fax:
E-mail: 
8.2.3 Serious Adverse Event Definition 
A serious adverse event (SAE) is any  untoward medical occurrence (whether considered to be 
related to investigational product or not) that at any  dose:
Results in death.
Is life -threatening. Note: The term ‘life- threatening’ in the definition of “serious” 
refers to an event in which t he subject was at risk of death at the time of the event. It 
does not refer to an event which hy potheticall y might have caused death if it was 
more severe.
Requires inpatient hospitalization or prolongation of existing hospitalization. Note: 
Hospitalizatio ns, which are the result of elective or previousl y scheduled surgery for 
pre-existing conditions, which have not worsened after initiation of treatment, should 
not be classified as SAEs. For example, an admission for a previously  scheduled 
ventral hernia r epair would not be classified as an SAE; however, complication(s) 
resulting from a hospitalization for an elective or previously  scheduled surgery  that 
meet(s) serious criteria must be reported as SAE(s).
Results in persistent or significant disability /incapacity .
Is a congenital abnormality /birth defect.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 106 
 
07 Dec 2018
For non-commercial use only
Shire Page 107
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Is an important medical event. Note: Important medical events that may  not result in 
death, be life -threatening, or require hospitalization may  be considered an SAE when, 
based upon appropriate medical jud gment, they  may  jeopardize the subject and may  
require medical or surgical intervention to prevent 1 of the outcomes listed in this 
definition. Examples of such medical events include allergic bronchospasm requiring 
intensive treatment in an emergency  room or at home; blood dy scrasias or 
convulsions that do not result in inpatient hospitalization; or the development of drug 
dependency  or drug abuse.
For this protocol the following events will not be collected as SAE(s).
Pre-existing conditions that have not worsened during study  participation:
oPreplanned (planned prior to the initiation of the study ) hospitalizations 
oPreplanned treatments or surgeries
Hospitalization for the administration of foscarnet when it is the investigator's choice 
of therap y for the subjects randomized to 'control' treatment arm, or hospitalization 
for ganciclovir or cidofovir administration if this is a required practice at a local site.
8.2.4 Serious Adverse Event Collection Time Frame
All SAEs (regardless of relationship to study ) are c ollected from the time the subject signs the 
informed consent until the end of defined follow -up period stated in Section 7.1.3, and must be 
reported to the Shire Global Drug Safet yDepartment   within 24 hours of the first awareness of 
the event. 
In addit ion, any SAE(s) considered “related” to the investigational product and discovered b y the 
investigator at an y interval after the study has completed must be reported to the Shire Global 
Drug Safet y Department within 24 hours of the first awareness of the e vent.
8.2.5 Serious Adverse Event Onset and Resolution Dates
The onset date of the SAE is defined as the date the event meets serious criteria. The resolution 
date is the date the event no longer meets serious criteria, the date the s ymptoms resolve, or the 
even t is considered chronic. In the case of hospitalizations, the hospital admission and discharge 
dates are considered the onset and resolution dates, respectivel y.
In addition, any signs or symptoms experienced by the subject after signing the informed conse nt 
form, or leading up to the onset date of the SAE, or following the resolution date of the SAE, 
must be recorded as an AE, if appropriate.
8.2.6 Fatal Outcome
Any SAE that results in the subject’s death (ie, the SAE was noted as the primary  cause of death) 
must have fatal checked as an outcome with the date of death recorded as the resolution date. For 
all other events ongoing at the time of death that did not contribute to the subject’s death, the 
outcome should be considered not resolved, without a resolution date recorded.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 107 
 
07 Dec 2018
For non-commercial use only
Shire Page 108
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
For an y SAE that results in the subject’s death or any ongoing events at the time of death, unless 
another stud y treatment action was previousl y taken (eg, drug interrupted, reduced, withdrawn), 
the action taken with the study  treatment sho uld be recorded as “dose not changed” or “not 
applicable” (if the subject never received investigational product). The study  treatment action of 
“withdrawn” should not be selected solely  as a result of the subject’s death. 
8.2.7 Regulatory Agency, Institutional Review Board, Ethics Committee, and Site 
Reporting
The sponsor and/or the clinical CRO is responsible for notify ing the relevant regulatory  
authorities US central IRBs/European Union (EU) central ECs of related, unexpected SAEs.
The study  population is HS CT or SOT recipients with cy tomegalovirus infections. The following 
SAEs are common in this study  population and are anticipated to occur, hence these SAEs 
(including fatal outcomes) will not be considered unexpected and will not be individually 
reported t o the regulatory agencies, IRBs, Ethics Committees, and investigators, provided 
there is no increased frequency of these events*:
Any CMV infection, including CMV reactivation/recurrence, CMV s yndrome, and 
tissue invasive CMV disease
Any other bacterial, viral infection, or fungal infection
Acute and chronic graft versus host disease, graft rejection, and graft failure  
Reactivation of the malignancy  under treatment in HSCT recipients
This includes fatal outcomes for the aforementioned SAEs.
*Maribavir Ph ase 2 (studies 1263- 202 and 1263- 203) data will be used as reference.
However, these are AESI and will be closel y monitored and recorded on the CRF . Refer to 
Section 8.1.4 for more information on AESI.
In addition, if the event is serious (fulfilling serio usness criteria) it will be reported on SAE 
report form per Section 8.2.2 . An independent DMC will be established per Section 9.4.
In addition sponsor or the sponsor's delegate is responsible for notify ing active sites of all 
related, unexpected SAEs occur ring during all interventional studies across the maribavir 
program.
The investigator is responsible for notifying the local IRB, local EC, or the relevant local 
regulatory  authority  of all SAEs that occur at his or her site as required.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 108 
 
07 Dec 2018
For non-commercial use only
Shire Page 109
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
9. DATA MANAGEMENT AN D STATISTICAL METHODS
9.1 Data Collection
The investigators’ authorized site personnel must enter the information required b y the protocol 
on the CRF. A study  monitor will visit each site in accordance with the monitoring plan and 
review the CRF data against the source data for completeness and accuracy . Discrepancies 
between source data and data entered on the CRF will be addressed b y qualified site personnel. 
When a data discrepancy warrants correction, the correction will be made by authorized site 
personnel . Data collection procedures will be discussed with the site at the site initiation visit 
and/or at the investigator’s meeting. Once a subject is randomized, it is expected that site 
personnel will complete the CRF entry  within approximately  3 business day s of the subject’s 
visit.
9.2 Clinical Data Management
Data are to be entered into a clinical database as specified in the CRO’s data management plan. 
Quality  control and data validation procedures are applied to ensure the validity  and accuracy  of 
the 
clinical database.
Data are to be reviewed and checked for omissions, errors, and values requiring further 
clarification using computerized and manual procedures. Data queries requiring clarification are 
to be communicated to the site for resolution. Only  authorized personnel will make corrections to 
the clinical database, and all corrections are documented in an auditable manner.
9.3 Statistical Analysis Process 
The study  will be anal yzed by  the sponsor or its agent. All statistical analyses will be performed
using SASVersion 9.1 2 or higher (SAS Institute, Cary , NC 27513). 
The statistical anal ysis plan (SAP) will provide the statistical methods and definitions for the 
analysis of the efficacy  and safet y data, as well as describe the approaches to be taken for 
summarizing other study  information such as subject disposition, demographics, and baseline 
characteristics, investigational product exposure, and prior and concomitant medications. The 
SAP will also include a description of how missing, unused, and sp urious data will be addressed 
and plan for subgroup analysis. In addition, the SAP will include statistical method to summarize 
the maribavir pharmacokinetics data and explore the relationship between maribavir C min
(predose concentration) and efficacy  and safet y measures of interest. To preserve the integrit y of 
the statistical anal ysis and study  conclusions, the SAP will be finalized prior to database lock. 
Maribavir PK concentrations will be anal yzed by a population PK analy sis approach. A separate 
SAP w ill be prepared for this analy sis and a separate report will present the pharmacokinetic 
analysis results in addition to the primary  clinical study  report.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 109 
 
07 Dec 2018
For non-commercial use only
Shire Page 110
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
9.4 Data Monitoring Committee
An independent data monitoring committee (DMC) will be established to act in an expert, 
advisory  capacit y for periodic assessment of the data to monitor participant safet y and to ensure 
the validity  and scientific merit of the trial.
Further details regarding the DMC can be found in the DMC charter, which will be available 
prior to the administration of study  treatment.
9.5 Endpoint Adjudication Committee
An independent Endpoint Adjudication Committee has been established to confirm the diagnosis 
of CMV tissue invasive disease and CMV s yndrome for symptomatic subjects at baseline and to 
confirm the change over time (no change, improvement, worsening, or resolution), or diagnosis 
of new tissue invasive CMV disease and CMV s yndrome.
The roles, responsibilities, and rules governing operation of the Endpoint Adjudication 
Committee are dis cussed in full in the Endpoint Adjudication Committee charter, which will be 
available prior to the administration of investigational product.
9.6 Sample Size Calculation and Power Considerations 
In the Phase 2 Study  SHP620 -202, the proportion of subjects wit h undetectable plasma CMV 
DNA was 70%, 63%, and 68% for the 400 mg, 800 mg, and 1200 mg BID dose groups, 
respectivel y, within 6 weeks. The proportion of subjects with undetectable plasma CMV DNA 
was 70%, 65%, and 75% for the 400 mg, 800 mg, and 1200 mg BID dose groups, respectively , 
within 12 weeks. Therefore, it is assumed that at least 60% of maribavir treated subjects will 
have achieved undetectable plasma CMV DNA at Visit 9/Week 7 and Visit 10/Week 8 when 
calculating the sample size.
A proportion of approximately  40% is considered as a reasonable estimate of the proportion of 
subjects with confirmed undetectable plasma CMV DNA at Visit 9/Week 7 and Visit 10/Week 8 
in the investigator assigned treatment group when calculating the sample size. I t is believ ed that 
the treatment difference of 20% higher in maribavir group compared to the control group is 
larger than a clinicall y meaningful difference.
For the proposed trial, to demonstrate statistical superiority  in the reduction of CMV DNA, it is 
assumed tha t the proportion of subjects with confirmed unquantifiable plasma CMV DNA at
Visit 9/Week 7 and Visit 10/Week 8 in the maribavir and control groups is 60% and 40%, 
respectivel y, a total of 315 subjects is required in the ratio of 2:1 (210 subjects in marib avir 
group and 105 subjects in the control group) to provide 90% power in h ypothesis testing at an 
alpha level of 0.05 (2 -sided test). The sample size is estimated based on a 2 -group continuity  
corrected Chi -square test of equal proportions by  using nQuery Advisor 7.0. Considering 10% 
drop-outs, 351 subjects (234 subjects in maribavir group and 117 subjects in the control group) 
will be enrolled and randomized.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 110 
 
07 Dec 2018
For non-commercial use only
Shire Page 111
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
9.7 Study Analysis Population
The enrolled set will consist of all subjects who have signed an informed consent and have 
begun some study  procedures.
The randomized set will consist of all subjects in the enrolled set who have been 
randomized to the study . Subjects will be anal yzed in the treatment gr oup to which they  are 
randomized.
The safety set will consist of all subjects who have taken any dose of study treatment. 
Subjects will be anal yzed according to the treatment actually received.
The per-protocol (PP) set will consist of all subjects in the randomized set who do not have 
predefined major protocol deviations that may  affect the primary  efficacy  assessment . 
The pharmacokinetic set will consist of all subjects in the safet y set who had plasma 
samples drawn and tested for maribavir concentration s.
oThe adolescent pharmacokinetic set will consist of all subjects ≥12 to <18 years of 
age in the safet y set who had plasma samples drawn and tested for maribavir 
concentrations. 
The randomized set and the PP set will be used for efficacy  anal yses, with t he randomized set as 
the primary  analy sis set and the PP set as the supportive one. 
9.8 Efficacy Analyses
The following definitions will be used for stud y analyses: 
Confirmed viremia clearance : defined as plasma CMV DNA concentration below the lower 
limit of quantification (<LLOQ; ie, <137 IU/mL) when assessed b y COBAS® 
AmpliPrep/COBAS®TaqMan®CMV Test at a central specialt y laboratory, in 2 consecutive 
post-baseline samples, separated b y at least 5 day s.
Recurrence of CMV viremia : defined as plasma CMV DNA concentration ≥LLOQ when 
assessed b y COBAS® AmpliPrep/COBAS®TaqMan®CMV Test in 2 consecutive plasma 
samples at least 5 day s apart, after achieving confirmed viremia clearance.
Rebound of CMV viremia: defined as increase in viral DNA load for >1 log 10above nadir 
without prior clearance of viremia.
Recurrence of the Symptomatic CMV infection : defined as the presence of signs or s ymptoms 
of the tissue invasive CMV disease or CMV s yndrome (same or new s ymptomatology ) 
confirmed as per Ljungman et al., 2017 , after the period of resolution of symptomatic infection 
in subjects sy mptomatic at baseline.
Subjects in the investigator -assigned t reatment arm who are unable to continue taking 
investigator -assigned anti -CMV treatment due to the lack of anti- viral activity  and/or intolerance 
to the assigned treatment (as evaluated starting at Visit 5/Week 3) may  be evaluated for entry  
into a maribavi r rescue arm. Subjects who take rescue medication will be considered as failures 
for primary  efficacy  analy ses. The data collected post -maribavir rescue initiation will be 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 111 
 
07 Dec 2018
For non-commercial use only
Shire Page 112
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
included in separate secondary  analy ses for efficacy  and exploratory  analysis for PK . Summary  
of all safet y analyses will be provided separately  for the maribavir rescue arm. The same is 
applicable for patients who might be discontinued from maribavir treatment due to intolerance. 
Subjects who discontinue due to intolerance and without viremia clearance at Study  Week 8 will 
be considered failures in both treatment arms.
9.8.1 Primary Efficacy Endpoint
The primary  efficacy  endpoint (a binary  response) for the study  is confirmed clearance of plasma 
CMV DNA (CMV viremia clearance) at the end of Study  Week 8.
For clearance of CMV viremia to be declared at the end of Study  Week 8, the subject must have 
received exclusively  study -assigned treatments.
Confirmed CMV viremia clearance at the end of Study  Week 8 (Visit10) is defined as plasma 
CMV DNA co ncentrations <LLOQ (ie, <137 IU/mL ), when assessed by  COBAS®
AmpliPrep/COBAS®TaqMan®CMV Test at a central specialt y laboratory , in 2 consecutive 
postbaseline samples separated b y at least 5 day s, regardless of whether either study -assigned 
treatment was discontinued before the end of the stipulated 8 weeks of therapy  (see examples in 
Table 7 below).
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 112 
 
07 Dec 2018
For non-commercial use only
Shire Page 113
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Table 7: Assessments of Virological Responders at Study Week 8
ScenarioCMV DNA Weeks on Study
Week 6 Week 7 Week 8 Week 9* Response Rationale
1 + / - - - +/-/NA Yes2 consecutive “ -” at Week 7 and 
Week 8
2 + / - - + +/-/NA NoNot 2 consecutive “ -” at Week 7 
and Week 8
3 + / - + - +/-/NA NoNot 2 consecutive “ -” at Week 7 
and Week 8
4 + / - - NA - Yes2 consecutive “ -” as shown by 
available data and both “ -” at 
week 7 and week 9 for missing 
week 8, otherwise nonresponder
5 - NA - +/-/NA Yes2 consecutive “ -” as shown by 
available data and both ‘ -‘ at 
week 6 and week 8 for missing 
Week 7, otherw ise nonresponder
6 - NA NA - Yes2 consecutive “ -” as shown by 
available data at week 6 and week 
9 and both “ -”, otherwise 
nonresponder
NA = not available for evaluation of study drug effect ; reason could be not assessable by lab, or starting 
alternative anti -CMV treatment, withdraw al from study, etc.
*Week 9 data only to be used if Week 8 data are unavailable or missing.
Notes: Scenarios in the table above are provided as examples and may not be all -inclusive of all possibilities.
Only CMV DNA data evaluable for assessment of effect of study drug will be included (ie, prior to the 
start of alternative anti -CMV treatment if any).
“-” = CMV DNA concentration <LLOQ (<137 IU/mL) 
“-” = CMV DNA concentration ≥LLOQ (ie, quantifiable)
Confirmed clearance of plasma CMV DNA (CMV v iremia clearance) = 2 consecutive postbaseline 
assessments of CMV DNA target <LLOQ, separated by at least 5 days.
Statistical Methodology  for Primary  Efficacy  Endpoint:
The difference in proportion of subjects with confirmed CMV viremia clearance, at the end of 
Study  Week 8, between treatment groups (maribavir and investigator’s choice of anti -CMV 
treatment) will be obtained using Cochran -Mantel -Haenszel (CMH) weighted average across all 
strata, and anal yzed using CMH test with transplant ty pe and baseline plasma CMV DNA 
concentration as 2 stratification factors. The 95% confidence limits of the weighted average of 
difference across strata will be provided using the normal approximation. I f the minimum 
number of subjects in a response category  in a treatment group for the high viral load group is 
less than 5, the high and intermediate viral load groups will be collapsed into 1 stratum level. 
The baseline plasma CMV DNA levels will be the last central laboratory  assessment before the 
first dose of study  treatment. If the p- value from the CMH test is ≤0.0505 and the proportion of 
response from marib avir is higher, it will be concluded that maribavir is more efficacious 
compared to the control group.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 113 
 
07 Dec 2018
For non-commercial use only
Shire Page 114
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Subjects who are unable to continue taking investigator’s assigned anti -CMV treatment due to 
the lack of anti- viral activity  and/or intolerance to the assigned treatment (as evaluated starting at 
Visit 5/Week 3) may be evaluated for entry  into a maribavir rescue arm. Subjects who take 
rescue medication will be considered as failures for primary  efficacy  anal yses. The data collected 
postmaribavir rescue in itiation, will be included in separate secondary  anal yses for efficacy  and 
exploratory  anal ysis for PK. Summary  of all safety  analy ses will be provided separatel y for the 
maribavir rescue arm. Since intolerance to the assigned treatment alone will not qual ify a subject 
for the rescue arm, such subjects will not be considered nonresponders for the purpose of the 
primary  efficacy  anal ysis. The same is applicable for subjects that might be discontinued from 
maribavir treatment due to intolerance. Subjects that do not achieve confirmed CMV viremia 
clearance will be considered failures in both treatment arms. Subjects who discontinue without 
confirmed CMV viremia clearance at Study  Week 8 will be considered failures in both treatment 
arms .
Sensitivity  and support ive anal yses of the primary endpoint of CMV viremia clearance at 
Week 8 will be conducted to evaluate the robustness of the result from the primary  method. This 
will be specified in the SAP. Two examples are given below:
Subjects who discontinue study  treatment early  without CMV DNA measurement 
available for evaluation of study  drug effect at Week 8 (see Table 7). However, they  meet 
the criteria of confirmed CMV viremia clearance defined as 2 consecutive post baseline 
assessments of CMV DNA target <LLOQ, separated by  at least 5 day s, at the time of 
study  discontinuation will be included as responders.
Multivariate regression analy sis to evaluate treatment difference after controlling for 
important demographic and baseline c linical characteristics. The list of demographic and 
baseline clinical characteristics to be considered will include but will not be limited to 
transplant ty pe (HSCT versus SOT), CMV viral load resistant versus refractory , CMV 
serostatus, immune function s tatus, presence of GVHD, high dose steroids use at 
baseline, prior use of CMV proph ylaxis.
The anal ysis of primary  efficacy  endpoint and the key  secondary  efficacy  endpoint will be 
conducted using both the randomized set and PP set.
9.8.2 Key Secondary Efficacy Endpoint
The key  secondary  endpoint of this study  is a binary  response (y es/no) with following criteria:
Achievement of CMV viremia clearance and resolution or improvement of tissue -
invasive CMV disease or CMV sy ndrome for subjects sy mptomatic at baseline or 
achievement of clearance of viremia and no s ymptoms of tissue invasive CMV disease or 
CMV sy ndrome for subjects as ymptomatic at baseline at the end of Study  Week 8, 
followed b y maintenance of this treatment effect for an additional 8 weeks off treatment
(ie, Follow -up Week 16) .
For treatment effect of clearance of CMV viremia and CMV infection s ymptom control 
(resolution or improvement of tissue invasive disease or CMV s yndrome for symptomatic 
subjects at baseline, or no new s ymptoms for subjects as ymptomatic at baseline) to be declared at 
the end of Study  Week 8, regardless of whether either study -assigned treatment was discontinued 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 114 
 
07 Dec 2018
For non-commercial use only
Shire Page 115
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
before the end of the stipulated 8 weeks of therapy , and maintenance of such effect through 
Week 16, the subject must have received exclusively  a study -assigned treatment.
The investigator will perform the initial diagnosis of tissue -invasive CMV disease or CMV 
syndrome (absence or presence) for the s ymptomatic subjects at baseline and new occurrence of 
tissue invasive CMV dis ease or CMV s yndrome for the as ymptomatic subjects at baseline 
through the stud y, and will continue with the assessment of the infection status (ie, no change, 
improvement, worsening, or resolution) at subsequent visits through the study . All investigator -
assessed cases of tissue invasive CMV disease and CMV sy ndrome will be reviewed and 
adjudicated b y an independent EAC both for the confirmation of the diagnosis of baseline and 
new s ymptomatic CMV infection and for the outcome (ie, no change, improvement, worsening, 
or resolution).
All investigator -assessed cases of tissue invasive CMV disease and CMV s yndrome will be 
reviewed and adjudicated by  an independent EAC both for the confirmation of the diagnosis at 
baseline and new tissue invasive CMV disease or CMV sy ndrome and for the outcome (ie, no 
change, improvement, worsening, or resolution). An adjudicated baseline disease diagnosis of 
“confirmed” or “probable” will be accepted (onl y “probable” for CMV s yndrome). An 
adjudicated outcome of “improved” or “ab sent” will constitute improvement of tissue invasive 
CMV disease or CMV s yndrome. New cases of tissue invasive CMV disease or CMV syndrome 
identified by  the investigator will also be adjudicated. Endpoint Adjudication Committee
adjudicated cases will be us ed for the efficacy  analy ses.
Criteria for defining the key secondary  efficacy  endpoint are:
First being a responder at the end of Study  Week 8, irrespective of study  treatment duration, 
based on CMV viremia clearance and assessment of the tissue invasive CMV disease or 
CMV sy ndrome status (ie, resolution or improvement of tissue invasive CMV disease or 
CMV sy ndrome for subjects sy mptomatic at baseline or no sy mptoms of tissue invasive 
CMV disease or CMV s yndrome for subjects as ymptomatic at baseline).
AND 
Maintenance of this treatment effect (both CMV viremia clearance and tissue -invasive 
disease or CMV s yndrome control) through Study Week 16 (criteria for the CMV viremia 
clearance are presented in Table 8).
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 115 
 
07 Dec 2018
For non-commercial use only
Shire Page 116
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Table 8: Assessments of Responders for Key Secondary Endpoint
Response 
(both 
virological 
response and 
symptom atic 
CMV 
infection 
control) at 
Study Week 
8CMV DNA Assessment Week
Key 
secondary 
endpoint 
responder*Rationale
9 10 11 12 14 16 181
Yes +/- +/- +/- +/- +/-+/-+/-/NA NoAny 2 consecutive “+”in FU by 
week 16
Yes +/- +/- +/- +/- +/- - +/-/NA YesWeek16 is “-” and no 2 
consecutive “+” during FU
Yes +/- +/- +/- +/- +/- + +/-/NA NoWeek 16 is “+ ”and week 18 is 
“+”or NA, c riteria of 2 
consecutive “+” is m et
Yes +/- +/- +/- +/- +/- + - YesWeek 16 is “+”, and 2 
consecutive “+” criteria is not met 
based on w eek 18 data
Yes +/- +/- + - - NA - YesWeek 16 is missing, 2 
consecutive “+” criteria is not met 
based on w eek 14 and 18 data
Yes +/- +/- + - - NA +/NA NoWeek 16 is missing, 2 
consecutive “+” criteria may be 
met based on available w eek 18 
data
Yes +/-/NA +/-/NA +/-/NA +/-/NA NA NA +/-/NA NoLack of data to show maintaining 
effect through week 16 
No No
1Week 18 data will be used only if Week 16 data are unavailable or missing.
*Must also meet the criterion of CMV infection symptom control to be a responder.
NA=not available for evaluation of study drug effect; reason could be starting alternative anti-CMV treatment, withdrawal from 
study, etc.
Notes: Scenarios in the table above are provided as examples and may not be all -inclusive of all possibilities.
Only CMV viremia data prior to receiving nonstudy CMV treatment or rescue treatment will be included in the 
assessment.
Statistical Methodology  for Key  Secondary  Endpoint
The key  secondary  endpoint will be analy zed using the same approach as the primary  endpoint.
The anal ysis of primary  efficacy  endpoint and the key  secondary  efficacy  endpoint will be 
conducted using both the randomize d set and PP set.
9.8.3 Multiplicity Adjustment 
The h ypothesis -testing of the primary  and key  secondary  endpoint will be adjusted for multiple 
comparisons using a fixed- sequence testing procedure to control the family -wise Ty pe 1 error 
rate at 5% level. The statistical test will be performed sequentiall y in the order of primary 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 116 
 
07 Dec 2018
For non-commercial use only
Shire Page 117
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
efficacy  endpoint, and the key  secondary  endpoint. First, the primary  endpoint analy sis (CMV 
viremia clearance at Week 8) will be assessed at α=0.05. If and onl y after the primary  efficacy 
endpoint is statistically  significant, the key  secondary  endpoint will be assessed at α=0.05.
9.8.4 Subgroup Analyses
The primary  and key  secondary  endpoints will be examined for the following subgroups 
(inclusive, but not limited to):
Subjects sy mptomatic at baseline
SOT/HSCT recipients 
CMV DNA viral load (high, intermediate, low)
Resistant (y es/no)
Adolescents ≥12 to <18 y ears of age (exploratory anal ysis: may  be conducted if sample 
size is adequate)
The proportion of subjects achieving the primary  efficacy  endpoint and the key  secondary  
efficacy  endpoint, and the corresponding 95% CIs will be calculated for each group separatel y. 
In addition, the difference in each respective proportion between treatment group and the 
associated 95% CI will be prese nted.
9.8.5 Secondary Efficacy Endpoints
The secondary efficacy endpoints of this study are as follows:
The achievement of the confirmed CMV viremia clearance after 8 weeks of receiving 
study -assigned treatment.
oThe proportion of subjects achieving the confirmed CMV viremia clearance after 
receiving 8 weeks of study- assigned treatment, and the corresponding 95% CI s 
will be calculated for each treatment group separately . The difference in each 
respective proportion between treatment groups and the associated 95% C I will be 
calculated using the same approach as the primary efficacy  endpoint, and will be 
assessed using CMH test with transplant ty pe and baseline CMV DNA 
concentration as 2 stratification factors.
The achievement of the confirmed CMV viremia clearance a nd CMV infection sy mptom 
control after receiving 8 weeks of stud y-assigned treatment, followed b y maintenance of 
this treatment effect through Study Weeks 12 (4 weeks post treatment period), 16 (8 
weeks post treatment/follow- up phase), and 20 (12 weeks post treatment).
oThe proportion of subjects who achieved confirmed CMV viremia clearance and
CMV infection sy mptom control after 8 weeks of receiving study -assigned 
treatment and maintaining the effect through Study Weeks 12, 16, and 20, and the 
correspondin g 95% CIs will be calculated for each treatment group separately . 
The difference in each respective proportion between treatment groups and the 
associated 95% CI will be calculated using the same approach as the primary  
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 117 
 
07 Dec 2018
For non-commercial use only
Shire Page 118
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
efficacy  endpoint, and will be asses sed using CMH test with transplant type and 
baseline CMV DNA concentration as 2 stratification factors.
The maintenance of the CMV viremia clearance, and CMV infection s ymptom control, at 
the end of Study  Week 8, through weeks 12 and 20, regardless of whet her either study -
assigned treatment was discontinued before the end of the stipulated 8 weeks of therap y.
oThe proportion of subjects who maintained confirmed CMV viremia clearance 
andCMV infection s ymptom control at end of Study  Week 8 and maintained 
the effect through Study  Week 12 and 20, and the corresponding 95% CIs will 
be calculated for each treatment group separatel y. The difference in each 
respective proportion between treatment groups and the associated 95% CI 
will be calculated using the same app roach as the primary  efficacy  endpoint, 
and will be assessed using CMH test with transplant ty pe and baseline CMV 
DNA concentration as 2 stratification factors.
The recurrence of CMV viremia during the first 8 weeks of the stud y, in the follow -up 
period of 12 weeks, and at any  time during the 20 weeks of the study , regardless of 
whether either stud y-assigned treatment was discontinued before the end of the stipulated 
8 weeks of therap y.
oThe proportion of subjects with recurrence of CMV viremia during the first 8 
weeks of the stud y, and the corresponding 95% Cl will be calculated. 
oThe proportion of subjects with recurrence of CMV viremia, in the 12 weeks 
of the follow -up phase and the cor responding 95% Cl will be calculated.
oThe proportion of subjects with recurrence of CMV viremia an y time on study  
and the corresponding 95% Cl will be calculated.
Additional subgroup analysis will be done for the subjects who completed 8 weeks of 
study -assigned treatment with the same ty pe of endpoints:
oThe proportion of subjects with recurrence of CMV viremia during the 8 weeks 
of study  treatment, and the corresponding 95% Cl will be calculated.
oThe proportion of subjects with recurrence of CMV viremia, in the 12 weeks of 
the follow-up phase and the corresponding 95% Cl will be calculated.
oThe proportion of subjects with recurrence of CMV viremia at an y time on the 
study  and the corresponding 95% Cl will be calculated.
The recurrence of CMV viremia during study -assigned treatment and in the follow -up 
period after the subject is discontinued from study -assigned treatment.
oThe proportion of subjects with recurrence of CMV viremia while on study 
treatment, and the corresponding 95% Cl will be calculated.
oThe pr oportion of subjects with recurrence of CMV viremia, in the period 
from the termination of study treatment to the end of the study , and the 
corresponding 95% Cl will be calculated.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 118 
 
07 Dec 2018
For non-commercial use only
Shire Page 119
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
The maribavir CMV resistance profile
oThe proportion of maribavir subjects w ho developed maribavir CMV 
resistance on stud y and the corresponding 95% CI will be calculated.
All causes mortalit y by the end of the stud y (Visit 18/Week 20[Follow -up Week 12]) 
oThe proportion of subjects who died at the end of the study  and the 
correspo nding 95% CIs will be calculated for each group separatel y. In 
addition, the difference in each respective proportion between treatment group 
and the associated 95% CI  will be presented.
The time to all causes mortality  will also be summarized using the Ka plan-
Meier method.
The secondary  efficacy  endpoints assessed for the maribavir rescue arm are as follows:
The confirmed clearance of plasma CMV DNA at the end of 8 weeks after starting 
maribavir rescue treatment
oThe proportion of subjects receiving maribavir rescue treatment who achieved 
the CMV viremia clearance at the end of 8 weeks after starting maribavir 
rescue treatment and the corresponding 95% CI will be calculated.
Achievement of viremia clearance at the end of 8 weeks after starting maribav ir rescue 
treatment and resolution or improvement of tissue invasive CMV disease or CMV 
syndrome for subjects who are s ymptomatic at the start of maribavir treatment or subjects 
who are as ymptomatic at the start of maribavir treatment remain s ymptom free, followed 
by maintenance of the treatment effect for an additional 8 weeks when off maribavir 
rescue treatment (as evidenced b y sustained clearance of viremia and improvement or 
resolution of sy mptomatic infection and no new tissue invasive CMV disease or C MV 
syndrome development between end of treatment and up to Week 16)
oThe proportion of subjects receiving maribavir rescue treatment who achieved 
the confirmed CMV viremia clearance and tissue invasive disease or CMV 
syndrome control at the end of 8 weeks a fter starting maribavir rescue 
treatment and maintain the effect through Week 16 and the corresponding 
95% CI  will be calculated.
The anal ysis of the secondary  efficacy  endpoints will be conducted using the Randomized and 
PP set unless otherwise specified. Secondary  efficacy  endpoints will be summarized by  treatment 
arm, and, if indicated, analyzed statisticall y at α=0.05 (2- sided), without adjustment for multiple 
comparisons.
9.8.6 Exploratory Efficacy Endpoints
The exploratory efficacy endpoints are as follows:
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 119 
 
07 Dec 2018
For non-commercial use only
Shire Page 120
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
The randomized set will be used for the anal ysis of the exploratory  efficacy endpoints. 
Descriptive statistics will be used to summarize the data. Summary  statistics will incl ude the 
number of subjects (N), mean, standard deviation, median, minimum and maximum (range) 
values for continuous variables, and incidences and percentages for categorical variables. The 
denominator for the percentages will be based on the number of pati ents with nonmissing 
information in the randomized set. Time -to-event endpoints will be summarized using Kaplan -
Meier estimation. Ninet y-five percent (95%) confidence intervals for the estimated 25%, 50%, 
and 75% times will be presented.
9.9 Safety Analyses
The safety  anal yses will include evaluation and procedures to meet the secondary  objective of 
assessing the safet y and tolerability  of maribavir.
Safet y evaluation will be made during the periods as illustrated in Figure 1 , ie, screening phase, 
treatment phase, and follow -up phase. 
Two observation periods are defined for the purpose of anal yses:
1)The on- treatment observation period starts at the time of study  treatment initiation through 
7days after the last dose of study  treatment or through 21 day s if cidofovir is used. For 
subjects who transfer from the study treatment to either maribavir rescue or to a nonstudy  
CMV treatment, the on treatment observation period starts at the time of the study  treatment 
initiation throug h 7 day s after the last dose of study  treatment (or through 21 day s if cidofovir 
is used), or until the maribavir rescue treatment initiation or until the nonstudy  CMV 
treatment initiation, whichever is earlier. This will serve as the primary  analy sis of s afety.
2)The overall -study  observation period minus the period on rescue arm starts at the time study  
treatment start through the end of the study . For subjects who receive maribavir rescue 
therap y, the overall -study  observation period minus the period on re scue arm starts at the 
time study  treatment start through the time before receiving maribavir rescue therapy .
Similar observation periods are defined for the safety  anal ysis of the maribavir rescue arm.
The events that occur from the time of I CF signature to first dose will be collected but will not be 
evaluated in the safet y analyses. They will be listed as pretreatment adverse events.
An AE (classified by preferred term) that has a start date on or after the first dose of study 
treatment or that has a start date before the date of first dose of stud y treatment, but increases in 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 120 
 
07 Dec 2018
For non-commercial use only
Shire Page 121
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
severit y after the first dose of study treatment will be considered a treatment -emergent AE 
(TEAE).
Safet y endpoints will be summarized descriptively for the on treatment period, an d overall -study  
period, as appropriate. Baseline assessments will be the last assessment before the first dose of 
study  treatment. The safety  set population will be used to anal yze the safety  data. Summary  of all 
safet y analyses will be provided separatel yfor the maribavir rescue arm.
The safety  endpoints include the following:
TEAEs and treatment- emergent SAEs, overall study  AEs and overall study  SAEs 
Clinical laboratory  evaluations 
Safet y assessment will also include vital sign measurements, ph ysical e xamination, and ECG.
The number of events, incidence, and percentage of TEAEs and overall- study  AEs will be 
display ed for each treatment group by system organ class (SOC) and by  Preferred Terms using 
the Medical Dictionary  for Regulatory  Activities (MedDRA®). Summaries in terms of severit y 
and relationship to study  medication will also be provided. Treatment -emergent SAEs will be 
summarized separatel y in a similar fashion. Summaries of AEs causing discontinuation of study  
medication, withdrawals, AEs leadin g to death, SAEs and adverse of events special interest 
(AESI) will be provided.
Adverse events of special interest, eg, tissue invasive CMV disease, dy sgeusia, GI events 
(nausea, vomiting and diarrhea), neutropenia, increased immunosuppressant drug concentration 
levels, graft rejection, opportunistic infections, and GVHD will be analy zed according to primary  
System Organ Classes (SOCs) and Preferred Terms (PTs). MedDRA queries (SMQs) may  be 
used, as applicable. Additional grading of events of special interest will be applicable. Summary  
tables with SOCs and PTs will be generated presenting the number and percentage of subjects b y 
AE, severit y, seriousness, and relationship to study medication.
Usage of concomitant medications and procedures will be su mmarized descriptively  for each of 
the treatment groups and the maribavir rescue treatment group for the on treatment period and 
overall -study  period. Treatment of hemopoietic growth factors, blood and blood transfusion 
products will be summarized separate ly
Change from baseline in vital signs and clinical laboratory  tests will be summarized for each 
treatment group with descriptive statistics at each assessment visit. Summary and shift tables will 
be produced for selected laboratory  parameters based on Nat ional Cancer Institute (NCI ) 
common terminology  criteria for adverse events (CTCAE v4.0).
Abnormal ph ysical examination findings will be listed.
Summary  of ECG findings will be provided b y treatment groups.
An independent data monitoring committee (DMC) wi ll be established to assess the data for 
safet y and to ensure the validity and scientific merit of the trial. Detailed plans for the DMC’s 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 121 
 
07 Dec 2018
For non-commercial use only
Shire Page 122
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
purpose and responsibilities will be described in the DMC charter and the statistical analy sis 
plan.
9.10 Other Analyses
9.10.3 Pharmacokinetic Analyses 
The Pharmacokinetic Set will be used to anal yze the pharmacokinetic endpoints. The adolescent 
pharmacokinetic set will consist of all subjects ≥12 to <18 years of age in the safet y set who 
had plasma samples drawn and tested for maribavir concentrations.
Pharmacokinetic endpoints for maribavir treatment either from treatment phase or rescue 
treatment are as follows:
Secondary  endpoint
For all subjects who received maribavir treatment:
Maribavir C min(predose maribavir concentration)
For adolescent subjects who provided intensive PK samples at Visit 3/Week 1:
AUC (0-tau): area under the concentration time curve over the 12 -hour dosing interval at steady  
state
Cmax: maximum concentration
Tmax: time when maximum concentration is observed
CL/F: apparent oral clearance
Vz/F: apparent volume of distribution 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 122 
 
07 Dec 2018
For non-commercial use only
Shire Page 123
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Exploratory  endpoints:
Blood samples at predose (C min) and 2 -4 hour postdose administration will be assessed for 
plasma maribavir concentration levels. Maribavir PK will be analy zed for all subjects with 
maribavir plasma concentration results. Maribavir PK concentrations will be summarized by  visit 
and planned sampling time. A scatter plot of all reportable maribavir concentration vs actual 
sampling time will be generated. A listing of subjects with maribavir concentration below the 
quantitation limit will be provided along with the Week 8 efficacy  response. Anal ysis on the 
relationship between C min(predose maribavir concentration) and efficacy  endpoints of interest 
will be conducted b y graphical exploration and by statistical models.
In a separate anal ysis and report, maribavir concentrations will be anal yzed by  population PK 
analysis approach using nonlinear mixed effect model approach using NONMEM v7 or above. 
Post hoc maribavir PK parameters such as AUC, C max, and C minwill be generated and 
summarized by  identified covariates; relationship between post hoc maribavir PK parameter 
estimates (AUC, C max, and C min) and efficacy  and safet y measures of interest will be explored. 
This analy sis may be conducted by  combining maribavir PK data from other Phase 2 and Phase 3 
studies.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 123 
 
07 Dec 2018
For non-commercial use only
Shire Page 124
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
10. SPONSOR’S AND INVEST IGATOR’S RESPONSIBIL ITIES
This study  is conducted in accordance with current applicable regulations, ICH, EU Directive 
2001/20/EC and its updates/revisions, and local ethical and legal requirements.
The name and address of each third part y vendor (eg, CRO) used in this study  will be maintained 
in the investigator’s and sponsor’s files, as appropriate.
10.1 Sponsor’s Responsibilities
10.1.1 Good Clinical Practice Compliance
The study  sponsor and any  third party  to whom aspects of the study  management or monitoring 
have been delegated will undertake their assigned roles for this study  in compliance with all 
applicable industry regulations, I CH Good Clinical Practice (GCP) Guideline E6, EU Directive 
2001/20/EC , Integrated Addendum to I CH E6 (R1): Guideline for Good Clinical Practice E6 
(R2) Current Step 4 version dated 9 November 2016, and updates/revisions, as well as all 
appli cable national and local laws and regulations.
Visits to sites are conducted by  representatives of the study  sponsor and/or the company  
organizing/managing the research on behalf of the sponsor to inspect study  data, subjects’ 
medical records, and CRFs in accordance with current GCP and the respective local and 
(inter)national government regulations and guidelines. Records and data may additionall y be 
reviewed b y auditors or by regulatory authorities.
The sponsor ensures that local regulatory  authorit y requ irements are met before the start of the 
study . The sponsor (or a nominated designee) is responsible for the preparation, submission, and 
confirmation of receipt of an y regulatory  authority  approvals required prior to release of 
investigational product for shipment to the site.
10.1.2 Indemnity/Liability and Insurance
The sponsor of this research adheres to the recommendations of the Association of British 
Pharmaceutical Industry  Guidelines. If appropriate, a cop y of the indemnity document is 
supplied to the investigator before study  initiation, per local country  guidelines.
The sponsor ensures that suitable clinical study  insurance coverage is in place prior to the start of 
the study . An insurance certificate is supplied to the CRO/investigator as necessary .
10.1.3 Public Posting of Study Information
The sponsor is responsible for posting appropriate study  information on applicable websites. 
Information included in clinical study  registries may  include participating investigators’ names 
and contact information.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 124 
 
07 Dec 2018
For non-commercial use only
Shire Page 125
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
10.1.4 Submi ssion of Summary of Clinical Study Report to Competent Authorities 
of Member States Concerned and Ethics Committees
The sponsor will provide a summary  of the clinical study  report to the competent authorit y of the 
member state(s) concerned as required b y regulatory  requirement(s) and to comply  with the 
Community  guideline on GCP. This requirement will be fulfilled within 6 months of the end of 
the study  completion date for pediatric studies and within 1 y ear for nonpediatric studies as per 
guidance. The spo nsor will provide the ECs with a copy  of the same summary .
10.1.5 Study Suspension, Termination, and Completion
The sponsor may  suspend or terminate the study , or part of the study , at any  time for any  reason. 
If the stud y is suspended or terminated, the sponsor will ensure that applicable sites, regulatory  
agencies and IRBs/ECs are notified as appropriate. Additionally , the discontinuation of a 
registered clinical study  which has been posted to a designated public website will be updated 
accordingl y.
The sponsor will make an end of study  declaration to the relevant competent authority  as 
required b y Article 10 (c) of Directive 2001/20/EC and its updates/revisions.
10.2 Investigator’s Responsibilities
10.2.1 Good Clinical Practice Compliance
The investigator must undertake to perform the study  in accordance with ICH GCP Guideline 
E6, EU Directive 2001/20/EC, Integrated Addendum to I CH E6 (R1): Guideline for Good 
Clinical Practice E6 (R2) Current Step 4 version dated 9 November 2016, and updates/revisions, 
and applicable regulatory requirements and guidelines.
It is the investigator’s responsibility  to ensure that adequate time and appropriatel y trained 
resources are available at the site prior to commitment to participate in this study . The 
investigator should also be able to es timate or demonstrate a potential for recruiting the required 
number of suitable subjects within the agreed recruitment period.
The investigator will maintain a list of appropriately  qualified persons to whom the investigator 
has delegated significant stud y-related tasks, and shall, upon request of the sponsor, provide 
documented evidence of any  licenses and certifications necessary  to demonstrate such 
qualification. Curriculum vitae for investigators and subinvestigators are provided to the study  
sponsor ( or designee) before starting the study .
If a potential research subject has a primary  care phy sician, the investigator will, with the 
subject’s consent, inform them of the subject’s participation in the study .
A coordinating principal investigator is appoi nted to review the final clinical study  report for 
multicenter studies. Agreement with the final clinical study  report is documented by  the signed 
and dated signature of the principal investigator (single- site study ) or coordinating principal 
investigator (multicenter study ), in compliance with Directive 2001/83/EC and its 
updates/revisions as amended by  Directive 2003/63/EC and I CH Guidance E3.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 125 
 
07 Dec 2018
For non-commercial use only
Shire Page 126
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
The investigator is responsible for supervising any individual or party  to whom the investigator 
delegates stud y tasks conducted at the trial site. If the investigator/institution retains the services 
of an y part y to perform study  tasks they  should ensure this part y is qualified to perform those 
study  tasks and should implement procedures to ensure the integrity  of the study  tasks performed 
and an y data generated.
10.2.2 Protocol Adherence and Investigator Agreement
The investigator and an y coinvestigators must adhere to the protocol as detailed in this 
document. The investigator is responsible for enrolling only those subje cts who have met 
protocol eligibility  criteria. Investigators are required to sign an investigator agreement to 
confirm acceptance and willingness to comply  with the study  protocol.
If the investigator suspends or terminates the study  at their site, the in vestigator will promptly  
inform the sponsor and the I RB/EC and provide them with a detailed written explanation. The 
investigator will also return all investigational product, containers, and other study  materials to 
the sponsor. Upon study  completion, the investigator will provide the sponsor, I RB/EC, and 
regulatory  agency  with final reports and summaries as required by  (inter)national regulations.
Communication with local I RBs/ECs, to ensure accurate and timel y information is provided at 
all phases during the study , may  be done by  the sponsor, applicable CRO, investigator, or for 
multicenter studies, the coordinating principal investigator according to national provisions and 
will be documented in the investigator agreement.
10.2.3 Documentation and Retention of Records
10.2.3.1 Case Report Forms
Case report forms are supplied by  the sponsor/CRO and should be handled in accordance with 
instructions from the sponsor.
The investigator is responsible for maintaining adequate and accurate medical records from 
which accurate information is recorded onto CRFs, which have been designed to record all 
observations and other data pertinent to the clinical investigation. Case report forms must be 
completed b y the investigator or designee as stated in the site delegation log.
All dat a sent to the sponsor must be endorsed b y the investigator.
The CRA/study  monitor will verify  the contents against the source data per the monitoring plan. 
If the data are unclear or contradictory , queries are sent for corrections or verification of data.
10.2.3.2 Recording, Access, and Retention of Source Data and Study Documents
Original source data to be reviewed during this study  will include, but are not limited to: 
subject’s medical file, subject diary , original clinical laboratory  reports, and histology  and 
pathology  reports.
The investigator should maintain adequate and accurate source documents and trial records that 
include all pertinent observations on each of the site’s trial subjects. Source data should be 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 126 
 
07 Dec 2018
For non-commercial use only
Shire Page 127
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
attributable, legible, contemporaneous, original , accurate, and complete. Changes to source data 
should be traceable, should not obscure the original entry  and should be explained if necessary  
(eg, via an audit trail).
All key  data must be recorded in the subject’s medical records.
The investigator must permit authorized representatives of the sponsor, the respective national, 
local, or foreign regulatory  authorities, the IRB/EC, and auditors to inspect facilities and to have 
direct access to original source records relevant to this study , regardless of media.
The CRA/study  monitor (and auditors, IRB/EC, or regulatory  inspectors) may  check the CRF 
entries against the source documents. The consent form includes a statement by  which the 
subject agrees to the monitor/auditor from the sponsor or its represent atives, national or local 
regulatory  authorities, or the I RB/EC, having access to source data (eg, subject’s medical file, 
appointment books, original laboratory reports, X -rays, etc.). Nonstudy  site personnel will not 
disclose an y personal information or personal medical information (applicable in the UK).
These records must be made available within reasonable times for inspection and duplication, if 
required, b y a properly  authorized representative of any  regulatory  agency  (eg, the US Food and 
Drug Admini stration (FDA), EMA, UK Medicines and Healthcare products Regulatory  Agency ) 
or an auditor.
Essential documents must be maintained according to ICH GCP requirements and may  not be 
destroy ed without written permission from the sponsor.
10.2.3.3 Audit/Inspection
To ensure compliance with relevant regulations, data generated b y this study must be available 
for inspection upon request by  representatives of, for example, the US FDA (as well as other US 
national and local regulatory  authorities), the EMA, the Medicines an d Healthcare products 
Regulatory  Agency , other regulatory  authorities, the sponsor or its representatives, and the 
IRB/EC for each site.
10.2.3.4 Financial Disclosure
The investigator is required to disclose an y financial arrangement during the study  and for 1 year
after, whereb y the outcome of the study could be influenced b y the value of the compensation for 
conducting the study , or other pay ments the investigator received from the sponsor. The 
following information is collected: an y significant payments from the sponsor or subsidiaries 
such as a grant to fund ongoing research, compensation in the form of equipment, retainer for 
ongoing consultation or honoraria; an y proprietary interest in investigational product; an y 
significant equity  interest in the sponsor or subsidiaries as defined in 21 CFR 54 2(b) (1998).
10.2.4 Compliance to all Local, State, and National Controlled- substance 
Biohazard and Infectious Disease Regulations and Legislation
When using controlled substances, biohazardous material, or substances for infe ctious diseases, 
the investigator must at all times comply  with all local, state, and national laws pertaining to 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 127 
 
07 Dec 2018
For non-commercial use only
Shire Page 128
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
registration and reporting with the appropriate regulatory  body  and control and handling of such 
substances.
10.3 Ethical Considerations
10.3.1 Informed C onsent
It is the responsibility  of the investigator to obtain written informed consent and assent, where 
applicable from all study  subjects prior to any  study -related procedures including screening 
assessments; parents will sign the assent form, as applica ble. All consent and assent 
documentation must be in accordance with applicable regulations and GCP. Each subject or the 
subject’s legall y-authorized representative, as applicable, is requested to sign and date the subject 
informed consent form or a certified translation if applicable, after the subject has received and 
read (or been read) the written subject information and received an explanation of what the study  
involves, including but not limited to: the objectives, potential benefits and risk, inconve niences, 
and the subject’s rights and responsibilities. A copy of the informed consent and assent 
documentation (ie, a complete set of subject information sheets and full y executed signature 
pages) must be given to the subject or the subject’s legally -authorized representative, as 
applicable. This document may  require translation into the local language. Signed consent forms 
must remain in each subject’s stud y file and must be available for verification at an y time.
Within the source documents, site personn el should document instruction of and understanding 
by a parent or both parents/legall y-authorized representative/caregiver of the safe, responsible 
storage and administration of investigational product to the study  subject.
10.3.2 Institutional Review Board or E thics Committee
For sites outside the EU, it is the responsibility  of the investigator to submit this protocol, the 
informed consent document (approved b y the sponsor or their designee), relevant supporting 
information, and all types of subject recruitment information to the I RB/EC for review, and all 
must be approved prior to site initiation.
For sites within the EU, the applicant for an EC opinion can be the sponsor, the investigator, or 
for multicenter studies the coordinating principal investigator or sponsor, according to national 
provisions.
Responsibility  for coordinating with IRBs/ECs is defined in the investigator agreement.
Prior to implementing changes in the study , the sponsor and the IRB/EC must approve any  
revisions of all informed consent doc uments and amendments to the protocol unless there is a 
subject safet y issue.
Investigational product supplies will not be released until the sponsor/CRO has received written 
IRB/EC approval of and copies of revised documents.
For sites outside the EU, the investigator is responsible for keeping the IRB/EC apprised of the 
progress of the stud y and of an y changes made to the protocol, but in an y case at least once a 
year; for sites within the EU, this can be done by  the sponsor, the investigator or for multi center 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 128 
 
07 Dec 2018
For non-commercial use only
Shire Page 129
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
studies the coordinating principal investigator, according to national provisions. The investigator 
must also keep the local IRB/EC informed of an y serious and significant AEs.
10.4 Privacy and Confidentiality
All US-based sites and laboratories or entities providing support for this study , must, where 
applicable, compl y with Health Insurance Portability  and Accountability Act (HIPAA). A site 
that is not a covered entity as defined b y HIPAA must provide documentation of this fact to the 
CRO/sponsor .
The c onfidentialit y of records that may be able to identify subjects will be protected in 
accordance with applicable laws, regulations, and guidelines.
After subjects have consented to take part in the study , the sponsor and/or its representative 
reviews their medical records and data collected during the study . These records and data may , in 
addition, be reviewed b y others including the following: independent auditors who validate the 
data on behalf of the sponsor; third parties with whom the sponsor may  develo p, register, or 
market SHP620; national or local regulatory  authorities; and the I RB(s)/EC(s) which gave 
approval for the study  to proceed. The sponsor and/or its representatives accessing the records 
and data will take all reasonable precautions in accord ance with applicable laws, regulations, and 
guidelines to maintain the confidentialit y of subjects’ identities.
Subjects are assigned a unique number for identification. The results of studies containing 
subjects’ unique identify ing number and relevant med ical records will be recorded. They  may  be 
transferred to, and used in, other countries which may  not afford the same level of protection that 
applies within the countries where this study  is conducted. The purpose of any  such transfer 
would include: to su pport regulatory  submissions, to conduct new data analy ses to publish or 
present the stud y results, or to answer questions asked by regulatory or health authorities.
10.5 Study Results/Publication Policy
Shire will endeavor to publish the results of all qualify ing, applicable, and covered studies 
according to external guidelines in a timely  manner regardless of whether the outcomes are 
perceived as positive, neutral, or negative. Additionally, Shire adheres to external guidelines (eg, 
Good Publication Practices) when forming a publication steering committee, which is done for 
large, multicenter Phase 2 -4 and certain other studies as determined b y Shire. The purpose of the 
publication steering committee is to act as a noncommercial bod y that advises or decides on 
dissemination of scientific study  data in accordance with the scope of this policy . A description 
of this clinical study may also be available on other externally  facing public websites and 
registries. A summary  of the study results may  be potentially  disclosed as per local and country  
specific requirements.
All publications relating to Shire products or projects must undergo appropriate technical and 
intellectual propert y review, with Shire agreement to publish prior to release of information. The 
review i s aimed at protecting the sponsor’s proprietary  information existing either at the 
commencement of the study  or generated during the study . To the extent permitted by  the 
publisher and cop yright law, the principal investigator will own (or share with other authors) the 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 129 
 
07 Dec 2018
For non-commercial use only
Shire Page 130
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
copy right on his/her publications. To the extent that the principal investigator has such sole, joint 
or shared rights, the principal investigator grants the sponsor a perpetual, irrevocable, 
royalty-free license to make and distribute copies of such publications.
The term “publication” refers to an y public disclosure including original research articles, review 
articles, oral presentations, abstracts and posters at medical congresses, journal supplements, 
letters to the editor, invited lectur es, opinion pieces, book chapters, electronic postings on 
medical/scientific websites, or other disclosure of the study results, in printed, electronic, oral or 
other form.
Subject to the terms of the paragraph below, the investigator shall have the right to publish the 
study  results, and any  background information provided by  the sponsor that is necessary  to 
include in an y publication of study  results, or necessary  for other scholars to verify  such study  
results. Notwithstanding the foregoing, no publicati on that incorporates the sponsor’s 
confidential information shall be submitted for publication without the sponsor’s prior written 
agreement to publish, and shall be given to the sponsor for review at least 60 days prior to 
submission for publication. If r equested in writing by  Shire, the institution and principal 
investigator shall withhold submission of such publication for up to an additional 60 day s to 
allow for filing of a patent application.
If the stud y is part of a multicenter study, the first publi cation of the study  results shall be made 
by the sponsor in conjunction with the sponsor’s presentation of a joint, multicenter publication 
of the compiled and analy zed study  results. If such a multicenter publication is not submitted to a 
journal for publ ication by  the sponsor within an 18-month period after conclusion, abandonment, 
or termination of the study at all sites, or after the sponsor confirms there shall be no multicenter 
study  publication of the study results, an investigator may  individually  publish the study  results 
from the specific site in accordance with this section. The investigator must, however, 
acknowledge in the publication the limitations of the single- site data being presented.
Unless otherwise required by  the journal in which the publication appears, or the forum in which 
it is made, authorship will comply  with the International Committee of Medical Journal Editors 
(ICMJE) current standards. Participation as an investigator does not confer any  rights to 
authorship of publications.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 130 
 
07 Dec 2018
For non-commercial use only
Shire Page 131
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
11. REFERENCES 
Asberg, A., Humar, A., Rollag, H., Jardine, A. G., Mouas, H., Pescovitz, M. D., Sgarabotto, D., 
Tuncer, M., Noronha, I. L.and Hartmann, A. 2007. Oral valganciclovir is noninferior to 
intravenous ganciclovir for the treatment o f cytomegalovirus disease in solid organ 
transplant recipients. Am J Transplant, 7, 2106-13.
Ascioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., 
Donnelly , J. P., Edwards, J. E., Erjavec, Z., Fiere, D., L ortholary , O., Maertens, J., Meis, 
J. F., Patterson, T. F.and R 2002. Defining Opportunistic Invasive Fungal Infections in 
Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: 
An International Consensus. Clinical Infectious Diseases, 34, 7-14.
Avery , P. 2007. Management of late, recurrent, and resistant cy tomegalovirus in transplant 
patients. Transplant Rev, 21, 65-76.
Avery , R. K., Mart y, F. M., Strasfeld, L., Lee, I., Arrieta, A., Chou, S., Tatarowicz, W. and 
Villano, S. 2010. Oral marib avir for treatment of refractory  or resistant cy tomegalovirus 
infections in transplant recipients. Transpl Infect Dis, 12, 489-96.
Biron, K. K., Harvey , R. J., Chamberlain, S. C., Good, S. S., Smith, A. A., 3rd, Davis, M. G., 
Talarico, C. L., Miller, W. H. , Ferris, R., Dornsife, R. E., Stanat, S. C., Drach, J. C., 
Townsend, L. B. and Koszalka, G. W. 2002. Potent and selective inhibition of human 
cytomegalovirus replication by  1263W94, a benzimidazole L -riboside with a unique 
mode of action. Antimicrob Agent s Chemother, 46, 2365 -72.
Boeckh, M., Nichols, W. G., Papanicolaou, G., Rubin, R., Wingard, J. R. and Zaia, J. 2003. 
Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known 
challenges, and future strategies. Biol Blood Marrow Transplant, 9, 543- 58.
Boeckh, M., Zaia, J. A., Jung, D., Skettino, S., Chauncey , T. R.and Bowden, R. A. 1998. A study  
of the pharmacokinetics, antiviral activity , and tolerability  of oral ganciclovir for CMV 
prophy laxis in marrow transplantation. Biol B lood Marrow Transplant, 4, 13 -9.
Busca, A., de Fabritiis, P., Ghisetti, V., Allice, T., Mirabile, M., Gentile, G., L ocatelli, F.and 
Falda, M. 2007. Oral valganciclovir as preemptive therap y for cy tomegalovirus infection 
post allogeneic stem cell transplant ation. 
Transpl Infect Dis, 9, 102-7.
Chevillotte, M., Ersing, I., Mertens, T.and von Einem, J. 2010. Differentiation between 
polymorphisms and resistance -associated mutations in human cy tomegalovirus DNA 
polymerase. Antimicrob Agents Chemother, 54, 5004 -11.
Chou, S. 2011. Phenoty pic diversity  of cy tomegalovirus DNA poly merase gene variants 
observed after antiviral therap y. J Clin Virol, 50, 287 -91.
Chou, S., Marousek, G., Li, S. and Weinberg, A. 2008. Contrasting drug resistance phenot ypes 
resulting from cy tomegalovirus DNA poly merase mutations at the same exonuclease 
locus. 
J Clin Virol, 43, 107 -9.
Chulay , J., Biron, K., Wang, L., Underwood, M., Chamberlain, S., Frick, L., Good, 
S., Davis, 
M., Harvey , R., Townsend, L ., Drach, J. and Koszalka, G. 1999. Development of novel 
benzimidazole riboside compounds for treatment of cy tomegalovirus disease. Adv Exp 
Med Biol, 458, 129-34.
de la Hoz, R. E., Stephens, G. and Sherlock, C. 2002. D iagnosis and treatment approaches of 
CMV infections in adult patients. J Clin Virol, 25 Suppl 2, S1-
12.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 131 
 
07 Dec 2018
For non-commercial use only
Shire Page 132
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
De Pauw, B., Walsh, T. J., Donnelly , J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, 
P. G., Maertens, J., L ortholary , O., Kauffman, C. A., Denning, D. W. and Patterso 2008. 
Revised Definitions of Invasive Fungal Disease from the European Organization for 
Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the 
National Institute of Allergy and Infectious Diseases My coses Study  Group 
(EORTC/MSG) Consensus Group. Clinical Infectious Diseases, 46, 1813- 1821.
Drew, W. L., Miner, R. C., Marousek, G. I. and Chou, S. 2006. Maribavir sensitivity  of 
cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J Clin Virol, 37, 
124-7.
Dykewicz, C. A. 2001. Summary  of the Guidelines for Preventing Opportunistic I nfections 
among Hematopoietic Stem Cell Transplant Recipients. Clin Infect Dis, 33, 139-44.
Emery , V. C., Sabin, C. A., Cope, A. V., Gor, D., Hassan -Walker, A. F.and Griffiths, P. D. 2000. 
Application of viral- load kinetics to identify patients who develop cy tomegalovirus 
disease after transplantation. Lancet, 355, 2032-6.
Erice, A. 1999. Resista nce of human cy tomegalovirus to antiviral drugs. Clin Microbiol Rev, 12, 
286-97.
Farrugia, E. and Schwab, T. R. 1992. Management and prevention of cy tomegalovirus infection 
after renal transplantation. Mayo Clin Proc, 67, 879-90.
Freifeld, A. G., Bow, E. J ., Sepkowitz, K. A., Boeckh, M. J., I to, J. I ., Mullen, C. A., Raad, II, 
Rolston, K. V., Young, J. A. and Wingard, J. R. 2011. Clinical practice guideline for the 
use of antimicrobial agents in neutropenic patients with cancer: 2010 update by  the 
infectiou s diseases society  of america. Clin Infect Dis, 52, e56-93.
Harris, A. C., Young, R., Devine, S., Hogan, W. J., Ay uk, F., Bunworasate, U., 
Chanswangphuwana, C., Efebera, Y. A., Holler, E., L itzow, M., Ordemann, R., Qay ed, 
M., Renteria, A. S., Reshef, R., W
olfl, M., Chen, Y. B., Goldstein, S., Jagasia, M., 
Locatelli, F., Mielke, S., Porter, D., Schechter, T., Shekhovtsova, Z., Ferrara, J. L .and 
Levine, J. E. 2016. I nternational, Multicenter Standardization of Acute Graft- versus -Host 
Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD 
International Consortium. Biol Blood Marrow Transplant, 22, 4-10.
Hodson, E. M., Jones, C. A., Webster, A. C., Strippoli, G. F., Barclay , P. G., Kable, K., 
Vimalachandra, D. and Craig, J. C. 2005. Antiviral medications to prevent 
cytomegalovirus disease and early  death in recipients of solid -
organ transplants: a 
systematic review of randomised controlled trials. Lancet, 365, 2105-15.
Humar, A., Gregson, D., Caliendo, A. M., McGeer, A., Malkan, G., Krajden, M ., Corey , P., 
Greig, P., Walmsley , S., Lev y, G.and Mazzulli, T. 1999. Clinical utility  of quantitative 
cytomegalovirus viral load determination for predicting cy tomegalovirus disease in liver 
transplant recipients. Transplantation, 68, 1305- 11.
Jagasia, M. H., Greinix, H. T., Arora, M., Williams, K. M., Wolff, D., Cowen, E. W., Palmer, J., 
Weisdorf, D., Treister, N. S., Cheng, G. S., Kerr, H., Stratton, P., Duarte, R. F., 
McDonald, G. B., Inamoto, Y., Vigorito, A., Arai, S., Datiles, M. B., Jacobsohn, D., 
Heller, T., Kitko, C. L., Mitchell, S. A., Martin, P. J., Shulman, H., Wu, R. S., Cutler, C. 
S., Vogelsang, G. B., Lee, S. J., Pavletic, S. Z.and Flowers, M. E. 2015. National 
Institutes of Health Consensus Development Project on Criteria for Clinical Trial s in 
Chronic Graft -versus -Host Disease: I. The 2014 Diagnosis and Staging Working Group 
report. Biol Blood Marrow Transplant, 21, 389- 401.e1.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 132 
 
07 Dec 2018
For non-commercial use only
Shire Page 133
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Kanj, S., Sharara, A., Clavien, P.and Hamilton, J. 1996. Cy tomegalovirus infection following 
liver transplantation : review of the literature. Clin Infect Dis, 22, 537-49.
Kern, E. R., Hartline, C. B., Ry bak, R. J., Drach, J. C., Townsend, L . B., Biron, K. K.and 
Bidanset, D. J. 2004. Activities of benzimidazole D -and L -ribonucleosides in animal 
models of cy tomegalovir us infections. Antimicrob Agents Chemother, 48, 1749 -55.
Klumpp, T. R. 1993. Antibody -mediated neutropenia following bone marrow transplantation. Int 
J Clin Lab Res, 23, 4-7.
Komatsu, T. E., Pikis, A., Naeger, L. K.and Harrington, P. R. 2014. Resistance of human 
cytomegalovirus to ganciclovir/valganciclovir: a comprehensive review of putative 
resistance pathway s. Antiviral Res, 101, 12-25.
Kotton, C. N., Kumar, D., Caliendo, A. M., Asberg, A., Chou, S., Danziger -Isakov, L.and 
Humar, A. 2013. Updated international consensus guidelines on the management of 
cytomegalovirus in solid -organ transplantation. Transplantation, 96, 333- 60.
Krosky , P., Baek, M.and Coen, D. 2003. The human cy tomegalovirus UL97 protein kinase, an 
antiviral drug target, is required at the stage of nuclear egress. J Virol, 77, 905 -
14.
Lansky , S. B., List, M. A., Lansky , L. L., Ritter -Sterr, C.and Miller, D. R. 1987. The 
measurement of performance in childhood cancer patients. Cancer, 60, 1651 -
6.
Legendre, C.and Pascual, M. 2008. I mproving outcomes for solid
-organ transplant recipients at 
risk from cy tomegalovirus infection: late -onset disease and indirect consequences. Clin 
Infect Dis, 46, 732-40.
Levey , A. S., Coresh, J., Greene, T., Stevens, L. A., Zhang, Y. L., Hendriksen, S., Kusek, J. 
W
.and Van Lente, F. 2006. Using standardized serum creatinine values in the 
modification of diet in renal disease stud y equation for estimating glomerular filtration 
rate. Ann Intern Med, 145, 247 -54.
Limay e, A. P., Corey , L., Koelle, D. M., Davis, C. L .and Boeckh, M. 2000. Emergence of 
ganciclovir -resistant cy tomegalovirus disease among recipients of solid -organ 
transplants. Lancet, 356, 645 -9.
Ljungman, P., Boeckh, M., Hirsch, H. H., Josephson, F., Lundgren, J., Nichols, G., Pikis, A., 
Razonable, R. R., Mi ller, V., Griffiths, P. D.and Disease Definitions Working Group of 
the Cy tomegalovirus Drug Development, F. 2017. Definitions of Cy tomegalovirus 
Infection and Disease in Transplant Patients for Use in Clinical Trials. Clin Infect Dis,
64, 87-91.
Ljungman, P., Deliliers, G. L ., Platzbecker, U., Matthes-Martin, S., Bacigalupo, A., Einsele, H., 
Ullmann, J., Musso, M., Trenschel, R., Ribaud, P., Bornhauser, M., Cesaro, S., Crooks, 
B., Dekker, A., Gratecos, N., Klingebiel, T., Tagliaferri, E., Ullmann, A. J., Wacker, 
P.and Cordonnier, C. 2001. Cidofovir for cy tomegalovirus infection and disease in 
allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the 
European Group for Blood and Marrow Transplantation. Blood, 97, 388-92.
Ljungman, P., Griffiths, P.and Pay a, C. 2002. Definitions of cy tomegalovirus infection and 
disease in transplant recipients. Clin Infect Dis, 34, 1094-7.
Ljungman, P., Perez -Bercoff, L., Johnsson, J., Avetisy an, G., Sparrelid, E., Aschan, J., Barkholt, 
L.,Larsson, K., Winiarski, J., Yun, Z.and Ringden, O. 2006. Risk factors for the 
development of cy tomegalovirus disease after allogeneic stem cell transplantation. 
Haematologica, 91, 78- 83.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 133 
 
07 Dec 2018
For non-commercial use only
Shire Page 134
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Loiseau, P., Busson, M., Balere, M. L., Dormoy , A., Bignon, J. D., Gagne, K., Gebuhrer, L., 
Dubois, V., Jollet, I ., Bois, M., Perrier, P., Masson, D., Moine, A., Absi, L., Reviron, D., 
Lepage, V., Tamouza, R., Toubert, A., Marry , E., Chir, Z., Jouet, J. P. , Blaise, D., 
Charron, D.and Raffoux, C. 2007. HLA Association with hematopoietic stem cell 
transplantation outcome: the number of mismatches at HLA- A, -B, -C, -DRB1, or -DQB1 
is strongl y associated with overall survival. Biol Blood Marrow Transplant, 13, 965-74.
Lu, H.and Rosenbaum, S. 2014. Developmental pharmacokinetics in pediatric populations. 
Journal of Pediatric Pharmacology and Therapeutics, 19, 262-76.
Lurain, N. S.and Chou, S. 2010. Antiviral drug resistance of human cy tomegalovirus. Clin 
Microbiol Rev, 23, 689- 712.
Majhail, N. S., Rizzo, J. D., Lee, S. J., Aljurf, M., Atsuta, Y., Bonfim, C., Burns, L. J., Chaudhri, 
N., Davies, S., Okamoto, S., Seber, A., Socie, G., Szer, J., L int, M. T., Wingard, J. R.and 
Tichelli, A. 2012. Recommended screening a nd preventive practices for long -term 
survivors after hematopoietic cell transplantation. Rev Bras Hematol Hemoter, 34, 109-
33.
Marr, K. A., Carter, R. A., Boeckh, M., Martin, P.and Corey , L. 2002. Invasive aspergillosis in 
allogeneic stem cell transplant recipients: changes in epidemiology  and risk factors. 
Blood, 100, 4358-66.
Nishihori, T., Shaheen, M., El -Asmar, J., Aljurf, M.and Kharfan- Dabaja, M. 2015. Therapeutic 
strategies for cy tomegalovirus in allogeneic hematopoietic cell transplantation. 
Immunot herapy, 7, 1059-71.
Paya, C., Hermans, P., Wiesner, R., Ludwig, J., Smith, T., Rakela, J.and Krom, R. 1989. 
Cytomegalovirus hepatitis in liver transplantation: prospective anal ysis of 93 consecutive 
orthotopic liver transplantations. J Infect Dis, 160, 752 -8.
Peus, D., Newcomb, N.and Hofer, S. 2013. Appraisal of the Karnofsky  Performance Status and 
proposal of a simple algorithmic sy stem for its evaluation. BMC Med Inform Decis Mak,
13, 72.
Pouria, S., State, O. I ., Wong, W.and Hendry , B. M. 1998. CMV infection is associated with 
transplant renal artery  stenosis. Qjm, 91, 185-
9.
Razonable, R. R.and Emery , V. C. 2004. Management of CMV infection and disease in 
transplant patients. 27 -29 February  2004. Herpes, 11, 77-
86.
Reusser, P., Einsele, H., Lee, J., Voli n, L., Rovira, M., Engelhard, D., Finke, J., Cordonnier, C., 
Link, H., Ljungman, P.and I nfectious Diseases Working Part y of the European Group for 
Blood and Marrow Transplantation 2002. Randomized multicenter trial of foscarnet 
versus ganciclovir for preemptive therapy  of cy tomegalovirus infection after allogeneic 
stem cell transplantation. Blood, 99, 1159-64.
Richardson, W. P., Colvin, R. B., Cheeseman, S. H., Tolkoff- Rubin, N. E., Herrin, J. T., Cosimi, 
A. B., Collins, A. B., Hirsch, M. S., McCluskey , R. T., Russell, P. S.and Rubin, R. H. 
1981. Glomerulopath y associated with cytomegalovirus viremia in renal allografts. N 
Engl J Med, 305, 57-63.
Rubin, R. H. 1989. The indirect effects of cy tomegalovirus infection on the outcome of organ 
transplantation. Jama, 261, 3607 -9.
Salzberger, B., Bowden, R. A., Hackman, R. C., Davis, C.and Boeckh, M. 1997. Neutropenia in 
allogeneic marrow transplant recipients receiving ganciclovir for prevention of 
cytomegalovirus disease: risk factors and outcome. Blood, 90, 2502-8.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 134 
 
07 Dec 2018
For non-commercial use only
Shire Page 135
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Schag, C. C., Heinrich, R. L .and Ganz, P. A. 1984. Karnofsk y performance status revisited: 
reliability , validit y, and guidelines. J Clin Oncol, 2, 187-93.
Schwartz, G. J., Feld, L . G.and Langford, D. J. 1984. A simple estimate of glomerular filtration 
rate in full- term infants during the first y ear of life. J Pediatr, 104, 849-54.
Schwartz, G. J., Hay cock, G. B., Edelmann, C. M., Jr.and Spitzer, A. 1976. A simple estimate of 
glomerular filtration rate in children derived from body  length and plasma creati nine. 
Pediatrics, 58, 259-63.
Shulman, H. M., Cardona, D. M., Greenson, J. K., Hingorani, S., Horn, T., Huber, E., Kreft, A., 
Longerich, T., Morton, T., My erson, D., Prieto, V. G., Rosenberg, A., Treister, N., 
Washington, K., Ziemer, M., Pavletic, S. Z., L ee, S. J., Flowers, M. E., Schultz, K. R., 
Jagasia, M., Martin, P. J., Vogelsang, G. B.and Kleiner, D. E. 2015. NIH Consensus 
development project on criteria for clinical trials in chronic graft- versus -host disease: II. 
The 2014 Pathology  Working Group Rep ort. Biol Blood Marrow Transplant, 21, 589-
603.
Singh, N., Wannstedt, C., Key es, L., Wagener, M. M., de Vera, M., Cacciarelli, T. V.and 
Gayowski, T. 2004. Impact of evolving trends in recipient and donor characteristics on 
cytomegalovirus infection in live r transplant recipients. Transplantation, 77, 106 -10.
Strasfeld, L., Lee, I., Tatarowicz, W., Villano, S.and Chou, S. 2010. Virologic characterization of 
multidrug -resistant cy tomegalovirus infection in 2 transplant recipients treated with 
maribavir. J Infect Dis, 202, 104 -8.
Tombly n, M., Chiller, T., Einsele, H., Gress, R., Sepkowitz, K., Storek, J., Wingard, J. R., 
Young, J., Boeckh, M., Center for International Blood and Marrow Research, National 
Marrow Donor Program, European Blood and Marrow Transplant Group, American 
Society  of Blood and Marrow Transplantation, Canadian Blood and Marrow Transplant 
Group, Infectious Disease Society  of America, Society  for Healthcare Epidemiology  of 
America, Association of Medical Microbiology  and I nfectious Disease Cana daand 
Centers for Disease Control and Prevention 2009. Guidelines for preventing infectious 
complications among hematopoietic cell transplantation recipients: a global perspective. 
Biol Blood Marrow Transplant, 15, 1143-238.
Valcy te Prescribing Information. South San Francisco, CA: Genentech Inc.
Williams, S. L ., Hartline, C. B., Kushner, N. L., Harden, E. A., Bidanset, D. J., Drach, J. C., 
Townsend, L. B., Underwood, M. R., Biron, K. K.and Kern, E. R. 2003. In vitro activities 
of benzimidazole D -and L -ribonucleosides against herpesviruses. Antimicrob Agents 
Chemother, 47, 2186-92.
Winston, D. J., Wirin, D., Shaked, A.and Busuttil, R. W. 1995. Randomised comparison of 
ganciclovir and high -dose acy clovir for long -term cy tomegalovirus prophylaxis i n liver -
transplant recipients. Lancet, 346, 69-74.
Wolf, D., Courcelle, C., Prichard, M.and Mocarski, E. 2001. Distinct and separate roles for 
herpesvirus -conserved UL97 kinase in cy tomegalovirus DNA s ynthesis and 
encapsidation. Proc Natl Acad Sci U S A, 98, 1895-
900.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 135 
 
07 Dec 2018
For non-commercial use only
Shire Page 136
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
12. APPENDICES
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 136 
 
07 Dec 2018
For non-commercial use only
Shire Page 137
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Appendix 1 PROTOCOL HISTORY
Document Date Global/Country/Site Specific
Original Protocol 25 April 2016 Global
Amendment 1 08 July 2016 Global
Amendment 2 01 December 2016 Global 
Amendment 2.1a 18May 2017 Germ any
Amendment 3 01 March 2017 Global (except Germany)
Amendment 3.1a 10 October 2017 Germ any, Singapore
Amendment 4 26 March 2018 Global (except Germany and Singapore)
Amendment 5 11 July 2018 Global (except Germany and Singapore)
Amendment 5.1a,b 20 August 2018 Germ any, Singapore, Sw itzerland
Amendment 6 07 December 2018 Global (except Germany, Singapore, Sw itzerland)
Amendment 6.1 07 December 2018 Germ any, Singapore, Sw itzerland
aSummary of changes for country -specific amendments are included in the respective documents.  
bAmendment 5.1 replaces Amendment 3.1 (no intervening protocol version).
Amendment 5 to protocol SHP620 -303 incorporated the following changes:
Added a stud y visit at Study  Day  4 (+/ -1) for subjects taking a narrow therapeutic index 
immunosuppressive agent (ie, tacrolimus, cyclosporine, everolimus, sirolimus) at 
baseline to align the protocol with a recent recommendation from the data monitoring 
committee (DMC).
Added a visit for subjects not taking a narrow therapeutic index immunosuppressive 
agent at baseline who begin therap y during the course of the treatment period (4 days 
after starting the immunosuppressive agent), and subjects in the investigator -assigned
therap y arm who enter the maribavir rescue arm (4 days after starting maribavir) to align 
the protocol with a recent recommendation from the DMC.
Updated definition of symptomatic CMV infection to include both tissue invasive CMV 
disease and CMV s yndrome throughout the protocol.
Noteworth y changes to the protocol are captured in the table below. Other minor editorial 
revisions (including changes for consistency  and clarity ) are not described in this table.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 137 
 
07 Dec 2018
For non-commercial use only
Shire Page 138
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Protocol Am endments
Summary of Change(s) Since La st Version of Approved Protocol
Amendment Number
5Amendment Date
11 Jul 2018Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
Updated the definition for “Refractory”:
Documented failure to achieve >1 log 10(common logarithm to base 10) 
decrease in CMV DNA level in whole blood or plasma after a 14 day or 
longer treatment period w ith IV ganciclovir/oral valganciclovir, IV 
foscarnet, or IV cidofovir. This definition applies to the current CMV 
infection and the most recently administered anti -CMV agent.Definitions , Synopsis , Section 3.1
Updated the definition for “Resistant”:
Documented failure to achieve >1 log 10(common logarithm to base 10) 
decrease in CMV DNA level in whole blood or plasma after a 14 day or 
longer treatment period w ith IV ganciclovir/oral valganciclovir, IV 
foscarnet, or IV cidofovir. This definition applies to the current CMV 
infection and the most recently administered anti -CMV agent.
AND
Documentation of 1 or more CMV genetic mutations associated w ith 
resistance to ganciclovir/valganciclovir, foscarnet, and/or cidofovir.Definitions , Synopsis , Section 3.1
Updated inclusion criterion 4 to cla rify that the subject must have a 
current CMV infection that is refractory to the most 
recently administered of the four anti -CMV treatment 
agents; that refractory is defined as documented failure 
to achieve >1 log 10(common logarithm to base 10) 
decrease in CMV DNA level in whole blood or plasma 
after a 14 day or longer treatment period with IV 
ganciclovir/oral valganciclovir, IV foscarnet, or IV 
cidofovir; and that subjects with documentation of 1 or 
more CMV genetic mutations associated with 
resistance t o ganciclovir/valganciclovir, foscarnet, 
and/or cidofovir must also meet the definition of 
refractory CMV infection.Synopsis , Section 4.1
Removed the statement that prospectively, the study may enroll an 
additional cohort of 150 subjects with tissue -invasive 
CMV disease, in a 2:1 ratio (maribavir: investigator -
assigned anti -CMV therapy) to subsequently confirm 
the clinical benefit of maribavir in improvement or 
resolution of tissue -invasive CMV disease in a total of 
210 subjects (inclusive of 6 0 subjects enrolled 
initially); and that feasibility of this approach w ill be 
confirmed during the study conduct.Synopsis , Section 2.2, Section 3.1
Clarified EAC review procedure. Synopsis , Section 3.1
Updated number of site visits to 19 times. Synopsi s, Section 3.1
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 138 
 
07 Dec 2018
For non-commercial use only
Shire Page 139
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Protocol Am endments
Summary of Change(s) Since La st Version of Approved Protocol
Amendment Number
5Amendment Date
11 Jul 2018Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
Added Visit 2A/2A -R to the Study design Flow Chart. Synopsis , Section 3.1
Clarified the screening CMV DNA concentration limits (in whole blood 
or plasma) used for stratification of eligible subjects 
and specified that the most recent qPCR results should 
be used.Synopsis , Section 3.1, Section 6.2.2
Clarified that, for subjects randomized to investigator -assigned 
anti-CMV treatment, switching between valganciclovir 
and ganciclovir is allowed, while switching to another 
CMV agent is not .Synopsis , Section 6.2.3
Clarified that, in the randomized set, subjects w ill be analyzed in the 
treatment group to which they are randomized.Synopsis , Section 9.7
Clarified that the safety set will consist of all subjects who have taken 
any dose of study treatment and that subjects will be 
analyzed according to the treatment actually received. Synopsis , Section 9.7
Removed the following statement: “Since intolerance alone w ill not 
qualify the patient for the rescue, such patients will not 
be considered nonresponders for the purpose of the 
primary analysis.”Synopsis , Section 9.8
Removed the following statement: “It is expected that 60 subjects w ith 
tissue invasive disease (symptomatic subjects) w ill be 
enrolled in this study.Synopsis , Section 9.8.2
Clarified that the on treatment observation period will serve as the 
primary analysis of safety.Synopsis , Section 9.9
Clarified the overall study observatio n period as follows: “The overall -
study observation period minus the period on rescue 
arm starts at the time of the start of the study treatment 
through the end of the study or through the time before 
receiving maribavir rescue therapy for subjects who 
receive maribavir rescue therapy.”Synopsis , Section 9.9
Clarified that similar observation periods are defined for the safety 
analysis of the maribavir rescue arm.Synopsis , Section 9.9
Updated the definition of treatment emergent adverse events. Synopsis , Section 9.9
Clarified exploratory endpoint to be  Synopsis , Section 9.10.3
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 139 
 
07 Dec 2018
For non-commercial use only
Shire Page 140
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Protocol Am endments
Summary of Change(s) Since La st Version of Approved Protocol
Amendment Number
5Amendment Date
11 Jul 2018Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
Added a column for additional visit 2A/2A -R to co llect the follow ing 
assessments: Hematology/Chemistry, 
Immunosuppressant drug concentration levels, Study 
diary; Concomitant medications, therapies, and 
procedures, as w ell as Adverse events.Table 1, Section 7.1.2
Added Visit 2A/2AR (Day 4) ± 1 day and Study Visit 3/3R (Day 7) +2 
days to the definition of the permissible assessment 
window . Table 1 , Footnotes, Section 7.1.2
Clarified that local laboratory will be used for Visit 2A/2AR (Day 4) 
potassium and magnesiu m levels, and Day 4 after 
starting tacrolimus, cyclosporine, everolimus, or 
sirolimus if the subject is not taking at V2/2R.Table 1 , Footnotes, Section 7.2.3.5
Clarified when a blood sample to measure immunosuppressant drug 
concentration level will be obtained for subject 
receiving immunosuppressant drugs and for subjects 
not receiving immunosuppressant drugs at Day 0, but 
who started any time after Day 0. Table 1, Footnotes, Section 7.2.3.5
Added new footnote to clarify that Visit 2A/2AR is only required for 
subjects taking tacrolimus, cyclosporine, everolimus, 
or sirolimus at Visit 2/2R.Table 1 , Footnotes 
Updated timeframe for collection of medical history data from 5 years to 
2 years.Section 7.2.3.1
Updated for consistencies with changes in Table 1. Section 7.2.5 , Table 5
Updated the blood volume expected to be drawn from each subject 
regardless of age or sex.Section 7.2.5
Clarified criteria for reporting CMV infection as an AE or as an SAE. Section 8.1.5 , Table 6
Amendment 4 to Protocol SHP620- 303 incorporates the following major changes:
Modified adverse event collection period to indicate that collection of nonserious adverse 
events that are not related to study  treatment will be restricted to 30 day s after the last 
dose of study  drug.
Amended exclusion criterion 6 regarding patients who have tissue invasive CMV disease 
with central nervous sy stem involvement to indicate that such central nervous sy stem 
involvement includes the retina (eg CMV retinitis).
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 140 
 
07 Dec 2018
For non-commercial use only
Shire Page 141
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Modified the reporting requirements for prior therapeutic or diagnostic interventions 
performed prior to study  enrollment.
Clarified procedure requirements for subjects moving from investig ator-assigned 
treatment to rescue arm to indicate that procedures do not need to be repeated when the 
end-of-treatment visit is performed on the same day  as rescue arm entry .
Clarified that study  treatment may  be interrupted for up to 7 consecutive day s, or up to 2 
study  treatment interruptions for a total of up to 7 days.
Clarified language regarding sample size calculation, removing anticipated treatment 
discontinuation rate for foscarnet -treated subjects.
Clarified restrictions regarding re- screening of subjects who have previously  screen -
failed.
Limited hepatitis testing requirements at screening to antibody  testing.
Added GVHD assessment criteria forms from cited publications in the appendices.
Added letermovir to list of prohibited medications during study , and washout instructions 
for letermovir use prior to study  entry
Noteworth y changes to the protocol are captured in the table below. Other minor editorial 
revisions (including changes for consistency  and clarity ) are not described in this table.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 141 
 
07 Dec 2018
For non-commercial use only
Shire Page 142
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
4Amendment Date
26 Mar 2018Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
Updated signatory to , MD Protocol Signature Page
Updated Emergency Contact Information to provide more extensive 
information on the reporting of serious adverse events 
(SAEs).Emergency Contact Information
Replaced “Pharmacovigilance” w ith “Drug Safety” to reflect the 
department name changeEmergency Contact Information , 
Section 8.1.7 , Section 8.2.2, Section 
8.2.4
Updated PDD medical monitor to , MD, PhD, MBA, 
, PPD, Drug SafetyEmergency Contact Information
Clarified the definition for “Refractory”: requires 2 weeks of continuous
treatment, and applies to the current infection and the 
most recently administered anti -CMV agent.
The definition for “Resistant” is inclusive of the definition for “Refractory” 
and has been amended accordingly.Definitions, Synopsis, Section 3.1, 
Section 4.1
Updated number of sites to approximately 140 sites w orldwide. Synopsis, Section 3.3
Updated planned study period to 2016 –2019. Synopsis
Clarified changes to the investigator treatment of choice after 
randomization to include note that changes between IV 
ganciclovir and oral valganciclovir are allowed and that 
combination therapy with cidofovir and foscarnet is 
prohibited due to risk of nephrotoxicity.Synopsis, Section 3.1, Se ction 6, 
Section 6.2.3
Updated permitted duration of treatment interruption from originally 4 to 7 
consecutive days, or up to 2 study treatment interruptions 
for a total of up to 7 days.Synopsis, Section 3.1, Section 6.2.3
Changed exclusion criterion 3 to include the recently -approved anti -CMV 
agent letermovir.Synopsis, Section 4.2
Changed exclusion criterion 6 to exclude subjects w ith CMV retinitis 
present at baseline.Synopsis, Section 4.2
Clarified language regarding sample size calculation, removi ng mention of 
anticipated treatment discontinuation rate for foscarnet -
treated subjects.Synopsis, Section 9.6
Clarified that the end of the on -treatment period is 7 days after the last dose 
of study drug or 21 days if cidofovir is used.Synopsis, Section 9.9
Removed paragraph on the reporting of disease under study from Synopsis 
to avoid redundancy with Section 8.1.5.Synopsis
Clarified several footnotes in the Schedules of Assessment to provide Table 1, Footnotes
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 142 
 
07 Dec 2018
For non-commercial use only
Shire Page 143
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
4Amendment Date
26 Mar 2018Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
additional details regarding the timing and requirements 
of several study assessments.
Clarified procedure requirements for subjects moving from IAT to Rescue 
Arm.Study Schedules , Section 4.5
Clarified procedure for tissue invasive CMV disease assessment in 
symptomatic and asymptomatic subjects.Study Schedules , Section 7.2.2.3
Added new in vitro data on the effects of maribavir on drug metabolism 
enzymes.Section 1.2.1
Included letermovir in the list of prior medications to be recorded on the 
CRF.Section 5.1
Updated medical history to be recorded from “any therapeutic or diagnostic 
intervention performed within 3 m onths prior to the first 
dose of study treatment on Visit 2/Week0/Day 0” to “any 
therapeutic or diagnostic intervention performed within 
30 days prior to the first dose of study treatment on Visit 
2/Week0/Day 0”Section 5.1
Added additional precaution with concomitant medication. Section 5.2.1
Added procedure to be followed for subjects developing new CMV retinitis 
while in the maribavir treatment arm.Section 5.2.2
Added letermovir to the list of systemic anti -CMV therapies prohibited for 
concomitant use in subjects receiving maribavir (except 
unintentional administration for no longer than 1 day).Section 5.2.2
Added letermovir to the list of concomitant medications prohibited while 
the subject is receiving investigator -assigned anti -CMV 
treatment.Section 5.2.2
Clarified that in cases where IV anti -CMV agents cannot be ordered, 
prepared, and administered immediately after 
randomization, the f irst dose of drug must be given 
within 24 hours of randomization.Section 6.2.3
Clarified restrictions regarding rescreening of subjects who have previously 
screen -failed.Section 7.1.1
Clarified clinical laboratory assessments for hepatitis. Section 7.2.3.5
Amended adverse event collection period to specify that follow ing the 
30 day capture period for all adverse events, only those 
adverse events deemed related to investigational product 
or other protocol -mandated procedures and all SAEs 
(regardless of causality assessment) will be collected Section 7.2.3.6, Section 8.1
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 143 
07 Dec 2018
For non-commercial use only
Shire Page 144
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
4Amendment Date
26 Mar 2018Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
through the end of the study (Visit 18/Week 20 [Follow -
up Week 12]). 
Updated e -mail contact address for the Shire Global Drug Safety 
DepartmentSection 8.2.2
Updated tabular presentation of assessments of responders for key 
secondary efficacy endpoint to provide clearer rationales.Section 9.8.2
Added additional descriptive summary to the study secondary efficacy 
endpoint of all causes mortality by the end of the study.Section 9.8.5
Clarified safety endpoints for analysis. Section 9.9
Clarified the shift analysis of laboratory results. Section 9.9
Reproduced GVHD assessment criteria forms (from cited publications). Appendix 10, Appendix 11
Updated w ording and added two additional references:
Ascioglu, S., Rex, J. H., De Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., 
Denning, D. W., Donnelly, J. P., Edw ards, J. E., Erjavec, Z., Fiere, 
D., Lortholary, O., Maertens, J., Meis, J. F., Patterson, T. F. & R 
2002. Defini ng Opportunistic Invasive Fungal Infections in 
Immunocompromised Patients w ith Cancer and Hematopoietic 
Stem Cell Transplants: An International Consensus. Clinical 
Infectious Diseases, 34, 7 -14.
De Pauw , B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., E dwards, J. E., 
Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., 
Kauffman, C. A., Denning, D. W. & Patterso 2008. Revised 
Definitions of Invasive Fungal Disease from the European 
Organization for Research and Treatment of Cancer/Invasive 
Fungal Infections Cooperative Group and the National Institute of 
Allergy and Infectious Diseases Mycoses Study Group 
(EORTC/MSG) Consensus Group. Clinical Infectious Diseases, 
46, 1813 -1821. References, Appendix 13
Amendment 3 to Protocol SHP620- 303 incorporated the following major changes:
Modified primary , key  secondary , and secondary  objectives and corresponding endpoints 
to include subjects who discontinue study  treatment earl y and meet the criteria of 
confirmed CMV viremia clearance as responders in the prim ary efficacy  analy sis.
Added an intensive pharmacokinetic sampling schedule at Visit 3/Week 1 for adolescent 
subjects ( ≥12 to <18 years of age).
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 144 
 
07 Dec 2018
For non-commercial use only
Shire Page 145
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Modified Inclusion Criterion 5 to indicate that the investigator is willing to treat the 
subject with at least 1 of the available anti -CMV drugs. Note: Combination therap y with 
foscarnet and cidofovir is not permitted in the IAT arm due to the potential for serious 
nephrotoxicity .
Clarified Inclusion Criterion 9 to indicate that urine- based pregnancy  tests may  be 
performed per institutional requirements (in addition to protocol -required serum β -hCG 
testing); however they  are not sufficient for eligibility  determination.
Modified Inclusion Criterion 10 to allow subjects the option to receive tablets crushed 
and/or di spersed in water via a nasogastric or orogastric tube.
Clarified in Exclusion Criterion 13 that subjects who have received an unapproved agent 
or device within 30 day s before initiation of study  treatment will not be eligible.
Added recommendations related to male contraception in clinical trials, per the clinical 
trial facilitation group (CTFG). Male subjects will be required to use a condom in 
conjunction with highl y effective method of birth control for their female partners of 
child- bearing age. Both ma le participants and their female partners must use this form of 
birth control from the time prior to the first dosing until 90 day s after the last dose of 
study  treatment.
Noteworth y changes to the protocol are captured in the table below. Other minor edit orial 
revisions (including changes for consistency  and clarity ) are not described in this table.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 145 
 
07 Dec 2018
For non-commercial use only
Shire Page 146
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
3Amendment Date
01 Mar 2017Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
Updated signatory to , MD, MSc. Protocol Signature Page
Added investigator -assigned anti -CMV treatment (IAT) to the 
abbreviations list.Abbreviations
Added clarifying text to indicate that initiation of study treatment (ie, first 
dose) w ill only occur after completion of all required 
Visit 2/Day 0 procedures, confirmation of eligibility, and 
completion of randomization.Synopsis, Table 1(footnote “c”), 
Section 3.1
Modified Exclusion Criterion 8 to indicate that historical results for human 
immunodeficiency virus (HIV) w ill be accepted to assess 
eligibility and no additional study testing will be 
required. 
“Have known (previously documented) positive re sults for human 
immunodeficiency virus (HIV).” Subjects must have a confirmed negative 
result within 3 months of study entry or be w illing to be tested at screening. 
Local laboratory results are acceptable.”Synopsis, Table 1 (footnote “i”), 
Section 3.1, S ection 
4.2,Section 7.1.1, 
Section 7.2.3.5
Added the rationale for the inclusion of adolescent subjects ≥12 to <18 
years of age in the study.Synopsis , Section 2.1, Section 2.3
Modified primary objective and corresponding endpoint and analysis to 
clarify that subjects who discontinue study treatment 
early and meet the criteria of confirmed CMV viremia 
clearance at Study Week 8 will be considered as 
responders in the primary efficacy analysis.Synopsis , Section 2.4.1, Section 
9.8.1.
Modified key secondary objective and corresponding endpoints and 
analyses to clarify that subjects who discontinue study 
treatment early and meet the criteria of confirmed CMV 
viremia clearance will be considered for responder 
evaluation in the efficacy analysis.Synopsis , Sect ion 2.4.2, Section 9.8.2
Modified secondary objectives and corresponding endpoints and analyses 
to include subjects who discontinue study treatment early 
and meet the criteria of confirmed CMV viremia 
clearance as responders in the efficacy analysis.
Adde d the former primary and key secondary objectives as secondary 
objectives:
•“To compare the efficacy of maribavir to anti -CMV therapy (IAT) on 
CMV viremia clearance after completion of 8 weeks of study treatment 
in transplant recipients who are refractory or resistant to prior anti -
CMV treatment.”
•“To compare the efficacy of the 2 study treatment arms on CMV 
viremia clearance and tissue invasive CMV disease improvement or 
resolution after completion of 8 w eeks of treatment and maintenance of 
this treatment effect through Study Weeks 12 (4 w eeks of post Synopsis , Section 2.4.3, Section 9.8.5
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 146 
 
07 Dec 2018
For non-commercial use only
Shire Page 147
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
3Amendment Date
01 Mar 2017Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
treatment period),16 (8 w eeks post treatment/follow -up phase), and 20 
(12 w eeks of post treatment).” 
Added the following secondary objectives and corresponding endpoints:
•“To assess the 2 study treatment arms for maintenance of CMV 
viremia clearance and resolution or improvement of tissue invasive 
CMV disease, achieved at the end of Study Week 8, through Weeks 12 
and 20.
•“To evaluate the incidence of recurrence of CMV viremia in the 2 
study treatment arms, dur ing 8 w eeks of study, during the 12 w eeks of 
the follow -up phase, and at any time during the study.” 
•“To evaluate the incidence of recurrence of CMV viremia in the 2 
study treatment arms, when on treatment and off treatment.”
Deleted the following seconda ry objective and the corresponding endpoint 
since it is redundant with the modified primary objective:
“To assess the 2 study treatment arms for maintenance of CMV viremia 
clearance achieved while on study treatment, irrespective of its duration, at 
8 weeks of study.”
Deleted the following exploratory objectives and corresponding endpoints 
that are redundant with the modified secondary objective.Synopsis , Section 2.4.4, Section 9.8.6
Modified the following for clarity:
“The CMV infection must be refractory to 1 or more of the anti -CMV 
agents (ganciclovir, valganciclovir, foscarnet, or cidofovir) currently 
administered to the subject, and the subjects must meet the remaining 
specified eligibility criteria.”Synopsis , Section 3.1
Modified Inclusion Criterion 5:
Per “ The investigator is willing to treat the subject ’s judgment, be 
eligible for treatment with at least 1 of the available anti -CMV drugs 
(ganciclovir, valganciclovir, foscarnet, or cidofovir)”. The treatment 
for which a subject w ould be eligible, if randomized to investigator 
assigned treatment, must be d ocumented prior to randomization. Note: 
Com bination therapy with foscarnet and cidofovir is not permitted in 
the IAT arm due to the potential for serious nephrotoxicity.Synopsis , Section 3.1 , Section 4.1
Updated Inclusion Criterion 10 to allow  subjects t he option to receive 
tablets crushed and/or dispersed in w ater:Synopsis , Section 4.1, Section 6.2.3
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 147 
 
07 Dec 2018
For non-commercial use only
Shire Page 148
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
3Amendment Date
01 Mar 2017Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
Be able to sw allow  tablets, or receive tablets crushed and/or dispersed 
in water via a nasogastric or orogastric tube
Added to Inclusion Criterion 9 that additional urine pregnancy tests may be 
performed per institutional requirements. Synopsis , Section 4.1, Section 7.1.1 
Clarified in Exclusion Criterion 13 that subjects who have received an 
unapproved agent or device within 30 days before 
initiation of study treatment will not be eligible.Synopsis , Section 4.2, Section 5.2.2
Clarified that the randomized set rather than the FAS will be used for 
efficacy analysis along with the per -protocol set and that 
the randomized set w ould be used for the primary 
analysis and the per -protocol set w ould be used as the 
supportive analysis.Synopsis , Section 9.7
Added the definition of adolescent pharmacokinetic set. Synopsis , Section 9.7
Updated Tables 7 and 8 to include additional scenarios for responder 
determination. Synopsis , Section 9.8.1, Section 9.8.2
Updated the primary, key secondary, secondary, and exploratory endpoints 
to align with updates made to the objectives.Synopsis , Section 9.8.1, Section 
9.8.2, Section 9.8.5, Section 9.8.6
Added an additional subgroup analysis for adolescents:
Adolescents ≥12 to <18 years of age (exploratory analysis: may be 
conducted if sample size is adequate)Synopsis , Section 9.8.4
Added PK parameters assessed as secondary endpoints for adolescent 
subjects who provided intensive PK sample at 
Visit 3/Week 1. The secondary PK endpoint for all 
subjects who received maribavir will be maribavir C min
(predose maribavir concentration).Synopsis , Section 9.10.3
Clarified that urine test results are not sufficient for eligibility 
determination.Table 1 (footnote “h”), Section 7.1.1
Table 1 (footnote “m”) , Section 
7.1.2, Section 7.2.2.4
Added an intensive PK sampling schedule (at Visit 3/Week 1) for 
adolescent subjects participating in the study.Table 1 (footnote “o”), Section 7.1.2, 
Section 7.2.4.1
Clarified that female subjects 12 years of age and older, who are 
amenorrheic for reasons other than menopause (12 
consecutive months of spontaneous amenorrhea in 
patients with previous normal menstruation), including 
subjects who did not yet have the menarche, w ould be Section 4.4.1
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 148 
 
07 Dec 2018
For non-commercial use only
Shire Page 149
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
3Amendment Date
01 Mar 2017Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
allow ed to participate provided they agree to abstinence 
or an acceptable form of contracept ion defined in the 
protocol.
Added recommendations related to male contraception in clinical trials, per 
the clinical trial facilitation group (CTFG): Male subjects 
will be required to use a condom in conjunction with 
highly effective method of birth control for their female 
partners of child -bearing age. Both male participants and 
their female partners must use this form of birth control 
from the time prior to the first dosing until 90 days after 
the last dose of study treatment.Section 4.4.2
Removed text requiring retinal images to be collected and provided to 
support diagnosis and mention of EAC analysis of 
individual histopathology slides:
“In cases of CMV retinitis, the retinal images taken by the ophthalmologist 
may be collected and provided used as the evidence supporting the 
diagnosis.”
“EAC might request the individual histopathology slides to be read by an 
independent pathologist.”Section 7.2.2.3
Added the additional blood draw  volume required for intensive PK 
sampling for adolescents:
“Subjects betw een the ages of 12 and 18 years will have an additional 24 
mL of blood drawn for intensive PK visits.”Section 7.2.5, Table 5
Updated the reference safety information section to indicate that the 
country -specific pr oduct package inserts for cidofovir 
should be checked to assess the expectedness of an AE 
for this study.
The respective summary of product characteristics (SmPC) for a 
comparator anti -CMV treatment (valganciclovir, ganciclovir, and 
foscarnet) or UScountry -specific product package insert for cidofovir.Section 8.2.1
Amended reference safety information to include fatal outcomes:
The study population is HSCT or SOT recipients with cytomegalovirus 
infections. The follow ing SAEs are common in this study population and 
are anticipated to occur, hence these SAEs (including fatal outcomes) will 
not be considered unexpected and will not be individually reported to the 
regulatory agencies, IRBs, Ethics Committees, and investigators , provided 
there is no increased frequency of these events *:
Any CMV infection, including CMV reactivation/recurrence, CMV 
syndrome, and tissue invasive CMV dis ease
Any other bacterial, viral infection, or fungal infection
Acute and chronic graft versus host disease and graft rejection and loss 
Reactivation of the malignancy under treatment in HSCT recipientsSection 8.2.7
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 149 
 
07 Dec 2018
For non-commercial use only
Shire Page 150
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
3Amendment Date
01 Mar 2017Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
This includes fatal outcom es for the aforem entioned SAEs.
*Maribavir phase 2 (studies 1263 -202 and 1263 -203) data will be used 
as reference.
Added new text to clarify subject entry into the study rescue arm:
“Subjects in the investigator -assigned treatment arm who are unable to 
continue taking investigator -assigned anti -CMV 
treatment due to the lack of anti -viral activity and/or 
intolerance to the assigned treatment (as evaluated 
starting at Visit 5/Week 3) may be evaluated for entry 
into a maribavir rescue arm. Subjects who take rescue 
medication will be considered as failures for primary 
efficacy analyses. The data collected post -maribavir 
rescue initiation will be included in separate secondary 
analyses for efficacy and exploratory analysis for PK. 
Summary of all safety analyses will be provided 
separately for the maribavir rescue arm. Since intolerance 
alone will not qualify the patient for the rescue, such 
patients will not be considered nonresponders for the 
purpose of the primary analysis. The same is applicable 
for patients who migh t be discontinued from maribavir 
treatment due to intolerance. Subjects who discontinue 
due to intolerance and w ithout viremia clearance at Study 
Week 8 w ill be considered failures in both treatment 
arms.”Section 9.8
Added additional reference to an upda ted industry regulation: Integrated 
Addendum to ICH E6 (R1): Guideline for Good Clinical 
Practice E6 (R2) Current Step 4 version dated 9 
November 2016.Section 10.1.1, Section 10.2.1
Updated the table in Appendix 4 w ith the following pUL97 substitutions: 
D456N, M460L, C480R, P521L, C592F, L595T, 
N597D/I, G598D/V, and C603Y and the following 
pUL54 substitutions: L862F, D879G, and A972V.Section 12
Applied editorial changes throughout the document for clarity. Synopsis and throughout document, 
as needed
Amendment 2 to Protocol SHP620- 303 incorporated the following major changes:
An additional pregnancy  test at Visit 6/Week 4 performed at monthly interval.
Addition of highl y effective method of female and male contraception per the 
recommendations related to contraception and pregnancy  testing in clinical trials by  
clinical trial facilitation group (CTFG).
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 150 
 
07 Dec 2018
For non-commercial use only
Shire Page 151
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Modification of Inclusion Criterion 10 to only allow enrollment of subjects who will be 
able to swallow tablets.
Inclusion of cut off levels for CMV DNA concentration in whole blood for evaluating 
eligibility  at screening. 
Emphasis on potent inducers of C ytochrome P450 (CYP) 3A4 and/or P -glycoprotein 
(P-gp) and caution for concomitant use of potent inhibitors of CYP 3A4, in alignment 
with the guidance to the investigators provided in the maribavir investigator’s brochure.
Caution and recommendation for careful monitoring of concentration levels of 
concomitant medications that are substrates of CYP 2C19 and P -gp both after initiation 
of maribavir (when subs trate levels may  increase) and after discontinuation of maribavir
(when substrate levels may decrease), in alignment with the guidance to the investigators 
provided in the maribavir investigator’s brochure .
Specified that since intolerance to assigned trea tment alone does not qualify a subject for 
the rescue arm, such subjects will not be considered nonresponders for the purpose of 
primary  anal ysis. The same is applicable for subjects that might be discontinued from 
maribavir treatment due to intolerance.
Creation of a list of definitions relevant for anal yses for eas y access and convenience.
Noteworth y changes to the protocol are captured in the table below. Other minor editorial 
revisions (including changes for consistency  and clarity ) are not described in this table.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 151 
 
07 Dec 2018
For non-commercial use only
Shire Page 152
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
2Amendment Date
01 Dec 2016Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
Created a list of definitions pertaining to evaluations/analyses for the study 
for easy access and convenience, and for consistency 
throughout the document.The list of definitions follows the list 
of abbreviations in the “Table of 
Content”, also in Section 9.8
Added screening value for CMV DNA concentration in whole blood along 
with that in plasma to Inclusion Criterion 3: “ To be 
eligible for the study, subjects must have a documented 
CMV infection in whole blood or plasma, with a 
screening value of ≥2730 IU/mL in whole blood or ≥
910 IU/mL in plasma in 2 consecutive assessments…”Synopsis, Section 3.1, Section 4.1
Specified CMV DNA concentration in whole blood for stratification based 
on baseline plasma CMV DNA concentration: “high viral 
load w ith CMV DNA ≥273000 IU/mL in whole blood
or ≥91000 IU/mL in plasm a, intermediate viral load ≥
27300 IU/mL in whole blood or ≥9100 IU/mL in 
plasma , and low  viral load <27300 IU/m L in whole 
blood or <9100 IU/mL in plasma as determined by the 
local or central specialty laboratory qPCR results….”Synopsis, Section 3.1, Section 6.2.2
Amended Inclusion Criterion 10 to only allow  enrollment of subjects who 
will be able to swallow tablets. Subjects who have the 
condition at baseline that requires orogastric or 
nasogastric ad ministration of study treatment will not be 
enrolled until the results of additional in vitro recovery 
study, with 200mg maribavir tablets are available. 
Emphasized in “dosing” section that if subjects develop 
the condition requiring nasogastric or orogast ric tube 
administration while on study treatment, maribavir tablets 
may be administered via this method to avoid 
interruption or discontinuation of treatment.Synopsis , Section 4.1, Section 6.2.3
Added that there is no clinical experience with investigator assigned 
treatments (ganciclovir, valganciclovir, or cidofovir) in 
pregnant subjects and based on the reproductive toxicity 
observed in animal studies these should be considered a 
potential teratogen and carcinogen in humans (Valcyte 
and Vistide Prescribing Information). The reproductive 
toxicity studies with foscarnet (Foscavir) in animals were 
conducted using exposures that are inadequate to define 
the potential of teratogenicity at levels to which w omen 
will be exposed (Foscavir Prescribing Information).Section 4.4.1
Added recommendations related to contraception in clinical trials, per the 
clinical trial facilitation group (CTFG). Elaborated on 
highly effective method of contraception for sexually 
active females of child bearing potential participating in 
the study. Added that vasectomized male partner is a 
highly effective birth control method provided that Section 4.4.1
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 152 
 
07 Dec 2018
For non-commercial use only
Shire Page 153
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
2Amendment Date
01 Dec 2016Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
partner is the sole sexual partner of the female trial 
participant who is of child bearing potential and that the 
vasectomized partner has received medical assessment of 
the surgical success.
Added caution and recommendation for careful monitoring of 
concentration levels of concomitant medications that are 
substrates of CYP 2C19 and P -gp both after initiation of 
maribavir (when substrate levels may increase) and after 
discontinuation of maribavir (when substrate levels may 
decrease), in alignment with the guidance to the 
investigators provided in the maribavir investigator’s 
brochure.Section 5.2.1
Added caution for concom itant use of potent inhibitors of CYP 3A4 and 
emphasized prohibition of potent inducers of Cytochrome 
P450 (CYP) 3A4 and/or P -glycoprotein (P -gp), in 
alignment with the guidance to the investigators provided 
in the maribavir investigator’s brochure. Secti on 5.2.1, Section 5.2.2
Added an additional pregnancy test at Visit 6/ Week 4 so that these test are 
performed at monthly interval since the female subjects 
included in the study could potentially receive drugs with 
known teratogenic effect.Schedule of Assessment 1, 
Section 7.1.2, Section 7.2.3.5
Specified that since intolerance to assigned treatmen t alone does not qualify 
a subject for the rescue arm, such subjects will not be 
considered non responders for the purpose of the primary 
efficacy analysis. Also added that this is applicable to 
subjects that might discontinue for maribavir treatment 
due t o intolerance. Subjects who do not achieve 
confirmed viremia clearance will be considered failures 
in both treatment arms.Section 9.8.1
Amendment 1 to Protocol SHP620- 303 incorporated the following major changes:
Removal of the restriction to utilize onl y a single commerciall y available anti -CMV 
treatment for 8 weeks of the study  for the subjects in the I nvestigator -assigned anti -CMV 
treatment arm. Subjects may  also continue on prior therapy  if this is the best treatment 
option selected b y the investigator.
Addition of assessment of “ invasive bacterial and fungal infection ” to the list of safet y 
endpoints since it is one of the adverse events of special interest in the study  population. 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 153 
 
07 Dec 2018
For non-commercial use only
Shire Page 154
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Update to the table for prior medications/procedures/diagnostic interventions.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 154 
 
07 Dec 2018
For non-commercial use only
Shire Page 155
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
1Amendment Date
08 Jul 2016Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
In order to facilitate recruitment and optimal inclusion of broader patient 
population, hematopoietic stem cell transplant (HSCT) 
and solid organ transplant (SOT) recipients, whose CMV 
infections are refractory to available anti -CMV treatment 
(ie, ganciclo vir, valganciclovir, foscarnet, or cidofovir), 
the restriction to utilize only a single commercially 
available anti -CMV treatment for 8 w eeks of the study 
was removed for the subjects in the Investigator -assigned 
anti-CMV treatment arm. Subjects may also c ontinue on 
prior therapy if this is the best treatment option selected 
by the investigator.
Added text in Section 2.2
Investigator assigned anti -CMV treatment with 1 or 2 of the 4 anti -CMV 
drugs (ganciclovir, valganciclovir, foscarnet, or cidofovir) 
with additional strategies when deemed necessary by 
investigator (eg, change in the dose of the anti -CMV 
drug, reduction of immunosuppressant, addition of IVIG 
or CMV Ig) is th e active control group for this study. The 
subject on single or dual therapy with anti –CMV 
agents at the tim e of enrollment, m ay either change 
therapy at the tim e of randomization/treatm ent 
initiation or rem ain on the sam e therapy as the 
investigator assigned anti -CMV treatm ent, if 
randomized to this study arm. If the treatm ent was 
continued or started as 2 anti -CMV agents, 
withdrawal of 1 agent, while continuing the second 
one will be possible.
Added text in Section 3.1 
The subjects randomized to maribav ir treatm ent arm  will discontinue 
the therapy they were currently on at the tim e of enrollment. For 
subjects randomized to the investigator assigned treatm ent arm , the 
investigator will determ ine at the tim e of randomization/treatm ent 
initiation whether th e subject will change the therapy they were 
currently on at the tim e of enrollment, or will rem ain on the sam e 
therapy (single or dual anti -CMV agent therapy) after randomization. 
If the treatm ent was continued or started as 2 anti- CMV agents, 
withdrawal o f 1 agent, while continuing the second one will be possible. 
Addition of another anti -CMV agent will be declared as failure for the 
purpose of study analysis. After random ization, changes to the 
investigator treatm ent of choice could include, change in dos ing, dosing 
regim en, but will not include an addition of another anti -CMV agent. 
Modified text in Synopsis and Section 3.1 
“Subjects Randomized to Investigator -Assigned Anti -CMV 
Investigator- assigned anti -CMV treatm ent strategies for the 8 weeks of Synopsis , Section 2.2, Section 3.1
(Study design -Study Treatment 
Phase), Section 5.2.2 (Prohibited 
treatment during study drug 
treatment), and Section 6 (Identity of 
study treatments) and 6.2.3 (Dosing)
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 155 
 
07 Dec 2018
For non-commercial use only
Shire Page 156
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
1Amendment Date
08 Jul 2016Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
the study treatm ent phase must only utilize up to 2 available anti -CMV 
agents from  the following: ganciclovir, valganciclovir, foscarnet, or 
cidofovir. 
If investigator’s decision is to change the p re-study anti -CMV agent(s), 
the investigator can select up to 2 new anti -CMV drugs as the study 
treatm ent. 
Investigator m ay also decide to keep the subject on the same anti -CMV 
drug(s), which was/were used for treatm ent of subject prior to 
randomization/ treatm ent initiation. 
If the treatm ent was continued or started as 2 anti- CMV agents, 
withdrawal of 1 agent, while continuing the second one will be possible. 
After random ization changes to the investigator treatm ent of choice 
could include, change in dos ing, change in dosing regimen, but will not 
include an addition of another anti -CMV agent. 
Dose adjustment is allowed as deemed appropriate by the investigator. 
The rationale for dose adjustm ent will be 
documented; change to another anti- CMV agent 
during the study treatment period is not allowed.
Investigational anti -CMV agents are not perm itted. 
Additional treatm ent strategies can complement the 
use of a single anti -CMV agent, for exam ple, reducing 
or m odifying the immunosuppressant drug use, use of 
IVIg or CMV Ig.”
Subjects will follow  the investigator’s prescribed anti -CMV treatment. 
Subjects will remain on their investigator- assigned anti -CMV therapy for 
the 8 w eeks of the study treatment phase. The subject m ay stop treatm ent 
due to intolerance based on investigator judgm ent, however if the 
interruption is longer than protocol specified and/or subject is not able 
to continue with 8 weeks of treatm ent it may result in classifying the 
subject as a failure for analysis purposes. Subjects may be assessed f or 
entry into a rescue arm, starting at Visit 5/Week 3 (after a minimum 3 
weeks of treatment), for treatment with maribavir 400 mg BID for 8 w eeks. 
Subjects must meet 1 of the follow ing criteria to be eligible to enter the 
maribavir rescue arm:
Modified text in Section 6:
Study investigators will choose and prescribe an anti-CMV drug of their 
choice from the available products utilized for treatment of CMV 
infection/disease in clinical practice, as endorsed in published guidance 
documents, institutional gui delines, and other published literature (Kotton 
et al., 2013; Tomblyn et al., 2009). The investigator -assigned anti -CMV 
treatment arm may only utilize 1 or 2 (only if subject’s current dual 
therapy at enrollm ent is continued after random ization or started at 
randomization) of the following 4 noninvestigational anti-CMV agents: 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 156 
 
07 Dec 2018
For non-commercial use only
Shire Page 157
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
1Amendment Date
08 Jul 2016Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
(change from ganciclovir to valganciclovir or vice versa will be allow ed):
Modified text in Section 6.2.3
Investigator -assigned anti -CMV treatment strategies for the 8 weeks of the 
study treatm ent phase must only utilize a single 1or 2 of the available 
anti-CMV agent from  the following: ganciclovir, valganciclovir, foscarnet, 
or cidofovir. The subject receiving 1 or 2 anti –CMV agents at the tim e 
of enrollm ent, may either change thera py at the tim e of 
randomization/treatm ent initiation or rem ain on the sa me therapy as 
the investigator assigned anti -CMV agent, if random ized to this study 
treatm ent arm . After randomization, changes to the investigator 
treatm ent of choice could include, c hange in dosing, change in dosing 
regim en, but will not include an addition of another anti -CMV agent. If 
the treatm ent was continued or was started (post -randomization) as 2 
anti-CMV agents, withdrawal of one agent while continuing with the 
second one wil l be possible. 
Dose adjustment isallowed as deemed appropriate by the investigator. The 
rationale for dose adjustment will be documented; change of treatm entto 
another anti -CMV agent or addition of another anti -CMV agent during the 
study treatment will be considered declared as treatment failure except for 
change of therapy from ganciclovir to valganciclovir and vice versa. 
Clarified that the investigator -assigned anti -CMV agents to which the CMV 
infection is refractory is currently administered to an 
eligible subject.Synopsis , Section 3.1 (Study Design 
and Flow  Chart)
Clarified the definition for “Refractory” that the documented failure to 
achieve >1 log 10decrease in CMV DNA level in whole 
blood or plasma c ould be after 2 or more w eeks of 
treatment with IV ganciclovir, oral valganciclovir, IV 
foscarnet, or IV cidofovir or could be after treatment with 
any combination of this anti -CMV agents.Synopsis , Section 3.1 (Study Design 
and Flow  Chart)
Removed a redu ndant statement not necessary for the definition of and 
clarified that “Resistant ” will be defined as: 
Documented failure to achieve >1 log 10(common logarithm to base 10) 
decrease in CMV DNA level in whole blood or plasma after of 2 or more 
weeks of treatment with IV ganciclovir, oral valganciclovir, IV foscarnet, 
or IV cidofovir (or any combination thereof). Results from the same 
laboratory a nd the same sample type (blood or plasma) are to be used to 
determine the refractoriness ”Synopsis , Section 3.1 (Study Design 
and Flow  Chart)
Specified for clarity this study w ill also assess improvement or resolution of 
tissue -invasive CMV disease at the end of the 8 -week 
study treatment phase and during the follow -up phase for 
subjects with disease present at baseline.Synopsis , Section 3.1 (Study Design 
and Flow  Chart)
To be consistent with other sections in the protocol, it w as clarified that 
subject enrollment will be monitored to achieve an 
approximate target of 60% of subjects who have a CMV 
infection with documented resistance to any of the Synopsis , Section 3.1 (Study design)
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 157 
 
07 Dec 2018
For non-commercial use only
Shire Page 158
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
1Amendment Date
08 Jul 2016Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
anti-CMV agents (ganciclovir, valganciclovir, foscarnet, 
or cidofovir) proven by according to the central 
specialty results from samples taken at baseline. 
To facilitate study conduct and to be consistent with other sections in the 
protocol, the following details w ere added in the synopsis 
for the Screening Phase: “ Histor ical laboratory results 
(local laboratory) for tests specified in the Schedule of 
Assessment 1 may be used during screening for the 
assessment of the eligibility, including local CMV DNA 
quantification test results. If local laboratory results are 
not avai lable, the central laboratory assessments may be 
conducted. All clinical laboratory results required for 
eligibility verification must be available prior to 
randomization”
It was added that the historical laboratory results from local laboratory for 
CMV DN A quantification test may be used for assessment of eligibility at 
screening.Synopsis , Section 3.1 (Screening 
Phase) 
Added information that the blood sample taken for CMV DNA test at the 
first visit of the maribavir rescue treatment period w ill be 
used as the ‘baseline’ assessment for the purpose of the 
analyses of the response to maribavir rescue treatment 
(including resistance analyses). Synopsis , Section 3.1
The follow ing statements were added for clarity: 
“CMV DNA quantification may be performed in the local or central 
specialty laboratory. Already available results from  the local 
laboratory (historical results) will be acceptable for screening, if taken 
within the tim e frames indicated and if from  the same laboratory .”
“All clinical laboratory re sults required for eligibility verification m ust 
be available prior to randomization. ”Section 3.1 (Screening Phase)
Since not all required tests at baseline will be performed at screening for 
assessing eligibility, the text was modified to state that 
samples for all hematology/chemistry tests, and for the 
CMV DNA quantification test specified at baseline will 
be collected even if these tests w ere performed within 7 
days prior to the first dose, and central laboratory results 
were available. 
Modified text in the Synopsis
“The screening and Visit 2/Week 0/Day 0 visits can occur on the same day 
in the case when historical local laboratory results are 
available for determ ination of eligibility. All Visit 
2/Day 0 procedures m ust be com pleted prior to study 
treatm ent administration. The whole blood/plasm a 
samples for CMV DNA quantification, hem atology, 
and chemistry testing m ust be taken for all subjects at Synopsis , Section 3.1 (Study 
design -Study Treatment Phase), 
Section 7.1.1 (Screening Period), 
Schedule of assessment (Table 1), 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 158 
 
07 Dec 2018
For non-commercial use only
Shire Page 159
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
1Amendment Date
08 Jul 2016Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
Visit 2/Week 0/Day 0. The test results of these assays 
will not be available prior to the start of treatm ent.” 
Modified text in Section 3.1
“The screening and Visit 2/Week 0/Day 0 visits can occur on the same day 
if the historical laboratory results, including CMV DNA quantification 
results, nee ded for evaluation of eligibility are available, or results can 
be obtained the same day. All Visit 2/Day 0 procedures, including blood 
collection for CMV DNA quantification, hem atology and chemistry 
analysis in the central laboratory, m ust be completed pr ior to study 
treatm ent administration. Central laboratory results of CMV DNA 
quantification and genotyping, hem atology, and chem istry from  
samples taken at Visit 2/Day 0 will not be available to for the screening 
of subjects. ”
Modified text in Section 7.1. 1
At screening, either central or local laboratory results for CMV DNA 
quantification hematology/chemistry/pregnancy testing can be used 
for qualification. 
Schedule of Assessment 1 
Footnotes “c” and “g” were modified to reflect that all required tests at
baseline will performed prior to study treatment initiation and these central 
specialty laboratory results will not be available for screening purpose.
Footnote “c”:
“Screening and Visit 2/Day 0 visits can occur on the same day in the case 
when historical laboratory values are available for determination of the 
eligibility . All Visit 2/Day 0 procedures must be completed prior to 
initiation of study treatment. The test results for the sam ples taken at 
Visit 2, from  central laboratory or central specialty laboratory, will not 
be available to be used for screening .”
Footnote “g”:
“Clinical laboratory test will be performed at a central laboratory for all 
specified time points during the study including baseline. Central or local 
laboratory results for hematology/chemistry/pregnancy testing can be used 
for eligibility and their results must be available prior to randomization. 
Local laboratory -human chorionic gonadotropin test results can be used 
for the assessme nt of pregnancy on Day 0/Week 0. Only Central lab results 
for hematology/chemistry/pregnancy testing obtained within 7 days prior to 
initiation of study treatment will be acceptable for randomization (test will 
not be repeated on Day 0). Local or central l aboratory analysis performed 
on samples taken between Day -7 and Day - 14 will be repeated on Day 0 
before randomization.”
The sentences within the Inclusion Criterion 4 w ere m odified:
to remove “requiring the change of current therapy” to align w ith the Inclusion Criterion 4 in the Synopsis 
and Section 4.1
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 159 
 
07 Dec 2018
For non-commercial use only
Shire Page 160
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
1Amendment Date
08 Jul 2016Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
fact that subjects on the anti -CMV agent ganciclovir, valganciclovir, 
foscarnet, or cidofovir immediately prior to randomization may 
continue on the same if randomized to the investigator -assigned 
treatment arm, and 
to indicate that the subject could be refractory or resistant after 2 or 
more w eeks of treatment with IV ganciclovir, oral valganciclovir, IV 
foscarnet, or IV cidofovir or after treatment with any combination of 
these anti -CMV agents
Modified Inclusion Criterion 4 is as follows:
“Have a current CMV infection refractory or resistant to treatment and 
requiring the change of current therapy . Refractory is defined as 
docume nted failure to achieve >1 log 10decrease in CMV DNA level in 
whole blood or plasma after 2 or more weeks of treatment with IV 
ganciclovir, oral valganciclovir, IV foscarnet, or IV cidofovir (or any 
combination thereof ). Resistant is defined as documented failure to 
achieve >1 log 10(common logarithm to base 10) decrease in CMV DNA 
level in whole blood or plasma after an interval of 2 or more w eeks of 
treatment with IV ganciclovir, oral valganciclovir, IV foscarnet, or IV 
cidofovir (or any combination thereof) AND documentation of 1 or more 
CMV genetic mutations associated w ith resistance to ganciclovir, 
valganciclovir, foscarnet, or cidofovir.
A statement within Exclusion Criterion 2 w as modified for cl arity and to 
align with the study design:
“A subject who is not continuing with the sam e anti -viral drug(s)
(ganciclovir, valganciclovir, or foscarnet) for the study treatm ent (if 
randomized to the investigator assigned anti -CMV treatment arm ), 
must discontinue their use before the first dose of study drug. Ifsubject is 
currently being treated with cidofovir and is assigned another anti -
CMV agent by the investigator, the subject must discontinue its use at 
least 14 days prior to randomization at Visit 2/Day 0 and the first dose of 
study treatment.Exclusion Criterion 2 in the Synopsis 
and Section 4.2
A statement within the Exclusion Criterion 3 was modified to: “ Subjects 
receiving artesunate must discontinue the use at least 1 
dayprior to rando mization at Visit 2/Day 0 and the first 
dose of study treatment ”Exclusion Criterion 3 in the Synopsis 
and 4.2.
Added a note for subjects with biopsy in Exclusion Criterion #7:
“Serum aspartate aminotransferase (AST) > 5 times upper limit of normal 
(ULN) at screening, or serum alanine aminotransferase (ALT) >5 times 
ULN at screening, or total bilirubin ≥3.0 x ULN at screening (except for 
documented Gilbert ’s syndrome), by local or central lab. NOTE: 
Subjects with biopsy confirmed CMV hepatitis will not be excluded 
from  study participation despite AST or ALT >5 times ULN at 
screening . Exclusion Criterion 7 in Synopsis and 
Section 4.2
It was clarified in Exclusion Criterion 10 that breast feeding females will be Exclusion Criterion 10 in the 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 160 
 
07 Dec 2018
For non-commercial use only
Shire Page 161
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
1Amendment Date
08 Jul 2016Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
excluded from the study. 
Be female and pregnant or nursing breast feedingSynopsis and Section 4.2
Replaced “reactivation” of the malignancy under treatment with “relapse or 
progression” of the malignancy under treatment and 
modified the rest of the text for clarity in Exclusion 
Criterion 13:
“Have active malignancy with the exception of nonmelanoma skin cancer. 
Subjects who have had a HSCT and who experience relapse or 
progression of the malignancy under treatment with HSCT , as per 
investigator’s opinion are not to be enrolled.”Exclusion Criterion 13 in the 
Synopsis and Section 4.2
“Disease symptomatology” was replaced w ith “disease status”, wherever 
applicable.Synopsis and other sections of the 
protocol.
Transplant status will not be collected at screening. Schedule of Assessment 1 (Table 1), 
Section 7.1.1 (Study 
Schedule -Screening Period)
Liver function assessment by Child -Pugh classification will be performed at 
baseline, ie, Visit 2/Week 0. It w ill not be performed at 
screening.Schedule of Assessment 1 (Table 1), 
Section 7.1.1 (Study 
Schedule -Screening Period), Section 
7.1.2, and Section 7.2.3.1
It was added that the e- diary will only be utilized for study treatments that 
are given orally. The IV a dministration will be tracked in 
the source documents and CRF. Footnote “s” in Schedule of 
Assessment 1 (Table 1), Section 7.1.2
(Study Schedule -Study Drug 
Administration)
For subjects who may withdraw consent during the study treatment phase 
or the foll ow-up phase, it was clarified that during the 
period after the study treatment discontinuation, and until 
the end of the study, subjects might be administered an 
anti-CMV treatment for lack of efficacy, recurrence of 
CMV virem ia, or for worsening or new on set of CMV 
disease as deemed necessary by the investigator.Synopsis , Section 4.5 
(Discontinuation and/or w ithdraw al)
Added for clarification that subjects who enter the rescue arm  will be 
classified as failure for the purpose of analysis of the 
primary endpoint.Synopsis and Section 3.1, and 
Section 6
Specified that study treatment interruption of up to 4 consecutive days at 2 
separate occurrences during the 8 w eeks of study 
treatment is allowed in both treatment arms (maribavir or 
Investigator -assigned commercially available anti -CMV 
treatment). Synopsis. Section 3.1, Section 6.2.3
Added “ In addition, viral UL27 gene will be tested” to reemphasize that 
besides genotyping viral UL97 and UL54 CMV genes 
isolated from Visit 2/Day 0 plasma samples, viral UL27 
gene will be genotyped too to identify mutations 
conferring resistance to commercially available 
anti-CMV agents.Synopsis and Section 7.2.2.2
Added new text to Section for Tissue Invasive Disease Assessment to Section 7.2.2.3
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 161 
 
07 Dec 2018
For non-commercial use only
Shire Page 162
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
1Amendment Date
08 Jul 2016Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
provide more information about this assessment.
In cases of CMV retinitis, the retinal images taken by the 
ophthalmologist may be collected and provided as the evidence 
supporting the diagnosis. 
EAC might request the individual histopathology slides to be read 
by an independent pathologist.
Presence and presentation of CMV syndrome in SOT subjects at 
baseline or a new onset should be reported as the event of special 
interest per definition provided in the Appendix 3. 
Added assessment of “ invasive bacterial and fungal infection ” to the list 
of safety endpoints since it is one of the adverse events of 
special interest in the study population. 
Added AEs of GI events (nausea, vomiting, and diarrhea) to be consistent 
with other sections.
Added that additional grading of ev ents of special interest will be 
applicable.
Added that incidence of invasive bacterial and fungal infections for each 
treatment group for on treatment period and overall -study period w ill be 
provided. 
Added new text to state that additional shift tables may be produced for 
selected laboratory parameters using severity grades based on National 
Cancer Institute (NCI) common terminology criteria for adverse events 
(CTCAE v4.0) or using normal/above normal/below normal range.Synopsis , Schedule of Assessments, 
Section 7.1, and Section 9.9
Follow ing prior medications/procedures/diagnostic interventions were 
added to Table 3.
Any therapeutic or diagnostic intervention performed within 3 months prior 
to the first dose of study treatment on Visit 2/Week 0/Day 0:
Dialysis
X-rays, CT scans, MRI, ultrasound imaging (along with significant 
findings)
Anti-Rejection Therapies, Adjuvant Therapies and Other Related 
Therapies
Anti -rejection m edications (for example belatacept) including T -
cell depleti ng therapies
Photopheresis
Induction therapies
Pre-transplant irradiation
Chemotherapy agentsSection 5.1 (Table 3)
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 162 
 
07 Dec 2018
For non-commercial use only
Shire Page 163
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
1Amendment Date
08 Jul 2016Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
It was clarified that CMV specific T -cell transfer is considered 
investigational
A footnote note was added to Table 3 :
*Subjects for whom  transplant was perform ed>3 m onths from  the 
time of screening limited (no dose data) inform ation for induction 
therapy will be collected. Similarly for anti -CMV treatment data older 
than >3 m onth prior to screening will be recorded in more limited 
manner (dose prescribed, major i nterruptions, overall treatm ent 
duration)
Added diagnostic assessment imaging, such as X- ray, CT scans Section 5.2
Based on the summary of product characteristic (SmPC) for valganciclovir, 
it was added that In vivo drug interaction studies with 
Valcyte have not been performed. Since valganciclovir 
is extensively and rapidly metabolized to ganciclovir; 
drug interactions associated with ganciclovir should 
be expected for valganciclovir (Valcyte Sm PC).Section 5.2.2
It was added that r egulatory T -cells (Tregs), which is an experimental 
treatment, is not allow ed for the control of transplant 
tolerance.Section 5.2.2
It was added that presence of CMV syndrome in SOT patients at baseline or 
a new onset should be reported as adverse event of 
special interestFootnote “f” in Schedule of 
Assessment 2 (Table 2) Section 
7.2.2.3 (Tissue Invasive CMV 
Disease Assessments)
Added a separate subsection under “Study Evaluations and 
Procedures -Efficacy” (now  Section 7.2.2.6) for graft -
versus -host-disease (GVHD) assessment for HSCT 
recipients only. Rearranged and relocated the text 
relevant to this assessment in Section 8.1.4 for emphasis 
and clarity. Section 7.2.2.6 (GVHD assessment)
Section 8.1.4 (Adverse events of 
special interest [AESI])
Added a new citation Loiseau et al. 2007 in the section for GVHD 
assessments
Loiseau P, Busson M, Balere ML et al. 2007. HLA association with 
hematopoietic stem cell transplantation outcome: the number of mismatches 
at HLA -A, -B, -C, -DRB1, or -DQB1 is strongly associated with overall 
survival. Biol Blood Marrow  Transplant, 13(8), 965 -74.Section 7.2.2.6 andSection 11
(References)
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 163 
 
07 Dec 2018
For non-commercial use only
Shire Page 164
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
1Amendment Date
08 Jul 2016Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
Added a new citation, Harris et al 2016 as the guidance for acute GVHD 
staging and grading and for the confidence levels of the 
diagnosis:
Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, 
Chanswangphuuwana C, Efebra Y, Holler E, Litzow M, Ordemann R, 
Qayed M, Renteria AS, Reshef R, Wolfi M, Chen Y -B, Goldstein S, Jagasia 
M Locatelli F, Mielke S, Porter D, Schechter T, Shekhovts ova Z, Ferrara 
JLM and Levine JE, 2016. International, multicenter Standardization of 
Acute Graft -versus -host Disease Clinical Data collection: A report from the 
Mount Sinai Acute GVHD international Consortium. Biol Blood Marrow  
Transplant, 22, 4 -10
Added Table 1 and Table 2 in Appendix 9 from this citation.Section 7.2.2.6, Section 8.1.4, 
Section 11, and Appendix 9 in 
Section 12
Elaborated the reason for comorbidity assessment by the follow ing 
addition:
“Transplant patients often have m ultiple other comorbidities, resulting 
from  their immunosuppressed status (co -infections, graft versus host 
disease, transplant malfunctioning due to rejection), toxicities from  
therapies for m aintenance of the transplant or reactivation of the 
baseline disease for whic h they had been transplanted (malignancy for 
example), and other concomitant diseases resulting in a very diverse 
population that m ight be enrolled into the study. The comorbidity 
assessment will be conducted to allow for the comparison of the 
population e nrolled into 2 treatm ent arms and to account for the 
subjects’ health status when assessing overall and individual subject 
response.” Com orbidities are a physiological burden of disease and its 
interaction with ongoing treatment could impact the response t o therapy.”Section 7.2.2.7 (Comorbidity Status)
To be consistent with the schedule of assessment 1 (Table 1), a correction 
was made in Section 7.2.3.4 that electrocardiogram 
(ECG) w ill be performed at baseline (Visit2/Day0) and 
not at screening.Section 7.2.3.4 (Electrocardiogram)
Modified text for clarity and consistency with regards to local laboratory 
data and reference range.
“During screening, clinical laboratory tests will be performed by the 
central laboratory, however local laboratory results if available might be 
utilized for the assessment of the eligibility. If local laboratory results 
are used for assessment of the eligibility, the reference ranges must be 
provided. This also applies to CMV DNA quantification results. At 
baseline (Visit 2/Wee k 0) blood samples will be taken for CMV DNA 
quantification ”Section 7.2.3.5 (Clinical laboratory 
evaluation)
Added that the samples for chemistry are preferred to be taken under fasting 
conditions, although this is not mandatory. The 
information whether samples were taken under fasting 
conditions will be collected. Section 7.2.3.5 (Clinical laboratory 
evaluation)
Added a note that only the levels of immunosuppressant drugs that are 
routinely conducted at the site w ill be collected since sites Section 7.2.3.5 (Clinical laboratory 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 164 
 
07 Dec 2018
For non-commercial use only
Shire Page 165
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
1Amendment Date
08 Jul 2016Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
differ in the immunosuppressant drug levels they 
routinely monitor.evaluation)
International normalized ratio (INR) and prothrombin time will be 
performed at baseline only. It was stated in the original 
version that this assessment will performed only at 
screening visit only.Section 7.2.3.5
Replaced an incorrect citation Boeckh et al 2003 w ith Boeckh et 1998:
Boeckh M, Zaia JA, Jung D, Skettino S, Chauncey TR and Bow den RA 
1998. A study of the pharmacokinetics, antiviral activity, and tolerability of 
oral ganciclovir for (MV prophylaxis in marrow  transplantation. Biol Blood 
Marrow Transplant, 4:13-19. Footnote ” o” in Schedule of 
Assessment 1 (Table 1), Section 
7.2.4.1, and Section 11 (References)
Volume of blood to be drawn from each subject per visit (Table 5) was 
updated to reflect reduction in number of samples 
collected for  Section 7.2.5 (Volume of blood to be 
draw n from each subject per visit), 
Table 5
Removed the following text to align with the case report form for the study: 
“The CTCAE identifies 5 distinct severity grades, 
including Grade 5=death related to AE. In this study, 
investigators will be instructed to utilize only severity 
Grades 1 –4 for each event. Should any death occur during 
the study, this will be recorded in the CRF as the outcome 
of an AE rather than as a severity grade. Other detailed 
instructions will be provided in the study manual.”Section 8.1.1 (Severity 
Categorization)
Added that CMV syndrome (applicable only in SOT patients) and details of 
the presentation will be collected as an adverse event of 
special interest.Section 8.1.4
For the events of diarrhea recorded, it w as further clarified that additional 
information for each case of diarrhea will be collected, 
including the information whether additional condition 
such as GVHD, GI -CMV or enteric infection confirmed 
by culture/PCR or other method is present. Section 8.1.4
Modified the infections of interest to add more details for monitoring and 
reporting invasive fungal and bacterial infections.
New  text:
“Invasive fungal (eg, aspergillus, candida, Pneumocystis jiroveci , etc.) or 
bacterial infections (eg, S taphylococcus aureus , Streptococcus pneumonia , 
enterococcus, pseudomonas); see Appendix 13. Baseline conditions will be 
captured as part of medical history, while new events will be captured as 
AEs. The additional information such as diagnostic method used for the 
pathogen and the source of the sample used for the diagnosis w ill be 
collected. Additionally the presence of viral infections frequently occurring 
in transplant population will also be collected.” Section 8.1.4
Added the following:
CMV syndrome (applicable in SOT patients only)Section 8.1.4 and Section 8.1.5
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 165 
 
07 Dec 2018
For non-commercial use only
Shire Page 166
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
1Amendment Date
08 Jul 2016Global/Country/Site Specific
Global
Description and Rationale for Change Section(s) Affected by Change
“New onset of CMV syndrome (applicable only in SOT patients) and 
details of the presentation will be reported as the event of special interest” . 
Modified make sentence concise and indicate the time point, ie, “baseline” 
“If, at the end of the study treatment phase or at the end of the follow -up 
phase, there are abnormal clinical laboratory, vital sign, or ECG values 
which were not present at the pretreatme nt value observed closest to the 
start of study treatment baseline, further investigations should be performed 
until the values return to within the reference range or until a plausible 
explanation (eg, concomitant disease) is found for the abnormal values .”Section 8.1.6
Removed the collection of subjects’ initials and dates of birth in Section 
10.4 (Privacy and Confidentiality) since these information 
should not be used for identifying purposes. The unique 
number in itself is sufficient for that purpose.Section 10.4 (Privacy and 
Confidentiality)
Added a page after the protocol signature page for the summary of changes 
for Amendment 1, per the sponsor’s approved protocol 
template.
Added an appendix (Appendix 1) for protocol history and a table for 
summary of changes for the current and future 
amendm ents, per the sponsor’s approved protocol 
template. With the addition of this new appendix, all 
other appendices were renumbered throughout the 
document.Section 12 (Appendices)
Modified Appendix 3 (Definition of Tissue Invasive CMV Disease and 
CMV Syndrome) to remove probable and proven 
methods of tissue invasive CMV disease diagnosis. 
Added CMV syndrome definition and the details of the 
assay performed for diagnosis.Section 12 (Appendices)
Remove d illegible snapshots from renumbered Appendices 10 
(Recommendations For Chronic GVHD Diagnosis and 
Grading; previously 9a) and 11(Diagnostic Criteria for 
Chronic GVHD; previously 9b) and indicated source 
figures and tables within the articles cited in tho se 
appendices for reference.Section 12 (Appendices)
Added a new Appendix 13 with details for invasive bacterial and fungal 
assessments. Following new journal articles cited in this 
new appendix were added to the list of references:
Klumpp 1993; Dykewicz 2001; Majhail et al. 2012; Salzberger et al. 1997; 
Marr et al. 2002; Freifeld et al. 2011Section 11 (References) and 
Section 12 (Appendices)
Applied editorial changes throughout the document for clarity Synopsis and Sections, as needed
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 166 
 
07 Dec 2018
For non-commercial use only
Shire Page 167
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Appendix 2 CHILD -PUGH CLASSIFICATION OF CH RONIC LIVER DISEASE
Score Bilirubin
(mg/dL)Albumin
(mg/dL)INR Hepatic Encephalopathy
(grade)Ascites
(grade)
1 <2 >3.5 <1.7 None None
2 2-3 2.8-3.5 1.7 -2.2Mild
(controlled medically)Mild
(controlled medically)
3 >3 <2.8 >2.2Marked
(poor control)Marked
(poor control)
Child -Pugh Class: A Score of 5 -6
B Score of 7 -9
C Score >9
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 167 
 
07 Dec 2018
For non-commercial use only
Shire Page 168
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Appendix 3 DEFINITIONS OF TISSUE INVASIVE CMV DISEASE AND CMV 
SYNDROME
TISSUE INVASIVE DISEASE 
The following definitions of CMV disease are based on a commonl y cited reference that was 
intended for application to transplant recipients ( Ljungman et al., 2002 ; Ljungman et al., 2017 ). 
Definitions often require clinical judgment regarding compatible symptoms or other factors. The 
investigator should utilize his/her best clinical judgment for this categorization, and apply  these 
definitions whenever possible for consistency . When reporting CMV disease, the presence of any  
co-pathogens that may  be contr ibuting to the organ disease must be reported as well.
Pneumonia: “CMV pneumonia” is defined b y the presence of signs and/or symptoms of 
pulmonary  disease combined with the detection of CMV in bronchoalveolar lavage fluid or lung 
tissue samples. Detection of CMV should be performed b y virus isolation, histopathologic 
testing, immunohistochemical anal ysis, or in situ hy bridization. Detection of CMV by  PCR alone 
may be too sensitive for the diagnosis of CMV pneumonia and is therefore insufficient for this 
purpose. The presence of fungal copathogens, such as Aspergillus species, together with 
radiologic signs t ypical of Aspergillus pneumonia (eg, a halo sign or a crescent sign) indicates 
fungal pneumonia rather than CMV pneumonia. CMV documented b y culture from BAL might 
be used as the evidence in the absence of other preferred assay s.
Gastrointestinal disease: “CMV gastrointestinal disease” is defined by  the identification of a 
combination of clinical sy mptoms from the upper or lower gastrointestinal tract, findings of 
macroscopic mucosal lesions on endoscopy , and demonstration of CMV infection (by  culture, 
histopathologic testing, immunohistochemical analy sis, or in situ hy bridization) in a 
gastrointestinal tract biopsy  specimen. Detection of CMV by  PCR alone i s insufficient for the 
diagnosis of CMV gastrointestinal disease. Patients with CMV disease that involves the 
intestinal tract usually  have mucosal abnormalities that can be seen by  the endoscopist, but the 
appearance of some of these lesions is subtle. The spectrum of endoscopic lesions is variable and 
ranges from patch y erythema, exudates, and microerosions to diffusel y edematous mucosa, to 
multiple mucosal erosions, to deep ulcers and pseudotumors. The diagnostic y ield for CMV is 
higher when mucosal abnormalities are targeted for study . If CMV is detected in normal mucosa 
near a lesion consistent with those ty pical of CMV infection, this can be accepted as CMV 
gastrointestinal disease.
Cytomegalovirus documented in blood by  PCR or antigenemia or CMV docum ented b y PCR 
from tissue biopsies might be used in the absence of other preferred methods of diagnosis.
Hepatitis: 
“CMV hepatitis” is defined by  the findings of elevated bilirubin and/or enzy me levels 
during liver function testing, absence of an y other doc umented cause of hepatitis, and detection 
of CMV infection (b y culture, histopathologic testing, immunohistochemical analysis, or in situ 
hybridization) in a liver biopsy  specimen. Detection of CMV by  PCR alone is insufficient for the 
diagnosis of CMV hepa titis because it can impl y the presence of transient viremia. 
Documentation of CMV (ie, b y immunohistochemical anal ysis) within the liver tissue is needed. 
Other pathogens, such as hepatitis C virus, may  be present without excluding the diagnosis of 
CMV he patitis.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 168 
 
07 Dec 2018
For non-commercial use only
Shire Page 169
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Central Nervous System (CNS) disease: Cy tomegalovirus “CNS disease” is defined b y the 
identification of CNS symptoms together with the detection of CMV in cerebrospinal fluid 
samples, by culture or PCR, or in brain biopsy  specimens, by  culture, hi stopathologic testing, 
immunohistochemical analy sis, or in situ hy bridization.
Retinitis: The diagnosis of disease requires typical ophthalmological signs judged b y an 
ophthalmologist experienced with the diagnosis of CMV retinitis. I f the presentation is atypical 
or an experienced ophthalmologist is not available, it is recommended that the diagnosis is 
supported by  CMV documented in vitreous fluid by  PCR. The images of retina taken during 
ophthalmological exam should be provided.
Nephritis : Cytomegalovirus nephritis can be defined by  the detection of CMV infection (by  
culture, immunohistochemical anal ysis, or in situ hy bridization) together with the identification 
of histologic features of CMV infection in a kidney  biops y specimen obtained fr om a patient 
with renal d ysfunction.
Cystitis : Cystitis is defined by  the detection of CMV infection (by  culture, 
immunohistochemical analy sis, or in situ hy bridization) together with the identification of 
conventional histologic features of CMV infection in a bladder biops y specimen obtained from a 
patient with cy stitis.
Myocarditis: My ocarditis is defined by  the detection of CMV infection (b y culture, 
immunohistochemical analy sis, or in situ hy bridization) together with the identification of 
conventional histologic features of CMV infection in a heart biops y specimen obtained from a 
patient with my ocarditis.
Pancreatitis : The definition of CMV pancreatitis requires the detection of CMV infection (by  
culture, immunohistochemical anal ysis, or in situ hy bridi zation) together with the identification 
of conventional histologic features of CMV infection in a pancreatic biopsy  specimen obtained 
from a patient with pancreatitis.
Other CMV disease categories: Cytomegalovirus can also cause disease in other organs, a nd 
the definitions of these additional disease categories include the presence of compatible 
symptoms and signs, and documentation of CMV by  biops y (detection of CMV by PCR alone is 
insufficient), with other relevant causes excluded.
CMV SYNDROME (only dia gnosed in SOT recipients): 
The definition requires detection of CMV in blood by  viral culture, antigenemia or a DNA/RNA -
based assay  together with at least 2 of the following :
a.Fever ≥38°C for at least 2 day s
b.New or increased malaise (toxicity  grade ≥2) or new or increased fatigue 
(toxicity  grade ≥3) (National Cancer Institute: Common Terminology  
Criteria for Adverse Events, version 4.0)
c.Leukopenia or neutropenia on 2 separate measurements at least 24 hours apart 
defined as: a WBC count of <3,500 cells/μL , if the WBC count prior to the 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 169 
 
07 Dec 2018
For non-commercial use only
Shire Page 170
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
development of clinical symptoms was ≥4,000 cells/ μL or a WBC decrease 
of >20%, if the WBC count prior to the development of clinical s ymptoms was 
<4,000 cells/μL . The corresponding neutrophil counts are <1,500 cells/μL  or a 
decrease of >20% if the neutrophil count before the onset of s ymptoms was 
<1,500 cells/μL . 
d.≥5% at ypical l ymphocy tes
e.Thrombocy topenia defined as a platelet count of <100,000 cells/μL  if the 
platelet count prior to the development of clinical symptoms was ≥
115,000 cells/mL  or a decrease of >20% if the platelet count prior to the 
development of clinical symptoms was <115,000 cells/ mL
f.Elevation of hepatic transaminases (ALT or AST) to 2 × upper limit of 
normal (applicable to nonliver transplant recipients)
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 170 
 
07 Dec 2018
For non-commercial use only
Shire Page 171
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Appendix 4 CMV GENETIC MUTATIONS AS SOCIATED WITH RESIST ANCE TO 
ANTI -CMV DRUGS
Specific mutations in the UL 97 and/or UL54 human cy tomegalovirus (HCMV) genes are 
associated with resistance to certain anti-CMV drugs (ganciclovir/valganciclovir, foscarnet, or 
cidofovir). The UL97 gene encodes a viral protein kinase, while the UL54 gene encodes a viral 
DNA poly merase.
Ganciclovir (administered intravenously , orall y, or through its oral prodrug valganciclovir) is a 
guanosine analog that acts as a chain terminator once incorporated into the elongating viral DNA 
chain. In order for the drug to be incorporated into the viral DNA chain, ganciclovir first needs to 
be monophosphory lated by  the UL97 HCMV protein kinase. Cellular kinases then di -and 
tri-phosphory late the drug into a form that can be incorporated into the viral DNA chain. 
Mutations in the UL 97 gene that inactivate the UL97 kinase prevent the monophosphory lation 
step and result in resistance to ganciclovir/valganciclovir. Foscarnet is a p yrophosphate analog 
that blocks the release of py rophosphate by  the UL54 viral poly merase. Cidofovir is a cy tosine 
monophosphate analog that is dependent on diphosphory lation by  cellular kinases for its 
inhibition of viral DNA synthesis.
The tables below list the mutations in UL 97 that are proven to confer resistance to 
ganciclovir/valganciclovir and the mutations in UL54 that confer resistance to one or multiple 
anti-CMV agents, mostly based on the phenotyping, except in the case of deletions, that do not 
need to be confirmed due to the lo cation of the deleted residues.
Since foscarnet and cidofovir do not require phosphory lation by  the viral UL97 kinase for their 
activity , they  are unaffected by  mutations in the UL97 gene. Mutations in the UL54 gene that 
inactivate the viral DNA poly merase prevent incorporation of ganciclovir/valganciclovir and/or 
cidofovir into the elongating viral DNA chain, leading to resistance to the drug(s). Similarly , 
mutations in the UL 54 gene can lead to foscarnet resistance.
The tables below are the reference for the investigators while the full list of reportable mutations 
should they  be found in the clinical study  anal yses will be provided in the resistance anal ysis 
plan.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 171 
 
07 Dec 2018
For non-commercial use only
Shire Page 172
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Reference for the Investigators: UL97 Mutations Known to Confer Resistance to 
Ganciclovir/Va lganciclovir
UL97 Mutation Ganciclovir/Valganciclovir
L405P R
D456N R
M460I R
M460L R
M460T R
M460V R
V466G R
C480R R
C518Y R
H520Q R
P521L R
del590 to 593 R
del590to 600 R
del590 to 603 R
del591 to 594 R
del591 to 607 R
C592F R
C592G R
del594 to 601 R
A594E R
A594G R
A594P R
A594T R
A594V R
L595F R
L595S R
L595T R
L595W R
del595 R
del595 to 603 R
del597 to 599 R
del597 to 603 R
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 172 
 
07 Dec 2018
For non-commercial use only
Shire Page 173
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Reference for the Investigators: UL97 Mutations Known to Confer Resistance to 
Ganciclovir/Va lganciclovir
UL97 Mutation Ganciclovir/Valganciclovir
E596G R
E596Y R
E596D R
N597D R
N597I R
G598D R
G598S R
G598V R
K599T R
del600 R
del601 R
del600 to 601 R
del601 to 602 R
del601 to 603 R
C603R R
C603S R
C603W R
C603Y R
C607F R
C607Y R
I610T R
A613V R
Source: Lurain and Chou, 2010 ;Komatsu et al., 2014
R=resistant
Mutations in bold letters are the most common mutations.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 173 
 
07 Dec 2018
For non-commercial use only
Shire Page 174
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Reference for the Investigators: UL54 Mutations Known to Confer Resistance to One or 
More of the Anti -CMV drugs
UL54 Mutation Cidofovir Foscarnet Ganciclovir
D301N R S R
E303D4R S R
E303G4R S R
N408D R S R
N408K4R S R
N408S R S R
N410K R S R
F412C R S R
F412L R S R
F412S R S R
F412V R S R
D413A R S R
D413E R S R
D413N R S R
D413Y4R S R
P488R R S R
N495K S R S
K500N R S R
L501I R S R
T503I R S R
A505V3R S R
K513N R S R
K513E R S R
K513R R S R
D515E S S R
D515Y S R R
L516R R S R
L516W R S R
I521T R S R
P522A R S R
P522S R S R
del524 R S R
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 174 
 
07 Dec 2018
For non-commercial use only
Shire Page 175
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Reference for the Investigators: UL54 Mutations Known to Confer Resistance to One or 
More of the Anti -CMV drugs
UL54 Mutation Cidofovir Foscarnet Ganciclovir
V526L R S R
C539G R S R
C539R R S R
D542E4R S S
L545S R S R
L545W R S R
T552N S R S
Q578H R R R
Q578L S R S
S585A S R S
D588E S R S
D588N S R R
F595I S R S
T700A S R S
V715M S R S
V715A S R S
I726T S S R
I726V3R S R
E756K R or S3R R or S3
E756D S R S
E756Q S R S
L773V R R R
L776M S R R
V781I S R R3
V787A S R R
V787L S R R
L802M S R R or S3
K805Q R S S
A809V S R R
V812L4R R R
T813S R R R
T821I S R R
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 175 
 
07 Dec 2018
For non-commercial use only
Shire Page 176
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Reference for the Investigators: UL54 Mutations Known to Confer Resistance to One or 
More of the Anti -CMV drugs
UL54 Mutation Cidofovir Foscarnet Ganciclovir
P829S S S R
A834P R R R
T838A S R S
G841A R R R
G841S S R R
M844V S R R
V946L S R S
L862F S S R
D879G R
L957F ND ND R
A972V R
del981 to 982 R R R
A987G R S R
Source : Chou, 2011 ; Chou et al., 2008 ; Chevillotte et al., 2010 ; Erice, 1999 ; Komatsu et al., 2014
1Most UL54 mutations also have UL97 mutations.
2R and S denote resistant and sensitive, respectively. ND indicates Not Determined
3Low-grade or variable resistance.
4Also confers resistance to CMX001
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 176 
 
07 Dec 2018
For non-commercial use only
Shire Page 177
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Appendix 5 KARNOFSKY PERFORMANC E STATUS SCALE
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 177 
 
07 Dec 2018
For non-commercial use only
The Karnofsky Performance Scale  Index allows patients to be classified as to their functional 
impairment. This can be used to c ompare effectiveness of differ ent therapies and to assess the 
prognosis in individual patients . The lower the Karnofsky score , the worse the survival for most 
serious illnesses.  
KARNOFSKY PERFORMANCE STATUS SC ALE DEFINITIONS RATING (%) 
CRITERIA 
  100  Normal no complaints; no evidence of disease.
90 Able to carry on normal activity; minor signs 
or symptoms of disease.  Able to carry on normal activity and to work; no special care needed.  
80 Normal activity with effort; some signs or symptoms of disease.  
70 Cares for self; unable to carry on normal activity or to do active work.  
60 Requires occasional assist ance, but is able to 
care for most of his personal needs.  Unable to work; able to live at home and care for most personal needs; varying amount of assistance needed.  
50 Requires considerable assistance and frequent medical care.  
40 Disabled; requires special care and assistance.  
30 Severely disabled; hospital admission is indicated although death not imminent. 
20 Very sick; hospital admission necessary; active supportive treatment necessary.  
10 Moribund; fatal processes progressing rapidly.  Unable to care for self ; requires equivalent of 
institutional or hospital care; disease may be progressing rapidly. 
0 Dead  
References: 
Crooks, V, Waller S, et al. The use of the Karnofsky Performanc e Scale in determining outcomes 
and risk in geriatric outpatient s. J Gerontol. 1991; 46: M139-M 144. 
O'Toole DM, Golden AM. Evaluati ng cancer patients for rehabilit ation potential. West J Med. 
1991; 155:384-387. 
Oxford Textbook of Palliative Medicine, Oxford University Press . 1993;109. 
Schag CC, Heinrich RL, Ganz PA. K arnofsky performance status re visited: Reliability, validity, 
and guidelines. J Clin Oncology. 1984; 2:187-193. 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 178 
 
07 Dec 2018
For non-commercial use only
Shire Page 178
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Appendix 6 LANSKY PERFORMANCE S TATUS SCALE
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 179 
 
07 Dec 2018
For non-commercial use only
Lansky play-performance scale for pediatric patients  
This scale may be used with children age 1-16 who have any type of malignancy. 
It may be used for
 both inpatients &  outpatients, and for patients undergoing active 
treatment as well as long- term follow -up. It is rated by parents based on their 
child's activity over the past week. Parents fill out the assessment based on the directions on the form, and the form is readministered over time to assess for changes in performance status.  
An excerpt of the relevant directions for parents is as follows:  
"Think about your child's play and activity over the past week. Think about both good days and bad 
days. Average out this pe riod. Now read the descriptions and 
pick the one that best describes your child's play during the past week." 
Rating  Description  
100  fully active, normal  
90  minor restrictions with strenuous physical activity  
80  active, but gets tired more quickly  
70  both greater restriction of, and less time spent in, active play  
60  up and around, but minimal active play; keeps busy with quieter activities  
50  lying around much of the day, but gets dressed; no active play ; participates 
in all quiet play and activities  
40  mostly in bed; participates in quiet activities  
30  stuck in bed; needs help even for quiet play  
20  often sleeping; play is entirely limited to very passive activities  
10  does not play nor get out of bed  
0  unresponsive  
 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 180 
 
07 Dec 2018
For non-commercial use only
Shire Page 179
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Appendix 7 SCALES AND ASSESSMENTS
The follow ing scales/assessments will be utilized in this study : 
A separate master file containing each scale/assessment listed above will be provided to the site. 
Updates to scales/assessments during the stud y (if applicable) will be documented in the tables 
above and a new master file containing the revised scale/assessment will be provided to the site.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 181 
 
07 Dec 2018
For non-commercial use only
Shire Page 180
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Appendix 8 ACUTE GRAFT -VERSUS -HOST DISEASE: CLINIC AL STAGING AND 
GRADING 
The clinical staging and grading of acute GVHD is done through evaluation of the skin, liver, 
and gastrointestinal tract (upper and lower) ( Harris et al., 2016 ).
GVHD Target Organ Staging
Stage Skin (Active Erythema Only) Liver
(Bilirubin)Upper GI Lower GI (stool 
output/day)
0No active (erythematous) GVHD 
rash<2 mg/dL No or intermittent 
nausea, vomiting, or 
anorexiaAdult: <500 mL/day or <3 
episodes/day
Child: <10 mL/kg/day or 
<4 episodes/day
1Maculopapular rash
<25% BSA2-3 mg/dL Persistent nausea, 
vomiting or 
anorexiaAdult: 500 -999 mL/day or 
3-4 episodes/day
Child: 10 -19.9 mL/kg/day 
or 4-6 episodes/day
2Maculopapular rash
25-50% BSA3.1-6 mg/dL Adult: 1000 -1500 mL/day 
or 5-7 episodes/day
Child: 20 -30 mL/kg/day or 
7-10 episodes/day
3Maculopapular rash
>50% BSA6.1-15 mg/dL Adult: >1500 mL/day or >7 
episodes/day
Child: >30 mL/kg/day or 
>10 episodes/day
4Generalized erythroderma
(>50% BSA) plus bullous formation 
and desquamation >5% BSA>15 mg/dL Severe abdominal pain with 
or without ileus or
grossly bloody stool 
(regardless of stool volume
Source : Table 1, Harris et al., 2016
Overall clinical grade (based on most severe target organ involvement):
Grade 0: No stage 1 -4 of any organ.
Grade I: Stage 1 -2 skin without liver, upper GI, or lower GI involvement.
Grade II: Stage 3 rash and/or stage 1 liver and/or stage 1 upper GI and/or stage 1 lower GI.
Grade III: Stage 2 -3 liver and/or stage 2 -3 lower GI, with stage 0 -3 skin and/ or stage 0 -1 upper GI. Grade IV: Stage 4 skin, liver, 
or lower GI involvement, with stage 0-1 upper GI.
The differences in GVHD diagnosis make it challenging to conduct multicenter trials because of 
the dif ﬁcult y determining whether a patient trul y experi enced GVHD. To address these vary ing 
practices, Harris et al., 2016 developed a structure for collecting granular GVHD data and 
assigning con ﬁdence levels for the attribution of symptoms to GVHD based on the treatment 
decisions made b y the clinician.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 182 
 
07 Dec 2018
For non-commercial use only
Shire CONFIDENTIAL Page 181
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Confidence Level Criteria
Confidence 
LevelPathologic 
EvidenceClinical 
AssessmentTreatm ent for 
Acute GVHDComments
Confirmed Unequivocal 
pathologic
evidence of GVHDGVHD is the 
etiology for 
symptomsNot applicable GVHD is clearly present even if 
other etiologies may coexist 
simultaneously.
Probable Not required GVHD most likely 
etiology for
symptoms (as 
evidenced by
treatment being 
provided)Yes GVHD is most likely present, but 
other etiologies may also explain 
the symptoms, and there is 
insufficient evidence to make a 
confirmed diagnosis.
Possible Not required GVHD in 
differential 
diagnosis
(but no treatment 
is being provided)No GVHD may be present, but other 
etiologies are fa vored to the 
degree that GVHD treatment is 
not initiated.
Negative Unequivocal 
evidence of a 
diagnosis other than 
GVHD (eg, drug 
rash)GVHD is not 
considered as an 
explanation for the 
symptomsNo and the 
symptoms 
resolve without 
GVHD treatmentA “negative” biopsy (eg, normal 
skin) is not unequivocal evidence 
of a diagnosis other than GVHD.
Source : Table 2, Harris et al., 2016
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 183 
 
07 Dec 2018
For non-commercial use only
Shire CONFIDENTIAL Page 182
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Appendix 9 RECOMMENDATIONS FOR CHRONIC GVHD DIAGNOSIS AND 
GRADING 
A. Organ Scoring of Chronic GVHD as published in NIH GVHD Consensus for GVHD 
Consensus for Clinical Trials: I . The 2014 Diagnosis and Staging Working Group Report, 
Jagasia et al., 2015 (Figure 1).
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 184 
 
07 Dec 2018
For non-commercial use only
Shire CONFIDENTIAL Page 183
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
EYES 
Keratoco njunctivitis 
sicca (KCS) confir med 
by ophthalmologist: 
0 Yes 
0 No 
0 Not examined SCORE O 
0 No symptoms SCORE l 
0 Mild dry eye 
symptom s not 
affecting ADL 
(requirement of 
lubricant eye 
drops :0 3 x p er 
day) SCORE2 
0 Mode rate dry eye 
symp toms partiall y 
affect ing ADL 
(requi ring lubricant 
eye drops > 3 x per 
day or puncta ! 
plugs) , 
WITHO UT new 
vision impairment 
due to KCS SCORE3 
0 Severe dry eye 
symp toms significantly 
affecting ADL (special 
eyewa re to relieve pain) 
OR unable to work 
because of ocular 
symp toms OR loss of 
vision due to KCS 
0 Abnormali ty present but explained entirely by non-GVHD docum ented cause (specifY). ,_· 
Gl T ract 
Check all that apply: 
0 Esophagea l web/ 
proxi mal stricture 
or ring 
0 Dysphagi a 
0 Anorexia 
ONa usea 
OVomiting 
0 Diarrhea 
0 Weight loss ::>:5%* 
0 Failure to thrive 0 No symptoms OSymptoms 
without 
significant weig ht 
loss• (<5%) 0 Sym ptoms 
assoc iated with 
mild to moderate 
weight loss• 
(5-15 %)0R 
moderate diarrhea 
without 
significant 
interferen ce with 
daily living 0 Symptoms associate d 
with signi ficant weight 
loss• > 15%, requires 
nutritional supple ment for 
most calor ie needs OR 
esophagea l dilation O R 
severe diarrhea with 
signifi cant interfere nce 
with daily living 
0 Abnormali ty present but explai ned entirely by non-GVHD documented cause (specify): ____________ _ 
L IVER 0 Normal total 0 Normal total 0 Elevate d total 
bilirubin and bilirubin with ALT bilirubin but 
ALTorAP 2:3 to 5 x ULN or :03 mg/dL or 
< 3 x ULN AP::>:3xULN ALT > 5 ULN 
0 Abnormalit y present but explained entirely by 11011-G VHD documented cause (specifY): 
LUNGS** 
Symotom score: 
Lung score: 
Pulmo11ary [u11ction tests 
0 Not performed 0 No symptom s 
0 FEVI2:80 % 0 Mild symptoms 0 Moderate 
(shortne ss of symptom s 
breath after (shortness of breath 
climbi ng one flight after walking on 
of steps) flat ground) 
0 FEV I 60-79% 0 FEVI 40-59% 0 Elevat ed total 
bilirubin> 3 m g/dL 
0 Severe symptom s 
(shortness of breath at 
rest; requiring o,) 
0 FEVI :039% 
0 Abnormality present but explained entirely by non-G VHD documented cause (specify): _____________ ' 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 185 
 
07 Dec 2018
For non-commercial use only
Shire CONFIDENTIAL Page 184
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Organ scoring of chronic GVHD. ECOG indicates Eastern Cooperative Oncology Group; KPS, Karnofsky 
Performance Status; LPS, Lansky Performance Status; BSA, body surface area; ADL, activities of daily 
living; LFTs, liver function tests; AP, alkaline phosphatase; ALT, alanine aminotransferase; ULN, normal 
upper limit. *Weight loss within 3 months. †Skin scoring should use both percentage of BSA involved by 
disease signs and the cutane ous features scales. When a discrepancy exists between the percentage of total 
body surface (BSA) score and the skin feature score, OR if superficial sclerotic features are present (Score 
2), but there is impaired mobility or ulceration (Score 3), the high er level should be used for the final skin 
scoring. ‡To be completed by specialist or trained medical providers (see Supplemental Figure). **Lung 
scoring should be performed using both the symptoms and FEV1 scores whenever possible. FEV1 should 
be used in the final lung scoring where there is discrepancy between symptoms and FEV1 scores.
Source : Figure 1, Jagasia et al., 2015
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 186 
 
07 Dec 2018
For non-commercial use only
Shire CONFIDENTIAL Page 185
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Supplemental Genital Tract Chronic GVHD Scoring and Supplemental skin GVHD 
scoring ( supplemental mat erial for Jagasia et al., 2015)
Source : Supplemental Figure 1, supplemental material for Jagasia et al., 2015Suppl emen t Figure -Ge nital T1·act Chronic Gratl.-versus-Host Assessment a nd Sc01ing Form 
Name· Date of birth· Asses sment date· 
SCORE O SCORE I SCORE 2 SCORE3 
GEN ITAL TRAC T 0 N osigns 0 Mild signs and 0 Moderate signs 0 Severe signs with 
Check : females may have and may ha ve or wi thout 
symptoms* W ITH symptoms* with symptoms"' 0M ale 0F emal e discomfort on exam discomfort on exam 
Currently active: 
0 Yes 0No 
Check nllsic.ns that Of!LJlr_: D Erosions 
0 Lichen planus-like featw-es D Fissures 
0 Lichen sclerosis-like features D Ulcers 
0 Vaginal scarr ing (female) D Phimosis (male) 
0 ClitoraV labial agglutinat ion (female) D Urethral meatus scarrin g/ stenosis (male) 
0 Labial •·esorption (female) 
0 Abnormality present but NOT thought to represent GVHD (specifY ca11se): 
0 Abnorm ality thought to represent GVHD PLUS other causes(spe cifY ccn1.se): 
symptom s are not specific to cGVHD and can represent premat11r e gonadal fmltve or gem tal tract mfoct Jon. 
If a gynecologist is unavailab le, external examination may be to "discomf01t on exam" as fo llows: 
a) Spread the labia majora to inspect the vulva for the above signs. Touch the vestibular gland openings (Ske ne's and 
Bartl10lin 's), labia minora and majora gently with a qtip. V ulvar pain elicited by the gentle touch of a qtip is 
classified as discomfort on examination. Palpat e the vaginal walls with a s ingle digit to detect shortening, 
naJTowing or o ther signs of va ginal scarring. 
b) If the woman is sexually active, dete rmine whether qtip palpation or gentle palpati on of s carred • ·idges elicits pain 
similar to that which the woman expe11ences dm1n g intercourse. 
Fem ale genitali:1 : Severity of signs: 
1) Mild (any of the following); erythema on vulvar mucosal surfaces, vulvar lichen- planus or vulvar lichen -sclerosis. 
2) M oderate (any of the following); erosive inflammat ory chan ges of the vulvar mucosa, fissures in vulvar folds 
3) Seve re (any of the following); labial fusion, c litoral hood agglutinat ion, fibrinous vaginal adhesions, c ircumferential 
Jibrous vaginal banding , vag inal sho11enin g, synec hia, dense sclerotic c hanges, and complete vaginal stenosis. 
Male genitalia: Di agnosti c features include lichen planu s-like or lichen scleros is-like features and phymos is or urethral 
scan·ing or stenosis. Severi ty of signs: 
1) Mild: lichen planus-like Jeature; 
2) Moderate: lichen sclerosus-like feature or mod erate erytl1en1 a; 
3) Severe : phim osis or uretlu·aV meatal scarring. 
Biopsy obtained : D Y•s D No Site biopsied: ______ GVHD <onlirme d by histology: DY es D No 
Change from previou.'i n • aluation: 0 No p rior or current GVHD 0 .lmprovtd 0 Stable 0 Wor se 0 N/A (ba .. nnc) 
Completed by (print name) : _________________ Oate form com pl eted: _____ _ 
44 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 187 
 
07 Dec 2018
For non-commercial use only
Shire CONFIDENTIAL Page 186
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
B. NIH Severity Grading of Chronic GVHD as published in NIH GVHD Consensus for 
GVHD Consensus for Clinical Trials: I. The 2014 Diagnosis and Staging Working Group 
Report ( Jagasia et al., 2015)
NIH Global Severity of chronic GVHD
Mild chronic GVHD
1 or 2 Organs involved with no more than score 1 plus
Lung score 0
Moderate chronic GVHD
3 or More organs involved with no more than score 1
OR
At least 1 organ (not lung) with a score of 2
OR
Lung score 1
Severe chronic GVHD
least 1 organ with a score of 3
OR
Lung score of 2 or 3
Key points:
In skin: higher of the 2 scores to be used for calculating global severity.
In lung: FEV1 is used instead of clinical score for calculating global severity.
If the entire abnormality in an organ is noted to be unequivocally explained by a non- GVHD 
documented cause, that organ is not included for calculation of the global severity.
If the abnormality in an organ is attributed to multifactorial causes (GVHD plus other 
causes) the scored organ will be used for calculation of the global severity regardless of the 
contributing causes (no downgrading of organ severity score).
Source : Table 2, Jagasia et al., 2015
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 188 
 
07 Dec 2018
For non-commercial use only
Shire CONFIDENTIAL Page 187
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Appendix 10 DIAGNOSTIC CRITERIA FOR CHRONIC GVHD 
A.Signs and Symptoms of Chronic GVHD ( Table 1 in Jagasia et al., 2015)
Signs and Symptoms of chronic GVHD
Organ or Site Diagnostic 
(Sufficient to 
Establish the 
Diagnosis of 
chronic GVHD)Distinctive ∗(Seen in 
chronic GVHD, but 
Insufficient Alone to 
Establish a Diagnosis)Other Features or 
Unclassified Entities†Comm on‡(Seen 
with Both Acute 
and chronic 
GVHD)
Skin Poikiloderma
Lichen planus –
like features
Sclerotic features 
Morphea- like 
features
Lichen sclerosus –
like featuresDepigmentation
Papulosquamous lesionsSweat impairment
Ichthyosis
Keratosis pilaris
Hypopigmentation
HyperpigmentationErythema
Maculopapular 
rash
Pruritus
Nails Dystrophy
Longitudinal ridging, 
splitting or brittle features
Onycholysis
Pterygium unguis
Nail loss (usually symmetric, 
affects most nails)
Scalp and body hair New  onset of scarring or 
nonscarring scalp alopecia 
(after recovery from 
chemoradiotherapy)
Loss of body hair
ScalingThinning scalp hair, 
typically patchy, coarse 
or dull (not explained by 
endocrine or other 
causes)
Prem ature gray hair
Mouth Lichen planus –
like changesXerostomia
Mucoceles
Mucosa l atrophy
Ulcers
PseudomembranesGingivitis
Mucositis
Erythema
Pain
Eyes New  onset dry, gritty, or 
painful eyes
Cicatricial conjunctivitis
KCS
Confluent areas of punctate 
keratopathyPhotophobia
Periorbital 
hyperpigmentation
Blepharitis (erythema of 
theeyelids with edema)
Genitalia Lichen planus –
like features
Lichen sclerosus –
like featuresErosions
Fissures
Ulcers
Females Vaginal scarring 
or clitoral/labial 
agglutination
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 189 
 
07 Dec 2018
For non-commercial use only
Shire CONFIDENTIAL Page 188
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Signs and Symptoms of chronic GVHD
Organ or Site Diagnostic 
(Sufficient to 
Establish the 
Diagnosis of 
chronic GVHD)Distinctive ∗(Seen in 
chronic GVHD, but 
Insufficient Alone to 
Establish a Diagnosis)Other Features or 
Unclassified Entities†Comm on‡(Seen 
with Both Acute 
and chronic 
GVHD)
Males Phimosis or 
urethral/meatus 
scarring or 
stenosis
GI Tract Esophageal web
Strictures or 
stenosis in the 
upper to mid third 
of the esophagusExocrine pancreatic 
insufficiencyAnorexia
Nausea
Vom iting
Diarrhea
Weight loss
Failure to thrive 
(infants and 
children
Liver Total bilirubin, 
alkaline 
phosphatase > 2 × 
upper limit of 
norm al
ALT > 2 × upper 
limit of normal
Lung Bronchiolitis 
obliterans 
diagnosed with 
lung biopsy
BOS§Air trapping and 
bronchiectasis on chest CTCryptogenic organizing 
pneumonia
Restrictive lung diseaseǁ
Muscles, fascia, 
jointsFasciitis
Joint stiffness or 
contractures 
secondary to 
fasciitis or 
sclerosisMyositis or polymyositis¶Edema
Muscle cramps
Arthralgia or arthritis
Hem atopoietic and 
ImmuneThrombocytopenia
Eosinophilia
Lymphopenia
Hypo-or hyper -
gammaglobulinemia
Autoantibodies (AIHA, 
ITP)
Raynaud's phenomenon
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 190 
 
07 Dec 2018
For non-commercial use only
Shire CONFIDENTIAL Page 189
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Signs and Symptoms of chronic GVHD
Organ or Site Diagnostic 
(Sufficient to 
Establish the 
Diagnosis of 
chronic GVHD)Distinctive ∗(Seen in 
chronic GVHD, but 
Insufficient Alone to 
Establish a Diagnosis)Other Features or 
Unclassified Entities†Comm on‡(Seen 
with Both Acute 
and chronic 
GVHD)
Other Pericardial or pleural 
effusions
Ascites
Peripheral neuropathy
Nephrotic syndrome
Myasthenia gravis
Cardiac conduction 
abnormality or 
cardiomyopathy
ALT indicates alanine aminotransferase; AIHA, autoimmune hemolytic anemia; ITP, idiopathic thrombocytopenic purpura.
∗In all cases, infection, drug effect, malignancy, or other causes must be exclud ed.
†Can be acknowledged as part of the chronic GVHD manifestations if diagnosis is confirmed.
‡Common refers to shared features by both acute and chronic GVHD.
§BOS can be diagnostic for lung chronic GVHD only if distinctive sign or symptom present in ano ther organ (see text).
‖Pulmonary entities under investigation or unclassified.
¶Diagnosis of chronic GVHD requires biopsy.
Source : Table 1, Jagasia et al., 2015
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 191 
 
07 Dec 2018
For non-commercial use only
Shire CONFIDENTIAL Page 190
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
B.Histological Criteria for GVHD by Organ system according to NIH Consensus 
Development Project on Criteria for Clinical Trials in Chronic Graft -versus -Host 
Disease: II. The 2014 Pathology  Working Group Report (Table 1 in Shulman et al., 
2015). Chronic GVHD is supported by  histologic evidence of GVHD from any  affected 
site. I nvestigators are expected to consider recommendations for chronic GVHD 
diagnosis including not only
 clinical but histological evidence.
Histological Criteria for GVHD by Organ System
Organ or System Minimal Criteria for 
Acute/Active GVHD∗Specific Criteria for Chronic GVHD†
Liver Global assessment of 
dysmorphic or 
destroyed small bile 
ducts ±cholestasis, 
lobular and portal 
inflammationDuctopenia, portal fibrosis, chronic cholestasis reflect 
chronicity but are not specific for chronic GVHD
GI Variable apoptotic 
criteria ( ≥1/piece) in 
cryptsDestruction of glands, ulceration or submucosal fibrosis may 
reflect severe or long -standing disease but are not specific for 
chronic GVHD
Skin, in general Apoptosis in epidermal 
basal layer or low er 
Malphigian layer or 
infundibulum/outer root 
sheath/hair bulge of hair 
follicle or 
acrosyringium/sweat 
ducts ±lichenoid 
inflammation ±vacuolar 
change ±lymphocytic 
satellitosis
Skin, lichen 
planus –likeCom bination of epidermal orthohyperkeratosis, 
hypergranulosis and acanthosis resembling lichen 
planus ±lichenoid inflammation and/or vacuolar changes of 
eccrine units
Skin morpheic 
(localized or 
diffuse)Thickening and homogenization of collagen bundl es 
throughout reticular dermis or pandermal sclerosis with 
overlying interface changes ±thickening and 
homogenization of subcutaneous septa
Skin, lichen 
sclerosus –likeHom ogenization ±sclerosis of papillary dermal collagen 
with overlying interface chan ges including melanophages in 
the papillary dermis and sparse lymphocytic infiltrate
Skin, fasciitis Thickening of fascial septa with adjacent 
inflammation ±sclerosis of subcutis
Oral/oropharyngeal 
mucosa and 
conjunctivaLichenoid interface 
lymphocytes with 
infiltration of mucosa 
(exocytosis) and 
variable apoptosis‡
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
Page 192 
 
07 Dec 2018
For non-commercial use only
Shire CONFIDENTIAL Page 191
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
Histological Criteria for GVHD by Organ System
Organ or System Minimal Criteria for 
Acute/Active GVHD∗Specific Criteria for Chronic GVHD†
Minor salivary or 
lacrimal glandPeriductal lymphocytic infiltrate w ith infiltration and 
damaged intralobular ducts, fibroplasia in periductal stroma, 
mixed lymphocytic and plasmacytic in flammation with 
destruction of acinar tissue§
Lung CBO: dense eosinophilic scarring beneath the respiratory 
epithelium, resulting in luminal narrow ing or complete 
fibrous obliteration. May be preceded by lymphocytic 
bronchiolitis without intraluminal fibrosisǁ
Kidney Mem branous nephropathy, minimal change disease
Lesions of Uncertain Pathogenesis
Lung COP
Skeletal Muscle Myositis
∗Conditions that result in lesser degrees of change include immunosuppressive treatment, biopsy very soon after onset 
of signs, suboptimal or small tissue sample, insufficient serial sectioning, confounding infection, drug reaction, or 
inflammatory conditi ons.
† After the diagnosis of chronic GVHD has been established or following immunosuppressive treatment, the 
histological manifestations of active disease may meet only minimal diagnostic criteria for activity. Different 
manifestations of cutaneous chroni c GVHD may all be present together in 1 biopsy or in separate but concurrent 
biopsies.
‡ Inflammation of the oral mucosa and within the minor salivary glands may persist from prior chemo -irradiation or 
prior inflammation. The distinction between acute and chronic GVHD requires the addition of distinctive oral 
manifestations.
§ The distinction of past acinar destruction and fibrosis from ongoing chronic GVHD activity can be difficult and relies 
on assessing lobules that are not completely fibrotic. Acinar and periductal inflammation with features of damage to 
ducts, such as vacuolar change, lymphocytic exocytosis nuclear dropout, dyspolarity or apoptosis, and resultant 
fibroplasia indicate chronic GVHD activity.
‖Constrictive bronchiolitis obliterans (CBO) should be distinguished from cryptogenic organizing pneumonia, which 
is also associated with GVHD but has a different clinicopathologic presentation and a more favorable outcome.
Source : Table 1, Shulman et al., 20 15
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 193 
 
07 Dec 2018
For non-commercial use only
Shire CONFIDENTIAL Page 192
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
C.Recommendations for Final Diagnosis Categories of GVHD (Shulman et al., 2015)
Recommendation for Final Diagnosis Categories
Category Definition Examples Comments
Not 
GVHDNo evidence for GVHD
Possible 
GVHDEvidence of GVHD but 
other possible 
explanationsObvious CMV enteritis with inclusions 
near the apoptotic changes
Focal colonic ulcers with marked 
apoptotic cryptitis and destruction of 
crypts associated with use of MMF
Coinfection with known active viral 
hepatitis
Clinical features which suggest or 
favor a drug reactionIndicate possible alternate 
diagnoses a nd reasons for 
suspicion
Likely 
GVHDClear evidence of GVHD 
without a competing cause 
of injury
OR
Clear evidence of GVHD 
with mitigating factors
OR
GVHD most likely 
diagnosis but relevant 
clinical information is 
limited
OR
GVHD is validated by 
sequential biopsy or by 
absence of competing 
diagnosisAbundant epithelial apoptosis without 
clinical or histological evidence of 
drug injury or infection
Evidence of CMV yet abundant 
apoptotic epithelial changes that are 
not associated with CMV infected 
cells by im munostaining
Single or rare apoptotic epithelial 
changes without other features of 
active GVHD and no alternative 
explanations
Limited sample or minimal or focal 
findings
Proximity to recent chemotherapy or 
radiotherapyIncluded old categories of 
“consiste nt with” and 
“unequivocal” GVHD
Source: Table 2, Shulman et al., 2015
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 194 
 
07 Dec 2018
For non-commercial use only
Shire CONFIDENTIAL Page 193
SHP620 -303 Protocol Amendment 6
Maribavir 07 Dec 2018
Appendix 11 MODIFICATION OF DIET IN RENAL DISEASE (MD RD) AND 
SCHWAR TZ FORMULAE
Subjects eligible for Study SHP620 -303 must have estimated glomerular filtration rate (eGFR) 
>30mL/min/1.73m2 as assessed by Modification of Diet in Renal Disease (MDRD) formula 
(Leve y et al., 2006 ) for subjects ≥18 years of age or Schwartz formula (Schwartz et al., 1976 ; 
Schwartz et al., 1984 ) for subjects <18 y ears of age.
MDRD formula 
For creatinine in µmol/L :
Creatinine levels in µmol/L can be converted to mg/dL by dividing those by 88.4.
For creatinine in mg/dL:
For standardized (IDMS -calibrated) serum creatinine assays:
eGFR (mL/min/1.73 m2) = 175 ×(Scr)-1.154×(Age)-0.203× (0.742 if Female) ×(1.212 if Black) 
(conventional units)
For non -standardized (non -IDMS -calibrated) serum creatinine assays:
Schwartz formula 
GFR (ml/min/1.73m2)=[length or height (cm) × k] / Scr (mg/dl)
k=0.55 mg creatinine/100 min × cm × 1.73m2for children 1 -13 years old
k=0.55 for adolescent females 13 -18 years old
k=0.7 for adolescent males 13 -18 years old
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 195 
 
07 Dec 2018
For non-commercial use only
Shire CONFIDENTIAL Page 194
SHP620 -303 Protocol Amendment 6
Maribavir 07 Dec 2018
Appendix 12 BACTERIAL AND FUNGAL INFECTIONS ASSESSMEN T
In HSCT population post -transplant infection remains a significant cause of morbidity  and 
mortality , particularl y after allogeneic transplantation. While the expected period of profound 
neutropenia after HSCT usually  occurs during the pre -engraftment stage, normal neutrophil 
recovery  is not alway s possible as neutrophil count is adversel y affected b y other risk factors and 
co-morbidities, such as graft failure or rejection, GVHD, relapse of the underl ying neoplasm, 
drug-induced m yelosuppression and concomitant infections ( Klumpp, 1993 ).
Due to the gradual immune sy stem reconstitution HSCT recipients are vulnerable to v arious 
opportunistic viral, bacterial or fungal pathogens at different stages after the transplant ( Tombly n 
et al., 2009 ). Opportunistic infection is defined as any  infection that occurs with increased 
frequency  or severit y in HSCT population ( Dykewicz, 2001 ).
Phases of opportunistic infections among allogeneic HSCT recipients Phase I: <15 -45 days post transplant; Ph ase II: 30- 100 days 
post transplant; Phase III: >100 days after HSCT. Abbreviations: EBV, Epstein -Barr virus; HHV, human herpes virus; PTLD, 
post-transplant lympho -proliferative disease (Figure 1, Tomblyn et al., 2009 ). 
Infectious complications are most frequent in the pre -engraftment period due to cy topenias and 
immune ablation and immune suppression but may continue for months or years in HSCT 
recipients with delayed immune reconstitution ( Majhail et al., 2012 ). During the earl y post -
transplant period HSCT recipients are susceptible to bacteremia and fungal infections with 
Candida and Aspergillus species, along with herpes simplex virus (HSV) reactivation. Candida 
often caus es superficial skin infection (thrush), with rare occasions of invasive disease 
manifested as esophagitis, endocarditis or hepatosplenic disease. During the early 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 196 
 
07 Dec 2018
For non-commercial use only
Shire CONFIDENTIAL Page 195
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
post-engraftment phase infections relate primaril y to impaired cell -mediated immunity , which is 
influenced b y a history  of GVHD and the requirement for ongoing immunosuppression. The 
predominant organisms in this phase are herpesviruses, along with Pneumocystis jiroveci and 
Aspergillus species. In the late post -engraftment period common pathogens include CMV, VZV 
and infections with encapsulated bacteria, such as Streptococcus pneumonia, Haemophilus 
influenzae ( Tombl yn et al., 2009; Majhail et al., 2012 ).
Prolonged neutropenia in the pre -engraftment phase results is a substantial risk for bacterial and 
fungal infections, and has been the most important risk factor for invasive aspergillosis 
(Schwartz et al., 1984 ; Salzberger et al., 1997; Marr et al., 2002 ).
The most common bacterial infections in neutropenia are provided in the table below.
Common Bacterial Pathogens in Neutropenic Patients
Comm on gram -positive pathogens
Coagulase -negative staphylococci
Staphylococcus aureus , including methicillin -resistant strains
Enterococcus species, including vancomycin -resistant stains
Viridans group streptococci
Streptococcus pneumoniae
Comm on gram  negative pathogens
Escherichia coli
Klebsiella species
Enterobacter species
Pseudomonas aeruginosa
Citrobacter species
Acinetobacter species
Stenotrophomonas maltophilia
Source: Table 1; Freifeld et al., 2011
Fever during neutropenia in immunocompromised patients may  be the onl y indication of a 
severe underl ying infection, because signs and symptoms of inflammation ty picall y are 
attenuated; pulmonary  infection may  have no signs on infiltrates on radiographs, CSF 
pleocy tosis might be low or abse nt in the setting of meningitis. The guidance document for 
management of neutropenic patients with fever ( Freifeld et al., 2011 ) also provides the details of 
the evidence to be used for the confirmation of the relevant bacterial or v iral infection.
In this stud y, a history of infections, including ongoing infections at baseline, will be 
documented as part of the subject’s medical history . Any  new infections that occur during the 
course of the study  will be recorded as adverse events. It is recommended that invasive fungal 
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 197 
 
07 Dec 2018
For non-commercial use only
Shire CONFIDENTIAL Page 196
SHP620 -303 Protocol Am endment 6
Maribavir 07 Dec 2018
infections be diagnosed and reported as possible, probable or proven per the criteria described b y 
Ascioglu et al., 2002 and later revised in De Pauw et al., 2008.
FUNGAL INFECTIONS
A.Aspergillus spp. or other mold infection :
Proven: Clinical signs and symptoms plus a tissue biopsy  revealing growth of an 
organism or positive histopathology .
Probable : Clinical signs and sy mptoms with bronchoalveolar lavage (BAL) y ielding 
positive growth or positive histopathology .
Possible : at least 3 clinical signs or s ymptoms and growth of an organism from nonsterile 
fluid (ie, sputum).
B.Candida spp. or other yeast (e.g. T. glabrata):
Proven fungemia : Any  single positive blood culture that is culture positive for Candida 
spp. or T. glabrata. [Note: Removal of indwelling catheters is strongl y encouraged.]
Tissue documented : Clinical signs and s ymptoms compatible with invasive yeast 
infection and a positive culture from a normally  sterile site with histologic evidence of 
tissue invasion (definite) or positive culture from sterile site without histologic evidence 
of invasion (probable).
BACTERIAL INFECTIONS 
C.Bacteremia: 
Any single positive blood culture that is culture positive for bacterial pathogens 
consistent with a serious bloodstream infection.
oUrinary  tract infections will not be captured as opportunistic infections of 
interest
D.Invasive Bacterial Tissue Infection:
Clinical signs and s ymptoms compatible with disease (sinusitis, pneumonia, intra -
abdominal abscess)
and 
Radiographic evidence of disease and pure or predominant culture or pathogen 
detection from a sterile site biopsy .
oPathogen detection in respiratory  secretion or sinus aspirates or CSF 
specimens will be considered if they  are predominant and compatible with the 
clinical picture.
Shire 
SHP620-303 Protocol Amendment 6 
Maribavir
CONFIDENTIAL 
 
Page 198 
 
07 Dec 2018
For non-commercial use only